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Albicidin derivatives, their use and synthesis 
DESCRIPTION 
Albicidin has been initially described as an antibiotic substance derived from Xanthomonas 
albilineans, a protobacterial sugarcane pathogen (US patent 4,525,354 to Birch and Patil, 
incorporated by reference herein). 
Since its first description in 1985, B-albicidin has eluded structural determination in spite of its 
interesting properties, namely its antibiotic activity against gram-negative bacteria, a group 
which encompasses many medically important pathogens such as, for example, Escherichia 
coti, Salmonella, Shigella, Pseudomonas, Moraxella, Helicobacter, Stenotrophomonas, 
Neisseria, Hemophilus and Legionella. 
However, the molecular structure of albicidin was determined only recently 
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The inventors found out that a variation of one building block of albicidin provides 
compounds, which comprise antibiotic properties, in particular an antibiotic activity against 
resistant pathogens. 
The problem underlying the present invention is the provision of new compounds, which 
comprise antibiotic properties, a method of their synthesis and their use. This problem is 
attained by the subject-matter of the independent claims. 
TERMS AND DEFINITIONS 
The term "purity" as used in the context of the present specification with respect to a 
preparation of a certain compound refers to the content of said compound relative to the sum 
of all compounds contained in the preparation. The term "compound" in this context is to be 
understood as a compound according to the general formula 1 (or any specific embodiments 
thereof) as well as any salts, hydrates or solvates thereof. Thus, the respective salts, 
hydrates or solvents are not considered as impurities according to the previous definition. 
The "purity" of a compound may be determined using elemental analysis, HPLC analysis 
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using UV diode array detection also in combination with mass spectrometry detection, or 
quantitative NMR analysis. 
DIPEA is N,N-Diisopropylethylamine (CAS No. 7087-68-5). HATU is (Dimethylamino)-N,N-
dimethyl(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methaniminium hexafluorophosphate (CAS 
No. 148893-10-1 ).TEA is Triethylamine (CAS No. 121-44-8). BTC is Bis(trichloromethyl) 
carbonate (CAS No. 32315-10-9). PFP is Pentafluorophenole (CAS No. 771-61-9). PNP is 
para-nitrophenol (CAS No. 100-02-7). HONB N-Hydroxy-5-norbornene-2,3-dicarboximide 
(CAS No. 21715-90-2). NHS is N-hydroxysuccinimidyl (CAS No. 6066-82-6). BOB is 
Benzotriazolyloxytris-(dimethylamino )-phosphonium hexafluorophosphate (CAS No. 56602-
33-6). pyBOP is Benzotriazol-1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate (CAS 
No. 128625-52-5). HBTU is N,N,N',N'-Tetramethyl-0-(1 H-benzotriazol-1-yl)uronium 
hexafluorophosphate (CAS No. 94790-37-1 ). DCC is N,N-Dicyclohexylcarbodiimide (CAS 
No. 538-75-0). DIC is N,N-Dicyclopropylcarbodiimide (CAS No. 693-13-0), EDC is 1-Ethyl-3-
(3-dimethylaminopropyl)carbodiimide (CAS No. 25952-53-8, 22572-40-3, 1892-57-5). TFFH 
is Fluoro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate (CAS. No. 164298-23-1 ). 
DEPT is 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H9-one (CAS No. 165534-43-0). 
A protecting group in the context of the present specification is a group employed to reduce 
the reactivity of a particular moiety. Protecting groups are well known to the persan skilled in 
the art of organic chemistry. P. G. M. Wuts, "Greene's Protective Groups in Organic 
Synthesis, "4th ed. (2006, Wiley; ISBN 978-0-471-69754-1; 5th edition June 2013 Wiley-
Blackwell). 
PGH is a suitable protection group for hydroxyl groups known in the art. 
PGA is a suitable protection group for carboxylic acid groups known in the art. 
PGN is a suitable protection group for a NH2 moiety of for example amino or amide groups 
known in the art. Hereinafter, due to simplicity reasons, a NH2 moiety will be described as an 
amino moiety irrespective of the further parts of the compound. 
M is a so called masked functional group such as - without being limited to - a -N02 group or 
a -N3 group. A masked functional group can be reduced under certain conditions to an -NH2 
functional group but does not interfere with the coupling reactions of an acid partner with an 
amino partner, as discussed further below. 
Protecting groups for use as PGN, PGH or PGA groups herein include, but are not limited to: 
(i) ethers such as methyl, substituted methyl (methoxymethyl, methylthiomethyl, 
(phenyidimethylsilyl) methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, 
p-nitrobenzyloxymethyl, o-nitrobenzyloxymethyl, (4-methoxyphenoxy) methyl, guaia-
colmethyl, t-butoxymethyl, 4- pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 
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2,2,2,-trichloroethoxymethyl, bis(2-chloroethoxymethyl), 2-(trimethylsilyl)ethoxymethyl, 
menthoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydroth iopyranyl, 
1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydroth iopyranyl, 
4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxy-
piperidin-4-yl, 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl, 1,4-dioxan- 2-yl, tetrahydrofuranyl, 
tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro- 7,8, 8-trimethyl-4, 7-methano-benzofuran-
2-yl), substituted ethyl (1-ethoxyethyl, 1-(2-chloroethoxy) ethyl, 1-[2-(trimethyl-silyl) ethoxy] 
ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoro-
ethyl, 1-methyl-1-phenoxyethyl, 2,2,2-trichloroethyl, 1, 1-dianisyl-2,2,2-trichloroethyl, 
1, 1, 1,3,3,3-hexafluoro-2-phenylisopropyl, 2-trimethylsilylethyl, 2-(benzylthio )ethyl, 2-(phenyl-
selenyl)ethyl), t-butyl, allyl, propargyl, p-chlorophenyl, p-methoxyphenyl, p-nitrophenyl, 
2, 4-dinitrophenyl, 2,3,5,6- tetrafluoro-4-(trifluoromethyl)phenyl, benzyl, substituted benzyl 
(p-methoxybenzyl, 3,4,-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 
2,6-dichlorobenzyl, p-phenylbenzyl, p-phenylenzyl, 2,6-difluorobenzyl, p-acylaminobenzyl, 
p-azidobenzyl, 4-azido-3-chlorobenzyl, 2- trifluoromethylbenzyl, p- (methylsulfinyl) benzyl), 2-
and 4-picolyl, 3-methyl-2-picolyl-N-oxido, 2-quinolinylmethyl, 1-pyrenylmethyl, diphenyl-
methyl, p,p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, a-naphthyldiphenylmethyl, 
p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl) 
methyl, 4-(4-'-bromophenacyloxy)phenyldiphenylmethyl, 4,4',4"-tris(4,5-dichlorophthalimido-
phenyl)methyl, 4,4',4"-tris(levulinoyloxyphenyl)methyl, 4,4',4"-tris(benzoyloxyphenyl)-
methyl, 4,4'-dimethoxy-3"-[N-(imidazolylmethyl)]trityl, 4,4'-dimethoxy-3"-[N-(imidazolylethyl) 
carbamoyl]trityl, 1, 1-bis(4-methoxyphenyl-l'-pyrenylmethyl, 9-Anthryl, 9-(9- phenyl) xanthenyl, 
4-(17-tetrabenzo[a,c,g.lgfluorenylmethyl)-4, 4"-dimethoxytrityl, 9-(9-phenyl-10-oxo )anthryl, 
1,3-benzodithiolan-2-yl, benzisothiazolyl, s,s-dioxido, silylethers (trimethylsilyl, triethylsilyl, 
triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, t-butyl-
dimethylsilyl, t-butyidiphenylsilyl, tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenyl-
methylsilyl, di-t-butylmethylsilyl, tris(trimethylsilyl)silyl(sisyl), (2-hydroxystyryl)dimethylsilyl, 
(2-hydroxystyryl)diisopropylsilyl, t-butylmethoxyphenylsilyl, t-butoxydiphenylsilyl); (ii) esters 
such as formate, benzoylformate, acetate, substituted acetate (chloroacetate, 
dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, 
phenoxyacetate, p-chlorophenoxyacetate, phenylacetate, p-P-phenylacetate, diphenyl-
acetate), nicotinate, 3-phenylpropionate, 4-pentenoate, 4-oxopentanoate (levulinate), 
4,4-( ethylenedithio )pentanoate, 5-[3-bis( 4-methoxyphenyl)hydroxymethylphenoxy ]levu linate, 
pivaloate, 1-adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 
2,4,6-trimethylbenzoate(mesitoate), carbonates (methyl, methoxymethyl, 9- fluorenylmethyl, 
ethyl, 2,2,2-trichloroethyl, 1, 1,-dimethyl-2, 2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenyl-
sulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, p-nitrophenyl, benzyl, 
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p-methoxybenzyl, 3,4,-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, 2-dansylethyl, 
2-(4-nitrophenyl)ethyl, 2-(2,4-dinitrophenyl)ethyl, 2-cyano-1-phenylethyl, S-benzylthio-
carbonate, 4-ethoxy-1-naphthyl, methyldithiocarbonate), 2-iodobenzoate, 4-azidobutyrate, 
4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 
2-(methylthiomethoxy)ethylcarbonate, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxy-
methyl)benzoate, 2-(chloroacetoxymethyl)benzoate, 2-[(2-chloroacetoxy)ethyl]benzoate, 
2-[2-(benzyloxy)ethyl]benzoate, 2-[2-(4-methoxybenzyloxy)ethyl]benzoate, 2,6-dichloro-4-
methylphenoxyacetate, 2,6-dichloro-4-(1, 1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1, 1-
dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccionoate, (E)-2-
methyl-2-butenoate (tigloate), o-(methoxycarbonyl) benzoate, p-P-benzoate, a-naphthoate, 
nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, 2-chlorobenzoate, 4-bromobenzoate, 
4-nitrobenzoate, 3'5'-dimethoxybenzoin, a wild and woolly photolabile fluorescent ester, 
N-phenylcarbamate, borate, dimethylphosphinothioyl, 2, 4-dinitrophenylsulfenate; and (iii) 
sulfonates (sulfate, allylsulfonate, methanesulfonate (mesylate), benzylsulfonate, tosylate, 
2-[ ( 4-nitrophenyl)ethyl]su lfonate). 
An activated carboxylic acid moiety in the context of the present specification relates to a 
carboxylic acid (COOH) derivative that undergoes amidation (condensation with an amine 
moiety) with primary or secondary under conditions that allow for the preservation of other 
chemical functionalities present in either reaction partner. Preferred reaction conditions are 
pH 4-9 and temperatures in the range of about -30 ° C to of about 
80 ° C, in particular at temperatures from 25 °C to 30 °C. 
Examples for activated carboxylic acid moieties are pentafluorophenol (PFP) esters, para-
nitrophenol (PNP) esters, 2,4,5-trichlorophenol esters, N-Hydroxy-5-norbornene-2,3-
dicarboximide (HONB) esters, N-hydroxy-succinimidyl (NHS) ester, carboxylic acid chloride 
(acyl chloride), carboxylic acid fluoride (acyl fluoride), carboxylic acid bromide (acyl bromide), 
which may be produced - without being limited to - by the reaction of the carboxylic acid and 
thionyl chloride phosphorus pentachloride, cyanuric chloride, S02C'2, S0C'2, 
triphenylphosphine and tetrachloromethane, Fluoro-N,N,N',N'-tetramethylformamidinium 
hexafluorophosphate (TFFH) or cyanuric fluoride, benzotriazole esters or carbodiimide 
esters, generated by use of the carboxylic acid and coupling agents such as 
Benzotriazolyloxytris-(dimethylamino)-phosphonium hexafluoro-phosphate (BOB), 
Benzotriazol-1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate (pyBOP), N,N,N',N'-
Tetramethyl-0-(1 H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU), ( 0-(7-
azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate) (HATU), N,N-
Dicyclohexylmethandiimin (DCC), N,N'-Diisopropylcarbodiimide (DIC), 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), or 3-(Diethoxyphosphoryloxy)-1,2,3-benzotriazin-
4(3H)-one (DEPT) bromotri(pyrrolidino)phosphonium hexafluorophosphate (PyBrop). 
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Furthermore carboxylic acid moieties can be activated with chloroformates (e.g. ethyl 
chloroformate). 
Further examples of activated carboxylic moieties are symmetric and mixed carbonic 
anhydrides. Carbonic anhydrides may be synthesized by use of coupling reagents, such as 
-without being limited to - 1, 1 '-Carbonyldiimidazol (COI), 1, 1 '-carbonylbis(3-
methylimidazoliumtriflate) (CBMIT) and the before mentioned coupling agents or from 
carboxylic acid and acid chloride (e.g. pivaloylchloride), or from carboxylic acid and 
chloroformates (e.g. ethyl chloroformate). Alternatively anhydrides may be synthesized from 
carboxylic acid and 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EDDQ) 
Coupling agents to achieve activated carboxylic moieties may further be - without being 
limited to - AOP (7-Azabenzotriazol-1-yloxytris( dimethylamino )phosphonium 
hexafluorophosphate - CAS 156311-85-2), PyAOP ([(7-azabenzotriazol-1-yl)oxy]tris-
(pyrrolidino) phosphonium hexafluorophosphate CAS - 156311-83-0), Brop 
(bromotris( dimethylamino )phosphonium hexafluorophosphate, CAS 50296-37-2), PyBrop 
(bromotri(pyrrolidino)phosphonium hexafluorophosphate, CAS 132705-51-2), PyClop 
(chlorotri(pyrrolidino)phosphonium hexafluorophosphate, CAS 128625-52-5), BOP-Cl (N,NO-
bis(2-oxo-3-oxazolidinyl)-phosphinic chloride, CAS 68641-49-6), TDBTU (2-(3,4-dihydro-4-
oxo-1,2,3-benzotriazin-3-yl)-1, 1,3,3-tetramethyluronium tetrafluoroborate, CAS: 125700-69-
8), TNTU (2-(5-norbornene-2,3-dicarboximido)-1, 1,3,3-tetramethyluronium tetrafluoroborate -
CAS 125700-73-4), TSTU (2-succinimido-1, 1,3,3-tetramethyluroniumtetrafluoroborate - CAS 
105832-38-0), BTC (bis(trichloromethyl)carbonate - CAS 32315-10-9), BTFFH 
(bis(tetramethylene)fluoroformamidinium hexafluorophosphate - CAS 164298-25-3 ), DFIH 
(1,3-dimethyl-2-fluoro-4,5-dihydro-1 H-imidazoliumhexafluorophosphate) 
Furthermore, imidazolium agents may be employed to achieve activated carboxylic moieties, 
whereby examples of imidazolium agents are - without being limited to - BOi (2-
(benzotriazol-1-yl)oxy-1,3-dimethylimidazolidinium hexafluorophosphate - CAS 123377-20-8) 
or CMBI (2-chloro-1,3-dimethyl 1 H-benzimidazoliumhexafluorophosphate). 
The coupling reactions may be supported by addition of bases or acylation catalysts such as 
-without being limited to - (N,N-Diisopropylethylamine) (DIEA), N-Methylmorpholine 
(NMM), 4-Dimethylaminopyridine (DMAP), 2,4,6-Trimethylpyridine (sym-collidine) or 2,6-di-
tert-butyl-4-dimethylaminopyridine (DBDMAP). The addition of bases allows a deprotonation 
of the carboxylic acid and facilitates the reaction to the respective activated carboxylic acid. 
Furthermore, bases may be added, in particular the above mentioned bases, in order to 
prevent a removal of the protecting group due to acidic by products. ln certain cases the 
coupling reaction may be catalyzed by addition of acylation catalysts as DMAP. 
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Alternatively, the carboxylic acid moiety may be activated by using a catalytic amount of a 
proton acid or a Lewis acid such as - without being limited to - boronic acid catalyst. 
The coupling reactions may also be achieved by the azide coupling method using diphenyl 
phosphorazidate (DPPA) or alternative azides. 
The term "substituted" refers to the addition of a substituent group to a parent moiety. 
"Substituent groups" can be protected or unprotected and can be added to one available site 
or to many available sites in a parent moiety. Substituent groups may also be further 
substituted with other substituent groups and may be attached directly or by a linking group 
such as an alkyl, an amide or hydrocarbyl group to a parent moiety. "Substituent groups" 
amenable herein include, without limitation, halogen, oxygen, nitrogen, sulphur, hydroxyl, 
alkyl, alkenyl, alkynyl, acyl (-C(O)Ra), carboxyl (-C(O)ORa), aliphatic groups, alicyclic groups, 
alkoxy, substituted oxy (-ORa), aryl, aralkyl, heterocyclic radical, heteroaryl, heteroarylalkyl, 
amino (-N(Rb)(Rc)), imino(=NRb), amido (-C(O)N(Rb)(Rc) or -N(Rb)C(O)Ra), hydrazine 
derivates (-C(NH)NRaRb), tetrazole (CN4H2), azido (-N3), nitro (-N02), cyano (-CN), 
isocyano (-NC), cyanato (-OCN), isocyanato (-NCO), thiocyanato (-SCN); isothio-
cyanato (-NCS); carbamido (-OC(O)N(Rb)(Rc) or -N(Rb)C(O)ORa), thiol (-SRb), 
sulfinyl (-S(O)Rb), sulfonyl (-S(0)2Rb), sulfonamidyl (-S(0)2N(Rb)(Rc)or -N(Rb)S(0)2Rb) and 
fluorinated compounds -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3, -OCF3, -SCF3, 
-SOCF3 or -S02CF3. Wherein each Ra, Rb and Re is, independently, H or a further substituent 
group with a preferred list including without limitation, H, alkyl, alkenyl, alkynyl, aliphatic, 
alkoxy, acyl, aryl, heteroaryl, alicyclic, heterocyclic and heteroarylalkyl. 
As used herein the term "alkyl," refers to a saturated straight or branched hydrocarbon 
moiety containing up to 8, particularly up to 4 carbon atoms. Examples of alkyl groups 
include, without limitation, methyl, ethyl, propyl, butyl, isopropyl, n-hexyl, octyl, and the like. 
Alkyl groups typically include from 1 to about 8 carbon atoms (C1-Cs alkyl), particularly with 
from 1 to about 4 carbon atoms (C1-C4 alkyl). 
As used herein the term "cycloalkyl" refers to an interconnected alkyl group forming a 
saturated or unsaturated ring or polyring structure containing 3 to 10, particularly 5 to 10 
carbon atoms. Examples of cycloalkyl groups include, without limitation, cyclopropane, 
cyclopentane, cyclohexane, norbornane, decaline or adamantan (Tricyclo[3.3.1.1 ]decan), 
and the like. Cycloalkyl groups typically include from 5 to 10 carbon atoms (Cs-C10 
cycloalkyl). 
Alkyl or cycloalkyl groups as used herein may optionally include further substituent groups. A 
substitution on the cycloalkyl group also encompasses an aryl, a hetreocylce or a heteroaryl 
6 
wo 2014/125075 PCT /EP2014/052922 
substituent, which can be connected to the cycloalkyl group via one atom or two atoms of the 
cycloalkyl group (like tetraline). 
As used herein the term "haloalkyl," refers to a saturated straight or branched hydrocarbon 
moiety containing 1 to 8, particularly 1 to 4, carbon atoms and at least one halogen atom, in 
particular Cl or F, connected to a carbon atom. Examples of haloalkyl groups include, without 
limitation, CF3, CHF2, CH2F, CH2CF3, CH2CHF2, CH2CH2F, CHFCF3, CHFCHF2, CHFCH2F, 
CF2CF3, CF2CHF2, CF2CH2F and the like. Haloalkyl groups typically include 1 to 4 carbon 
atoms (C1-C4 haloalkyl). More particularly haloalkyl groups comprise only Fas halogen 
atoms. 
As used herein the term "halo cycloalkyl" refers to an interconnected alkyl group forming a 
saturated or unsaturated ring or polyring structure containing 3 to 10, particularly 5 to 10 
carbon atoms and at least one halogen atom, in particular Cl or F, connected to a carbon 
atom. Examples of halo cycloalkyl groups include, without limitation, fluorocyclopropane, 
chlorocyclohexane, dichlorocyclohexane, chloroadamantan, and the like. Halo cycloalkyl 
groups typically include from 5 to 10 carbon atoms (Cs-C10 cycloalkyl). More particularly 
cyclohaloalkyl groups comprise only F as halogen atoms. 
Halo alkyl or halo cycloalkyl groups as used herein may optionally include further substituent 
groups. A substitution on the halo cycloalkyl group also encompasses an aryl, a hetreocylce 
or a heteroaryl substituent, which can be connected to the halo cycloalkyl group via one atom 
or two atoms of the halo cycloalkyl group (like tetraline). 
As used herein the term "alkenyl," refers to a straight or branched hydrocarbon chain moiety 
containing up to 8 carbon atoms and having at least one carbon-carbon double bond. 
Examples of alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, 1-methyl-2-
buten-1-yl, dienes such as 1,3-butadiene and the like. Alkenyl groups typically include from 
2 to about 8 carbon atoms, more typically from 2 to about 4 carbon atoms. Alkenyl groups as 
used herein may optionally include further substituent groups. 
As used herein the term "alkynyl," refers to a straight or branched hydrocarbon moiety 
containing up to 8 carbon atoms and having at least one carbon-carbon triple bond. 
Examples of alkynyl groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl, and the 
like. Alkynyl groups typically include from 2 to about 8 carbon atoms, more typically from 
2 to about 4 carbon atoms. Alkynyl groups as used herein may optionally include further 
substituent groups. 
As used herein the term "carboxy," refers to an carboxy (-C(=0)-0- or -0-C(=O)-) alkyl 
moiety containing 1 to 8, particularly 1 to 4 carbon atoms comprising at least one carboxy 
moiety, wherein the carboxy group is used to attach the carboxy group to a parent molecule. 
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Examples of carboxy groups include without limitation, formate, acetate, lactate, citrate, 
oxalate and the like. Carboxy groups as used herein may optionally include further 
substituent groups. ln particular "carboxy" groups include straight or branched polycarboxy 
groups (polyester), which comprise several interconnected momomere carboxy groups (e. g. 
-C(=O)-O-CH2-CH2-). Non limiting examples are polyehtylester or polyacrylate. 
As used herein the term "alkoxy," refers to an oxygen alkyl moiety containing 1 to 8, 
particularly 1 to 4 carbon atoms comprising at least one oxygen moiety, wherein the oxygen 
atom is used to attach the alkoxy group to a parent molecule. Examples of alkoxy groups 
include without limitation, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-
butoxy, n-pentoxy, neopentoxy, n-hexoxy and the like. Alkoxy groups as used herein may 
optionally include further substituent groups. ln particular "alkoxy" groups include straight or 
branched polyalkoxy groups (polyether), which comprise several interconnected momomere 
alkoxy groups (e. g. -O-CH2-CHd. Non limiting examples are polyehtyleneglycol (PEG) or 
polypropylenglycol (PPG). 
As used herein the term "heterocycle" refers to an interconnected alkyl group forming a 
saturated or unsaturated ring or polyring structure containing 3 to 10, particularly 5 to 10 
carbon atoms in which at least one carbon atom is replaced with an oxygen, a nitrogen or a 
sulphur atom forming a non aromatic structure. Examples of heterocycle groups include, 
without limitation, oxalane, pyrrolidine or piperidine. Heterocyclic groups as used herein may 
optionally include further substituent groups. A substitution on the heterocyclic group also 
encompasses an aryl, a cycloalkyl or a heteroaryl substituent, which can be connected to the 
heterocyclic group via one atom or two atoms of the heterocyclic group (comparable to 
indole). 
As used herein the term "aryl" refers to a hydrocarbon with alternating double and single 
bonds between the carbon atoms forming an aromatic ring structure, in particular a six (C6 to 
ten (C10) membered ring or polyring structure. The term "heteroaryl" refers to aromatic 
structures comprising a five to ten membered ring or polyring structure, comparable to aryl 
compounds, in which at least one member is an oxygen or a nitrogen or a sulphur atom. Due 
to simplicity reasons they are denominated Cs to C10 heteroaryl, wherein at least one carbon 
atom is replaced with an oxygen, a nitrogen or a sulphur atom forming an aromatic structure. 
For example a Cs heteroaryl comprises a five membered ring structure with at least one 
carbon atom being replaced with an oxygen, a nitrogen or a sulphur atom. Examples for such 
a Cs heteroaryl are triazole, pyrazole, imidazole, thiophen, furan or oxazole. A C6 heteroaryl 
can be pyridine, pyrimidine or triazine. A Cg heteroaryl can be indole and a C10 heteroaryl can 
be quinoline. Aryl or hetero aryl groups as used herein may optionally include further 
substituent groups. A substitution on the hetero aryl group also encompasses an aryl, a 
8 
wo 2014/125075 PCT /EP2014/052922 
cycloalkyl or a heterocycle substituent, which can be connected to the hetero aryl via one 
atom or two atoms of the hetero aryl group (comparable to indole). The same apllies to an 
aryl group. 
As used herein the term "linker" refers to a covalently connected straight chain or a ring 
structure of carbon, sulphur, nitrogen and/or oxygen atoms connecting a moiety comprising E 
or R4 (as defined below) to the parent moiety (termed PM) providing a distance between 
these moieties. The distance may comprise between 1 up to 5 atoms, in particular 2 or 3 
atoms, along the longitudinal extension direction of the parent moiety. The straight chain or 
the ring structure of the linker atoms may comprise further substituents. For example the 
linker may comprise a straight C4-chain (butyl) providing a distance of 4 atoms or a methyl 
group providing a distance of 1 atom. The linker may further comprises a -C(=O)N(CH3)- or 
-C(=O)N(H)- groupa providing a distance of 2 atoms. A -N(H)S(02)- group also provides a 
distance of 2 atoms. A distance of three atoms may be provided by a -OC(=O)N(H)- or 
-N(H)C(=O)N(H)- group. The linker may further comprise a ring structure like a triazole 
providing a distance of 3 atoms along the longitudinal extension direction of the parent 
moiety. 
As used herein the term "linking function" refers to a first linking function and a second linking 
function capable of selectively forming a covalent bond between each other (linking reaction 
or coupling reaction). Such linking reactions may be an organometallic coupling reaction, a 
Wittig reaction, an addition reaction, a condensation reaction a "click chemistry" reaction or 
an amide coupling reaction. 
As used herein "*" indicates a stereo center of a L- or D- enantiomer, which is located on the 
tertiary carbon atom below the asterisk *, and wherein the compound of a general formula 
comprising "*" is an essentially pure L-enantiomer, an essentially pure D-enantiomer or a 
mixture of the L- and D-enantiomer of the same molecular formula, wherein in particular such 
a compound is an essentially pure L-enantiomer or an essentially pure D-enantiomer. 
SUMMARY OF THE INVENTION 
According to a first aspect, the invention relates to antibiotically active compounds having a 
molecular structure as defined by formula 1 
1 2 3 4 2 X-BB-D-BC-D-BD-D-BE-X 
( 1 ) ' 
a. with X 1 being 
i. selected from a substituent group S1 or S2, or 
ii. R4-01-, with R4 being selected from a substituent group S3, S4 or S5, or 
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iii. BA-01- with BA-01-being selected from 
E-_l7'-0_1 ~ 
, and 
with E being selected from a substituent group S3, S4 or S5, and 
b. with BB being selected from a substituent group S3 or S4, and 
c. with BC 





~?z, ', _)..__(CH2):--~ (CH2), 
, L or with p being 1, 2, 3, 4 or 5, 
in particular p being 2 or 3, and with r being 2, 3, 4 or 5, in particular r being 2, 
or 
ii. with -02-BC- being 
with p being 1, 2, 3, 4 or 5, in particular p 
being 2 or 3, and 
d. with BD being selected from a substituent group S3 or S4, and 
e. with BE being selected from a substituent group S3, and 
f. with X2 being 
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i. selected from a substituent group S1 or S2, and wherein a linker 0 5 may be 
optionally situated between BE and the substituent group S1 or S2, or 
ii. being -05-BF, wherein BF is selected from a substituent group S2 
with S1 being 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -N02, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3 or -CF3, 
with S2 being 
- -B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -
(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -
(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -
(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-
S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-
NRCC(=O)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=Ü)QRa, -(CH2)m-NRcC(=S)Ra, 
-(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-NRcS(02)Ra, -(CH2)m-
P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-
(M)-C( =Ü)OH, -(CH2)m-O-C( =Ü)-(M)-C( =Ü)ORa, -(CH2)m-O-C( =Ü)-(M)-Ra, -(CH2)m-O-
(CH2)q-P( =O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra 
- with Raa being selected independently from each other from -Ra or -ORa, 
- with Rba being selected independently from each other from -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
- with m being selected from 0, 1 or 2, in particular O or 1, 
- with q being selected from 0, 1 or 2, in particular O or 1, 
- with each Ra, Rb or Re being selected, where applicable, independently from 
with S3 being 
each other from hydrogen, -CN, a substituent group S3, a substituent group 
S4 or a substituent group S5, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
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with S4 being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
with S5 being 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-C16 
alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or unsubstituted 
C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, 
with R2 and R3 of BA being selected, where applicable, independently from each other from -
H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, 
a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -
CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -
OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3,more particularly with R2 and R3 being selected independently from each other from -H, 
-For -CH3, 
with L1, L2, L3, L 4 or L5 being selected independently from each other from,-H, -CH3, -
CH2CH2CH2NHC(NRC)N(Rb)(Ra), -CH2CON(Rb)(Ra), -CH2C(=O)ORa, -CH2SRa, -
CH2CH2C(=O)N(Rb)(Ra), -CH2CH2C(=O)ORa, -CH2(C3H3N2), -CH2CH2CH2CH2, -
CH2CH2SCH3, -CH2(C6Hs), -CH2CH2CH2-, -CH20Ra, -CH(ORa)CH3, -CH2(CsH6N)ORa, -
CH2(C6H4)0Ra, -CH(CH3)2, -CCH, -CN, -OCH3 -CF3, -Ra, -CH(Rb)(Ra), -CH2C(=O)Ra, -
C(=O)ORa, -OC(=O)NRbRa, -C(=O)NRbRa, -CH2C(=O)NRb (ORa), -CH2S(02)Ra, -S(02)0Ra, -
CH2S(02)0Ra, -CH2NRbC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(ORb)(ORa), -
CH2P(=O)(ORb)(Ra), -CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
with Ra and Rb being selected, where applicable, independently from each other from 
hydrogen, -CN, a substituent group S3, a substituent group S4 or a substituent group 
S5, 
with R8 of -02-BC- being selected from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -CH2CF3, -
CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with R8 being selected from H 
or CH3, more particularly R8 is H. 
with Y being selected from -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3), -CF3 or -
C(=O)NH2, and 
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with Z being selected from -H, -OH, -CH3, -CH2CH3, -OCH3 -NH2 -NHCH3, -N(CH3)2 or -
N(CH3)3+, in particular Z is -H and Y is -CN or -C(=O)NH2, 
with 0 1 ,02, 0 3, 0 4 or 0 5 being each, independently from each other, a linker which 
comprises carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which is covalently 
connecting the moiety, BA and BB (01), BB and BC (02), BC and BD (03), BD and BE (04) 
and BE and BF (05). 
lt is understood that a general expert will identify - on basis of his basic knowledge -
combinations of the above mentioned selection, which will not lead to stable compounds. For 
example, concerning X the substituents -NRa2 and -NHRa are not possible with a C2 alkynyl. 
Furthermore, concerning E connected to a vinyl group a C3 heterocycle, like aziridine, is not 
a stable compound. The same applies for other combinations. 
lt is understood that the invention relates to compounds characterized by the general formula 
1, wherein these compounds comprise no deuterium atoms in their structure. Furthermore 
the compounds may comprise one, two or more deuterium atoms (any hydrogen of the 
structure may be "exchanged") instead of hydrogen atoms. lt is also possible that the 
compounds comprise only deuterium atoms instead of hydrogen atoms (all the H are 
"exchanged" with deuterium). 
lt is understood that the invention relates to essentially pure L- and D- enantiomers of the 
general formula 1 or mixtures of the L- and D-enantiomers of the same molecular formula, 
whereby the stereo center concerning the building block BC is indicated by an asterisk "*" 
and located on the tertiary carbon atom below the asterisk. Thus, the general formula 1 with 
the stereo center marked with an asterisk encompasses the essentially pure L- and the D-
enantiomers. 
A second aspect of the invention relates to the synthesis of compounds according to the 
general formula 1. 
A further aspect of the invention relates to compounds according to the invention or obtained 
by a method according to the invention for use in a method of treatment of diseases, in 
particular for use in a method of treatment of bacterial infections. 
DETAILED DESCRIPTION OF THE INVENTION 
According to a first aspect, the invention relates to antibiotically active compounds having a 
molecular structure as defined by formula 1 
1 2 3 4 2 X-BB-D-BC-D-BD-D-BE-X 
( 1 ) ' 
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a. with X1 being 
i. selected from a substituent group S1 or S2, or 
ii. R4-01-, with R4 being selected from a substituent group S3, S4 or S5, or 
iii. BA-01- with BA-01-being selected from 
E--17'0_1 ~ 
, and 
with E being selected from a substituent group S3, S4 or S5, and 
b. with BB being selected from a substituent group S3 or S4, and 
c. with BC 





~?z, ', _)..__(CH2):--~ (CH2), 
, L or with p being 1, 2, 3, 4 or 5, 
in particular p being 2 or 3, and with r being 2, 3, 4 or 5, in particular r being 2, 
or 
ii. with -02-BC- being 
with p being 1, 2, 3, 4 or 5, in particular p 
being 2 or 3, and 
d. with BD being selected from a substituent group S3 or S4, and 
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e. with BE being selected from a substituent group S3, and 
f. with X2 being 
i. selected from a substituent group S1 or S2, and wherein a linker 0 5 may be 
optionally situated between BE and the substituent group S1 or S2, or 
ii. being -05-BF, wherein BF is selected from a substituent group S2 
with S1 being 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -N02, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3 or -CF3, 
with S2 being 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -
(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -
(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-ÜC(=S)ORa, -(CH2)m-
OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-
S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-
NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)QRa, -(CH2)m-NRcC(=Ü)NRaRb, -
(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-
NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-
S(02)NRbRa, -(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -
(CH2)m-O-C(=O)-(M)-Ra, -(CH2)m-O-(CH2)q-P(=Ü)(Rba)(Raa), -(CH2)m-C(=O)O-
(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-
(CH2)q-S(02)0Ra,, 
- with Raa being selected independently from each other from -Ra or -ORa, 
- with Rba being selected independently from each other from -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
- with m being selected from 0, 1 or 2, in particular O or 1, 
- with q being selected from 0, 1 or 2, in particular O or 1, 
- with each Ra, Rb or Re being selected, where applicable, independently from 
with S3 being 
each other from hydrogen, -CN, a substituent group S3, a substituent group 
S4 or a substituent group S5, 
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a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
with S4 being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
with S5 being 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-C16 
alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or unsubstituted 
C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, 
with R2 and R3 of BA being selected, where applicable, independently from each other from -
H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, 
a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -
CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -
OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3,more particularly with R2 and R3 being selected independently from each other from -H, 
-For -CH3, 
with L1, L2, L3, L 4 or L5 being selected independently from each other from,-H, -CH3, -
CH2CH2CH2NHC(NRC)N(Rb)(Ra), -CH2CON(Rb)(Ra), -CH2C(=O)ORa, -CH2SRa, -
CH2CH2C(=O)N(Rb)(Ra), -CH2CH2C(=O)ORa, -CH2(C3H3N2), -CH2CH2CH2CH2, -
CH2CH2SCH3, -CH2(C6Hs), -CH2CH2CH2-, -CH20Ra, -CH(ORa)CH3, -CH2(CsH6N)ORa, -
CH2(C6H4)0Ra, -CH(CH3)2, -CCH, -CN, -OCH3 -CF3, -Ra, -CH(Rb)(Ra), -CH2C(=O)Ra, -
C(=O)ORa, -OC(=O)NRbRa, -C(=O)NRbRa, -CH2C(=O)NRb (ORa), -CH2S(02)Ra, -S(02)0Ra, -
CH2S(02)0Ra, -CH2NRbC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(ORb)(ORa), -
CH2P(=O)(ORb)(Ra), -CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
with Ra and Rb being selected, where applicable, independently from each other from 
hydrogen, -CN, a substituent group S3, a substituent group S4 or a substituent group 
S5, 
with R8 of -02-BC- being selected from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -CH2CF3, -
CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with R8 being selected from H 
or CH3, more particularly R8 is H. 
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with Y being selected from -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3), -CF3 or -
C(=O)NH2, and 
with Z being selected from -H, -OH, -CH3, -CH2CH3 , -OCH3 ,-NH2 -NHCH3, -N(CH3)2 or -
N(CH3)3+, in particular Z is -H and Y is -CN or -C(=O)NH2, 
with 0 1 ,02 , 0 3 , 0 4 or 0 5 being each, independently from each other, a linker which 
comprises carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which is covalently 
connecting the moiety, BA and BB (01), BB and BC (02), BC and BD (03), BD and BE (04) 
and BE and BF (05). 
ln an embodiment of the present invention the compound according to the general formula 1 
does not include a compound of the general formula 2a 








0 Ou A) ~ 1 H O ::71 N ~N~ 0 ~N~ H 
O ~~0~AJ H 
Ü 3'~n2' 
R R (2a) 
or the general formula 2b 
R10~ 1 H 
~N~ H O ~COOH 
0 ~N0~N 
0 3',,l,..,2' R R (2b) 
or the general formula 2c 
1 OH 
OÙCOOH 1 OH O ., I 
00~1 N ~ 
FN dJJ H Yn HO ::71 ~~ ~N~ ~ 
0 3'~,..,2'~ R R (2c) 
wherein R1 is H or CO(NH2), R2' is CO(NH2) or CN, R3' is H or OCH3, FN is H2N or Ma, wherein 
Ma is a masked functional group, in particular a -N02 or -N3 moiety, and wherein the -NH2, -
NH-, -COOH or -OH moieties can comprise a removable protecting group (PGN, PGH or PGA), 
17 
wo 2014/125075 PCT /EP2014/052922 
in particular an allyl moiety and/or an activated carboxylic acid moiety coact, in particular a -
COCI moiety. 
According to a first sub aspect (sub aspect 1) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (3), 
x
1
'Q 3 4 S BC-0-B0-0-BE-0-BF 02/ (formula 3), 
with X1 , 0 2 , BC, 0 3 , BD, 04, BE, os and BF having the same meaning as defined previously. 
According to another sub aspect (sub aspect 2) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (4), 
1 
X~RB 1 1 3 4 s ~ N......._ O-BO-O-BE-0-BF BC .... 
0 (formula 4), 
with X1 , RB, BC, 0 3 , BD, 04, BE, os and BF having the same meaning as defined previously. 
According to another sub aspect (sub aspect 3) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (5), 
1 4 S X'°' 00-BE-O-BF 
1 .,,. 3 ' 1 
.,,,,, 0 2 0 ....._, 
'se ..... 
(formula 5), 
with X1 , 0 2 , BC, 0 3 , 04, BE, os and BF having the same meaning as defined previously. 
According to another sub aspect (sub aspect 4) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (6), 
0 s 
1 d BE-0-BF 
X~RB O ~ N/ 
1 1 Jl. 1 1a ~ N,BC N ~ R 
• a 0 R (formula 6), 
with X1, RB, BC, BE, os and BF having the same meaning as defined previously. 
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According to another sub aspect (sub aspect 5) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (7), 
(formula 7), 
with X1, 0 2 , BC, 0 3 , 04, R11n, os and BF having the same meaning as defined previously or 
further below. 
According to another sub aspect (sub aspect 6) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (8), 
1 0 p~ 05-BF 
X ~ 8 0 ~ N ~ Jl. ~13 R11 
N'BC NA} R n 
1 8 
0 R (formula 8), 
with X1, R8 , BC, R11n, os and BF having the same meaning as defined previously or further 
below. 
According to another sub aspect (sub aspect 7) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (9), 
(formula 9), 
with X1, 0 2 , BC, 0 3 , 04, R11 , os and BF having the same meaning as defined previously or 
further below. 
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According to another sub aspect (sub aspect 8) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (10), 
(formula 10), 
with X1, R8 , BC, R11 , os and BF having the same meaning as defined previously or further 
below. 
According to another sub aspect (sub aspect 9) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (11 ), 
1 OH o& s,....BF 0 9" I D 
x1~R
8 
O dN ~ 1 1 Il 1 1 a ~ N,BC ............ N ~ R 
18 
0 R (formula 11 ), 
with X1, R8 , BC, os and BF having the same meaning as defined previously. 
According to another sub aspect (sub aspect 10) of the first aspect, the invention relates to 
antibiotically active compounds having a molecular structure as defined by a general formula 
(12), 
(formula 12), 
with X1, 0 2 , BC, 0 3 , 04, R11 , R10n, T and os having the same meaning as defined previously 
or further below. 
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According to another sub aspect (sub aspect 11) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (13), 
(formula 13), 
with E, R2 , R3 , 01, 0 2 , BC, 0 3 , 04, R11 , R10n, T and os having the same meaning as defined 
previously or further below. 
According to another sub aspect (sub aspect 12) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (14), 
(formula 14), 
with R2 , R3 , 01, 0 2 , BC, 0 3 , 04, R1n, R11 , R10n, T and os having the same meaning as defined 
previously or further below. 
According to another sub aspect (sub aspect 13) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (15), 
(formula 15), 
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with Y, Z, R2,R3 , 01, 0 2 , 0 3 , 04, R11 , R10n, R1n, T and os having the same meaning as defined 
previously or further below. 
According to another sub aspect (sub aspect 14) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (16), 
1 OH 0 
oolfw .. BF 
1 1 18 
X~R8 o d'N ~ R 
1 1 Jl I la 
.& N,BC N ~ R 
1 8 
0 R (formula 16), 
with X1, R8 , BC and BF having the same meaning as defined previously. 
According to another sub aspect (sub aspect 15) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (17), 
1 OH 0)6- s.,..BF 
1 0 ~ 1 D 
X~ ~N~ 
~D2 D3v ~8 
'sé (formula 17), 
with X1, R8 , 0 2 , BC, 0 3 , os and BF having the same meaning as defined previously. 
According to another sub aspect (sub aspect 16) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (18), 
1 OH 0 
0 o&"'N""BF 
1 1 18 
X~R8 0 ~N~ R 
1 ,& N )l A) ~a 
'se ~8 
0 R (formula 18), 
with X1, R8 , BC, os and BF having the same meaning as defined previously. 
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According to another sub aspect (sub aspect 17) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (19), 
1 OH O ~T 
o
0x:rN~ 1 1 1 1 R10 
x~R8 0 dN ~ R8 n 
1 .& N )l ~ 1 1 8 
'se N R 
O ka (formula 19), 
with X1, R8 , BC, R10n, and T having the same meaning as defined previously or further below. 
According to another sub aspect (sub aspect 18) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (20), 
R10 
1 OH ob~r 0°X:rNÀJ 
1 d 11 XUyR8 0 ~ N ~ R8 
1 .& N )l ~ 1 la 
'se N R 
0 18 
R (formula 20), 
with X1, R8 , BC, R10 and T having the same meaning as defined previously or further below. 
According to another sub aspect (sub aspect 19) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (21 ), 
0 NT 
0 Q1 NA>Z10 
X1 8 d ~8 Rn r O ~ I N ~ R11 
N }l ~ la n 
'se N R 
o I a 
R (formula 21 ), 
with X1, R8 , BC, R11n, R10n and T having the same meaning as defined previously or further 
below. 
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According to another sub aspect (sub aspect 20) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (22), 
1 OH Ob~T 0°x:(NJJ 
1 d 11 X~R8 0 ~ N ~ R8 
1 .& N )l ~ 1 ~8 
'se N 
0 18 
R (formula 22), 
with X1, R8 , BC and T having the same meaning as defined previously or further below. 
According to another sub aspect (sub aspect 21) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (23), 
T 
D 
1 4 R10 
X 8 D n ~ 0 ~ 11 N)l~ Rn 
'se ~8 0 R (formula 23), 
with X1, R8 , BC, 04, os, R11n, R10n and T having the same meaning as defined previously or 
further below. 
According to another sub aspect (sub aspect 22) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (24), 
1 R10 
6~R11 :tr1 
1 4 1 
X~Rs O ~D ~ 
I.& N )l)0 
'se N 
o la 
R (formula 24), 
with X1, R8 , BC, 04, os, R11 , R10 and T having the same meaning as defined previously or 
further below. 
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According to another sub aspect (sub aspect 23) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (25), 
1 R10 
R11 0 ohT 
06:(:(NM 
1 d 11 XVyRa O -9' N ~ Ra 
1 .& N )l ~ 1 la 
'se N R 
0 la R (formula 25), 
with X1, R8 , BC, R11 , R10 and T having the same meaning as defined previously or further 
below. 
According to another sub aspect (sub aspect 24) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (26), 
(formula 26), 
with E, R2 , R3 , 01, R8 , BC, R11n, R10n and T having the same meaning as defined previously 
or further below. 
According to another sub aspect (sub aspect 25) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (27), 
with E, R2 , R3 , 01, R8 , BC, R11 , R10 and T having the same meaning as defined previously or 
further below. 
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According to another sub aspect (sub aspect 26) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (28), 
with E, R2 , R3 , 0 1, R8 , BC, R10 and T having the same meaning as defined previously or 
further below. 
According to another sub aspect (sub aspect 27) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (29), 
o ~I oN,q: 
1 a d ~ la Rn 
D~R O ~ N '' R 
R~ R
2 1 .& N )l ~ 1 1 a R11 
'se N R n 
0 1 a R (formula 29), 
with R1n, R10n, R11n, R2 , R3 , 01, R8 , BC and T having the same meaning as defined previously 
or further below. 
According to another sub aspect (sub aspect 28) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (30), 
with R1n, R11 , R10 , 01, R2 , R3 , R8 , BC and T having the same meaning as defined previously 
or further below. 
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According to another sub aspect (sub aspect 29 of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (31 ), 
with R1n, R11 , R10 , R2 , R3 , R8 , BC and T having the same meaning as defined previously or 
further below. 
According to another sub aspect (sub aspect 30) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (32), 
with R1n, R2 , R3 , 0 1, R8 , BC and T having the same meaning as defined previously or further 
below. 
According to another sub aspect (sub aspect 31) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (33), 
with R1n, R2 , R3 , R8 , BC and T having the same meaning as defined previously or further 
below. 
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According to another sub aspect (sub aspect 32) of the first aspect, the invention relates to 
compounds having a molecular structure as defined by a general formula (34), 
R10 
1 
R11 O OXYT 
1 1 1 RM-..::::: oo~N ~ ~ .& ~ ~ H 
1 ~HO~~ 
Rn O ~N0N~ 
0 ,,l., H 
z y (formula 34), 
with R1, R1n, R11 , R10, Z, Y and T having the same meaning as defined previously or further 
below. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 10 or 14 to 
23, x1 is 
-OH-OH, -F, -Cl, -Br, 1, -CCH, -CN, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2CH3 or -CF3, 
-B(ORa)(ORb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -(CH2)m-
OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRb(ORa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-
OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-
SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-
OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-NRcC(=O)Ra, -(CH2)m-NRcC(=O)ORa, -(CH2)m-
NRcC(=O)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)ORa, 
-(CH2)m-NRcS(02)Ra, -(CH2)m-P(=O)(ORb)(ORa), -(CH2)m-P(=O)(ORb)(Ra) or -(CH2)m-
S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -(CH2)m-O-C(=O)-(M)-C(=O)ORa, -(CH2)m-
O-C(=O)-(M)-Ra, -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-
P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other from -Ra or -ORa, 
with Rba being selected independently from each other from -Rb or -ORb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
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with each Ra, Rb or Re being selected, where applicable, independently from each 
other from 
hydrogen, -CN, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 
halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-
C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or 
unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or 
a C1-C16 haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-
Cs alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 10 or 14 to 
23, x1 is 
with Ra being a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a 
substituted or unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 
alkynyl, or a C1-C16 haloalkyl, in particular a substituted or unsubstituted C1-Cs 
alkyl, a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted 
C2-Cs alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or unsubstituted 
C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, in particular a substituted or 
unsubstituted 1,2,3-triazole, a substituted or unsubstituted 1,2,4-triazole, a 
substituted or unsubstituted indole, a substituted or unsubstituted isoindole, a 
substituted or unsubstituted quinoline or a substituted or unsubstituted 
isoquinoline, or 
29 
wo 2014/125075 PCT /EP2014/052922 
-[(CH2)m1-0-C( =Ü)-(CH2)m2]p1-C( =O)QRd or -[(CH2)m1-0-(CH2)m2]p1-0Rd with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8 
ln some embodiments, in particular according to any one of the sub aspects 1 to 10 or 14 to 
23, x1 is 
-NRa2, -NHRa or -C(=O)ORa, in particular X is -NRa2 or -NHRa, 
- with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted 
C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a substituted or 
unsubstituted C1-Cs haloalkyl. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 10 or 14 to 
23, X1 is R4-01-, with 0 1 having the same meaning as defined above, and wherein 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-C16 alkoxy, 
a substituted or unsubstituted C1-C16 carboxy, a substituted or unsubstituted C2-C16 
alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a 
substituted or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-C10 
cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl. 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 10 or 14 to 
23, X1 is R4-01-, with 0 1 having the same meaning as defined above, and wherein 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F, 
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a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetraline or indane, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F; or 
R4 is selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 1,2,4-
triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, 
naphatalene, coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, 
benzofurane, benzothiophene, benzimidazol, benzthiazole, benzoxazole or 
benzpyridazin or hydroxylated, methylated or halogenated derivatives thereof. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 10 or 14 to 
23, X1 is R4-01-, with 0 1 having the same meaning as defined above, and wherein 
a substituted or unsubstituted C1-Cs alkyl or a substituted or unsubstituted C5-C10 
cycloalkyl, a substituted or unsubstituted Cs-C10 heteroaryl or a substituted or 








ln some embodiments, in particular according to any one of the sub aspects 1 to 10 or 14 to 
23, X1 is R4-01-, with 0 1 having the same meaning as defined above, and wherein 
an unsubstituted C1-Cs alkyl or an unsubstituted C5-C10 cycloalkyl. 
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ln some embodiments, in particular according to any one of the sub aspects 1 to 10 or 14 to 
23, X1 is BA-01-, with 0 1 having the same meaning as defined above, and BA is selected from 
R2 
EAr,<z_ 








in particular BA is selected from 
E-~ (BA2), or 
more particularly BA is 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular with R2 and R3 
being selected, where applicable, independently from each other from -H, -F, -CN, -OH, -
NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly 
with R2 and R3 being selected independently from each other from -H, -For -CH3, and 
a. E is 
- a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-C16 
alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or 
unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or a C1-
C16 haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, a substituted 
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or unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs alkenyl, a 
substituted or unsubstituted C2-Cs alkynyl, a substituted or unsubstituted C1-Cs 
haloalkyl, a substituted or unsubstituted C3-C10 cycloalkyl, or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
- a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted 
C3-C10 halo cycloalkyl, 
- a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted 
C3-C10 halo heterocycle; in particular a substituted or unsubstituted C4-C10 
heterocycle or a substituted or unsubstituted C4-C10 halo heterocycle, 
- a substituted or unsubstituted Cs-C10 heteroaryl; 
- a substituted or unsubstituted C5-C10 aryl, or 
b. E is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, 
a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl, or 
c. E is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C5-C10 
cycloalkyl, a substituted or unsubstituted Cs-C10 heteroaryl or a substituted or 
unsubstituted Cs-C10 aryl, or 
d. E is 
- a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F, 
- a substituted or unsubstituted Cs-CB heteroaryl, 
- a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetraline or indane, 
- a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F, 
- selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 
1,2,4-triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, 
naphatalene, coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, 
benzofurane, benzothiophene, benzimidazol, benzthiazole, benzoxazole or 
benzpyridazin or hydroxylated, methylated or halogenated derivatives thereof, or 
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e. E is selected from . 
vCO-ï 





- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n being 1, and 
- with each R1 independently from any other R1 being selected from 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
- -B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), ), -(CH2)m-C(=O)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
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with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted 
or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-
C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo 
cycloalkyl, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl, in particular 
- with each R1 independently from any other R1 being -OH, -F, -Cl, 1, -CN, -OCH3, -
OCF3, -OCONH2 or -CF3. 
f. E is 
- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly 1, and 
- each R1 independently from any other R1 is selected from 
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-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-
C(=O)ORa, -(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -
(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted 
or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-
C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo 
cycloalkyl, 
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g. E is 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl, or 
- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n 1, and 
- with each R1 independently from any other R1 being selected from 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NH CH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
- -B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)ORa, -(CH2)m-
OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-
NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-
NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-
S(02)NRbRa, -(CH2)m-O-C( =Ü)-(M)-C( =Ü)OH' -(CH2)m-O-C( =Ü)-(M)-
C( =O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), -
(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -
(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
37 
wo 2014/125075 PCT /EP2014/052922 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from hydrogen, -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -
CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C5Hs -CH2C6Hs. 
h. with E being 
- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly 1, and 
- with each R1 independently from any other R1 being 
i. E is 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -
OCONH2 or -N02, 
a substituted or unsubstituted Cs-CB heterocycle, 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB 
halo heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F, 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F, 
a substituted or unsubstituted C6 aryl. 
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with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n being1, and with each R1 independently from any other R1 being -
OH, -F, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, or 
j. E is 
- with n of R1n being 5 and R1 is F, or 
- with n of R1n being 5, and one to four of R1 being F and the other ones of R1 being 
selected independently from any other R1 from -H, -OH, -Cl, -1, -CN, -OCH3, -OCF3, -
OCONH2 or -CF3, in particular from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
- with n of R1n being 1, and R1 being selected from -OH, -OCH3, -OCF3, -OCONH2 or -
CF3, or 
- with n of R1n being 5, and one to three of R1 being F and the other ones of R1 being 
selected independently from any other R1 from -H, -OH, -Cl, 1, -CN, -OCH3, -OCF3, -
OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
- with n of R1n being 2, and each R1 being selected independently from any other R1 
from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
- with n of R1n being 5, and one or two of R1 being F and the other ones of R1 being 
selected independently from any other R1 from -H,-OH, -Cl, 1, -CN, -OCH3, -OCF3, -
OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
- with n of R1n being 3, and each R1 being selected independently from any other R1 
from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
k. E is 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n being 1, and with each R1 independently from any other R1 being -
OH, OCH3, -For -CF3. 
1. E is 
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with n of R1n being 1, 2, 3, 4 or 5, in particular n of R1n being 1, 2 or 3, 
with one R1 being a substituent Q, with Q being selected from 
- -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, -(CH2)m-O-
S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -(CH2)m-O-
S(02)0Ra, with m being selected from 0, 1 or 2, in particular from O or 1, with Ra being 
-CH3, -CH2CH3, -C5Hs, -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
- -C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a substituted or 
unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 alkyl, 
- -(CH2)m-[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)QRd, in particular -(CH2)-[-0-C(=O)-
(CH2)2]p1-C(=O)QRd with 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
- -(CH2)m-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
- -(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in 
particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently from each 
other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -C5Hs -
CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl, 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, , 
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and with the other R1 being selected independently from each other R1 from -OH, -F, -
Cl, 1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular from -OH, -F, -OCH3, -OCF3, -
OCONH2 or -CF3, or 
m. E is 
with n of R1n being 5, and one to four of R1 being F, one R1 being the 
substituent Q, and, where applicable, the other ones of R1 being selected 
independently from any other R1 from -H, -OH, -Cl, 1, -CN, -OCH3, -OCF3, -
OCONH2 or -CF3, in particular from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, 
or 
with n of R1n being 5, and one to three of R1 being F, one R1 being the 
substituent Q, and, where applicable, the other ones of R1 being selected 
independently from any other R1 from -H,-OH, -Cl, 1, -CN, -OCH3, -OCF3, -
OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 5, and one or two of R1 being F, one R1 being the 
substituent Q, and, where applicable, the other ones of R1 being selected 
independently from any other R1 from -H,-OH, -Cl, 1, -CN, -OCH3, -OCF3, -
OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 5, and one of R1 being F, one R1 being the substituent 
Q, and, where applicable, the other ones of R1 being selected 
independently from any other R1 from -H,-OH, -Cl, 1, -CN, -OCH3, -OCF3, -
OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 3, one R1 being the substituent Q, and the other R1 
being selected independently from each other R1 from -OH, -OCH3, -OCF3, 
-OCONH2 or -CF3, or 
with n of R1n being 2, one R1 being the substituent Q and the other R1 
being -H,-OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 1 with R1 being the substituent Q, 
with Q having the same meaning as defined previously, and wherein in particular Q is in 
para position with respect to the attachment position of the phenyl moiety of E to the 
parent moiety, 
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and wherein in particular any hydrogen of the phenyl group may be substituted with F, or 
n. E is 
- with each T being selected independently from each other from -CH2, -NH, -Sor -0, -
CHCH3, -C(CH3)2 or -NRc, 
- with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, and 
- with T" being selected from -CH or =N, and 
- with R5 and R6 being selected independently from each other from -H, -F, -CH3, -
CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular 
with R5 and R6 being selected independently from each other from H, -For -CH3, 
and 
- with R6' being selected from -CH3, -OH, -OCH3 or -OCH2CH3 
- with R7 being selected from =NH, =Sor =Ü, and 
- with m of R9m being selected from 0, 1, 2 or 3, and each R9 being selected 
independently from each other -Cl, -F, Br, 1, -OH, -CCH, -CN -CH3, -CH2CH3, -
OCH3, -COOH, -COQRb, -C(O)NH2, -C(O)NH(Rb); -C(O)N(Rb)2,-NHC(=O)QRb, -
NRbC(=O)QRb, -NRbC(=O)OH, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
C1-Cs haloalkyl, or 
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o. E is 
or 
- with m of R9m being 0, and 
- with each T being selected independently from each other from -CH2, -CHCH3, -
C(CH3)2, -NH, NRc, -S or -0, in particular form -C(CH3)2, -NH, -S or -0, 
with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CF3, -
CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3 
- with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, in 
particular from -0, -Sor -NH, and 
- with T" being selected from -CH or =N, in particular T" is =N, and 
- with R5 and R6 being selected independently from each other from -H, -F -CH3, -
CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular 
with R5 and R6 being selected independently from each other from H, -For CH3, 
and 
- with R6' being selected from OH, -OCH3, -OCH2CH3 or -CH3, 
- with R7 being selected from =NH, =Sor =Ü, in particular R7 is =Ü, or 
p. E is selected from 
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0 ~ 1 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-C16 alkoxy, 
a substituted or unsubstituted C1-C16 carboxy, a substituted or unsubstituted C2-C16 
alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a 
substituted or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-C10 
cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle; in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl; 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C5-C10 cycloalkyl, a 
substituted or unsubstituted Cs-C10 heteroaryl or a substituted or unsubstituted Cs-C10 aryl. 
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ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, E 
is 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F, 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetraline or indane, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F, 
selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 1,2,4-
triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, 
naphatalene, coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, 
benzofurane, benzothiophene, benzimidazol, benzthiazole, benzoxazole or 
benzpyridazin or hydroxylated, methylated or halogenated derivatives thereof 
selected from . 
m-~ 






- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n being 1, and 
- with each R1 independently from any other R1 being selected from 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
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-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)R\ -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H, -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted 
or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-
C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo 
cycloalkyl, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
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a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl, in particular 
with each R1 independently from any other R1 being -OH, -F, -Cl, 1, -CN, -OCH3, -OCF3, -
OCONH2 or -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly 1, and 
with each R1 independently from any other R1 being selected from 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2-CH3, -CF3, -OCONH2 or -N02, 
- -B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -
(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -
(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-ÜC(=S)ORa, -(CH2)m-
OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-
S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-
NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -
(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-NRcS(02)Ra, -(CH2)m-
P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-
C( =Ü)-(M)-C( =Ü)OH, -(CH2)m-O-C( =Ü)-(M)-C( =Ü)ORa, -(CH2)m-O-C( =Ü)-(M)-Ra, -
( CH2)m-O-(CH2)q-P( =Ü )(Rba)( Raa), -( CH2)m-C( =Ü)O-( CH2)q-P( =Ü }( Rba) (Raa_(CH2)m-
C( =O)O-(CH2)q-S( 02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
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with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from each 
other from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-
C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or 
unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or 
a C1-C16 haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, a 
substituted or unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-
Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted or 
unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-C10 
cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 
halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n 1, and 
- with each R1 independently from any other R1 being selected from 
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OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-
C(=O)ORa, -(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -
(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted 
or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-
C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo 
cycloalkyl, 
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q. E is 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl, or 
- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n 1, and 
- with each R1 independently from any other R1 being selected from 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NH CH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
- -B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)ORa, -(CH2)m-
OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)QRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
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with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, , 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from hydrogen,-CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -
CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C5Hs -CH2C6Hs 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more particularly 
1, and 
with each R1 independently from any other R1 being 
- -OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -
N02, 
- a substituted or unsubstituted Cs-CB heterocycle, 
- a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F, 
- a substituted or unsubstituted Cs-CB heteroaryl, 
- a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F, 
- a substituted or unsubstituted C6 aryl. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
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with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more particularly 
n of R1n being1, and with each R1 independently from any other R1 being -OH, -F, -Cl, 1, -CN, 
-OCH3, -OCF3, -CONH2 or -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
with n of R1n being 5 and R1 is F, or 
with n of R1n being 5, and one to four of R1 being F and the other ones of R1 being selected 
independently from any other R1 from -H, -OH, -Cl, 1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, 
in particular from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 1, and R1 being selected from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 5, and one to three of R1 being F and the other ones of R1 being selected 
independently from any other R1 from -H, -OH, -Cl, 1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, 
in particular -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 2, and each R1 being selected independently from any other R1 from -OH, 
-OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 5, and one or two of R1 being F and the other ones of R1 being selected 
independently from any other R1 from -H,-OH, -Cl, 1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, 
in particular -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 3, and each R1 being selected independently from any other R1 from -OH, 
-OCH3, -OCF3, -OCONH2 or -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more particularly 
n of R1n being 1, and with each R1 independently from any other R1 being -OH, OCH3, -F, -
OCONH2 or -CF3. 
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ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, E 
is 
with n of R1n being 1, 2, 3, 4 or 5, in particular n of R1n being 1, 2 or 3, 
with one R1 being a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra,-(CH2)m-O-
S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, 
with m being selected from 0, 1 or 2, in particular from O or 1, with Ra being -CH3, -
CH2CH3, -C5Hs -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
-C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a substituted or 
unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 alkyl, 
-(CH2)m-[(CH2)m1 -0-C( =Ü)-(CH2)m2]p1-C( =O)QRd, in particular -(CH2)-[-0-C( =Ü)-(CH2)2]p1-
C( =O)QRd with 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-[(CH2)m1 -O-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in particular 
from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
- with Raa and Rba being selected, where applicable, independently from each other 
from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -C5Hs -
CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
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with q being selected from 0, 1 or 2, in particular O or 1 , 
and with the other R1 being selected independently from each other R1 from -OH, 
-F, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular from -OH, -F, -OCH3, -OCF3, -
OCONH2 or -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
with n of R1n being 5, and one to four of R1 being F, one R1 being the substituent Q, 
and, where applicable, the other ones of R1 being selected independently from any 
other R1 from -H, -OH, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular from -
OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 5, and one to three of R1 being F, one R1 being the substituent Q, 
and, where applicable, the other ones of R1 being selected independently from any 
other R1 from -H,-OH, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular -OH, -
OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 5, and one or two of R1 being F, one R1 being the substituent Q, 
and, where applicable, the other ones of R1 being selected independently from any 
other R1 from -H,-OH, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular -OH, -
OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 5, and one of R1 being F, one R1 being the substituent Q, and, 
where applicable, the other ones of R1 being selected independently from any other R1 
from -H,-OH, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular -OH, -OCH3, -
OCF3, -OCONH2 or -CF3, or 
with n of R1n being 3, one R1 being the substituent Q, and the other R1 being selected 
independently from each other R1 from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 2, one R1 being the substituent Q and the other R1 being -H,-OH, -
OCH3, -OCF3, -OCONH2 or -CF3, or 
with n of R1n being 1 with R1 being the substituent Q, 
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with Q having the same meaning as defined previously, and wherein in particular Q is in para 
position with respect to the attachment position of the phenyl moiety of E to the parent 
moiety, 
and wherein in particular any hydrogen of the phenyl group may be substituted with F. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is 
with each T being selected independently from each other from -CH2, -NH, -Sor -0, -
CHCH3, -C(CH3)2 or -NRc, 
with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, and 
with T" being selected from -CH or =N, and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, -
CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with 
R5 and R6 being selected independently from each other from H, -For -CH3, and 
with R6' being selected from -OH, -OCH3, -OCH2CH3 or -CH3, 
with R7 being selected from =NH, =Sor =Ü, and 
with m of R9m being selected from 0, 1, 2 or 3, and each R9 being selected independently 
from each other from -Cl, -F, Br, -1, -OH, -CCH, -CN -CH3, -CH2CH3, -OCH3, -COOH, -
COQRb, -C(O)NH2, -C(O)NH(Rb); -NHC(=O)QRb, -NRbC(=O)QRb, -NRbC(=O)OH, -
C(O)N(Rb)2 -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted 
C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a C1-Cs haloalkyl. 
ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
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E is 
- with m of R9m being 0, and 
- with each T being selected independently from each other from -CH2, -CHCH3, -
C(CH3)2, -NH, NRc, -S or -0, in particular form -C(CH3)2, -NH, -S or -0, 
with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, 
- with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, in 
particular from -0, -Sor -NH, and 
- with T" being selected from -CH or =N, in particular T" is =N, and 
- with R5 and R6 being selected independently from each other from -H, -F -CH3, -
CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular 
with R5 and R6 being selected independently from each other from H, -For CH3, 
and 
- with R6' being selected from OH, -OCH3, -OCH2CH3 or -CH3, 
with R7 being selected from =NH, =Sor =Ü, in particular R7 is =Ü. 
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ln some embodiments, in particular according to any one of the sub aspects 11 or 24 to 26, 
E is selected from 
or 
ln some embodiments, in particular according to any one of the sub aspects 12, 13 or 27 to 
32, 
n of R1n is 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more particularly 1, and 
each R1 independently from any other R1 is selected from 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2-CH3, -CF3, -OCONH2 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -(CH2)m-
OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-
OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-
SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-
OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)QRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) 
or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -(CH2)m-O-C(=O)-(M)-
C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-
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C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-
(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an unsubstituted C1-
Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, with q being selected from 0, 1 
or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from each other 
from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted 
or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-
C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo 
cycloalkyl, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, in particular according to any one of the sub aspects 12, 13 or 27 to 
32, with n of R1n of BA being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n 1, and 
- with each R1 independently from any other R1 being selected from 
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-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NH CH3, -N(CH3)2, 
-CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
- -B(ORa)(ORb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)ORa, -(CH2)m-
OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(ORa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=O)Ra, -(CH2)m-NRcC(=O)ORa, -(CH2)m-
NRcC(=O)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)ORa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(ORb)(ORa), -(CH2)m-
P(=O)(ORb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=O)-(M)-C(=O)ORa, -(CH2)m-O-C(=O)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =O)(Rba)(Raa), -(CH2)m-C( =0)0-(CH2)q-P( =O)(Rba)(Raa), -(CH2)m-C( =0)0-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -ORb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
- with each Ra, Rb or Re being selected, where applicable, 
independently from each other from hydrogen, -CH3, -CH2CH3, -
CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -
C(CH3)3, -C5Hs -CH2C6Hs. 
ln some embodiments, in particular according to any one of the sub aspects 12, 13 or 27 to 
32, 
n of R1n is 0, 1, 2, 3, 4 or 5, in particular n of R1n is 0, 1, 2 or 3, more particularly 1, and 
with each R1 independently from any other R1 being 
- -OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -
OCONH2 or -N02, 
a substituted or unsubstituted Cs-CB heterocycle, 
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a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB 
halo heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F, 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F, 
a substituted or unsubstituted C6 aryl. 
ln some embodiments, in particular according to any one of the sub aspects 12, 13 or 27 to 
32, 
n of R1n is 0, 1, 2, 3, 4 or 5, in particular n of R1n is 0, 1, 2 or 3, more particularly 1, and 
with each R1 independently from any other R1 being -OH, -F, -Cl, -1, -CN, -OCH3, -OCF3, -
OCONH2 or -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 12, 13 or 27 to 
32, 
n of R1n is 5 and R1 is F, or 
n of R1n is 5, and one to four of R1 being F and the other ones of R1 are selected 
independently from any other R1 from -H, -OH, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -
CF3, in particular from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
n of R1n is 1, and R1 are selected from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
n of R1n is 5, and one to three of R1 are F and the other ones of R1 are selected 
independently from any other R1 from -H, -OH, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -
CF3, in particular from -OH, -OCH3, -OCF3 or -CF3, or 
n of R1n is 2, and each R1 is selected independently from any other R1 from -OH, -OCH3, 
-OCF3, -OCONH2 or -CF3, or 
n of R1n is 5, and one or two of R1 are F and the other ones of R1 are selected 
independently from any other R1 from -H,-OH, -Cl, 1, -CN, -OCH3, -OCF3, -OCONH2 or -
CF3, in particular from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
n of R1n is 3, and each R1 is selected independently from any other R1 from -OH, -OCH3, 
-OCF3, -OCONH2 or -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 12, 13 or 27 to 
32, 
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n of R1n is 0, 1, 2, 3, 4 or 5, in particular n of R1n is 0, 1, 2 or 3, more particularly n of R1n is 1, 
and with each R1 independently from any other R1 being -OH, OCH3, -F or -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 12, 13 or 27 to 
32, 
n of R1n is 1, 2, 3, 4 or 5, in particular n of R1n is 1, 2 or 3, 
with one R1 being a substituent Q, with Q being selected from 
- -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, -(CH2)m-O-
S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -(CH2)m-O-
S(02)0Ra, with m being selected from 0, 1 or 2, in particular from O or 1, with Ra 
being -CH3, -CH2CH3, -C5Hs -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-
methoxybenzyl 
- -C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a substituted or 
unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 alkyl, 
- -(CH2)m-[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd, in particular -(CH2)-[-0-C(=O)-
(CH2)2]p1-C(=O)QRd with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
- -(CH2)m-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
- -(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in 
particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently from each 
other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -C5Hs -
CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
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with q being selected from 0, 1 or 2, in particular O or 1, 
and with the other R1 being selected independently from each other R1 from -OH, -F, -Cl, 1, -
CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular from -OH, -F, -OCH3, -OCF3, -OCONH2 or 
-CF3. 
ln some embodiments, in particular according to any one of the sub aspects 12, 13 or 27 to 
32, 
n of R1n is 5, and one to four of R1 are F, one R1 is the substituent Q, and, where 
applicable, the other ones of R1 are selected independently from any other R1 from -H, -
OH, -Cl, 1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular from -OH, -OCH3, -OCF3, -
OCONH2 or -CF3, or 
n of R1n is 5, and one to three of R1 are F, one R1 is the substituent Q, and, where 
applicable, the other ones of R1 are selected independently from any other R1 from -H,-
OH, -Cl, 1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -
OCONH2 or -CF3, or 
n of R1n is 5, and one or two of R1 are F, one R1 is the substituent Q, and, where 
applicable, the other ones of R1 are selected independently from any other R1 from -H,-
OH, -Cl, 1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -
OCONH2 or -CF3, or 
n of R1n is 5, and one of R1 is F, one R1 is the substituent Q, and, where applicable, the 
other ones of R1 are selected independently from any other R1 from -H,-OH, -Cl, 1, -CN, -
OCH3, -OCF3, -OCONH2 or -CF3, in particular from -OH, -OCH3, -OCF3, -OCONH2 or -
CF3, or 
n of R1n is 3, one R1 is the substituent Q, and the other R1 are selected independently 
from each other R1 from -OH, -OCH3, -OCF3, -OCONH2 or -CF3, or 
n of R1n is 2, one R1 is the substituent Q and the other R1 is -H,-OH, -OCH3, -OCF3, -
OCONH2 or -CF3, or 
n of R1n is 1, with R1 being the substituent Q, 
with Q having the same meaning as defined previously, and wherein in particular Q is in para 
position with respect to the attachment position of the phenyl moiety of E to the parent 
moiety, 
and wherein in particular any hydrogen of the phenyl group may be substituted with F. 
ln some embodiments, in particular according to any one of the sub aspects 11 to 13 or 24 to 
31, R2 and R3 are selected, where applicable, independently from each other from -H, -F, -
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CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl. 
ln some embodiments, in particular according to any one of the sub aspects 11 to 13 or 24 to 
31, R2 and R3 are selected, where applicable, independently from each other from -H, -F, -
CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -
OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 11 to 13 or 24 to 
31, R2 and R3 are selected independently from each other from -H, -For -CH3. 
ln some embodiments, X1 is selected from 
NA NA 
ls ls 
HO R HO R 
0 
N;zz, oo__)l_N,Jz, 
ls 1 s 






, with R8 being selected from H or CH3, in particluar R8 is H 
and with V being selected from 0, NH or S, in particular from O or NH. 
ln some embodiments, X1 is selected from 
or 
HO 
with R8 being selected from H or CH3, in particluar R8 is H. 
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ln some embodiments, X1 is selected from 
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ln some embodiments, BB is 
r0(~ ~~ 
~ ~:n"13 l-,.~ 13 
"1.- or "1.- Rn 
with n of R13n being 0, 1, 2, 3 or 4, in particular n of R13n being 0, 1 or 2, 
with each R13 independently from any other R13 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3, -CF3 or -N02, in particular -OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -
OCH3, -OCF3, -, -CH3, -CH2CH3 or -CF3, 
with each R13 independently from any other R13 being 
- -OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3, -CH3, -CF3 or -N02, in particular -OH, -F, -Cl, -Br, -1, -CCH, -
CN, -N3, -OCH3, -OCF3, -, -CH3, -CH2CH3 or -CF3, wherein, each carbon atom 
of the cyclic system which comprises no substituent R13 comprises F instead 
of H. 
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ln some embodiments, BB is 
with n of R13n being 0, or 
with n of R13n being 1, 2, 3 or 4 with each R13 being F, in particular n is 4 and each R13 is F. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, BC is selected from 
with p being 1, 2, 3, 4 or 5, in particular p being 2 or 3, and 
with r being 2, 3, 4 or 5, in particular r being 2, 
with L 1, L 2, L 4, L 5 being selected independently from each other from side chains of ami no 
acids such as -H (Gly), -CH3 (Ala), -CH2CH2CH2NHC(NRc)N(Rb)(Ra) (Arg), -CH2CON(Rb)(Ra) 
(Asn), -CH2C(=O)ORa (Asp), -CH2SRa (Cys), -CH2CH2C(=O)N(Rb)(Ra) (Gin), -
CH2CH2C(=O)ORa (Glu), -CH2(C3H3N2) (His), -CH2CH2CH2CH2 (Lys), -CH2CH2SCH3 (Met), -
CH2(C6Hs) (Phe), -CH2CH2CH2- (Pro), -CH20Ra (Ser), -CH(ORa)CH3 (Thr), -CH2(CsH6N)ORa 
(Trp), -CH2(C6H4)0Ra (Tyr), -CH(CH3)2 (Val), 
or from 
-CCH, -CN, -OCH3, -CH3, -CF3, -Ra, -CH(Rb)(Ra), -CH20Ra, -CH2C(=O)Ra, -C(=O)ORa, -
OC(=O)NRbRa, -C(=O)NRbRa, -CH2C(=O)NRb(QRa), -CH2S(02)Ra, -S(02)0Ra, -
CH2S(02)0Ra, -CH2NHC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(QRb)(QRa), -
CH2P(=O)(QRb)(Ra), ), -CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
with Ra and Rb being selected, where applicable, independently from each 
other from 
a substituted or unsubstituted C1-C4 alkyl, a substituted or 
unsubstituted C1-C4 alkoxy, a substituted or unsubstituted C1-C4 
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carboxy, a substituted or unsubstituted C2-C4 alkenyl, a substituted 
or unsubstituted C2-C4 alkynyl, or a C1-C4 haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, and with 
with Y being -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) or -
C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, and wherein 
ln some embodiments L1, L2, L3, L4 and L5 comprise the structure elements of amino acids 
and their derivatives. The respective amino acid is named in brackets. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, BC is selected from 
with p being 1, 2, 3, 4 or 5, in particular p being 2 or 3, and 
with r being 2, 3, 4 or 5, in particular r being 2, 
with L 1, L 2, L 4, L 5 being selected independently from each other from side chains of ami no 
acids such as -H (Gly), -CH3 (Ala), -CH2CH2CH2NHC(NRc)N(Rb)(Ra) (Arg), -CH2CON(Rb)(Ra) 
(Asn), -CH2C(=O)ORa (Asp), -CH2SRa (Cys), -CH2CH2C(=O)N(Rb)(Ra) (Gin), -
CH2CH2C(=O)ORa (Glu), -CH2(C3H3N2) (His), -CH2CH2CH2CH2 (Lys), -CH2CH2SCH3 (Met), -
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CH2(C6Hs) (Phe), -CH2CH2CH2- (Pro), -CH20Ra (Ser), -CH(ORa)CH3 (Thr), -CH2(CsH6N)ORa 
(Trp), -CH2(C6H4)0Ra (Tyr), -CH(CH3)2 (Val), 
or from 
-CCH, -CN, -OCH3, -CH3, -CF3, -Ra, -CH20Ra, -CH2C(=O)Ra, -C(=O)ORa, -OC(=O)NRbRa, -
C(=O)NRbRa, -CH2C(=O)NRb(QRa), -CH2S(02)Ra, -S(02)0Ra, -CH2S(02)0Ra, -
CH2NHC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(QRb)(QRa), -CH2P(=O)(QRb)(Ra), ), -
CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
- with Ra and Rb being selected, where applicable, independently from each 
other from CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -
CH2CH(CH3)2, -C(CH3)3, -C5Hs ,-CH2C6Hs, mono methoxybenzyl, in 
particular para-methoxybenzyl, or dimethoxybenzyl or trimethoxybenzyl 
with Y being -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) or -
C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, and wherein 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, BC is selected from 
ty,~ ~x~ ~~~or~~ 
' ' 
with L 1 or L 4 being selected independently from each other from side chains of ami no acids 
such as -H (Gly), -CH3 (Ala), -CH2CH2CH2NHC(NRc)N(Rb)(Ra) (Arg), -CH2CON(Rb)(Ra) 
(Asn), -CH2C(=O)ORa (Asp), -CH2SRa (Cys), -CH2CH2C(=O)N(Rb)(Ra) (Gin), -
CH2CH2C(=O)ORa (Glu), -CH2(C3H3N2) (His), -CH2CH2CH2CH2 (Lys), -CH2CH2SCH3 (Met), -
CH2(C6Hs) (Phe), -CH2CH2CH2- (Pro), -CH20Ra (Ser), -CH(ORa)CH3 (Thr), -CH2(CsH6N)ORa 
(Trp), -CH2(C5H4)QRa (Tyr), -CH(CH3)2 (Val), 
or from 
-CCH, -CN, -OCH3, -CH3, -CF3, -Ra, -CH(Rb)(Ra), -CH20Ra, -CH2C(=O)Ra, -C(=O)ORa, -
OC(=O)NRbRa, -C(=O)NRbRa, -CH2C(=O)NRb(QRa), -CH2S(02)Ra, -S(02)0Ra, -
CH2S(02)0Ra, -CH2NHC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(QRb)(QRa), -
CH2P(=O)(QRb)(Ra), ), -CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
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with Ra and Rb being selected, where applicable, independently from each 
other from 
a substituted or unsubstituted C1-C4 alkyl, a substituted or 
unsubstituted C1-C4 alkoxy, a substituted or unsubstituted C1-C4 
carboxy, a substituted or unsubstituted C2-C4 alkenyl, a substituted 
or unsubstituted C2-C4 alkynyl, or a C1-C4 haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, and with 
with Y being -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) or -
C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, and wherein 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, BC is selected from 
with L 1 or L 4 being selected independently from each other from side chains of ami no acids 
such as -H (Gly), -CH3 (Ala), -CH2CH2CH2NHC(NRc)N(Rb)(Ra) (Arg), -CH2CON(Rb)(Ra) 
(Asn), -CH2C(=O)ORa (Asp), -CH2SRa (Cys), -CH2CH2C(=O)N(Rb)(Ra) (Gin), -
CH2CH2C(=O)ORa (Glu), -CH2(C3H3N2) (His), -CH2CH2CH2CH2 (Lys), -CH2CH2SCH3 (Met), -
CH2(C6Hs) (Phe), -CH2CH2CH2- (Pro), -CH20Ra (Ser), -CH(ORa)CH3 (Thr), -CH2(CsH6N)ORa 
(Trp), -CH2(C5H4)QRa (Tyr), -CH(CH3)2 (Val), 
or from 
-CCH, -CN, -OCH3, -CH3, -CF3, -Ra, -CH20Ra, -CH2C(=O)Ra, -C(=O)ORa, -OC(=O)NRbRa, -
C(=O)NRbRa, -CH2C(=O)NRb(QRa), -CH2S(02)Ra, -S(02)0Ra, -CH2S(02)0Ra, -
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CH2NHC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(QRb)(QRa), -CH2P(=O)(QRb)(Ra), ), -
CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
with Ra and Rb being selected, where applicable, independently from each other from CH3, -
CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C5Hs ,-
CH2C6Hs, mono methoxybenzyl, in particular para methoxybenzyl, or dimethoxybenzyl or 
trimethoxybenzyl. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, BC is selected from 
with L 1 or L 4 being selected independently from each other from side chains of ami no acids 
such as - H (Gly), -CH3 (Ala), -CH2CH2CH2NHC(NRc)N(Rb)(Ra) (Arg), -CH2CON(Rb)(Ra) 
(Asn), -CH2C(=O)ORa (Asp), -CH2SRa (Cys), -CH2CH2C(=O)N(Rb)(Ra) (Gin), -
CH2CH2C(=O)ORa (Glu), -CH2(C3H3N2) (His), -CH2CH2CH2CH2 (Lys), -CH2CH2SCH3 (Met), -
CH2(C6Hs) (Phe), -CH2CH2CH2- (Pro), -CH20Ra (Ser), -CH(ORa)CH3 (Thr), -CH2(CsH6N)ORa 
(Trp), -CH2(C6H4)0Ra (Tyr), -CH(CH3)2 (Val), 
or from 
-CCH, -CN, -OCH3, -CH3, -CF3, -Ra, -CH(Rb)(Ra), -CH20Ra, -CH2C(=O)Ra, -C(=O)ORa, -
OC(=O)NRbRa, -C(=O)NRbRa, -CH2C(=O)NRb(QRa), -CH2S(02)Ra, -S(02)0Ra, -
CH2S(02)0Ra, -CH2NHC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(QRb)(QRa), -
CH2P(=O)(QRb)(Ra), ), -CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
with Ra and Rb being selected, where applicable, independently from each 
other from 
a substituted or unsubstituted C1-C4 alkyl, a substituted or 
unsubstituted C1-C4 alkoxy, a substituted or unsubstituted C1-C4 
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carboxy, a substituted or unsubstituted C2-C4 alkenyl, a substituted 
or unsubstituted C2-C4 alkynyl, or a C1-C4 haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, and with 
with Y being -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) or -
C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, and wherein 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, BC is selected from 
with L 1 or L 4 being selected independently from each other from side chains of ami no acids 
such as H (Gly), -CH3 (Ala), -CH2CH2CH2NHC(NRc)N(Rb)(Ra) (Arg), -CH2CON(Rb)(Ra) (Asn), 
-CH2C(=O)ORa (Asp), -CH2SRa (Cys), -CH2CH2C(=O)N(Rb)(Ra) (Gin), -CH2CH2C(=O)ORa 
(Glu), -CH2(C3H3N2) (His), -CH2CH2CH2CH2 (Lys), -CH2CH2SCH3 (Met), -CH2(C6Hs) (Phe), -
CH2CH2CH2- (Pro), -CH20Ra (Ser), -CH(ORa)CH3 (Thr), -CH2(CsH6N)ORa (Trp), -
CH2(C5H4)QRa (Tyr), -CH(CH3)2 (Val), 
or from 
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-CCH, -CN, -OCH3, -CH3, -CF3, -Ra, -CH20Ra, -CH2C(=O)Ra, -C(=O)ORa, -OC(=O)NRbRa, -
C(=O)NRbRa, -CH2C(=O)NRb(QRa), -CH2S(02)Ra, -S(02)0Ra, -CH2S(02)0Ra, -
CH2NHC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(QRb)(QRa), -CH2P(=O)(QRb)(Ra), ), -
CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
with Ra and Rb being selected, where applicable, independently from each other from CH3, -
CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C5Hs ,-
CH2C6Hs, mono methoxybenzyl, in particular para methoxybenzyl, or dimethoxybenzyl or 
trimethoxybenzyl. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, BC is selected from 
ty~ ~x~ ty~ ~x~ 
L L or , in particular 
with L 1 or L 4 being selected independently from each other from side chains of ami no acids 
such as -H (Gly), -CH3 (Ala), -CH2CH2CH2NHC(NRc)N(Rb)(Ra) (Arg), -CH2CON(Rb)(Ra) 
(Asn), -CH2C(=O)ORa (Asp), -CH2SRa (Cys), -CH2CH2C(=O)N(Rb)(Ra) (Gin), -
CH2CH2C(=O)ORa (Glu), -CH2(C3H3N2) (His), -CH2CH2CH2CH2 (Lys), -CH2CH2SCH3 (Met), -
CH2(C6Hs) (Phe), -CH2CH2CH2- (Pro), -CH20Ra (Ser), -CH(ORa)CH3 (Thr), -CH2(CsH6N)ORa 
(Trp), -CH2(C6H4)0Ra (Tyr), -CH(CH3)2 (Val), 
or from 
-CCH, -CN, -OCH3, -CH3, -CF3, -Ra, -CH(Rb)(Ra), -CH20Ra, -CH2C(=O)Ra, -C(=O)ORa, -
OC(=O)NRbRa, -C(=O)NRbRa, -CH2C(=O)NRb(QRa), -CH2S(02)Ra, -S(02)0Ra, -
CH2S(02)0Ra, -CH2NHC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(QRb)(QRa), -
CH2P(=O)(QRb)(Ra), ), -CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
with Ra and Rb being selected, where applicable, independently from each 
other from 
a substituted or unsubstituted C1-C4 alkyl, a substituted or 
unsubstituted C1-C4 alkoxy, a substituted or unsubstituted C1-C4 
carboxy, a substituted or unsubstituted C2-C4 alkenyl, a substituted 
or unsubstituted C2-C4 alkynyl, or a C1-C4 haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
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unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, and with 
with Y being -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) or -
C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, and wherein 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, BC is selected from 
ty~ ~x~ ty~ ~x~ 
L L or , in particular 
with L 1 or L 4 being selected independently from each other from side chains of ami no acids 
such as H (Gly), -CH3 (Ala), -CH2CH2CH2NHC(NRc)N(Rb)(Ra) (Arg), -CH2CON(Rb)(Ra) (Asn), 
-CH2C(=O)ORa (Asp), -CH2SRa (Cys), -CH2CH2C(=O)N(Rb)(Ra) (Gin), -CH2CH2C(=O)ORa 
(Glu), -CH2(C3H3N2) (His), -CH2CH2CH2CH2 (Lys), -CH2CH2SCH3 (Met), -CH2(C6Hs) (Phe), -
CH2CH2CH2- (Pro), -CH20Ra (Ser), -CH(ORa)CH3 (Thr), -CH2(CsH6N)ORa (Trp), -
CH2(C6H4)0Ra (Tyr), -CH(CH3)2 (Val), 
or from 
-CCH, -CN, -OCH3, -CH3, -CF3, -Ra, -CH20Ra, -CH2C(=O)Ra, -C(=O)ORa, -OC(=O)NRbRa, -
C(=O)NRbRa, -CH2C(=O)NRb(QRa), -CH2S(02)Ra, -S(02)0Ra, -CH2S(02)0Ra, -
CH2NHC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=O)(QRb)(QRa), -CH2P(=O)(QRb)(Ra), ), -
CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
with Ra and Rb being selected, where applicable, independently from each other from CH3, -
CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C5Hs ,-
CH2C6Hs, mono methoxybenzyl, in particular para methoxybenzyl, or dimethoxybenzyl or 
trimethoxybenzyl. 
74 
wo 2014/125075 PCT /EP2014/052922 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, -02-BC- is 
with 
p being 1, 2, 3, 4 or 5, in particular p being 2 or 3, and with, where applicable, each RB being 
selected independently from each other from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -CH2CF3, -
CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with each RB being selected 
independently from each other from H or CH3, more particularly each RB being H. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 12 or 14 to 
38, -02-BC- is 
with 
p being 1, 2, 3, 4 or 5, in particular p being 2 or 3, and with RB being H or CH3. 
ln some embodiments, in particular according to any one of the sub aspects 1 or 2, BD is 
~7z, ~7z, 
l, ~:n'"12 '--,.~ 12 
"'l,- or "'l,- Rn 
with n of R12n being 0, 1, 2, 3 or 4, in particular n of R12n being 0, 1 or 2, 
with each R12 independently from any other R12 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3, -CF3 or -N02, in particular -OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -
OCH3, -OCF3, -, -CH3, -CH2CH3 or -CF3, or 
with each R12 independently from any other R12 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2CH3, -CH3, -CF3 or -N02, in particular -OH, -F, -Cl, -Br, 
-1, -CCH, -CN, -N3, -OCH3, -OCF3, -, -CH3, -CH2CH3 or -CF3, wherein each 
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carbon atom of the cyclic system which comprises no substituent R12 
comprises F instead of H. 
ln some embodiments, in particular according to any one of the sub aspects 1 or 2, BD is 
with n of R12n being 0, or 
with n of R12n being 1, 2, 3 or 4 with each R12 being F, in particular n is 4 and each R13 is F. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 6, 19, 21, 
24 or 27, BE is 
with n of R11n being 0, 1, 2, 3 or 4, in particular n of R11n being 0, 1, 2 or 3, 
with each R11 being selected independently from any other R11 from -OH, -F, -Cl, -Br, -1, -
CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -
CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in particular from 
-OH, -F, -OCH3, -OCF3 or -CF3, or 
with each R11 being selected independently from any other R11 from -OH, -F, -Cl, -Br, -1, -
CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -
CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in particular from 
-OH, -F, -OCH3, -OCF3 or -CF3, wherein, each carbon atom of the cyclic system which 
comprises no substituent R11 comprises F instead of H. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 6, 19, 21, 
24 or 27, BE is 
with n of R11n being 2, and with each R11 independently from any other R11 being -OH, -OCH3 
or -OCF3, in particular -OCH3 or -OCF3, more particularly with one R11 being -OH and the 
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other R11 being -OCH3 or -OCF3, in particular -OCH3, wherein more particularly OH is in ortho 
and OCH3 or -OCF3 in meta position with respect to the attachment position of the phenyl 
moiety of BE to os, or 
with n of R11n being 1, and with R11 being -OH, wherein in particular OH is in ortho position 
with respect to the attachment position of the phenyl of BE to os or 
with n of R11n being 1, and with R11 being -OCH3 or -OCF3, in particular or -OCH3, wherein 
more particularly -OCH3 or -OCF3 is in meta position with respect to the attachment position 
of the phenyl of BE to os, or 
with n of R11n being 0, or 
with n of R11n being 4 and each R11 is F. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 6, 19, 21, 
24 or 27, BE is 
with n of R11n being 1, 2, 3 or 4, in particular n of R11n being 1, 2 or 3, 
with one R11 being a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra,-
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -
(CH2)m-O-S(02)0Ra, with m being selected from 0, 1 or 2, in particular from 0 
or 1, with Ra being -CH3, -CH2CH3, -C5Hs, -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs 
or para-methoxybenzyl 
-C(=0)-0-Ra, -0-C(=O)-Ra, in particular -0-C(=O)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 
alkyl, 
-(CH2)m-[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd, in particular -(CH2)-[-0-
C(=O)-(CH2)2]p1-C(=O)ORd with 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
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-(CH2)m-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in 
particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently from 
each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -C5Hs , 
-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, and 
i. with the other R11 being selected independently from any other R11 from -OH, -F, -
Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -
CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
ii. with the other R11 being selected independently from any other R11 from -OH, -F, -
Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -
CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, wherein, 
each carbon atom of the cyclic system which comprises no substituent R11 
comprises F instead of H. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 6, 19, 21, 
24 or 27, BE is 
with n of R11n being O or 2, and with one R11 being Q and the other R11 being -OCH3 or -
OCF3, more particularly Q is in ortho and OCH3 or -OCF3 is in meta position with respect to 
the attachment position of the phenyl moiety of BB to 0 5, with Q having the same meaning 
as defined above. 
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ln some embodiments, in particular according to any one of the sub aspects 1 to 3, 
-04-BE is 
, or 
with each T"' being selected from -CH2, -NH, -S, -0, or -NRc, in particular T"' is 0, 
with n of R11n being 0, 1, 2 or 3, in particular n of R11n being 0, 1, or 2, 
i. with each R11 being selected independently from any other R11 from -OH, -F, -Cl, -
Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -
CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or 
-N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
ii. with each R11 being selected independently from any other R11 from -OH, -F, -Cl, -
Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -
CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or 
-N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, wherein, each carbon 
atom of the cyclic system which comprises no substituent R11 comprises F instead 
of H. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 3, 
-04-BE is 
, or 
with each T"' being selected from -CH2, -NH, -S, -0, or -NRc, in particular T"' is 0, 
with n of R11n being 2, and with each R11 independently from any other R11 
being -OH, -OCH3 or -OCF3, in particular -OCH3 or -OCF3, more 
particularly with one R11 being -OH and the other R11 being -OCH3 or -
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OCF3, in particular -OCH3, wherein more particularly OH is in ortho and 
OCH3 or -OCF3 in meta position with respect to the attachment position of 
the phenyl moiety of BE to os, or 
with n of R11n being 1, and with R11 being -OH, wherein in particular OH is 
in ortho position with respect to the attachment position of the phenyl of BE 
to os or 
with n of R11n being 1, and with R11 being -OCH3 or -OCF3, in particular or -
OCH3, wherein more particularly -OCH3 or -OCF3 is in meta position with 
respect to the attachment position of the phenyl of BE to os, or 
with n of R11n being 0, or 
with n of R11n being 4 and each R11 is F. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 3, 
-04-BE is 
, or 
with each T"' being selected from -CH2, -NH, -S, -0, or -NRc, in particular T"' is 0, 
with n of R11n being 1, 2 or 3, in particular n of R11n being 1 or 2, 
with one R11 being a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra,-
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -
(CH2)m-O-S(02)0Ra, with m being selected from 0, 1 or 2, in particular from 0 
or 1, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs 
or para-methoxybenzyl 
-C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 
alkyl, 
-(CH2)m-[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd, in particular -(CH2)-[-0-
C(=O)-(CH2)2]p1-C(=O)QRd with 
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m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in 
particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently from 
each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -C5Hs , 
-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, and 
i. with the other R11 being selected independently from any other R11 from -OH, -F, -
Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -
CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
ii. with the other R11 being selected independently from any other R11 from -OH, -F, -
Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -
CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, wherein, 
each carbon atom of the cyclic system which comprises no substituent R11 
comprises F instead of H. 
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ln some embodiments, in particular according to any one of the sub aspects 1 to 3, 
-04-BE is 
, or 
with each T"' being selected from -CH2, -NH, -S, -0, or -NRc, in particular T"' is 0, 
with n of R11n being O or 2, and with one R11 being Q and the other R11 being -OCH3 or -
OCF3, more particularly Q is in ortho and OCH3 or -OCF3 is in meta position with respect to 
the attachment position of the phenyl moiety of BB to 0 5, with Q having the same meaning 
as defined above. 
ln some embodiments, in particular according to any one of the sub aspects 7, 8, 10 to 13, 
22, 23, 25, 28, 29 or 32, 
R11 is a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra,-
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -
(CH2)m-O-S(02)0Ra, with m being selected from 0, 1 or 2, in particular from 0 
or 1, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs 
or para-methoxybenzyl 
-C(=0)-0-Ra, -0-C(=O)-Ra, in particular -0-C(=O)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 
alkyl, 
-(CH2)m-[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd, in particular -(CH2)-[-0-
C(=O)-(CH2)2]p1-C(=O)ORd with 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
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m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in 
particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently from 
each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -C5Hs , 
-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
- with m being selected from 0, 1 or 2, in particular O or 1, 
- with q being selected from 0, 1 or 2, in particular O or 1. 
ln some embodiments, X2 is 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, 
-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -(CH2)m-
OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-
OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -
(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-
OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -
(CH2)m-NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-
S(02)NRbRa, -(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-
C( =Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -
(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other from -Ra or -ORa, 
- with Rba being selected independently from each other from -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an unsubstituted 
C1-Cs alkyl, 
- with m being selected from 0, 1 or 2, in particular O or 1, 
- with q being selected from 0, 1 or 2, in particular O or 1, 
- with each Ra, Rb or Re being selected independently from each other from 
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hydrogen, -CN, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-C16 alkoxy, a 
substituted or unsubstituted C1-C16 carboxy, a substituted or unsubstituted C2-C16 alkenyl, 
a substituted or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, and 
wherein a linker 0 5 may be optionally situated between BE and X2 
ln some embodiments, X2 is 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2CH3, -CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -(CH2)m-
OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-
OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-
SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-
OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, 
-(CH2)m-NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-
S(02)NRbRa, -(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-
O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-P(=Ü)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-
P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other from -Ra or -ORa, 
- with Rba being selected independently from each other from -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
- with m being selected from 0, 1 or 2, in particular O or 1, 
- with q being selected from 0, 1 or 2, in particular O or 1, 
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- with each Ra, Rb or Re being selected independently from each other from 
- hydrogen, -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -
CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C5Hs, --CH2C6Hs, 
wherein a linker os may be optionally situated between BE and X2 
ln some embodiments, in particular according to any one of the sub aspects 1 to 9 or 14 to 
16, BF is 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 halo 
cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, BF is 
ITYT 
~R:o 
wherein os has the same meaning as defined previously, and 
with T being selected from 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-
C(=O)ORa, -(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-
OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, 
-(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -
(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -
(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-
NRCC(=O)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-
NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -
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(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-
(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently 
from each other from 
hydrogen, 
-CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a 
substituted or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted 
or unsubstituted C3-C10 halo heterocycle, in particular a substituted 
or unsubstituted C4-C10 heterocycle or a substituted or 
unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
with n of R10n being 0, 1, 2, 3 or 4, in particular n of R10n being 0, 1, 2 or 3, 4, and 
with each R10 independently from any other R10 being selected from 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
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C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-
NRcC(=Ü)ÜRa, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted 
or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-
C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo 
cycloalkyl, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
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unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, BF is 
wherein 0 5 and T have the same meaning as defined previously, 
with n of R1n being 0, 1, 2, 3 or 4, in particular n of R1n being 0, 1, 2 or 3, and 
with each R1 independently from any other R1 being selected from 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NH CH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, 
-(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-
OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-
S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-
NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=Ü)QRa, 
-(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-
NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-
S(02)NRbRa, -(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, 
-(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-
(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-
(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, in particular C1 to C2 alkyl, 
with m being selected from 0, 1 or 2, in particular O or 1, 
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with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -CH(CH3)2, -
CH2CH(CH3)2, -C(CH3)3, -C5Hs, -CH2C6Hs. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
BF is 
wherein 0 5 and T have the same meaning as defined previously, 
with n of R10n being 0, 1, 2, 3 or 4, in particular n of R10n being 0, 1, 2 or 3, and 
with each R10 independently from any other R10 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -
S02NHCH3, -CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -
CF3, 
a substituted or unsubstituted Cs-CB heterocycle, 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB 
halo heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F, 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F, 
a substituted or unsubstituted C6 aryl. 
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ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
BF is 
wherein os and T have the same meaning as defined previously, 
with n of R10n being 0, 1, 2, 3 or 4, in particular n of R10n being 0, 1, 2 or 3, and with each R10 
independently from any other R10 being --OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, 
-NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -
S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -
CF3. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
BF is 
wherein os and T have the same meaning as defined previously, 
with n of R10n being 2, and with each R10 independently from any other R10 being 
-OH, -OCH3 or -OCF3, in particular OH or -OCH3, more particularly with one R10 being -OH 
and the other R10 being -OCH3, wherein further in particular OH is in meta and OCH3 or -
OCF3 in ortho position with respect to the attachment position of the phenyl moiety of BF to 
os, or 
with n of R10n being 1, and with R10 being -OH, wherein in particular OH is in meta position 
with respect to the attachment position of the phenyl of BF to os or 
with n of R10n being 1, and with R10 being -OCH3 or -OCF3,in particular or -OCH3, wherein 
more particularly -OCH3 or or -OCF3is in ortho position with respect to the attachment 
position of the phenyl of BF to os, or 
with n of R10n being 0, or 
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with n of R10n being 4 and each R10 is F. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
BF is 
wherein os and T have the same meaning as defined previously, 
with n of R10n being 0, 1, 2, 3 or 4, in particular n of R1n being 0, 1, 2 or 3, and with each R10 
independently from any other R10 being -OH, OCH3, -For -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
BF is 
wherein os and T have the same meaning as defined previously, 
with n of R10n being 1, 2, 3 or 4, in particular n of R10n being 1, 2 or 3, 
with one R10 being a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra,-
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -
(CH2)m-O-S(02)0Ra, with m being selected from 0, 1 or 2, in particular from 0 
or 1, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs 
or para-methoxybenzyl 
-C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 
alkyl, 
-(CH2)m-[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd, in particular -(CH2)-[-0-
C(=O)-(CH2)2]p1-C(=O)QRd with 
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m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in 
particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently from 
each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -C5Hs -
CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
and with the other R10 being selected independently from each other R10 from - OH, -F, -Cl, -
Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -
CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in particular from 
-OH, -F, -OCH3, -OCF3 or -CF3. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
BF is 
wherein 0 5 and T have the same meaning as defined previously, 
with n of R10n being 5, and one to four of R1 being F, one R10 being the 
substituent Q, and, where applicable, the other ones of R10 being selected 
independently from any other R1 from -H, -OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, 
-OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -CHCH2, 
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-CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in 
particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
with n of R10n being 5, and one to three of R10 being F, one R10 being the 
substituent Q, and, where applicable, the other ones of R10 being selected 
independently from any other R10 from -H,-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, 
-OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -CHCH2, 
-CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in 
particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
with n of R10n being 5, and one or two of R10 being F, one R10 being the 
substituent Q, and, where applicable, the other ones of R10 being selected 
independently from any other R10 from -H,-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, 
-OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -CHCH2, 
-CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in 
particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
with n of R10n being 5, and one of R10 being F, one R10 being the substituent Q, 
and, where applicable, the other ones of R10 being selected independently 
from any other R10 from -H,-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, 
-NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -CHCH2, -CH20H, -
S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in particular from -
OH, -F, -OCH3, -OCF3 or -CF3, or 
with n of R10n being 3, one R10 being the substituent Q, and the other R10 being 
selected independently from each other R10 from -H,-OH, -F, -Cl, -Br, -1, -CCH, 
-CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, 
-CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in 
particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
with n of R10n being 2, one R10 being the substituent Q and the other R10 being 
-H,-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -
S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in particular from -OH, -F, -
OCH3, -OCF3 or -CF3, or 
with n of R10n being 1 with R10 being the substituent Q, 
with Q having the same meaning as defined previously, and wherein in particular Q is in 
ortho position with respect to the attachment position of the phenyl moiety to the parent 
moiety, 
and wherein in particular any hydrogen of the phenyl group may be substituted with F. 
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ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
BF is 
with n of R10n being 2, and with one R10 being Q and the other R10 being -OCH3 or -OCF3, 
more particularly Q is in meta and OCH3 or -OCF3 is in ortho position with respect to the 
attachment position of the phenyl moiety of BB to 04, with Q and T having the same meaning 
as defined above. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
, or 
with T having the same meaning as defined above, 
with each T"' being selected from -CH2, -NH, -S, -0, or -NRc, in particular T"' is 0, 
with n of R10n being 0, 1, 2 or 3, in particular n of R11n being 0, 1 or 2, 
with each R10 being selected independently from any other R10 from -OH, -F, -Cl, -Br, -1, -
CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -
CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in particular from 
-OH, -F, -OCH3, -OCF3 or -CF3, or 
with each R10 being selected independently from any other R10 from -OH, -F, -Cl, -Br, -1, -
CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -CH20CH3, -
CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -N02, in particular from 
-OH, -F, -OCH3, -OCF3 or -CF3, wherein, each carbon atom of the cyclic system which 
comprises no substituent R10 comprises F instead of H 
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ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
-05-BF is 
, or 
with T having the same meaning as defined above, 
with each T"' being selected from -CH2, -NH, -S, -0, or -NRc, in particular T"' is 0, 
with n of R10n being 2, and with each R10 independently from any other R10 being -OH, -OCH3 
or -OCF3, in particular -OCH3 or -OCF3, more particularly with one R10 being -OH and the 
other R10 being -OCH3 or -OCF3, in particular -OCH3, wherein more particularly OH is in ortho 
and OCH3 or -OCF3 in meta position with respect to the attachment position of T, or 
with n of R10n being 1, and with R10 being -OH, wherein in particular OH is in ortho position 
with respect to the attachment position of T, or 
with n of R10n being 1, and with R10 being -OCH3 or -OCF3, in particular or -OCH3, wherein 
more particularly -OCH3 or -OCF3 is in meta position with respect to the attachment position 
of T, or 
with n of R10n being 0, or 
with n of R10n being 4 and each R10 is F. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
-05-BF is 
, or 
with T having the same meaning as defined above, 
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with each T"' being selected from -CH2, -NH, -S, -0, or -NRc, in particular T"' is 0, 
with n of R10n being 1, 2 or 3, in particular n of R10n being 1 or 2, 
with one R10 being a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, -
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -
(CH2)m-O-S(02)0Ra, with m being selected from 0, 1 or 2, in particular from 0 
or 1, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs 
or para-methoxybenzyl 
-C(=0)-0-Ra, -0-C(=O)-Ra, in particular -0-C(=O)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 
alkyl, 
-(CH2)m-[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd, in particular -(CH2)-[-0-
C(=O)-(CH2)2]p1-C(=O)ORd with 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in 
particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently from 
each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -C5Hs , 
-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
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i. with the other R11 being selected independently from any other R11 from -OH, -F, -
Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -
CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
ii. with the other R11 being selected independently from any other R11 from -OH, -F, -
Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -
CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, wherein, 
each carbon atom of the cyclic system which comprises no substituent R11 
comprises F instead of H. 
ln some embodiments, in particular according to any one of the sub aspects 1 to 17, 19, 21, 
24 or 27, 
, or 
with T having the same meaning as defined above, 
with each T"' being selected from -CH2, -NH, -S, -0, or -NRc, in particular T"' is 0, 
with n of R11n being O or 2, and with one R11 being Q and the other R11 being -OCH3 or -
OCF3, more particularly Q is in ortho and OCH3 or -OCF3 is in meta position with respect to 
the attachment position of T, with Q having the same meaning as defined above. 
ln some embodiments, in particular according to the sub aspect 32, with R1 being a 
substituent Q, Q is selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra,-
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, 
-(CH2)m-O-S(02)0Ra, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
-C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-
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C14 alkyl, -[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd or -[(CH2)m1-0-
(CH2)m2]p1-0Rd, in particular -[(CH2)m1 -O-(CH2)m2]p1-0Rd with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-( CH2)m-C( =0)0-( CH2)q-P( =0 }( Rba) (Raa), -(CH2)m-O-( CH2)q-P( =0 }( Rba) (Raa), 
in particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently 
from each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -
C6Hs , -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-
methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
ln some embodiments, in particular according to the sub aspect 32, 
with n of R1n being 5, and one to four of R1 being F, one R1 being the substituent Q, and, 
where applicable, the other ones of R1 being selected independently from any other R1 from -
OH, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3, in particular from -OH, -OCH3, -OCF3 or -CF3, or 
with n of R1n being 5, and one to three of R1 being F, one R1 being the substituent Q, and, 
where applicable, the other ones of R1 being selected independently from any other R1 from -
OH, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3, in particular -OH, -OCH3, -OCF3 or -CF3, or 
with n of R1n being 5, and one or two of R1 being F, one R1 being the substituent Q, and, 
where applicable, the other ones of R1 being selected independently from any other R1 from -
OH, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3, in particular -OH, -OCH3, -OCF3 or -CF3, or 
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with n of R1n being 5, and one of R1 being F, one R1 being the substituent Q, and, where 
applicable, the other ones of R1 being selected independently from any other R1 from -OH, -
Cl, 1, -CN, -OCH3, -OCF3 or -CF3, in particular -OH, -OCH3, -OCF3 or -CF3, or 
with n of R1n being 3, one R1 being the substituent Q, and the other R1 being selected 
independently from each other R1 from -OH, -OCH3, -OCF3 or -CF3. 
with n of R1n being 2, one R1 being the substituent Q and the other R1 being -OH, -OCH3, -
OCF3 or -CF3, or 
with n of R1n being 1 with R1 being the substituent Q, and with Q having the same meaning 
as defined previously, and wherein in particular Q is in para position with respect to the 
attachment position of the phenyl moiety of E to the parent moiety. 
ln some embodiments, in particular according to any one of the sub aspects 7, 8, 10, 11 to 
13, 22, 23, 25, 28, 29 or 32, 
R11 is a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra,-
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, 
-(CH2)m-O-S(02)0Ra, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzy 
-C(=0)-0-Ra, -0-C(=O)-Ra, in particular -0-C(=O)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-
C14 alkyl, -[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd or -[(CH2)m1-0-
(CH2)m2]p1-0Rd, in particular -[(CH2)m1 -O-(CH2)m2]p1-0Rd with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-( CH2)m-C( =0)0-( CH2)q-P( =0 }( Rba) (Raa), -(CH2)m-O-( CH2)q-P( =0 }( Rba) (Raa), 
in particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
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with Raa and Rba being selected, where applicable, independently 
from each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -
C6Hs , -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-
methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
, and, in particular, wherein, each carbon atom of the cyclic system which 
comprises no substituent R13 comprises F instead of H. 
ln some embodiments, in particular according to any one of the sub aspects 7, 8, 10, 11 to 
13, 22, 23, 25, 28, 29 or 32, 
R10 is a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, -
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, 
-(CH2)m-O-S(02)0Ra, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzy 
-C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-
C14 alkyl, -[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)QRd or -[(CH2)m1-0-
(CH2)m2]p1-0Rd, in particular -[(CH2)m1 -O-(CH2)m2]p1-0Rd with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-( CH2)m-C( =Ü)O-( CH2)q-P( =Ü }( Rba) (Raa), -(CH2)m-O-( CH2)q-P( =Ü }( Rba) (Raa), 
in particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
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with Raa and Rba being selected, where applicable, independently 
from each other from -Ra or -ORa and 
- with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -
C6Hs , -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-
methoxybenzyl 
- with m being selected from 0, 1 or 2, in particular O or 1, 
- with q being selected from 0, 1 or 2, in particular O or 1, 
and, in particular, wherein, each carbon atom of the cyclic system which 
comprises no substituent R13 comprises F instead of H. 
ln some embodiments, in particular according to any one of the sub aspects 10 to 13, 18 to 
32, T is selected from 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-
C(=O)ORa, -(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-
OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, 
-(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -
(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -
(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-
NRCC(=O)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-
NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -
(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-
(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
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with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, 
-CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted 
C1-C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted 
or unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 
alkynyl, or a C1-C16 haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 
halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
ln some embodiments, in particular according to any one of the sub aspects 10 to 13, 18 to 
32, T is selected from 
a. -B(OH)2, -CN, -NH2, -OH, -OCH3, -C(=O)NH2, -C(=O)NH(CN), -C(=O)NH(OH), 
-CH20H, -CH2C(=O)OH, -CH2C(=O)NH(OH), -CH2C(=O)NH2, -
CH2NHS(02)0H, -CH2NHC(=O)OH, -P(=O)(OH)(OH), -CH2P(=O)(OH)(OH), -
CH2S(02)0H, -S(02)0H or -S(02)NH2 or 
b. -Ra, -CH2Ra, -SRa, -CH2SRa, -S(=O)Ra, -C(=O)NHRa, -CH2C(=O)NHRa, -
CH2NHS(02)Ra, -C(=O)ORa, -ORa or -NHRa,-C(=O)ORa, -CH2C(=O)NH(ORa), 
-C(=O)NHORa, -C(=O)NHRa, -(CH2)m-NHC(=O)ORa, -CH2NHS(02)Ra, -
CH20Ra, -CH2NHC(=O)Ra, -P(=O)(OH)(ORa), -CH2P(=O)(OH)(ORa), -
P(=O)(OH)(Ra), - CH2P(=O)(OH)(Ra), -CH2S(02)0Ra, -S(02)0Ra, -S(02)Ra or -
CH2S(02)Ra, or -S(02)NHRa, 
with Ra being selected from 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C2-C14 
alkenyl, a substituted or unsubstituted C2-C14 alkynyl, or a C1-C14 
haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, 
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more particularly Rais -CH3, -CF3, -CH2CH3, -CH2CF3, -CN, ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzy 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, -[(CH2)m1-C( =0)0-(CH2)m2]p1-0Rd in particular -
[-O-(CH2)2]p1-0Rd, -[-C(=O)O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
c. -Ra, -CH2Ra, -SRa, -CH2SRa, -S(=O)Ra, -C(=O)NHRa, -CH2C(=O)NHRa, -
CH2NHS(02)Ra, -C(=O)ORa, -ORa or -NHRa, 
with Ra being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-
C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, in particular according to any one of the sub aspects 10 to 13, 18 to 
32, T is selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, -(CH2)m-O-S(02)0H, 
-(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, with Ra being -
CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzy 
-C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a substituted or 
unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 alkyl, -[(CH2)m1-0-C(=O)-
(CH2)m2]p1-C( =Ü)QRd or -[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[(CH2)m1 -O-(CH2)m2]p1-0Rd 
with 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
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m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in particular from 
-(CH2)m-O-( CH2)q-P( =Ü) (Rba) (Raa), 
with Raa and Rba being selected, where applicable, independently 
from each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -
C6Hs , -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-
methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
ln some embodiments, in particular according to any one of the sub aspects 10 to 13, 18 to 
32, T is -C(=O)ORa 
with Ra being 
a substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted 
C1-C16 alkyl, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, -[(CH2)m1-C( =0)0-(CH2)m2]p1-0Rd, in particular 
-[-O-(CH2)2]p1-0Rd, -[-C(=O)O-(CH2)2]p1,, with 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8. 
ln some embodiments, in particular according to any one of the sub aspects 10 to 13, 18 to 
32, T is selected from the following compounds 
-B(OH)2, -CN, -OH, -CH20H, -CH20CH3, -OCH3, -C(=O)NH2, -C(=O)NH(CN), -
C(=O)OH, -C(=O)NH(CH3), -C(=O)NH(OH), -S(02)NH2, -CH2C(=O)OH, -
CH2C(=O)NHOH, -CH2-NH-S(0)2CF3, -CH2-C(=O)-NH-OCH3, -P(=O)(OH)2, -
CH2)P(=O)(OH)2, -P(=O)(OH)(OCH2CH3), -P(=O)(OH)(CH3), -CH2P(=O)(OH)(CH3), -
CH2S(0)2(0H), -S(0)2(0H), 
104 
wo 2014/125075 PCT /EP2014/052922 
0 S 
l-~---{l ~ 'YL{îl ~----u ~----u 
N- N-- OH OH 
' ' ' 
() O-._N /---11 
7z-'l("oH ~J ~~OH V 'r" 
' ' ' 




ln some embodiments, in particular according to any one of the sub aspects, each 0 1 to 0 5 is 
selected independently from each other from 
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R (017), R (018), R (019), 
with each R8 being -H, or, where applicable, with each R8 being selected 
independently from each other from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -
CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with each R8 
being selected independently from each other from H or CH3, more particularly 
R8 being H, and 
with V being, where applicable, S, NH or 0, in particular V being O. 
01 to 05 may also be a phosphor containing groups, in particular a 0-P containing 
functionality such as -OP(0)2-NH- or alike. 
ln some embodiments, in particular according to any one of the sub aspects, each 0 1 to 0 5 is 
selected independently from each other from 
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V 
~ .,)l-_N-~ ~/"N-~ 
la la 
(010), 
R (01 ), R 
(012), 
with each R8 being -H, or, where applicable, with each R8 being selected 
independently from each other from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -
CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with each R8 
being selected independently from each other from H or CH3, more particularly 
R8 being H, and 
with V being, where applicable, S, NH or 0, in particular V being O. 
ln some embodiments, in particular according to any one of the sub aspects, each 0 1 to 0 5 is 
selected independently from each other from 
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with each R8 being -H, or, where applicable, with each R8 being selected 
independently from each other from -H, -CH3, -CH2CH3, -OCH3, -OCF3, 
-CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with each R8 
being selected independently from each other from H or CH3, more particularly 
R8 being H, and 
with V being, where applicable, S, NH or 0, in particular V being O. 
ln some embodiments, in particular according to any one of the sub aspects, each 0 1 to os is 
selected independently from each other from 
V 





R (01 ), R (02), R (03) or 
with each R8 being -H, or, where applicable, with each R8 being selected 
independently from each other from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -
CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with each R8 
being selected independently from each other from H or CH3, more particularly 
R8 being H, and 
with V being, where applicable, S, NH or 0, in particular V being O. 
ln some embodiments, in particular according to any one of the sub aspects, each 0 1 to os is 
selected independently from each other from 
~,l~-~ ~~~-~ ~-0)_~-~ 
(01 a), (02a), (03a) or 
0 )l ~-~ ~-~ 
(04a), in particular from 
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~,l~-~ ~~~-~ ~ -1~-~ 
(01 a), (02a) or (04a). 
ln some embodiments, in particular according to any one of the sub aspects 11 to 13, 24 to 
31, R2 and R3 of BA are selected, where applicable, independently from each other from -H, -
F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, 
-OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3,more particularly 
with R2 and R3 being selected independently from each other from -H, -For -CH3. 
ln some embodiments, in particular according to any one of the sub aspects 2, 4, 6, 8, 9, 14 
to 31 each R8 is, where applicable, selected independently from each other from -H, -CH3, -
CH2CH3, -OCH3, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular 
with each R8 being selected independently from each other from H or CH3, more particularly 
each R8 being H. 
According to a sub aspect (sub aspect 32) of the first aspect, the invention relates to 
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(formula 
34), 
a. with n of R1n being 1, 2, 3, 4 or 5, in particular n of R1n being 1, 2 or 3, with R1 of BA being a 
substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, -
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, 
-(CH2)m-O-S(02)0Ra, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
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-C(=0)-0-Ra, -0-C(=O)-Ra, in particular -0-C(=O)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-
C14 alkyl, -[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd or -[(CH2)m1-0-
(CH2)m2]p1-0Rd, in particular -[(CH2)m1 -O-(CH2)m2]p1-0Rd with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-( CH2)m-C( =0)0-( CH2)q-P( =0 }( Rba) (Raa), -(CH2)m-O-( CH2)q-P( =0 }( Rba) (Raa), 
in particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently 
from each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -
C6Hs , -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-
methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, , 
and with the other R1 being selected independently from each other R1 from -OH, 
-F, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular from -OH, -F, -OCH3, -OCF3, -
OCONH2 or -CF3, or 
with n of R1n being 5, and one to four of R1 being F, one R1 being the substituent Q, and, 
where applicable, the other ones of R1 being selected independently from any other R1 from -
OH, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular from -OH, -OCH3, -OCF3, -
OCONH2 or -CF3, or 
with n of R1n being 5, and one to three of R1 being F, one R1 being the substituent Q, and, 
where applicable, the other ones of R1 being selected independently from any other R1 from -
OH, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -
OCONH2 or -CF3, or 
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with n of R1n being 5, and one or two of R1 being F, one R1 being the substituent Q, and, 
where applicable, the other ones of R1 being selected independently from any other R1 from -
OH, -Cl, -1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -
OCONH2 or -CF3, or 
with n of R1n being 5, and one of R1 being F, one R1 being the substituent Q, and, where 
applicable, the other ones of R1 being selected independently from any other R1 from -OH, -
Cl, 1, -CN, -OCH3, -OCF3, -OCONH2 or -CF3, in particular -OH, -OCH3, -OCF3, -OCONH2 or -
CF3, or 
with n of R1n being 3, one R1 being the substituent Q, and the other R1 being selected 
independently from each other R1 from -OH, -OCH3, -OCF3, -OCONH2 or -CF3. 
with n of R1n being 2, one R1 being the substituent Q and the other R1 being -OH, -OCH3, -
OCF3, -OCONH2 or -CF3, or 
with n of R1n being 1 with R1 being the substituent Q, and with Q having the same meaning 
as defined previously, and wherein in particular Q is in para position with respect to the 
attachment position of the phenyl moiety of E to the parent moiety, and 
b. R11 is a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, -
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, 
-(CH2)m-O-S(02)0Ra, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
-C(=0)-0-Ra, -0-C(=O)-Ra, in particular -0-C(=O)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-
C14 alkyl, -[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd or -[(CH2)m1-0-
(CH2)m2]p1-0Rd, in particular -[(CH2)m1 -O-(CH2)m2]p1-0Rd with 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
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-(CH2)m-C( =Ü)O-( CH2)q-P( =Ü }( Rba) (Raa), -(CH2)m-O-( CH2)q-P( =Ü }( Rba) (Raa), 
in particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently 
from each other from -Ra or -ORa and 
- with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -
C6Hs , -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-
methoxybenzyl 
- with m being selected from 0, 1 or 2, in particular O or 1, 
- with q being selected from 0, 1 or 2, in particular O or 1, 
and, in particular, wherein, each carbon atom of the cyclic system which 
comprises no substituent R11 comprises F instead of H, and 
c. with T being selected from 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-
C(=O)ORa, -(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-
OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, 
-(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -
(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -
(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-
NRCC(=O)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=Ü)ÜRa,-(CH2)m-
NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-
NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -
(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-
(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
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with q being selected from 0, 1 or 2, in particular O or 1, , 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, 
-CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted 
C1-C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted 
or unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 
alkynyl, or a C1-C16 haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 
halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, or 
with T being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, -
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, 
-(CH2)m-O-S(02)0Ra, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
-C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-
C14 alkyl, -[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)QRd or -[(CH2)m1-0-
(CH2)m2]p1-0Rd, in particular -[(CH2)m1 -O-(CH2)m2]p1-0Rd with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
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m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-C( =Ü)O-( CH2)q-P( =Ü }( Rba) (Raa), -(CH2)m-O-( CH2)q-P( =Ü }( Rba) (Raa), 
in particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently 
from each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -
C6Hs -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-
methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, or 
with T being selected from 
-B(OH)2, -CN, -NH2, -OH, -OCH3, -C(=O)NH2, -C(=O)NH(CN), -C(=O)NH(OH), 
-CH20H, -CH2C(=O)OH, -CH2C(=O)NH(OH), -CH2C(=O)NH2, -
CH2NHS(02)0H, -CH2NHC(=O)OH, -P(=O)(OH)(OH), -CH2P(=O)(OH)(OH), -
CH2S(02)0H, -S(02)0H or -S(02)NH2 or 
-Ra, -CH2Ra, -SRa, -CH2SRa, -S(=O)Ra, -C(=O)NHRa, -CH2C(=O)NHRa, -
CH2NHS(02)Ra, -C(=O)ORa, -ORa or -NHRa,-C(=O)ORa, -CH2C(=O)NH(ORa), 
-C(=O)NHORa, -C(=O)NHRa, -CH2NHS(02)Ra, -(CH2)-NHC(=O)ORa, -
CH20Ra, -CH2NHC(=O)Ra, -P(=O)(OH)(ORa), -CH2P(=O)(OH)(ORa), -
P(=O)(OH)(Ra), - CH2P(=O)(OH)(Ra), -CH2S(02)0Ra, -S(02)0Ra, -S(02)Ra or -
CH2S(02)Ra, or -S(02)NHRa, 
with Ra being selected from 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C2-C14 
alkenyl, a substituted or unsubstituted C2-C14 alkynyl, or a C1-C14 
haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, 
more particularly Rais -CH3, -CF3, -CH2CH3, -CH2CF3, -CN, ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzy 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, -[(CH2)m1-C( =0)0-(CH2)m2]p1-0Rd in particular -
[-O-(CH2)2]p1-0Rd, -[-C( =0)0-(CH2)2]p1-0Rd ,with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
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m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-Ra, -CH2Ra, -SRa, -CH2SRa, -S(=O)Ra, -C(=O)NHRa, -CH2C(=O)NHRa, -
CH2NHS(02)Ra, -C(=O)ORa, -ORa or -NHRa, 
with Ra being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-
C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, or 
with T being is -C(=O)ORa 
with Ra being 
a substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted 
C1-C16 alkyl, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, -[(CH2)m1-C( =0)0-(CH2)m2]p1-0Rd, in particular 
-[-O-(CH2)2]p1-0Rd, -[-C(=O)O-(CH2)2]p1,, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, or 
T is selected from the following compounds 
-B(OH)2, -CN, -OH, -CH20H, -CH20CH3, -OCH3, -C(=O)NH2, -C(=O)NH(CN), -
C(=O)OH, -C(=O)NH(CH3), -C(=O)NH(OH), -S(02)NH2, -CH2C(=O)OH, -
CH2C(=O)NHOH, -CH2-NH-S(0)2CF3, -CH2-C(=O)-NH-OCH3, -P(=O)(OH)2, -
CH2)P(=O)(OH)2, -P(=O)(OH)(OCH2CH3), -P(=O)(OH)(CH3), -CH2P(=O)(OH)(CH3), -
CH2S(0)2(0H), -S(0)2(0H), 
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d. R10 is a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra,-
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, 
-(CH2)m-O-S(02)0Ra, with Ra being -CH3, -CH2CH3, -C5Hs ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
-C(=Ü)-0-Ra, -0-C(=Ü)-Ra, in particular -0-C(=Ü)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-
C14 alkyl, -[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)QRd or -[(CH2)m1-0-
(CH2)m2]p1-0Rd, in particular -[(CH2)m1 -O-(CH2)m2]p1-0Rd with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
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m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-( CH2)m-C( =0)0-( CH2)q-P( =0 }( Rba) (Raa), -(CH2)m-O-( CH2)q-P( =0 }( Rba) (Raa), 
in particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently 
from each other from -Ra or -ORa and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -
C6Hs , -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-
methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
and, in particular, wherein, each carbon atom of the cyclic system which 
comprises no substituent R10 comprises F instead of H, and 
e. with Y being selected from -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) or -
C(=O)NH2, and 
f. with Z being selected from -H, -OH, -CH3, -CH2CH3 or -OCH3, in particular Z is H and Y is CN 
or -C(=O)NH2. 
ln some embodiments, the compounds of the invention comprise the following formula (1A) 





X d I H 
'.:::: 0 '7 N ~ 
~~._;.Â.N ,,_ 1 H 
0 ~" H z y 
(1A) 
wherein 
Z is -H, -OH, -CH3, -CH2CH3 or -OCH3 and Y is -CN, -C(=O)OH, -C(=O)OCH3, 
-C(=O)OCH2CH3, -C(=O)NHCH3, -C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, 
-C(=O)N(CH3)(CH2CH3) or -C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, and 
more particularly Z is H and Y is CN, and wherein 
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a. Xis 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -N02, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3 or -CF3, or 
- -B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -
(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-NRCC(=O)ORa, 
-(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-
S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -
(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-NRcS(02)Ra, -
(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-
O-C(=O)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -
(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-
C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other from -Ra or -ORa, 
with Rba being selected independently from each other from -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
with m being selected from 0, 1 or 2, 
with q being selected from 0, 1 or 2, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CN, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 
halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted 
C1-C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted 
or unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 
alkynyl, or a C1-C16 haloalkyl, in particular a substituted or unsubstituted 
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b. Xis 
c. Xis 
C1-Cs alkyl, a substituted or unsubstituted C2-Cs alkenyl, a substituted or 
unsubstituted C2-Cs alkynyl, or a substituted or unsubstituted C1-Cs 
haloalkyl; or wherein 
with D being a linker which comprises carbon, sulphur, nitrogen and/or oxygen 
atoms and which is covalently connecting R4 and the parent moiety PM, and 
with R4 being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs 
alkoxy, a substituted or unsubstituted C2-Cs alkenyl, a substituted or 
unsubstituted C2-Cs alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted 
C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo 
heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl; or wherein 
R2 
E,oAD- ~ E--f7'o-< 
or S 
with R2 and R3 being selected, where applicable, independently from each other 
from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or 
unsubstituted C1-C3 alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 
haloalkyl , in particular from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -
CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -
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CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 and R3 being 
selected independently from each other from H, For CH3, and 
with D being a linker which comprises carbon, sulphur, nitrogen and/or oxygen 
atoms and which is covalently connecting the moiety comprising E and the parent 
moiety, 
with E being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs 
alkoxy, a substituted or unsubstituted C2-Cs alkenyl, a substituted or 
unsubstituted C2-Cs alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted 
C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo 
heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted Cs-C10 aryl; or 
with E being 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2, more 
particularly n being 1, and 
with each R1 independently from any other R1 being 
OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -N02, -OCH3, -OCF3, -NH2, -
NHCH3, -N(CH3)2, -CH3, -CH2CH3, -OCONH2 or -CF3, or 
B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-
C(=O)ORa, -(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-
OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -
(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-
SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-
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OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-NRCC(=O)Ra, -
(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-NRcC(=S)Ra, -
(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-NRcS(02)Ra, -
(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(ORb)(Ra) or -(CH2)m-S(02)NRbRa, 
-(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-
O-C( =Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-P( =O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-
C( =0)0-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other from -Ra or -
ORa, 
with Rba being selected independently from each other from -Rb or -
QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
with m being selected from 0, 1 or 2, 
with q being selected from 0, 1 or 2, 
with each Ra, Rb or Re being selected, where applicable, independently 
from each other from 
hydrogen, -CN, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted 
or unsubstituted C3-C10 halo heterocycle, in particular a substituted 
or unsubstituted C4-C10 heterocycle or a substituted or 
unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a 
substituted or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in 
particular a substituted or unsubstituted C1-Cs alkyl, a substituted 
or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-
Cs alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl; or 
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with E being selected from 
with each T being selected independently from each other from -CH2, -NH, -Sor 
-0, -CHCH3, -C(CH3)2 or -NRc, 
with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, and 
with T" being selected from -CH or =N, and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, 
-CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in 
particular with R5 and R6 being selected independently from each other from H, 
-For -CH3, and 
with R6' being selected from OH, -OCH3, -OCH2CH3, -CH3, 
with R7 being selected from =NH, =Sor =Ü, and 
with m of R9m being selected from 0, 1, 2 or 3, and each R9 being selected 
independently from each other from -Cl, -F, Br, 1, -OH, -CCH, -CN -CH3, -
CH2CH3, -OCH3, -COOH, -COQRb, -C(O)NH2, -C(O)NH(CH3); -C(O)N(CH3)2 -
NHC(=O)OCH3, -NCH3C(=O)OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F 
or -CF3, 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, 
or a C1-Cs haloalkyl, wherein 
* indicates a stereo center of a L- or D- enantiomer, which is located on the tertiary carbon 
atom below the asterisk *, and wherein the compound of the general formula 1 is an 
essentially pure L-enantiomer, an essentially pure D-enantiomer or a mixture of the L- and D-
enantiomer of the same molecular formula. 
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ln some embodiments, the compounds of the invention are characterized by the formula 1 L 
(1 L). 
ln some embodiments, the compounds of the invention are characterized by the formula 1 D 
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0 ~" H 
z y (1 D). 
ln some embodiments, the compounds of the invention relates to a mixture of the L- and D-
enantiomer of the same molecular formula. 
ln some embodiments, Z of the general formula 1 is -H, -OH, -CH3, -CH2CH3 or -OCH3 and Y 
is -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -C(=O)NHCH2CH3, 
-C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) or -C(=O)NH2. 
ln some embodiments, Z of the general formula 1 is -H and Y is -CN or -C(=O)NH2. 
ln some embodiments, Z of the general formula 1 is -H and Y is -CN. 
ln some embodiments, the compounds of the invention are characterized by a general 
formula 1, 
with X being 
- -H, -OH, -F, -Cl, -Br, 1, -NH2, -CN, -COOH, -N3 or -N02, or 
- -NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, -ORa, -OC(=O)Ra -OC(=O)ORa, 
-OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa, -NHC(=O)ORa, 
-C(=S)Ra, -C(=S)ORa, -SRa, -OC(=S)Ra, -OC(=S)ORa, -OC(=S)NHRa, 
-NHC(=S)Ra, -NHC(=S)NHRa, -C(=S)NHRa or -NHC(=S)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
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a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted 
C3-C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 
heterocycle or a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, wherein 
Z is -H, -OH, -CH3, -CH2CH3 or -OCH3 and Y is -CN, -C(=O)OH, -C(=O)OCH3, 
-C(=O)OCH2CH3, -C(=O)NHCH3, -C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, 
-C(=O)N(CH3)(CH2CH3) or -C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, more 
particularly Z is H and Y is CN. 
ln some embodiments, the compounds of the invention are characterized by a general 
formula 1A, 
with X being 
-H, -OH, -F, -Cl, -Br, 1, -NH2, -CN, -COOH, -N3 or -N02, or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, -ORa or -OC(=O)Ra 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, wherein 
Z is -H, -OH, -CH3, -CH2CH3 or -OCH3 and Y is -CN, -C(=O)OH, -C(=O)OCH3, 
-C(=O)OCH2CH3, -C(=O)NHCH3, -C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, 
-C(=O)N(CH3)(CH2CH3) or -C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, more 
particularly Z is H and Y is CN. 
ln some embodiments, X of the general formula 1 A is 
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with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle,or 
a substituted or unsubstituted Cs-C10 heteroaryl, in particular a substituted or 
unsubstituted 1,2,3-triazole, a substituted or unsubstituted 1.2.4-triazole, a substituted 
or unsubstituted indole, a substituted or unsubstituted isoindole, a substituted or 
unsubstituted quinoline or a substituted or unsubstituted isoquinoline, wherein 
Z is -H, -OH, -CH3, -CH2CH3 or -OCH3 and Y is -CN, -C(=O)OH, -C(=O)OCH3, 
-C(=O)OCH2CH3, -C(=O)NHCH3, -C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, 
-C(=O)N(CH3)(CH2CH3) or -C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, more 
particularly Z is H and Y is CN. 
ln some embodiments, X of the general formula 1 A is 
-NRa2, -NHRa or -C(=O)ORa, in particular X is -NRa2 or -NHRa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, wherein 
Z is -H, -OH, -CH3, -CH2CH3 or -OCH3 and Y is -CN, -C(=O)OH, -C(=O)OCH3, 
-C(=O)OCH2CH3, -C(=O)NHCH3, -C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, 
-C(=O)N(CH3)(CH2CH3) or -C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, more 
particularly Z is H and Y is CN. 
ln some embodiments, the compound of the general formula 1 is an essentially pure L-
enantiomer, an essentially pure D-enantiomer or a mixture of the L- and D-enantiomer of the 
same molecular formula, wherein in particular the compound of the general formula 1 is an 
essentially pure L-enantiomer or an essentially pure D-enantiomer, more particularly an 
essentially pure L-enantiomer. 
ln some embodiments, the compound of the invention is characterized by the formula 1, 
wherein 
Z is -H, -OH, -CH3, -CH2CH3 or -OCH3 and Y is -CN, -C(=O)OH, -C(=O)OCH3, 
-C(=O)OCH2CH3, -C(=O)NHCH3, -C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, 
-C(=O)N(CH3)(CH2CH3) or -C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, and 
wherein 
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the compound of the general formula 1 Ais an essentially pure L-enantiomer, an essentially 
pure D-enantiomer or a mixture of the L- and D-enantiomer of the same molecular formula, 
and wherein 
Xis 
- with D being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms 
and which is covalently connecting R4 and the parent moiety PM, and 
- with R4 being 
Xis 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs 
alkoxy, a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted 
C2-Cs alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted 
C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted 
C3-C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 
heterocycle or a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl; or wherein 
- with R2 and R3 being selected, where applicable, independently from each other from -
H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 
alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular 
from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -
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OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -
CH2F or -CF3,more particularly with R2 and R3 being selected independently from each 
other from H, For CH3, and 
- with D being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms 
and which is covalently connecting the moiety comprising E and the parent moiety PM, 
- with E being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs 
alkoxy, a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted 
C2-Cs alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted 
C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted 
C3-C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 
heterocycle or a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted Cs-C10 aryl; or 
- with E being 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -N02, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, 
-CH3, -CH2CH3, -OCONH2 or -CF3, or 
- -B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -
(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -
(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-ÜC(=S)ORa, -(CH2)m-
OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-
S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-
NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=Ü)QRa, -
(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-
NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-
S(02)NRbRa, -(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -
(CH2)m-O-C(=O)-(M)-Ra, -(CH2)m-O-(CH2)q-P(=Ü)(Rba)(Raa), -(CH2)m-C(=0)0-
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(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-
(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other from -Ra or -ORa, 
with Rba being selected independently from each other from -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
with m being selected from 0, 1 or 2, 
with q being selected from 0, 1 or 2, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
- with E being 
hydrogen, -CN, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 
halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted 
C1-C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a 
substituted or unsubstituted C2-C16 alkenyl, a substituted or 
unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted 
C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl; 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more 
particularly n being 1, and 
with each R1 independently from any other R1 being 
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- with E being 
PCT /EP2014/052922 
-OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -
OCONH2 or -N02, or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, 
-OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -
NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted 
or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 
halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, or 
with each T being selected independently from each other from -CH2, -NH, -Sor 
-0, -CHCH3, -C(CH3)2 or -NRc, 
with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, and 
with T" being selected from -CH or =N, and 
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with R5 and R6 being selected independently from each other from -H, -F, -CH3, 
-CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in 
particular with R5 and R6 being selected independently from each other from H, 
-For -CH3, and 
with R6' being selected from -OH, -OCH3, -OCH2CH3, -CH3, 
with R7 being selected from =NH, =Sor =0, and 
with m of R9m being selected from 0, 1, 2 or 3, and each R9 being selected 
independently from each other from -Cl, -F, -Br, -1, -OH, -CCH, -CN -CH3, -
CH2CH3, -OCH3, -COOH, -COORb, -C(O)NH2, -C(O)NH(CH3); -C(O)N(CH3)2, -
NHC(=O)OCH3, -NCH3C(=O)OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F 
or -CF3, 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
C1-Cs haloalkyl. 
ln some embodiments, 0 of the general formula 1 A is selected from 
V 
~ ,)l-_N-~ ~/"N-~ 
1 a I a 
R (01 ), R 
V 
S.-o~~ ~ (010), (012), 
S/"8_< r,y-~ h~-, ~ 
<: S (013), o (013'), o o (013"), 
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R (020) or R (021 ), 
with each R8 being -H, or, where applicable, with each R8 being selected independently from 
each other from -H, -CH3, -CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3, in particular each R8 is selected independently from each other from H or CH3, and 
with V being, where applicable, S, NH or 0, in particular V being O. 
ln some embodiments, 0 of the general formula 1 A is selected from 
V 
~ ,)l-_N-~ ~/"N-~ 
1 s I s 
R (01 ), R 
V V 
~-~} ~-N)lO-~ )( l 8 S/""'o-~ l 8 >--o ~ 
R (07), ~ S (08), R (09), ~ ~ 
(010), (012), 
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with each R8 being -H, or, where applicable, with each R8 being selected independently from 
each other from -H, -CH3, -CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3, in particular each R8 is selected independently from each other from H or CH3, more 
particularly R8 is -H, and 
with V being, where applicable, S, NH or 0, in particular V being O. 
ln some embodiments, 0 of the general formula 1 A is selected from 
V 
~ ,)l-_N-~ ~~N-~ 
1 a I a 




(02), R (03), 
with each R8 being -H, or, where applicable, with each R8 being selected independently from 
each other from -H, -CH3, -CH2CH3, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3, in particular each R8 is selected independently from each other from H or CH3, more 
particularly R8 is -H, and 
with V being, where applicable, S, NH or 0, in particular V being O. 




(02), R (03) or 
with each R8 being -H, or, where applicable, with each R8 being selected independently from 
each other from -H, -CH3, -CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3, in particular each R8 is selected independently from each other from H or CH3, more 
particularly R8 is -H, and 
with V being, where applicable, S, NH or 0, in particular V being O. 
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ln some embodiments, R4 of the general formula 1 A is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, 
or a substituted or unsubstituted C1-Cs haloalkyl; or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl; or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle; in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl; or 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, R4 of the general formula 1 A is 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, R4 of the general formula 1 A is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a 
C1-Cs haloalkyl, a substituted or unsubstituted C3-C10 cycloalkyl, or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
ln some embodiments, R4 of the general formula 1 A is 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of the 
heterocycle to the D moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetralin or indane, 
a substituted or unsubstituted halo heteroaryl comprising one or two halogen atoms 
selected from Cl of F, particularly comprising one Cl or one F in para position (in case of 
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a C6 halo heteroaryl) in relation to the attachment position of the heterocycle to the D 
moiety; or 
R4 is selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 1,2,4-
triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, 
naphatalene, coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, 
benzofurane, benzothiophene, benzimidazol, benzthiazole, benzoxazole or 
benzpyridazin or hydroxylated, methylated or halogenated derivatives thereof .. 








ln some embodiments, R4 of the general formula 1 A is 
a substituted or unsubstituted C1-Cs alkyl or a substituted or unsubstituted C5-C10 
cycloalkyl, a substituted or unsubstituted Cs-C10 heteroaryl or a substituted or 
unsubstituted C5-C10 aryl. 
ln some embodiments, R4 of the general formula 1 A is 
a straight or branched C1-Cs alkyl or a C5-C10 cycloalkyl ring or polyring structure 
ln some embodiments, X of the general formula 1 A is 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, 
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-OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3,more particularly 
with R2 and R3 being selected independently from each other from H, For CH3. 
lt is understood that a general expert will identify - on basis of his basic knowledge -
combinations of the above mentioned selection, which will not lead to stable compounds. For 
example, the first mentioned structure will lead to stable compounds if R2 or R3 are selected 
from -H or -CH3 but not if they are chosen from -OH or NH2. However, the third mentioned 
structure will lead to stable compounds if R2 is -OH or NH2. 
ln some embodiments, X of the general formula 1 A is 
R2 
E,oAD- ~ or E--f?'o- ~ 
with R2 and R3 being selected independently from each other from H or CH3, in particular 
with R2 being H and R3 being CH3 or R2 being H and R3 being H. 
ln some embodiments, E of the general formula 1 A is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, 
or a substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted Cs-C10 aryl. 
ln some embodiments, E of the general formula 1 A is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a 
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C1-Cs haloalkyl, a substituted or unsubstituted C3-C10 cycloalkyl, or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
ln some embodiments, E of the general formula 1 A is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C5-C10 
cycloalkyl, or a substituted or unsubstituted Cs-C10 heteroaryl or a substituted or 
unsubstituted Cs-C10 aryl, or 
ln some embodiments, E of the general formula 1 A is 
a substituted or unsubstituted C3-C10 heterocycle or C3-C10 halo heterocycle, in particular 
a substituted or unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 
halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, E of the general formula 1 A is 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of the 
heterocycle to the D moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F in para position in 
relation to the attachment position of the heteroaryl to the D moiety; or 
E is selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 1,2,4-
triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, 
naphatalene, coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, 
benzofurane, benzothiophene, benzimidazol, benzthiazole, benzoxazole or 
benzpyridazin or hydroxylated, methylated or halogenated derivatives thereof ,or 
E is selected from . 
136 
wo 2014/125075 PCT /EP2014/052922 
~~ m-~ 
R , in particular from HO~O~O 
HOfXY~ 
or 
- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n being 1, and 
- with each R1 independently from any other R1 being selected from 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
- -B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other being -Ra or -ORa, 
- with Rba being selected independently from each other being -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
- with m being selected from 0, 1 or 2, 
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with q being selected from 0, 1 or 2, 
with each Ra, Rb or Re being selected, where applicable, independently 
from each other from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted or 
unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-C10 
cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl, in particular 
with each R1 independently from any other R1 being -OH, -F, -Cl, 1, -CN, -
OCH3, -OCF3 or -CF3. 
ln some embodiments, E of the general formula 1 A is 
with n of R1n being 0, 1, 2, 3, 4 or 5, or 
with n of R1n being 0, 1 or 2, or 
with n of R1n being O or 1, or 
with n of R1n being 1, or 
with n of R1n being O. 
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ln some embodiments, E of the general formula 1 A is 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -N02, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3, -OCONH2 or -CF3, or 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -(CH2)m-
OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -
(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -
(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -
(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, 
-(CH2)m-OS(02)ÜRa, -(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -
(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -(CH2)m-O-
C(=O)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), -
(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-
C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other from -Ra or -ORa, 
- with Rba being selected independently from each other from -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
- with m being selected from 0, 1 or 2, 
- with q being selected from 0, 1 or 2, 
- with each Ra, Rb or Re being selected, where applicable, independently from each 
other from 
hydrogen, -CN, 
- a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
- a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
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unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo 
heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
- a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-
C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or 
unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or 
a C1-C16 haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-
Cs alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl. 
ln some embodiments, E of the general formula 1 A is 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 0 
or 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -
N02, or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, 
-OC(=O)ORa, -OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, 
-C(=O)NHRa, -NHC(=O)ORa, -C(=S)Ra, -C(=S)ORa, -SRa, 
-OC(=S)Ra, -OC(=S)ORa, -OC(=S)NHRa, -NHC(=S)Ra, 
-NHC(=S)NHRa, -C(=S)NHRa or -NHC(=S)ORa, in particular 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, , 
- with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle; in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
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with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 0 
or 1, and 
a. with each R1 independently from any other R1 being 
-OH, -F, -Cl, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of 
the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F in para position 
in relation to the attachment position of the heteroaryl to the benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
b. with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
c. with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the remaining structure. 
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ln some embodiments, E of the general formula 1 A is 
with each T being selected independently from each other from -CH2, -NH, -Sor 
-0, -CHCH3, -C(CH3)2 or -NRc, 
with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, and 
with T" being selected from -CH or =N, and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, 
-CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in 
particular with R5 and R6 being selected independently from each other from H, 
-For -CH3, and 
with R6' being selected from OH, -OCH3, -OCH2CH3, -CH3, 
with R7 being selected from =NH, =Sor =Ü, and 
with m of R9m being selected from 0, 1, 2 or 3, and each R9 being selected 
independently from each other from -Cl, -F, -Br, -1, -OH, -CCH, -CN -CH3, -
CH2CH3, -OCH3, -COOH, -COQRb, -C(O)NH2, -C(O)NH(CH3); -C(O)N(CH3)2, -
NHC(=O)OCH3, -N CH3C(=O)OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -
CH2F or -CF3, 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, 
or a C1-Cs haloalkyl. 
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ln some embodiments, E of the general formula 1 A is 
or 
with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -0, 
and -CHCH3, -C(CH3)2,=N, -NRe, 
with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CF3, -CHFCF3, -
CF2CF3, -CHF2, -CH2F, -CF3 
with R5 and R6 being selected independently from each other from -H, -F,-CH3, -CH2CH3, 
-OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 and R6 are 
selected independently from each other from H, For CH3, and 
with R7 being selected from =NH, =Sor =Ü, and with m of R9m being selected from 0, 1, 2 or 
3, and each R9 being selected independently from each other from -Cl, -F, Br, 1, -OH, -CCH, -
CH3, -CH2CH3, -OCH3, -COOH, -COQRb, -C(O)NH2, -NHC(=O)OCH3, -N CH3C(=O)OCH3, -
C(O)NH(CH3); -C(O)N(CH3)2 -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, R2N-
COOH 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a C1-Cs haloalkyl. 
ln some embodiments, E of the general formula 1 A is 
or 
with m of R9m being 0, and 
with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -0, -
CHCH3, -C(CH3)2,=N, -NRe, 
with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CF3, -CHFCF3, -
CF2CF3, -CHF2, -CH2F, -CF3and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, -CH2CH3, -
OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 and R6 are 
selected independently from each other from H, For CH3, and 
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with R7 being selected from =NH, =Sor =0. 
ln some embodiments, E of the general formula 1 A is selected from 
or 
ln some embodiments, X of the general formula 1 A is 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, 
-OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, and 
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with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R1 and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
E being 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 
n being O or 1, and 
a. with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -N02, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3, -OCONH2 or -CF3, or 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -
(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -
(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -
(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-
S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-
NRCC(=O)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, 
-(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-NRcS(02)Ra, -(CH2)m-
P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-
(M)-C( =Ü)OH, -(CH2)m-O-C( =Ü)-(M)-C( =Ü)ORa, -(CH2)m-O-C( =Ü)-(M)-Ra, -(CH2)m-O-
(CH2)q-P( =O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other from -Ra or -ORa, 
with Rba being selected independently from each other from -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
with m being selected from 0, 1 or 2, 
with q being selected from 0, 1 or 2, 
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- a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
- a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo 
heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
- a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-
C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or 
unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or 
a C1-C16 haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-
Cs alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl; 
b. with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -
N02, or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, 
-OC(=O)ORa, -OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, 
-C(=O)NHRa, -NHC(=O)ORa, -C(=S)Ra, -C(=S)ORa, -SRa, 
-OC(=S)Ra, -OC(=S)ORa, -OC(=S)NHRa, -NHC(=S)Ra, 
-NHC(=S)NHRa, -C(=S)NHRa or -NHC(=S)ORa, in particular 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, , 
- with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle; in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl; or 
c. with each R1 independently from any other R1 being 
146 
wo 2014/125075 PCT /EP2014/052922 
-OH, -F, -Cl, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of 
the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted halo heteroaryl comprising one or two halogen atoms 
selected from Cl of F, particularly comprising one Cl or one F in para position (in case 
of a C6 halo heteroaryl) in relation to the attachment position of the heterocycle to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
d. with each R1 independently from any other R1 being 
-OH, -F, -Cl, -1, -CN, -OCH3, -OCF3 or -CF3; or 
e. with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the remaining structure. 
ln some embodiments, X of the general formula 1 A is 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, 
-OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
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OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, and 
with D being 
~)_~-~ 
, and with 
E being 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 
n being O or 1, and 
a. with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -N02, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3, -OCONH2 or -CF3, or 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, -
(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -
(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -
(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-
S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-
NRCC(=O)Ra, -(CH2)m-NRcC(=Ü)QRa, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, 
-(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-NRcS(02)Ra, -(CH2)m-
P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-
(M)-C( =Ü)OH, -(CH2)m-O-C( =Ü)-(M)-C( =Ü)ORa, -(CH2)m-O-C( =Ü)-(M)-Ra, -(CH2)m-O-
(CH2)q-P( =O)(Rba)(Raa), -(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-C(=O)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other from -Ra or -ORa, 
- with Rba being selected independently from each other from -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
- with m being selected from 0, 1 or 2, 
- with q being selected from 0, 1 or 2, 
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with each Ra, Rb or Re being selected, where applicable, independently from each 
other from 
hydrogen, -CN, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 
halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted 
C1-C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a 
substituted or unsubstituted C2-C16 alkenyl, a substituted or 
unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted 
C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl; 
b. with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -
N02, or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, 
-OC(=O)ORa, -OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, 
-C(=O)NHRa, -NHC(=O)ORa, -C(=S)Ra, -C(=S)ORa, -SRa, 
-OC(=S)Ra, -OC(=S)ORa, -OC(=S)NHRa, -NHC(=S)Ra, 
-NHC(=S)NHRa, -C(=S)NHRa or -NHC(=S)ORa, in particular 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, , 
- with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle; in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
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a substituted or unsubstituted C5-C10 aryl; or 
c. with each R1 independently from any other R1 being 
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-OH, -F, -Cl, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of 
the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted halo heteroaryl comprising one or two halogen atoms 
selected from Cl of F, particularly comprising one Cl or one F in para position (in case 
of a C6 halo heteroaryl) in relation to the attachment position of the heterocycle to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
d. with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
e. with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the remaining structure. 
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ln some embodiments, X of the general formula 1 A is 
R2 
E,o,}__o- ~ E--f7'o-< 
or S 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -N02, -NH2, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, 
-OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, and 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R1 and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
a. E is 
b. E is 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, 
a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted Cs-C10 aryl, or 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, 
a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
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c. E is 
d. E is 
e. E is 
alkynyl, a substituted or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted 
C3-C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C5-C10 
cycloalkyl, or a substituted or unsubstituted Cs-C10 heteroaryl or a substituted or 
unsubstituted Cs-C10 aryl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted Cs-C10 aryl, or 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of 
the heterocycle to the 'D moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F in para position 
in relation to the attachment position of the heteroaryl to the D moiety; or 
E is selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 
1,2,4-triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, 
naphatalene, coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, 
benzofurane, benzothiophene, benzimidazol, benzthiazole, benzoxazole or 
benzpyridazin or hydroxylated, methylated or halogenated derivatives thereof, or 
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f. . E is selected from . 
vCO-ï 





- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n being 1, and 
- with each R1 independently from any other R1 being selected from 
- -OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
- -B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-
NRcC(=Ü)ÜRa, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other being -Ra or -ORa, 
- with Rba being selected independently from each other being -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
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with q being selected from 0, 1 or 2, 
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with each Ra, Rb or Re being selected, where applicable, independently 
from each other from 
hydrogen, -CN 
- a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted or 
unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted 
C1-Cs alkoxy, a substituted or unsubstituted C2-Cs alkenyl, a 
substituted or unsubstituted C2-Cs alkynyl, a substituted or 
unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-C10 
cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl, 
- a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
- a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-
C10 halo heterocycle, 
- a substituted or unsubstituted Cs-C10 heteroaryl, 
- a substituted or unsubstituted C5-C10 aryl, in particular 
with each R1 independently from any other R1 being -OH, -F, -Cl, 1, -CN, -
OCH3, -OCF3, -OCONH2 or -CF3 
ln some embodiments, X of the general formula 1 A is 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -N02, -OH, -NH2, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
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substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, 
-OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, and 
with D being 
~)_~-~ ~~~-~ ~ -~Jl~-~ 
, or , and with 
a. E being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, 
a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted Cs-C10 aryl, or 
b. E being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, 
a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
alkynyl, a substituted or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted 
C3-C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl, or 
c. E being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C5-C10 
cycloalkyl, or a substituted or unsubstituted Cs-C10 heteroaryl or a substituted or 
unsubstituted C5-C10 aryl, or 
d. E being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
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a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, or 
e. E being 
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a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of 
the heterocycle to the D moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F in para position 
in relation to the attachment position of the heteroaryl to the D moiety; or 
E is selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 
1,2,4-triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, 
naphatalene, coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, 
benzofurane, benzothiophene, benzimidazol, benzthiazole, benzoxazole or 
benzpyridazin or hydroxylated, methylated or halogenated derivatives thereof, or 
E is selected from . 
m-~ 






- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n being 1, and 
- with each R1 independently from any other R1 being selected from 
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-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-
NRcC(=Ü)ÜRa, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other being -Ra or -ORa, 
- with Rba being selected independently from each other being -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
- with m being selected from 0, 1 or 2, 
- with q being selected from 0, 1 or 2, 
- with each Ra, Rb or Re being selected, where applicable, independently 
from each other from 
hydrogen, -CN 
- a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted or 
unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted 
C1-Cs alkoxy, a substituted or unsubstituted C2-Cs alkenyl, a 
substituted or unsubstituted C2-Cs alkynyl, a substituted or 
unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-C10 
cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl, 
- a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
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- a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-
C10 halo heterocycle, 
- a substituted or unsubstituted Cs-C10 heteroaryl, 
- a substituted or unsubstituted C5-C10 aryl, in particular 
with each R1 independently from any other R1 being -OH, -F, -Cl, 1, -CN, -
OCH3, -OCF3, -OCONH2 or -CF3. 
ln some embodiments, X of the general formula 1 A is 
R2 
E,oAD- ~ or E--f?'o- ~ 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, 
-OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, and 
with D being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R1 and the parent moiety, in particular 
D is a linker selected from the linkers characterized by general formula D1 to D21, D1 to 
D12, D1 to D6 or D1 to D4, and 
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with each T being selected independently from each other from -CH2, -NH, -Sor 
-0, -CHCH3, -C(CH3)2 or -NRc, 
with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, and 
with T" being selected from -CH or =N, and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, 
-CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in 
particular with R5 and R6 being selected independently from each other from H, 
-For -CH3, and 
with R6' being selected from -OH, -OCH3, -OCH2CH3, -CH3, 
with R7 being selected from =NH, =Sor =Ü, and 
with m of R9m being selected from 0, 1, 2 or 3, and each R9 being selected 
independently from each other from -Cl, -F, Br, 1, -OH, -CCH, -CN -CH3, -
CH2CH3, -OCH3, -COOH, -COQRb, -C(O)NH2, -C(O)NH(CH3); -C(O)N(CH3)2, -
NHC(=O)OCH3, -N CH3C(=O)OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -
CH2F or -CF3, 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, 
or a C1-Cs haloalkyl 
159 
wo 2014/125075 PCT /EP2014/052922 
ln some embodiments, X of the general formula 1 A is 
R2 
E,o,}__o- ~ E--f7'o-< 
or S 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, 
-OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, and 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R1 and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
E is 
or 
a. with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -
0, -CHCH3, -C(CH3)2,=N, -NRc, with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -
CH(CH3)2, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3and with R5 and R6 being 
selected independently from each other from -H, -F, -CH3, 
-CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 
and R6 are selected independently from each other from H, For CH3, and with R7 
being selected from =NH, =Sor =Ü, and with m of R9m being selected from 0, 1, 2 or 3, 
and each R9 being selected independently from each other from -Cl, -F, Br, 1, -OH, -
CCH, -CH3, -CH2CH3, -OCH3, -COOH, -COQRb, -C(O)NH2, -C(O)NH(CH3); -
C(O)N(CH3)2, -NHC(=O)OCH3, -N CH3C(=O)OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -
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CHF2, -CH2F or -CF3, with Rb being a substituted or unsubstituted C1-Cs alkyl, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, 
or a C1-Cs haloalkyl, or 
b. with m of R9m being 0, and with each T being selected independently from each other from 
-CH -CH2 -NH -S or -0 -CHCH3 -C(CH3)2 =N -NRc with Re being -CH20H -CH3 -
' ' ' ' ' ' ' ' ' ' 
CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, -CH2CH3, 
-OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 and R6 are 
selected independently from each other from H, For CH3, and with R7 being selected from 
=NH, =Sor =Ü, or 
c. with E being selected from 
or 
0~?7 
---< ~ 1 
0 ~ 
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ln some embodiments, X of the general formula 1 A is 
R2 
E,o,}__o- ~ E--f7'o-< 
or S 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, 
-OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, and 
with D being 
~ )-.~-~ ~/"~-~ ~ -~,,l~-~ 
, or , and with 
E being 
or 
a. with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -0, 
-CHCH3, -C(CH3)2,=N, -NRc, with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -
CH(CH3)2, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3 and with R5 and R6 being 
selected independently from each other from -H, -F, -CH3, 
-CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 and 
R6 are selected independently from each other from H, For CH3, and with R7 being 
selected from =NH, =Sor =Ü, and with m of R9m being selected from 0, 1, 2 or 3, and 
each R9 being selected independently from each other from -Cl, -F, Br, 1, -OH, -CCH, -
CH3, -CH2CH3, -OCH3, -COOH, -COQRb, -C(O)NH2, -C(O)NH(CH3); -C(O)N(CH3)2, -
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NHC(=O)OCH3, -N CH3C(=O)OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C2-
Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a C1-Cs haloalkyl, or 
b. with m of R9m being 0, and with each T being selected independently from each other from 
-CH -CH2 -NH -S or -0 -CHCH3 -C(CH3)2 =N -NRc with Re being -CH20H -CH3 -
' ' ' ' ' ' ' ' ' ' 
CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3 and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, -CH2CH3, 
-OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 and R6 are 
selected independently from each other from H, For CH3, and with R7 being selected from 
=NH, =Sor =Ü, or 
c. with E being selected from 
o:()?7 
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d. with E being selected from 
with each T being selected independently from each other from -CH2, -NH, -Sor 
-0, -CHCH3, -C(CH3)2 or -NRc, 
with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, and 
with T" being selected from -CH or =N, and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, 
-CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in 
particular with R5 and R6 being selected independently from each other from H, 
-For -CH3, and 
with R6' being selected from OH, -OCH3, -OCH2CH3, -CH3, 
with R7 being selected from =NH, =Sor =Ü, and 
with m of R9m being selected from 0, 1, 2 or 3, and each R9 being selected 
independently from each other from -Cl, -F, Br, 1, -OH, -CCH, -CN -CH3, -
CH2CH3, -OCH3, -COOH, -COQRb, -C(O)NH2, -C(O)NH(CH3); -C(O)N(CH3)2, -
NHC(=O)OCH3, -N CH3C(=O)OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -
CH2F or -CF3, 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, 
or a C1-Cs haloalkyl 
ln some embodiments, X of the general formula 1 A is 
with E-0- being selected from 
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NA NA 
la la 










, with R8 being selected from H or CH3, in particluar 
R8 is H and with V being selected from 0, NH or S, in particular from O or NH. 
ln some embodiments, X is 
or 
HO 
with R8 being selected from H or CH3, in particluar R8 is H. 
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with R8 being selected from H or CH3, in particluar R8 is H. 
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ln some embodiments, X of the general formula 1 A is 
0 R8 0 
< < 1 0 N'i 0 
0 
R8 :x 0 1 N'i 0 
0 
H 
:x 0 R8 N o=( 1 
0 N'i N H 
0 
H 
0 R8 N 
o=( o=( 1 N N'i 0 H 
0 
Rs 0 






with R8 being selected from H or CH3, in particluar R8 is H. 
ln some embodiments, X of the general formula 1 A is 
PCT /EP2014/052922 
with D being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R1 and the parent moiety, in particular 
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0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and with 
a. R4 being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, 
a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl; or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl; or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle; in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl; or 
a substituted or unsubstituted C5-C10 aryl, or 
b. R4 being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, or 
c. R4 being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, 
a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
alkynyl, a substituted or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted 
C3-C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl, or 
d. R4 being 
a straight or branched C1-Cs alkyl or a C5-C10 cycloalkyl ring or polyring structure 
e. R4 being 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of 
the heterocycle to the O moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
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a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetralin or indane, 
a substituted or unsubstituted halo heteroaryl comprising one or two halogen atoms 
selected from Cl of F, particularly comprising one Cl or one F in para position (in case 
of a C6 halo heteroaryl) in relation to the attachment position of the heterocycle to the 
D moiety; or 
R4 is selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 
1,2,4-triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, 
naphatalene, coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, 
benzofurane, benzothiophene, benzimidazol, benzthiazole, benzoxazole or 
benzpyridazin or hydroxylated, methylated or halogenated derivatives thereof, or 
f. R4 being 
a substituted or unsubstituted C1-Cs alkyl or a substituted or unsubstituted C5-C10 
cycloalkyl, a substituted or unsubstituted Cs-C10 heteroaryl or a substituted or 
unsubstituted C5-C10 aryl,or 








ln some embodiments, X of the general formula 1 A is 
with D being 
~)_~-~ ~~~-~ ~ -~Jl~-~ 
, or , and with 
a. R4 being 
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a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, 
a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
alkynyl, or a substituted or unsubstituted C1-Cs haloalkyl; or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-
C10 halo cycloalkyl; or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle; in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl; or 
a substituted or unsubstituted C5-C10 aryl, or 
b. R4 being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-
C10 halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or 
a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, or 
c. R4 being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, 
a substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs 
alkynyl, a substituted or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted 
C3-C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo cycloalkyl, or 
d. R4 being 
a straight or branched C1-Cs alkyl or a C5-C10 cycloalkyl ring or polyring structure 
e. R4 being 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of 
the heterocycle to the D moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetralin or indane, 
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a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F in para position 
in relation to the attachment position of the heteroaryl to the D moiety; or 
R4 is selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 
1,2,4-triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, 
naphatalene, coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, 
benzofurane, benzothiophene, benzimidazol, benzthiazole, benzoxazole or 
benzpyridazin or hydroxylated, methylated or halogenated derivatives thereof, 
f. R4 being 
a substituted or unsubstituted C1-Cs alkyl or a substituted or unsubstituted C5-C10 
cycloalkyl, a substituted or unsubstituted Cs-C10 heteroaryl or a substituted or 
unsubstituted C5-C10 aryl. 
ln some embodiments, X of the general formula 1 A is 
4/0-~ 








from H or CH3, in particluar R8 is H. 
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ln some embodiments, the compound of the invention is characterised by the general 
formula CAa 





0 °x:r~À) ~ H O ~~ "-
R3 ~N0NM 
0 ,,l., H 
z y 
(CAa) 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a substituted or 
unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in particular from -H, -F, -CN, -NHCH3, -
NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, 
-CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 and R3 being selected 
independently from each other from H, F or CH3, and 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R1 and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 0 
or 1, and with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
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a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the double bond. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAa with R2 and R3 being selected, where applicable, independently from each other 
from -H, -F, -CN, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -
NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, 
-CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 and R3 being 
selected independently from each other from H, For CH3, in particular R2 and R3 are 
selected independently from each other from H, For CH3, and with O being a linker as 
defined above, in particular O is a linker selected from the linkers characterized by general 
formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, and with n of R1n being 0, 1, 2, 3, 4 or 
5, in particular n of R1n being 0, 1 or 2, more particularly O or 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -
N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
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wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the double bond. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAa with R2 being H and R3 being CH3 or R2 being H and R3 being H, and with 0 
being a linker as defined above, in particular O is a linker selected from the linkers 
characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, and with n of 
R1n being O or 1, in particular n of R1n being 1, and 
with R1 being 
-OH, -F, -Cl, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -
N02, or 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, 
a substituted or unsubstituted C6 aryl; or 
with R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the double bond. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAb 
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with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a substituted or 
unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -NHCH3, -
NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, 
-CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 and R3 being selected 
independently from each other from H, For CH3, in particular R2 and R3 are selected 
independently from each other from H, F or CH3, and 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising T and the parent moiety, in particular 0 
is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 012, 
01 to 06 or 01 to 04, and 
with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -0, -
CHCH3, -C(CH3)2,=N, -NRc, with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, 
-CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3 and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, -CH2CH3, -
OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 and R6 are 
selected independently from each other from H, For CH3. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAb with R2 and R3 being selected, where applicable, independently from each other 
from -H, -F, -CN, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -
NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, 
-CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 and R3 being 
selected independently from each other from H, For CH3, in particular R2 and R3 are 
selected independently from each other from H, For CH3, and with O being a linker as 
defined above, in particular O is a linker selected from the linkers characterized by general 
formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, and with R5 and R6 being selected 
independently from each other from -H, -F, -CH3, -CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -
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CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 and R6 are selected independently from each 
other from H, For CH3, more particularly R5 and R6 are H, and 
with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -
O; -CHCH3, -C(CH3)2,=N, -NRe, with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -
CH(CH3)2, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3or 
with each T being O. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAb with R2 being H and R3 being CH3 or R2 being H and R3 being H, and with 0 
being a linker as defined above, in particular O is a linker selected from the linkers 
characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, and with R5 
and R6 being selected independently from each other from -H, -For -CH3, in particular R5 
and R6 are H, and 
with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -
O; or-CHCH3, -C(CH3)2,=N, -NRe, with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -
CH(CH3)2, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3 
with each T being O. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAc, with O being a linker of the formula 01 
1 OH 0 
I OH o
0
~oH ~ oo«~A) ~HO~~~ 
~N0NAJ 
0 ,l., H 
z y 
(CAc) 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a substituted or 
unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -NHCH3, -
NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, 
-CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 and R3 being selected 
independently from each other from H, For CH3, in particular R2 and R3 are selected 
independently from each other from H, F or CH3, and 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
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-OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the double bond. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAc with R2 and R3 being selected, where applicable, independently from each other 
from -H, -F, -CN, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -
NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, 
-CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 and R3 being 
selected independently from each other from H, For CH3, in particular R2 and R3 are 
selected independently from each other from H, For CH3, and with n of R1n being 0, 1, 2, 3, 4 
or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 
or -N02, or 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
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a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the double bond. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAc with R2 being H and R3 being CH3 or R2 being H and R3 being H, and with n of 
R1n being O or 1, in particular n of R1n being 1, and 
with R1 being 
-OH, -F, -Cl, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -
N02, or 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
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wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the double bond. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAd, with D being a linker of the formula 01 
1 OH 0 




5x ~~ R O OxfNJJ 
6 b H I H 
RT N~OdN~ 
R lb~t~IH 2 0 N 
0 H 
z y (CAd) 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a substituted or 
unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN,-NHCH3, -
NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, 
-CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 and R3 being selected 
independently from each other from H, For CH3, in particular R2 and R3 are selected 
independently from each other from H, F or CH3, and 
with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -0, -
CHCH3, -C(CH3)2,=N, -NRc, with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, 
-CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3 and 
with R5 and R6 being selected independently from each other from -H, -F,-CH3, -CH2CH3, -
OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 and R6 are 
selected independently from each other from H, For CH3. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAd with R2 and R3 being selected, where applicable, independently from each other 
from -H, -F, -CN, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -
NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, 
-CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 and R3 being 
selected independently from each other from H, For CH3, in particular R2 and R3 are 
selected independently from each other from H, For CH3, and with R5 and R6 being selected 
independently from each other from -H, -F, -CH3, -CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -
CF2CF3, -CHF2, -CH2F or -CF3, in particular R5 and R6 are selected independently from each 
other from H, For CH3, more particularly R5 and R6 are H, and 
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with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -
O; -CHCH3, -C(CH3)2,=N, -NRe, with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -
CH(CH3)2, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3or 
with each T being O. 
ln some embodiments, the compound of the invention is characterised by the general 
formula CAd with R2 being H and R3 being CH3 or R2 being H and R3 being H, and with R5 
and R6 being selected independently from each other from -H, -For -CH3, in particular R5 
and R6 are H, and 
with each T being selected independently from each other from -CH, -CH2, -NH, -Sor -
O; -CHCH3, -C(CH3)2,=N, -NRe, with Re being -CH20H, -CH3, -CH2CH3, -CH2CH2CH3, -
CH(CH3)2, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F, -CF3or 
with each T being O. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAa 





Cy-D~ d~ H 
1 
H O I N ~ N0N ~ H 
0 À" H z y 
(BAa) 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising Cy and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
with Cy being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAa with O being a linker as defined above, in particular O is a linker selected from 
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the linkers characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, 
and with 
Cy being 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of the 
heterocycle to the O moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetralin or indane, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F in para position in 
relation to the attachment position of the heteroaryl to the O moiety; or 
Cy being selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 1,2,4-
triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, naphatalene, 
coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, benzofurane, 
benzothiophene, benzimidazol, benzthiazole, benzoxazole or benzpyridazin or hydroxylated, 
methylated or halogenated derivatives thereof. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAb 






,,D----0 ~ H O ~~ '>-
Rn ~N0N~ 
0 ,,l., H 
z y (BAb) 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R1 and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
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-H, -OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -
N02, or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the O moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAb with O being a linker as defined above, in particular O is a linker selected from 
the linkers characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, 
and with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more 
particularly 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the O moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
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para position in relation to the attachment position of the heteroaryl to the 0 
moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the O moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAb with O being a linker as defined above, in particular O is a linker selected from 
the linkers characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, 
and with n of R1n being O or 1, in particular n of R1n being 1, and 
with R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the O moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 0 
moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
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wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the D moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAc with D being a linker of the formula 01 
1 OH 0 
I OH o
0
~oH oxfÀ) H O ~ 1 N 
Cy N d H Y ~ H O ~I ~ ~ O ~N0N ~ 
0 ,l., H 
z y (BAc) 
with Cy being 
a substituted or unsubstituted C3-C10 heterocycle or substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAc with 
Cy being 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of the 
heterocycle to the -C(=O)-NH- moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetralin or indane, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F in para position in 
relation to the attachment position of the heteroaryl to the -C(=O)-NH- moiety; or 
Cy being selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 1,2,3-triazole, 1,2,4-
triazole, imidazole, oxazol, thiazol, indole, isoindole, quinoline, isoquinoline, naphatalene, 
coumarin, aminocoumarin, umbelliferon, benzotriazole, psoralen, benzofurane, 
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benzothiophene, benzimidazol, benzthiazole, benzoxazole or benzpyridazin or hydroxylated, 
methylated or halogenated derivatives thereof. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAd with D being a linker of the formula 01 
1 OH 0 
_ I OH o
0
~oH o{rÀ) H O ~ 1 N 
R~ N~ oifN~ H 
lh ~r~I H 0 N 
0 H 
z y (BAd) 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -C(=O)NH- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAd with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more 
particularly 1, and 
with each R1 independently from any other R1 being 
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-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the -C(=O)NH- moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the -
C(=O)NH- moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, -CN, 1, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to th -C(=O)NH- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAd with n of R1n being O or 1, in particular n of R1n being 1, and 
with R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 
or -N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the -C(=O)NH- moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
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para position in relation to the attachment position of the heteroaryl to the -
C(=O)NH- moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -C(=O)NH- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PAa 
1 OH 0 








with R2 being selected, where applicable, from -H, -OH, -NH2, -NHCH3, -NH(CH3)2, a 
substituted or unsubstituted C1-C3 alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-
C3 haloalkyl , in particular from -H, -OH, -NH2, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -
OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F 
or -CF3, more particularly with R2 being selected from H or CH3, 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R1 and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
188 
wo 2014/125075 PCT /EP2014/052922 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -CR2-0 moiety 
ln some embodiments, the compound of the invention is characterised by the general 
formula PAa, with R2 being selected, where applicable, from -H, -OH, -NH2, -NHCH3, -
NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a substituted or unsubstituted C1-C3 
alkoxy or a C1-C3 haloalkyl , in particular from -H, -OH, -NH2, -NHCH3, -NH(CH3)2, -CH3, -
CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -
CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 being selected from H or CH3, with 
0 being a linker as defined above, in particular O is a linker selected from the linkers 
characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, and with n of 
R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 
or -N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
189 
wo 2014/125075 PCT /EP2014/052922 
para position in relation to the attachment position of the heteroaryl to the -
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -Cl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -CR2-0 moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PAa, with R2 being selected -H or -CH3, in particular with R2 being -H, with O being 
a linker as defined above, in particular O is a linker selected from the linkers characterized by 
general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, and with n of R1n being O or 1, 
in particular n of R1n being 1, and 
with R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 
or -N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -Cl, 
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wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -CR2-D moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PAb with D being a linker of the formula 01 
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with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -CH2-D- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PAb with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more 
particularly 1, and 
with each R1 independently from any other R1 being 
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-OH, -F, -Cl, Br, 1, CCH,-CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -Cl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -CH2-D- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPa 
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(PPa) 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -
OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3,more particularly 
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with R2 and R3 being selected independently from each other from H, For CH3, in particular 
R2 and R3 are selected independently from each other from H, For CH3, and 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R1 and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -C(R2) moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPa with R2 and R3 being selected, where applicable, independently from each other 
from -H, -F, -CN, -OH, -N02, -NH2, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 
alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -
F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -
OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3,more particularly with R2 and R3 being selected independently from each other from H, F 
or CH3, in particular R2 and R3 are selected independently from each other from H, For CH3, 
and with O being a linker as defined above, in particular O is a linker selected from the linkers 
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characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, and with n of 
R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 
or -N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, -1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -C(R2) moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPa with R2 being H and R3 being CH3 or R2 being H and R3 being H, and with 0 
being a linker as defined above, in particular O is a linker selected from the linkers 
characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, and with n of 
R1n being O or 1, in particular n of R1n being 1, and 
with R1 being 
-OH, -F, -Cl, -Br,-1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 
or -N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
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a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -C(R2) moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPb, with D being a linker of the formula 01 
1 OH 0 
I OH o
0
~oH ~ oo«~A) ~HO~~~ 
~N0NAJ 
0 ,l" H z y 
(PPb) 
with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -
OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3,more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, in particular 
R2 and R3 are selected independently from each other from H, For CH3, and 
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with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -C(R2) moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPb with R2 and R3 being selected, where applicable, independently from each other 
from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 
alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -
F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -
OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3,more particularly with R2 and R3 being selected independently from each other from H, F 
or CH3, in particular R2 and R3 are selected independently from each other from H, For CH3, 
and with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more 
particularly 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 
or -N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
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a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -C(R2) moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPb with R2 being H and R3 being CH3 or R2 being H and R3 being H, and with n of 
R1n being O or 1, in particular n of R1n being 1, and 
with R1 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 
or -N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
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a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -C(R2) moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPc and comprises a benzoic acid structural element or a similar element 
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with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -
OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3,more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising Cy and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
with Cy being 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
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a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPc, with R2 and R3 being selected, where applicable, independently from each 
other from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted 
C1-C3 alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from 
-H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -
OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3,more particularly with R2 and R3 being selected independently from each other from H, F 
or CH3, with O being a linker as defined above, in particular O is a linker selected from the 
linkers characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, and 
with 
Cy being 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of the 
heterocycle to the -C(R2) moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetralin or indane, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F in para position in 
relation to the attachment position of the heteroaryl to the -C(R2) moiety; or 
Cy being selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
thiazole, benzothiophene, chromene, pyrazine, pyridazine, pyridine or halogenated 
derivatives thereof. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPd 
1 OH 0 
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with R2 and R3 being selected, where applicable, independently from each other from -H, -F, 
-CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 alkyl, a 
substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -F, -CN, -
OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -
OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3,more particularly 
with R2 and R3 being selected independently from each other from H, For CH3, 
with Cy being 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
ln some embodiments, the compound of the invention is characterised by the general 
formula PPd with R2 and R3 being selected, where applicable, independently from each other 
from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-C3 
alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular from -H, -
F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -OCH2CH3, -
OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3,more particularly with R2 and R3 being selected independently from each other from H, F 
or CH3, with 
Cy being 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, particularly 
comprising one Cl or one F in para position in relation to the attachment position of the 
heterocycle to the -C(R2) moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetralin or indane, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two halogen 
atoms selected from Cl of F, particularly comprising one Cl or one F in para position in 
relation to the attachment position of the heteroaryl to the -C(R2) moiety; or 
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Cy being selected from the group of substituted or unsubstituted pyrrole, furan, thiophene, 
thiazole, benzothiophene, chromene, pyrazine, pyridazine, pyridine or halogenated 
derivatives thereof. 
ln some embodiments, the compound of the invention is characterised by the general 
formula P, 
1 OH 0 
2 1 OH o
0
~oH ~ j H o 0JylN-V 
R1;><Ao- YNUy o dNA) H 
n 1~ ~r~I H 0 N 
0 H 
z y (P) 
with R2 being selected, where applicable, from -H, -OH, -NH2, -NHCH3, -NH(CH3)2, a 
substituted or unsubstituted C1-C3 alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-
C3 haloalkyl , in particular from -H, -OH, -CH20H, -NH2, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, 
-CH2CH2CH3, -CH(CH3)2, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, 
-CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 being selected from H or 
CH3 -, and 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
-H, -OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -
N02, or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
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wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -OC(R2) moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula P with R2 being selected, where applicable, from -H, -OH, -NH2, -NHCH3, -NH(CH3)2, 
a substituted or unsubstituted C1-C3 alkyl, a substituted or unsubstituted C1-C3 alkoxy or a 
C1-C3 haloalkyl , in particular from -H, -OH, -CH20H, -NH2, -NHCH3, -NH(CH3)2, -CH3, -
CH2CH3, -CH2CH2CH3, -CH(CH3)2, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -
CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, more particularly with R2 being selected 
from H or CH3, in particular R3 is selected from H or CH3, and with n of R1n being 0, 1, 2, 3, 4 
or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -OC(R3) moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula P with R2 being CH3 or R3 being H, and with n of R1n being O or 1, in particular n of 
R1n being 1 , and 
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with R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -OC(R2) moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula FAa 





R4-D d~ H ~ H O ~I ~ 
~N0N~ 
0 ,,l" H z y (FAa) 
with O being a linker which comprises carbon, sulphur, nitrogen and/or oxygen atoms and 
which is covalently connecting the moiety comprising R4 and the parent moiety, in particular 
0 is a linker selected from the linkers characterized by general formula 01 to 021, 01 to 
012, 01 to 06 or 01 to 04, and 
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with R4 being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, 
or a substituted or unsubstituted C1-Cs haloalkyl; or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl. 
ln some embodiments, the compound of the invention is characterised by the general 
formula FAa with O being a linker as defined above, in particular Ois a linker selected from 
the linkers characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, 
and with R4 being a straight or branched C1-Cs alkyl or a Cs-C10 cycloalkyl ring or polyring 
structure. 
ln some embodiments, the compound of the invention is characterised by the general 
formula FAb with O being a linker of the formula 01 
(FAb) 
with R4 being 
a substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C1-Cs alkoxy, a 
substituted or unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, 
or a substituted or unsubstituted C1-Cs haloalkyl; or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl. 
ln some embodiments, the compound of the invention is characterised by the general 
formula FAb with O being a linker as defined above, in particular Ois a linker selected from 
the linkers characterized by general formula 01 to 021, 01 to 012, 01 to 06 or 01 to 04, 
and with R4 being a straight or branched C1-Cs alkyl or a Cs-C10 cycloalkyl ring or polyring 
structure. 
ln some embodiments, the compound of the invention is characterised by the general 
formula UAa 
204 
wo 2014/125075 PCT /EP2014/052922 
1 OH 0 
I OH o 0~oH 
oJv)l JJ ~ ~ 0 ~ ~ 
~~~Holfl~~ 
Il ,& Nr ~ 0 N 
R1 H 
n O Z y 
(UAa) 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 0 
or 1, and with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -HNC(=O)NH- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula UAa with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more 
particularly O or 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
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a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -HNC(=O)NH moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula UAa with n of R1n being O or 1, and 
with R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
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with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -HNC(=O)NH moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula UAa with n of R1n being O. 
ln some embodiments, the compound of the invention is characterised by the general 
formula AMa 
1 OH 0 
_ I OH o
0
~oH oxi'À) H O ~ 1 N 
R~ N~ 0 ~N ~ H 
~~0NAJ H 
0 ,l., H 
z y 
(AMa) 
with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
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a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -CH2NH- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula BAd with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more 
particularly 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -CH2NH- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula AMa with n of R1n being O or 1, in particular n of R1n being 1, and 
with R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
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a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -CH2NH- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula SAa 
1 OH 0 
_ 1 OH o
0
~oH 
P oxi'JJ H O ~ 1 N R~ S/N~ 0 dN ~ H 




with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more particularly 1, 
and with each R1 independently from any other R1 being 
-OH, -F, -Cl, -Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or -N02, 
or 
-NRa2, -NHRa, -Ra, -C(=O)Ra, -C(=O)ORa, ORa, -OC(=O)Ra, -OC(=O)ORa, -
OC(=O)NHRa, -NHC(=O)Ra, -NHC(=O)NHRa, -C(=O)NHRa or -NHC(=O)ORa, 
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with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted C3-C10 
halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted C3-C10 
halo heterocycle, in particular a substituted or unsubstituted C4-C10 heterocycle or a 
substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -S(02)NH- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula SAa with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1 or 2, more 
particularly 1, and 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
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-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -S(02)NH- moiety. 
ln some embodiments, the compound of the invention is characterised by the general 
formula SAa with n of R1n being O or 1, in particular n of R1n being 1, and 
with R1 being 
-OH, -F, -Cl, Br, 1, CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -CH3, -CF3, -OCONH2 or 
-N02, or 
a substituted or unsubstituted Cs-CB heterocycle 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F in para position in relation to the 
attachment position of the heterocycle to the benzene moiety, or 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F in 
para position in relation to the attachment position of the heteroaryl to the 
benzene moiety, or 
a substituted or unsubstituted C6 aryl; or 
with each R1 independently from any other R1 being 
-OH, -F, -Cl, 1, -CN, -OCH3, -OCF3 or -CF3; or 
with each R1 independently from any other R1 being 
-OH, -For -CF3, 
wherein in particular R1 is in para position in relation to the attachment position of the 
benzene moiety to the -S(02)NH- moiety. 
Particular embodiments of the invention are the compounds 1 to 50, 70 to 76 as depicted in 
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Chemical Formula: C42H35Ns012 
Exact Mass: 844,24527 
Chemical Formula: C43H37N7012 
Exact Mass: 843,25002 
Chemical Formula: C43H3sN5013S 
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Chemical Formula: C42H34N5010 
Exact Mass: 782,2336 
Chemical Formula: C43H35N5011 







Chemical Formula: C43H35N5011 
Exact Mass: 812,2442 
Chemical Formula: C44 H38N5010 
Exact Mass: 810,2649 
Chemical Formula: C44H3sN5011 




Compound 111 : 
Compound 112: 
PCT /EP2014/052922 
Che · m1cal Formula 
Exact Mass· 82C644H3sN5011 
· ,2599 
H~~ x1~02H 
0 ~~)L~d~û ~ ~ 1 
' 
Compound 114: CN 
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ln some embodiments the compounds 1 to 50, 70 to 76 and 78 to 117 comprise an 
essentially pure L-enantiomer structure, an essentially pure D-enantiomer structure or a 
mixture of the L- and D-enantiomer of the same molecular formula, wherein in particular the 
compounds 1 to 50, 70 to 76 and 78 to 117 comprise an essentially pure L-enantiomer 
structure. 
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22h 
Further embodiments of the present compounds are compounds 22a-22h. 
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ing to formula (1 L) mpounds may corn . prise one of th e following 
R10 
YÎl I I OH ~~ 06:(rOH OO~COOH ~ ~ ,r NJJ 
0 ~~ylN,() ~ ,,_ 1 H 
0 3' = H R /'.. 2' R 
and formula (1 0), 
(1 L) 
wherein 
R1. IS H or CO(NH,), (1D) 
R2' is CO(N H2) or CN 
R3' is H or OCH 3, 
' 
ln case of the compounds f 
following st . 
0 
formula (1 L) ereo1somer f and (1 0) c s o formula (1 L 1) (1 omprising a -OCH3 . ' L2), (101) and (102) mo1ety as R3' the 
are possible: 
(1 L 1) 
formula (1 L2) 
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1 OH 
OXYCOOH 1 OH O ., I 
R
1
0 0~ ~ 
-? 1 0 9' 1 N ~~~ 0 ~N "- H 




1 1 OH O ., 1 
RO~ 0~ ~ 1 H O I N ~ .& N~ 0 ~N ~ H 




R1 is H or CO(NH2), 
R2' is CO(NH2) or CN, 
ln some embodiments, concerning antibiotically active natural occurring L-albicidin 
compounds of the formula (1 L), 
a. R1 is H, R3' is H and R2' is CN (beta-Albicidin), or 
b. R1 is H, R3' is H and R2' is CO(NH2) (Asn-Albicidin), or 
c. R1 is CO(NH2), R3' is H and R2' is CN (Carbamoyl-Albicidin), or 
d. R1 is CO(NH2), R3' is H and R2' is CO(NH2) (Carbamoyl-Asn-Albicidin), or 
e. R1 is H, R3' is OCH3 and R2' is CN (beta-OMe-Albicidin), or 
f. R1 is H, R3' is OCH3 and R2' is CO(NH2) (Asn-OMe-Albicidin), or 




h. R1 is CO(NH2), R3' is OCH3 and R2' is CO(NH2) (Carbamoyl-OMe-Asn-Albicidin). 
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ln some embodiments, concerning antibiotically active synthetic D-albicidin compounds of the 
formula (1 D), 
a. R1 is H and R2' is CN (Enantio-beta-Albicidin), or 
b. R1 is H, and R2' is CO(NH2) (Enantio-Asn-Albicidin), or 
c. R1 is CO(NH2), and R2' is CN (Enantio-Carbamoyl-Albicidin), or 
d. R1 is CO(NH2), and R2' is CO(NH2) (Enantio-Carbamoyl-Asn-Albicidin), or 
e. R1 is H, R3' is OCH3 and R2' is CN (Enantio-beta-OMe-Albicidin), or 
f. R1 is H, R3' is OCH3 and R2' is CO(NH2) (Enantio-Asn-OMe-Albicidin), or 
g. R1 is CO(NH2), R3' is OCH3 and R2' is CN (Enantio-Carbamoyl-OMe-Albicidin), or 
h. R1 is CO(NH2), R3' is OCH3 and R2' is CO(NH2) (Enantio-Carbamoyl-OMe-Asn-
Albicidin). 
ln some embodiments, concerning antibiotically active natural occurring L-albicidin 
compounds of the formula (1 L), 
a. R1 is H and R2' is CN (beta-Albicidin), or 
b. R1 is H, and R2' is CO(NH2) (Asn-Albicidin). 
ln some embodiments, concerning antibiotically active synthetic D-albicidin compounds of the 
formula (1 D), 
a. R1 is H and R2' is CN (Enantio-beta-Albicidin), or 
b. R1 is H, and R2' is CO(NH2) ( Enantio-Asn-Albicidin). 
ln some embodiments, concerning antibiotically active natural occurring L-albicidin 
compounds of the formula (1 L), 
a. R1 is H and R2' is CN (beta-Albicidin). 
ln some embodiments, concerning antibiotically active synthetic D-albicidin compounds of the 
formula (1 D), 
a. R1 is H and R2' is CN (Enantio-beta-Albicidin). 
ln some embodiments, the compounds of the invention relates to a mixture of the L- and D-
enantiomer of the same molecular formula. 
ln some embodiments, the compounds of the invention relates to a mixture of 
beta-Albicidin and Enantio-beta-Albicidin, or 
Asn-Albicidin and Enantio-Asn-Albicidin, or 
Carbamoyl-Albicidin and Enantio-Carbamoyl-Albicidin, or 
Carbamoyl-Asn-Albicidin and Enantio-Carbamoyl-Asn-Albicidin, or 
beta-OMe-Albicidin and Enantio-beta-OMe-Albicidin, or 
Asn-OMe-Albicidin and Enantio-Asn-OMe-Albicidin, or 
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Carbamoyl-OMe-Albicidin and Enantio-Carbamoyl-OMe-Albicidin, or 
Carbamoyl-OMe-Asn-Albicidin and Enantio-OMe-Carbamoyl-Asn-Albicidin 
ln some embodiments, the compounds of the invention relates to a mixture of beta-Albicidin 
and Enantio-beta-Albicidin, or Asn-Albicidin and Enantio-Asn-Albicidin. 
ln some embodiments, the compounds of the invention relates to a mixture of beta-Albicidin 
and Enantio-beta-Albicidin. 
ln a another embodiment the compounds according to formula 1 L, 10, 1 L 1, 1 L2, 101 and/or 
102 may be exempted from the general formula (1 ). ln particular the natural occuring L-
albicidin compounds of formula 1 L may be exempted from the general formula 1. 
lt is understood that all the compounds of the general formulae 1 and embodiments thereof 
may comprise -depending on the selected substituents - at least one further stereocenter 
with an L- or 0- configuration. Thus, the embodiments of the invention encompass a pure 
compound with the same stereo centers ( e.g. a compound only with an L and a O stereo 
center or two L stereo centers) or a mixture of the respective enantiomers of the same 
molecular formula. 
The compounds of the general formula 1 can also be obtained in the form of their hydrates 
and/or also can include other solvents used for example for the crystallization of compounds 
present in the solid form. Oepending on the method and/or the reaction conditions, 
compounds of the general formula 1 can be obtained in the free form or in the form of salts. 
Particularly in the form of salts of alkali metals, alkaline earth metals, ammonium or 
alkylammonium. 
Pharmaceutically acceptable salts of compounds of the formula (1) mean both their organic 
and inorganic salts as described in Remington's Pharmaceutical Sciences (17th edition, 
page 1418 (1985)). Because of the physical and chemical stability and the solubility, 
preference is given for acidic groups inter alia to sodium, potassium, calcium and ammonium 
salts; preference is given for basic groups inter alia to salts of maleic acid, fumaric acid, 
succinic acid, malic acid, tartaric acid, methylsulfonic acid, hydrochloric acid, sulfuric acid, 
phosphoric acid or of carboxylic acids or sulfonic acids, for example as hydrochlorides, 
hydrobromides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, 
fumarates, malates, gluconates, and salts of amino acids, of natural bases or carboxylic 
acids. The preparation of pharmaceutically acceptable salts from compounds of the formula 
(1) which are capable of sait formation, including their stereoisomeric forms, takes place in a 
manner known per se. The compounds of the formula (1) form stable alkali metal, alkaline 
earth metal or optionally substituted ammonium salts with basic reagents such as 
hydroxides, carbonates, bicarbonates, alcoholates and ammonia or organic bases, for 
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example trimethyl- or triethylamine, ethanolamine, diethanolamine or triethanolamine, 
trometamol or else basic amino acids, for example lysine, ornithine or arginine. Where the 
compounds of the formula (1) have basic groups, stable acid addition salts can also be 
prepared with strong acids. Suitable pharmaceutically acceptable acid addition salts of the 
compounds of the invention are salts of inorganic acids such as hydrochloric acid, 
hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acid, and of organic acids such 
as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, 
gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-
toluenesulfonic and tartaric acid. The hydrochloride sait is a preferred sait. 
Salts with a pharmaceutically unacceptable anion such as, for example, trifluoroacetate 
likewise belong within the framework of the invention as useful intermediates for the 
preparation or purification of pharmaceutically acceptable salts and/or for use in 
nontherapeutic, for example in vitro, applications. 
The present invention furthermore relates to pharmaceutical preparations ( or pharmaceutical 
compositions) which contain an effective amount of at least one compound of the formula (1) 
and/or its pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, i. e. 
one or more pharmaceutically acceptable carrier substances (or vehicles) and/or additives 
(or excipients). The pharmaceuticals can be administered orally, for example in the form of 
pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatin capsules, 
solutions, syrups, emulsions, suspensions or aerosol mixtures. Administration, however, can 
also be carried out rectally, for example in the form of suppositories, or parenterally, for 
example intravenously, intramuscularly or subcutaneously, in the form of injection solutions 
or infusion solutions, microcapsules, implants or rods, or percutaneously or topically, for 
example in the form of ointments, solutions or tinctures, or in other ways, for example in the 
form of aerosols or nasal sprays. 
The pharmaceutical preparations according to the invention are prepared in a manner known 
perse and familiar to one skilled in the art, pharmaceutically acceptable inert inorganic 
and/or organic carrier substances and/or additives being used in addition to the compound(s) 
of the formula (1) and/or its (their) pharmaceutically acceptable salts and/or its (their) 
prodrugs. For the production of pills, tablets, coated tablets and hard gelatin capsules it is 
possible to use, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or 
its salts, etc. Carrier substances for soft gelatin capsules and suppositories are, for example, 
fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc. Suitable carrier 
substances for the production of solutions, for example injection solutions, or of emulsions or 
syrups are, for example, water, saline, alcohols, glycerol, polyols, sucrase, invert sugar, 
glucose, vegetable oils, etc. Suitable carrier substances for microcapsules, implants or rods 
are, for example, copolymers of glycolic acid and lactic acid. The pharmaceutical 
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preparations normally contain about 0.5 to about 90 % by weight of the compounds of the 
formula (1) and/or their pharmaceutically acceptable salts and/or their prodrugs. The amount 
of the active ingredient of the formula (1) and/or its pharmaceutically acceptable salts and/or 
its prodrugs in the pharmaceutical preparations normally is from about 0.5 to about 1000 mg, 
preferably from about 1 to about 500 mg. 
A prodrug within the meaning of the present invention is a precursor chemical compound of 
an biological active compound of general formula (1 ). lnstead of administering the active 
compopund or drug, a prodrug might be used instead to improve the absorption, distribution, 
metabolization and excretion.Prodrugs are often designed to improve bioavailability when a 
drug itself is poorly absorbed from the gastrointestinal tract. A prodrug may also be used to 
improve the selectively of the drug. This reduces adverse or unintended effects of a drug, 
especially important in treatments like chemotherapy, which can have severe unintended and 
undesirable side effects. 
An example of a prodrug withing the context of the present invention is shown below: 
wherein X can be a -OP03H or -OS03H moiety each with single or multiple substituents. 
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ln addition to the active ingredients of the formula (1) and/or their pharmaceutically 
acceptable salts and to carrier substances, the pharmaceutical preparations can contain one 
or more additives such as, for example, fillers, disintegrants, binders, lubricants, wetting 
agents, stabilizers, emulsifiers, preservatives, sweeteners, colorants, flavorings, aromatizers, 
thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot 
effect, salts for altering the osmotic pressure, coating agents or antioxidants. They can also 
contain two or more compounds of the formula (1) and/or their pharmaceutically acceptable 
salts. ln case a pharmaceutical preparation contains two or more compounds of the formula 
(1) the selection of the individual compounds can aim at a specific overall pharmacological 
profile of the pharmaceutical preparation. For example, a highly patent compound with a 
shorter duration of action may be combined with a long-acting compound of lower potency. 
The flexibility permitted with respect to the choice of substituents in the compounds of the 
formula (1) allows a great deal of contrai over the biological and physico-chemical properties 
of the compounds and thus allows the selection of such desired compounds. Furthermore, in 
addition to at least one compound of the formula (1) and/or its pharmaceutically acceptable 
salts, the pharmaceutical preparations can also contain one or more other therapeutically or 
prophylactically active ingredients. When using the compounds of the formula (1) the dose 
can vary within wide limits and, as is customary and is known to the physician, is to be suited 
to the individual conditions in each individual case. lt depends, for example, on the specific 
compound employed, on the nature and severity of the disease to be treated, on the mode 
and the schedule of administration, or on whether an acute or chronic condition is treated or 
whether prophylaxis is carried out. An appropriate dosage can be established using clinical 
approaches well known in the medical art. ln general, the daily dose for achieving the desired 
results in an adult weighing about 75 kg is from about 0.01 to about 100 mg/kg, preferably 
from about 0.1 to about 50 mg/kg, in particular from about 0.1 to about 10 mg/kg, (in each 
case in mg per kg of body weight). The daily dose can be divided, in particular in the case of 
the administration of relatively large amounts, into several, for example 2, 3 or 4, part 
administrations. As usual, depending on individual behavior it may be necessary to deviate 
upwards or downwards from the daily dose indicated. 
Furthermore, the compounds of the formula (1) can be used as synthesis intermediates for 
the preparation of other compounds, in particular of other pharmaceutical active ingredients, 
which are obtainable from the compounds of the formula 11 for example by introduction of 
substituents or modification of functional groups. 
The compounds of the invention may also exist in various polymorphous forms, for example 
as amorphous and crystalline polymorphous forms. Ali polymorphous forms of the 
compounds of the invention belong within the framework of the invention and are a further 
aspect of the invention. 
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The compounds of the general formula 1 may be present as optical isomers or as mixtures 
thereof. The invention relates both to the pure isomers and all possible isomeric mixtures and 
is hereinafter understood as doing so, even if stereochemical details are not specifically 
mentioned in every case. Enantiomeric mixtures of compounds of the general 
formula 1, which are obtainable by the process or any other way, may be separated in known 
manner - on the basis of the physical-chemical differences of their components - into pure 
enantiomers, for example by fractional crystallisation, distillation and/or chromatography, in 
particular by preparative HPLC using a chiral HPLC column. 
According to the invention, apart from separation of corresponding isomer mixtures, 
generally known methods of diastereoselective or enantioselective synthesis can also be 
applied to obtain pure diastereoisomers or enantiomers, e.g. by carrying out the method 
described hereinafter and using educts with correspondingly suitable stereochemistry. 
lt is advantageous to isolate or synthesise the biologically more active isomer, provided that 
the individual compounds have different biological activities. 
METHODS OF SYNTHESIS 
A compound of the general formula (1) can generally be regarded as a chain of up to six 
building blacks a-b-c-d-e-f, each block being linked to the next by a linker group, for example 
a peptide (amide) bond. 
The six building blacks are 
a: 
d: 




G-BB-J or X1-BB-J; 




G-BF or G-X2, 
with G being a second linking function capable of selectively forming a covalent bond by a 
reaction with a first linking function J yielding the respective and with X 1, BA, BB, BC, BD, 
BE, BF and X2 having the same meaning as defined previously. 
Thus, derivatives of the six building blacks are employed as intermediates in the synthesis of 
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J or G may be activated before a linking reaction (Jact or Gact) or may be reversibly 
inactivated by a removable protecting group (JP or GP) 
wherein a removable protecting group is employed, if necessary, to suppress 
unwanted side reaction. For example, if a first building block employed in a reaction 
comprise a COOH moiety, which is destined to react specifically with a NH2 moiety of 
a second building block, wherein said second building block comprises also a COOH 
moiety, the COOH moiety of said second building block is protected for avoiding a 
coupling reaction of said second building block with itself. The use of protecting group 
is a standard procedure for a skilled persan and a skilled persan will easily determine 
the necessity of a protecting group and will employ a suitable protecting group. 
There are different reaction pathways for providing a compound of the general formula 1 
using the above mentioned building blacks. 
lt is apparent to the skilled persan that a suitable reaction pathway will not necessarily involve 
the isolated building blacks in each case, but will take place between combinations of the 
above mentioned building blacks in order to arrive at the full sequence of six blacks (a-b-c-d-
e-f). Therefore, the above is to be understood as a teaching regarding the sequence of blacks, 
i.e. which block links to which other one through the linking functions J and G. 
For example, the reaction of the building block b with the building block c will yield a building 
compound b-c. This compound b-c can react as a further building block in subsequent 
reactions by removing or adding a protection group, if necessary. The further building block b-
e can react with a building block a, yielding a compound a-b-c. Said compound a-b-c can 
function as a reaction partner for the building block d. The same applies to further subsequent 
reactions in order to arrive at the full sequence of six blacks. 
Many ways to achieve the full sequence a-b-c-d-e-f are possible. The following examples show 
- without being limited to these combinations - three further possible combinations such as 
e + f yielding (e-f), d + (e-f) yielding (d-e-f), c + (d-e-f) yielding (c-d-e-f), a+ b yielding 
(a-b), (a-b) + (c-d-e-f) yielding (a-b-c-d-e-f), 
b + c yielding (b-c), (b-c) + d yielding (b-c-d), e + f yielding (e-f), (b-c-d) + (e-f) 
yielding (b-c-d-e-f), a+ (b-c-d-e-f) yielding (a-b-c-d-e-f) or 
c + d yielding (c-d), b + (c-d) yielding (b-c-d), e + f yielding (e-f), (b-c-d) + (e-f) 
yielding a+ (b-c-d-e-f) yielding (a-b-c-d-e-f). 
ln embodiments of the synthesis of the invention where one last coupling step is made to 
arrive at the backbone of the compound of the formula 1 (this "last step" may be followed by 
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subsequent reactions to remove protecting groups or to introduce modifications of the 
reactive groups), this last step of backbone formation can be: 
a+ b-c-d-e-f, or 
a-b + c-d-e-f, or 
a-b-c + d-e-f, or 
a-b-c-d + e-f, or 
a-b-c-d-e + f. 
ln embodiments of the synthesis of the invention where one coupling step is made to arrive 
at the intermediate a-b-c-d-e this step can be: 
a + b-c-d-e, or 
a-b + c-d-e, or 
a-b-c + d-e, or 
a-b-c-d + e. 
ln embodiments of the synthesis of the invention where one coupling step is made to arrive 
at the intermediate b-c-d-e-f, this step can be: 
b-c-d-e +f, or 
b-c-d + e-f, or 
b-c + d-e-f, or 
b +c-d-e-f. 
ln embodiments of the synthesis of the invention where one coupling step is made to arrive 
at the intermediate b-c-d-e, this step can be: 
b-c-d + e, or 
b-c + d-e, or 
b +c-d-e. 
ln the following some of these possible pathways are explained in more detail. Other 
pathways may be employed in a similar manner. 
Thus, a building block G-BC-J (c-J) is reacted with a building block G-BD-J (d-J) 
yielding a building block 
G-BC-03-BD-J (BZ1-J). 
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Furthermore, a building block X1-BB-J (X1-b-J) is reacted with a building block G-BC-03-BD-
JP (BZ1-J) yielding a building block 
X1-BB-D2-BC-D3-B0-J (BZ2a-J). 
Alternatively a building block G-BB-J (b-J) is reacted with a building block G-BC-03-BD-J 
(BZ1-J) yielding a building block 
G-BB-02-BC-03-BD-J (BZ2b-J). 
Furthermore, a building block G-BE-J (e-J) is reacted with a building block G-X2 (G-X2) 
yielding a building block 
G-BE-05-X2 (BZ3a) 
Alternatively, a building block G-BE-J (e-J) is reacted with a building block G-BF-J (BF-J) 
yielding a building block 
G-BE-05-BF (BZ3b). 
The building block X1-BB-D2-BC-D3-B0-J (BZ2a-J) is reacted with a building block G- BE-X2 
(BE-X2), wherein after an eventual removal of possible protecting groups the compound with 
a molecular structure as defined in formula 1 
X1-BB-D2-BC-D3-B0-D4-BE-X2 
is provided. 
Alternatively, the building block X1-BB-D2-BC-D3-B0-J (BZ2a-J) is reacted with a building 
block G-BE-05-X2 (BZ3a), wherein after an eventual removal of possible protecting groups 
the compound with a molecular structure as defined in formula 1, 
X1-BB-D2-BC-D3-B0-D4-BE-D5-X2 
is provided. 
ln another alterative, the building block X1-BB-D2-BC-D3-B0-J (BZ2a-J) is reacted with a 
building block G-BE-05-BF (BZ3b), wherein after an eventual removal of possible protecting 




ln a further alternative, the building block G-BB-02-BC-03-BD-J (BZ2b-J) is reacted with a 
building block G-BE-X2 (BE-X2), wherein a building block 
G-BB-D2-BC-D3-B0-D4-BE-X2 (BZ4a) 
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is provided. 
The building block G-BB-D2-BC-D3-B0-D4-BE-X2 (BZ4a) is then reacted with a building block 
BA-J (a-J), wherein after an eventual removal of possible protecting groups the compound 
with a molecular structure as defined in formula 1, with X1 being BA-D1-
BA-D1-BB-D2-BC-D3-B0-D4-BE-X2 
is provided. 
Alternatively, the building block G-BB-02-BC-03-BD-J (BZ2b-J) is reacted with a building 
block G-BE-05-X2 (BZ3a), yielding a building block 
G-BB-D2-BC-D3-B0-D4-BE-D5-X2 (BZ4b). 
The building block G-BB-D2-BC-D3-B0-D4-BE-D5-X2 (BZ4b) is reacted with BA-J (a-J), 
wherein after an eventual removal of possible protecting groups the compound with a 
molecular structure as defined in formula 1, with X1 being BA-D1-
BA-D1-BB-D2-BC-D3-BD-D4-BE-D5-X2 
ls provided. 
Alternatively, the building block G-BB-02-BC-03-BD-J (BZ2b-J) is reacted with a building 
block G-BE-05-BF (BZ3b) yielding a building block 
G-BB-02-BC-03-BD-04-BE-05-BF (BZ4c) 
The building block G-BB-02-BC-03-BD-04-BE-05-BF (BZ4c) is reacted with BA-J (a-J), 
wherein after an eventual removal of possible protecting groups the compound with a 
molecular structure as defined in formula 1, with X1 being BA-01- and X2 being 0 5-BF, 
BA-01-BB-02-BC-03-BD-04-BE-05-BF 
is provided. 
The method of synthesis is explained in the following with more specific building blacks, 
without being limited to these specific building blacks. 
ln most cases J refers to a COOH moiety, wherein said first linking function may be , if 
necessary, activated (Coact) or protected (CQQPGA), and G refers to a NH2 moiety, wherein 
said second linking function may be, if necessary, protected (FN). 
Thus, derivatives of the six building blacks are employed as intermediates in the synthesis of 
the invention as building blacks of the general formula 
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f: 
wherein 
FN is NPGN or M, wherein 
Mis a masked functional group, in particular Mis -N02 or -N3, and wherein, 
NPGN, cooPGA or oPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an activated 
carboxylic acid moiety, 
A building block c-COOH 
, or 
a building block FN-c-coact 
is reacted with a building block (H2N-d): 
yielding a building block BZ1 a 
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(BZ1 a). 




(X1-b-COOH) or ~ act CO (X1 -b-CQact) 
is reacted with the building block (BZa 1) yielding a building block BZ2a 
X~ 0 ~COOPGA 
~~0NN 
0 ,,l., H 
z y 
(BZ2a), 
wherein the depicted building block is representative for the other similar building blacks 
BZ2a derived from a reaction with the building block BZa1, which may be used in an 
analogue reaction yielding to analogue compounds. This building block is used further below 
to describe the further reactions, the other building blacks may be used in a similar manner. 
Subsequently the protecting group PGA may be removed and a building block BZ2a-COOH 
1 X'î7) ~COOH 
Vy~JNN 
0 ,,l" H z y 
(BZ2a-COOH), 
is provided, which can be optionally activated to provide a building block BZ2a-coact 
242 
wo 2014/125075 
X~ 0 ~Ca8ct 
~~0NN 
0 ,,l., H 
z y 






is reacted with a building block X1-b-COOH or a building block X1-b-Coac1, 
the protecting group PGA is removed and the reaction product is reacted with a building 












0 ,,l" H z y 
(BZ2a-COOH) apply. 















yielding a building block BZ3b 
1-5: PGA 
b:c(OPGH O O ~ COQ 
~ 1 ~ 




(BZ3b), wherein variants 
of the block BE are not depicted due to simplicity reasons. These variants may be used in a 
similar manner, yielding analogue building blacks BZ3b. The depicted building blacks BZ3b 
are used further below to describe the further reactions, the other building blacks may be 
used in a similar manner 




0 ~" H z y 
(BZ2a-COOH) or 
X~ 0 ~cdct 
~~v1lNN 
0 ~" H z y (BZ2a-coact) 
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is reacted with a building block BZ3b 
(BZ3b) 
wherein after removal of the protecting groups the compound with a molecular structure as 
defined in formula 1 
1 OH 
OXYCOOPGA 
1 OH O ~ I 
ooJvlll N ~ 
x1 d~ H 
~HO ~I ~~ ~N~N~ 
0 ,,l" H z y 
6:crOH T 
1 OH O ~ I 
ooJvlll N ~ 
X1 d~ H 
~HO ~I ~~ ~N~N~ 
0 ,,l" H z y 
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R1 6trT 1 OH O ~ I 
00~1 N ~ 
X1 d)J H ~ HO ::71 ~~ ~N~N~ 
0 ,,l" H z y 
1 OH O ~I T 
0~ ~ 0 ::7 1 N 1 
x1 d H Rn ~ HO ::71 ~~ ~N~N~ 
0 ,,l" H z y 
is provided 
An alternative of the second aspect of the invention relates to the synthesis of compounds 
according to the general formula 1, wherein 
a. x1 is 
with 0 1 being a linker derived from a reaction of J and Gand which comprises carbon, 
sulphur, nitrogen and/or oxygen atoms and which is covalently connecting R4 and the parent 
moiety, and 
with R4 being selected from a substituent group S3, S4 or S5, or 
b. x1 is 
R2 
E,0AD_1 - ~ or E--J:?'0_1 - ~ 
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with R2 and R3 of BA being selected, where applicable, independently from each other 
from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted 
C1-C3 alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl , in 
particular from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -
OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -
CHF2, -CH2F or -CF3,more particularly with R2 and R3 being selected independently 
from each other from -H, -For -CH3, and 
with 0 1 being a linker derived from a reaction of J and Gand which comprises carbon, 
sulphur, nitrogen and/or oxygen atoms and which is covalently connecting the moiety 
comprising E and the parent moiety, 
- with E being selected from a substituent group S3, S4 or S5, or 
- with E being 
- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n being 1, 
- with each R1 independently from any other R1 being selected from a substituent 
group S1 or S2, or 
- with E being 
with each T being selected independently from each other from -CH2, -NH, -Sor 
-0, -CHCH3, -C(CH3)2 or -NRc, 
with T' being selected from -CH2, -NH, -Sor -0, -CHCH3, -C(CH3)2 or -NRc, and 
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with T" being selected from -CH or =N, and 
with R5 and R6 being selected independently from each other from -H, -F, -CH3, 
-CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in 
particular with R5 and R6 being selected independently from each other from H, 
-For -CH3, and 
with R6' being selected from -OH, -OCH3, -OCH2CH3 or -CH3 
with R7 being selected from =NH, =Sor =0, and 
with m of R9m being selected from 0, 1, 2 or 3, and each R9 being selected 
independently from each other from -Cl, -F, Br, 1, -OH, -CCH, -CH3, -CH2CH3, -
OCH3, -COOH, -COORb, -C(O)NH2, -C(O)NH(Rb); -C(O)N(Rb)2, -NHC(=O)ORb, 
-NRbC(=O)ORb, -NRbC(=O)OH -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3, 
with Rb being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or 
a C1-Cs haloalkyl. 
ln some embodiments, a building block BB1 
1 :ÙOPGH PGA 
PGH Ü ~ COQ 
1 0 0 1 
G Oou~ "-
Y') H O ~~ ~ 
~N~N)l) 
0 ~" H z y 
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OPGH Qxr 0 ~ T 
G O O 1 
r7 N ~ 
~~JLNd~ H 
0 ,l., H 
z y 
PGH 
1 0 0 ~T G 00:c( 1 r7 r7 N ~ 
~~JLNd~ ~ 1 H R: 
0 ,l., H 
z y 
:a: b~ employed, which may be . p ov1ded. Said building block BBprov1ded analogously to th . (BB 1) 1 may b e prev1ousl d G-PPM e described by th y escribed synth . e general f es1s, ormula GBB1 
. (GBB1) 




6~~1 ~~ 0 ~N_(J ~ R: 
~~~NJl) H 
0 ,l., H 
z y 
(PPM) 






R3 E-J EAJ (B1 ), (C1 ), (C2), (C3), 
R2 
E)yJ R2 E,oAJ E~J R3 
wherein 
(C4), (C5) or (C6) 
cooPGA or oPGH signifies a COOH or OH moiety reversibly inactivated by a 
removable protecting group, 
coact signifies an activated carboxylic acid moiety, 
J is a first linking function which is formed in such a way as to form a covalent 
bond selectively with a second linking function G and to provide the linker 0 1, and 
E, D, R2 , R3 , R4, Z and Y have the same meaning as defined above, 
are reacted and yield protected compounds of the general formulas 
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E~D!.._PPM EAD-1 PPM E,0AD_1 PPM 
(PC3), R3 (PC4), (PC5) 
E--f7"o:!.._PPM 
or (PC6) 
After removal of the protecting groups the compound with a molecular structure as defined 
by the general formulas 
D1-PM 















with PM being th e parent moiety 
1 OH o 
_,..f I OH 00 .,-
\""- O O I OH 
0 H 
z y 
_,S' 1 OH Q ,QT 
I""- oot( 1 <" ~ <" N "'-
"'- 1 ~J)L) ~ ..._ 1 H R; 
0 ,l., H 
z y 
PCT /EP2014/052922 
Building blacks B1 and C produced a 1 to CG are kno . nalogously to kn wn compounds 
A 
wn corn ' commer . Il 
lternativel . pounds. c,a y available 
y rnstead of CG or may be 
E~ j 
(C6) the followin g compound 
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E~J 
(C6a) may be used in the above described manner, wherein the moiety 
may be introduced later by a reaction of the double bond according to literature procedure 
(Davies et al,J. Am. Chem. Soc. 1993, 115, 9468; IUPAC Gold book definition (http://www. 
iupac. org/ goldbook/ 001745. Pdf); Kishner et al. J. Russ. Phys. Chem. Soc. 43, 1132 
(1911 ); phenylcyclopropane in Organic Syntheses, Coll. Vol. 5, p.929 (1973); Vol. 47, p.98 
(1967); Ludger et al "Biosynthesis and Metabolism of Cyclopropane Rings in Natural 
Compounds" Chem. Rev., 2003, volume 103, pp 1625-1648; Coelho et al. Science 339 
(6117): 307-310. doi: 10.1126/science.1231434; Charette et al., A. Org. React. 2001, 58, 1; 
Paul et al. J. Am. Chem. Soc.; 2006; 128(19) pp 6302 - 6303). 
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with n of R1n being 0, 1, 2, 3 or 4, in particular n of R1n being 0, 1, 2 or 3, more particularly n 
of R1n being 1 , and with each R1 independently from any other R1 being selected from a 
substituent group S1 or S2. 
The connection of two compounds by the first and second linking function (G and J) 
providing a defined bond (a linker D) between these compounds is known in the art and can 
be achieved by standard reaction according to basic literature procedures or adapted basic 
literature procedures. For example, J of one compound may be -CH2)20H and G of another 
compound may be Cl. The reaction of these compounds in the presence of NaH yields a -
CH2)20- bond (linker D) between the two compounds providing a space of 3 atoms between 
these compounds. A reaction of 
-(C=O)CI (linking function J) with -NH2 (linking function G) yields a -(C=O)-NH- bond (linker 
D) providing a space of 3 atoms. Exemplary examples are given further below for one linker 
0 1• Analogue pathways apply for the other linkers 0 2 to 0 5 • 




R4-J E-J EAJ 
(B1 ), R3 (C1 ), (C2), (C3), 
R2 
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with J being COOH or cooact is reacted with a compound of the formula 55 
IXYOPGH PGA 
PGH O ~ COQ 
1 0 0 1 
H2N~ do ox:r~ ~ 
1 
H O I N ~ N0N .& H 
0 l~.,H 
CN (55) 
The above mentioned compounds B1 or C1 to C6 are known compounds, commercially 
available or may be produced analogously to known compounds. 
The synthesis of the invention comprises the compound 55, which is prepared according to 






M< lù PGA PGH Ü 17' COQ 
1 0 0 1 
H2N~ do ox:r~ " 
1 
H O I N ~ N-._;)lN ~ H 
0 l~ .. H CN 
55 
Scheme 1: 
Compound 52 was reacted with compound 53 in the presence of Bis-
(trichloromethyl)carbonate (BTC), 2,4,6-Collodine and N,N-diisopropylethylamine (DIPEA) 
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yielding compound 54 (step a). After isolation of compound 54, the N02-moiety of compound 
54 is converted with SnCb to the NH2-moiety of compound 55 (step b). 










ln scheme 2 compound 56 was reacted with compound 57 in the presence of N,N-
Dicyclohexyl-methandiimin (DCC) yielding compound 58 (step a). Alternatively 1 0-(7-
azabenzotriazol-1-yl)-N, N, N, N-tetramethyluronium hexafluorophosphate (HATU) and N, N-
diisopropyl-ethylamine (DIPEA) may be used. Compound 58 was treated with HCI/Dioxane 
to obtain compound 59 (step b). Subsequently, compound 59 was reacted with compound 60 
in the presence of triethylamine, yielding compound 53 (step c). 
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Scheme 3 describes the reaction of compound 61 with compound 62 in the presence of Bis-
(trichloromethyl)carbonate (BTC), 2,4,6-Collidine and N,N-diisopropylethylamine (DIPEA), 
yielding compound 63 (step a). After isolation of compound 63, the N02-moiety of compound 
47 is converted to the NH2-moiety of compound 53 by the use of SnCb. 
Compounds 57, 60, 61 or 62 are known compounds, commercially available or may be 
produced analogously to known compounds. Compound 60 can be synthesised according to 
Adamczyk, M., Fino, J., R., Org. Prep. Proced. !nt., 2009, 28, 470-474. For example, 
compound 61 and 62 may be produced by an adapted procedure according to Tichenor et al. 
(M. S. Tichenor, D. B. Kastrinsky and D. L. Boger, J. Am. Chem. Soc., 2004, 126, 8396). 
Comparable compounds to 57, 61 or 62 with different substituents on the phenyl moieties 
may be employed in a similar reaction to provide the respective building blacks comparable 
to compound 53. 
The method of choice of linking these compounds is a selective coupling reaction between 
the (activated) carboxylic acid moiety R4-COOH or R4-COoact or E-COOH or E-Cooact (acid 
partner), and the amino moiety (amino partner), whereby other functional groups of the 
amino and acid partner are protected. The reactive hydroxyl groups need to be transitionally 
(reversibly) protected by any of the many suitable protection groups for hydroxyl groups 
(PGH) known in the art. Likewise, the carboxylic acid moiety of the amino partner H2N- will 
be protected by any of the many suitable protection groups (PGA) known in the art for 
carboxylic acid groups to prevent homopolymer formation. Furthermore, any amino moiety of 
the acid partner will likewise be protected by any of the many suitable protection groups for 
amino groups (PGN) known in the art. 
Activation of the carboxylic acid moiety of the acid partner may be applied before the reaction 
of the acid partner with the amino partner and can be achieved by any of the methods known 
in the art for increasing the reactivity of carboxylic acids to amide formation with primary 
amines, in particular reference is made to the activation of the carboxylic acid as discussed. 
The reactions are carried out between -30 ° C to 80 ° C, in particular between 25 ° C to 60 ° C 
and further in particular between 25 to 30 °C. 
The PGH protecting groups can be C4H9 (t-Butyl), para-methoxybenzyl (PMB), benzyl or 
CH2CHCH2 (allyl), in particular CH2CHCH2 (allyl). 
The PGA protecting groups can be C4H9 (t-Butyl), para-methoxybenzyl (PMB), benzyl 9-
fluorenylmethyl (Fm) or CH2CHCH2 (allyl), in particular CH2CHCH2 (allyl). 
The activated carboxyl moiety can be 
( 0-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate) 
(HATU) ester, achieved by a coupling of the acid with HATU, or 
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Bis-(trichloromethyl)carbonate (BTC) ester, achieved by a coupling of the acid 
with BTC, or 
acyl chloride, achieved by a coupling of the acid with S0C'2 or 
N,N'-Oiisopropylcarbodiimide (OIC) ester, achieved by a of the acid coupling with 
OIC, or 
N,N'-Oicyclohexylcarbodiimide (OCC) ester, achieved by a coupling of the acid 
with OCC. 
The coupling reactions to the activated carboxyl moiety may be supported by addition of 
bases selected from (N,N-diisopropylethylamine) (OIPEA), N-methylmorpholine (NMM), 4-
dimethylaminopyridine (OMAP), triethylamine (TEA), 2,4,6-trimethylpyridine (sym-collidine), 
pyridine, N,N'-Oiisopropylcarbodiimide (OIC), 2,6-di-tert-butyl-4-dimethylaminopyridine 
(OBOMAP), in particular from N,N-diisopropylethylamine (OIPEA) or 2,4,6-Trimethylpyridine 
(sym-collidine). The addition of bases allows a deprotonation of the carboxylic acid and 
facilitates the reaction to the respective activated carboxylic acid. 
The solvent of the reactions is tetrahydrofuran, dioxane, acetonitrile, tert-butyl methyl ether, 
dichlormethane, chloroform, 1-methyl-2-pyrrolidinone, N,N-dimethylacetamide (OMA), or 
dimethylformamide, in particular tetrahydrofuran or dimethylformamide. Other solvents may 
be applied if necessary. 
The compound characterized by the general formula 1 is obtained by removal of the 
protecting groups. 




R with R8 being selected from -CH3, -CH2CH3, -OCH3, -OCF3, -CH2CF3, -
CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with R8 being CH3, , and with V being 
S or O. Reference is made to the description above. 




R , with R8 being selected from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -CH2CF3, -
CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular R8 being selected from H or CH3, 
more particularly R8 being H, and with V being S, NH or O. Reference is made to the 
description above, wherein the respective functional groups are switched. 
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An analogue pathway applies also for 0 1 being 
V V 
~-N)lO-~ ~-OAN-~ 
1 s I s 
R or R , with R8 being selected from -H, -CH3, -
CH2CH3, -OCH3, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular 
with R8 being selected from H or CH3, more particularly R8 being H, and with V being S, NH 
or O. Reference is made to the description above 
An analogue pathway applies also for 0 1 being 
V V 
V'o-~ or ~-O~~, with R' being selected tram -H, -CH,, -CH,CH,, -
OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, and with V being S, NH or 0,. 
Reference is made to the description above. 
An analogue pathway applies also for O being 
0 0 
\:"o)l_N/~ 7z:0__)l_~~ 
1 s I s 
R or R with R8 being selected from -H, -CH3, -
CH2CH3, -OCH3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3. Reference is made to 
the description above 
An analogue pathway applies also for 0 1 being 
S/""'o-~ rs-< 
<. or S , wherein the coupling step is achieved by a 
Williamson-Ether-Synthesis, a known organic name reaction. 
rs-< Optionally S may be oxidized yielding 
>~s-< ~ "l \\ s 
0 0 
as a linker 0 1. 
An analogue pathway applies also for 0 1 being 
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V 
~-NAN-~ 
1 a I a 
R R , with each R8 being selected independently from each other from -H, -
CH3, -CH2CH3, -OCH3, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in 
particular with each R8 being selected independently from each other from H or CH3, more 
particularly each R8 being H, and with V being S, NH or O. Reference is made to the 
description above. Concerning the coupling step reference is made to the description below 
and the experimental section. 
An analogue pathway applies also for 0 1 being 
O 0 ~ // 
~-N/s.........._ ~ 
la 
or R , with R8 being selected from -H, -CH3, -CH2CH3, -
OCH3, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with R8 being 
selected from H or CH3, more particularly R8 being H. Reference is made to the description 
above. Concerning the coupling step reference is made to the description below and the 
experimental section. 
An analogue pathway applies also for 0 1 being 
N"N'N~ r=(~ ~~ 
'7)=1 S __ N,w"N ~N"N......_~ 
L , < or S , Reference 
is made to the description above, wherein the coupling step is achieved by a Click reaction, a 
known organic reaction. 




R , wherine the respective heterocycle is produced with an adapted 
procedure of Zhang et al. ( Org. Lett., 2010, 12 (17), pp 3942-3945), using an aluminum-
based Lewis acids promotion for a condensation of substituted a-chloroglycinates with 
isonitriles or with cyanide ion. 
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ln case of 0 1 being 
a compound 
R2 
~-0-~ COOH ~ ~N-0-~ COOH E' 'Y H -








(C5a), (C6a) or 
E ~-0-COOH ~ - (C6a') 
is reacted with a compound of the formula 64 
IXYOPGH PGA 
PGH O ~ COQ 
1 0 0 1 
o
0x:(N ~ 
- ~ 1 H 
CINH3~ d ~ 
1 
H O I N ~ N~N ô H 





in the presence of an activation reagent and a base, yielding a compound of the general 
formula 1. 
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The above mentioned compounds B1a or C1a to C6a are known compounds, commercially 
available or may be produced analogously to known compounds. Reference is also made to 
the experimental section. 
An analogue pathway applies for 0 1 being 
~~N-~ ls 
R , with R8 being selected from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -CH2CF3, -
CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with R8 being selected from H or CH3, 
more particularly R8 being H. Reference is made to the description above 
Similar procedures may be applied where E is one of the moieties below 
R~ 
T, T', T", R5 , RB, RB', R7 , m or R9m having the same meaning as defined previously. 
The preparation further comprises a compound 




D 00~~,V ~ H O 'Y'~ 'S-
~N0NJJ 
0 ,l., H 
z y 
with n, R1, R2, R3, D, E, Z and Y having the same meaning as defined above. 
ln case of D being 
a compound 
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COOH cooact 
(49) or (50) 
is reacted with a compound of the formula 39 
IXJOPGH PGA 
PGH Ü ~ COQ 
1 0 0 1 
H2N~ d'O Oxr~ ~ 
1 
H O I N ~ N~N .& H 
0 l~.,H 
CN (39) 
according to the previously described reaction pathway. One specific example is given in 
scheme 4. Compound 49, 49a or 50 are known compounds, commercially available or may 
be produced analogously to known compounds. Other compounds for 49, 49a or 50 may be 
used in a similar way. 
49a 
BTC !THF RT 
2,4,6-Collidine 3 h, '75 % 
DIPEA 
Pd[P(Ph 3 )] 4! THF, RT 
Phenylsilane 1 O h, 48 % ÙO 
MeO ~ C02H 
0 0 1 
F~ MeOxY ~ 1 H O I N ~ A NY) 0 ~N .& H 
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Concerning the reaction pathway with respect to different 0 1 moieties as listed above 
reference is made to the previously described pathways with these functional groups 0 1. 
Scheme 1 to 3 or the reaction with compound 48 show exemplary reaction pathways for 
compounds with Z being H and Y being CN. lt is understood that compounds comprising 
other substituents Y such as -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, 
-C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) or 
-C(=O)NH2 can be produced according to a similar reactions pathway as depicted in 
schemes 1 to 3, whereby reactive moieties -C(=O)(NH2) or -C(=O)OH may be protected (-
C(=O)NPGN or -C(=O)QPGA until the global deprotection. The same applies for compounds 
where Z is -H, -OH, -CH3, -CH2CH3 or -OCH3. Oifferent protecting groups may be applied as 
discussed above. 
lt is further understood that the same reaction pathways may be used for different building 
blacks BC, as described above. Furthermore, The reaction of the two linking functions G and 
J yielding different O moieties (01 to 021) may be employed with respect for the other 
building block (e.g. a connection between building block BE with BF). 
Further examples with variations on different building blacks or different linkers O shall 
further clarify the systematic approach in providing a compound of the general formula 1. 
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An alternative pathway for building blacks comprising different BB or BD moieties is depicted 










1 OAllylO O~OAllyl 




1 OAllylO O~OAllyl 
AllylO~H O Otr~)J 
~I ~ N N d ~I 
...._ 0 ~ N 
o ~~0~ ,,_ 1 H 
O 'CN 
j final deprotection 
6lfoH 0 
1 OH O ~ I OH 
HO~ oo:((N ~ 
~I ~ ~ N d ~I H 
...._ 0 ~ N 
0 ~~0~ "- 1 H 
O 'CN 
Scheme 5: The starting materials may be provided by a reaction of 6-Amineonicotinic acid or 
allyl protected cinnamic acid with S0C'2 and are coupled with standard coupling procedures 
described above providing the a-b- building block in form of an ester. The respective acid is 
provided by a reaction with Dioxane/H20 and LiOH. Said acid (a-b-COOH) is reacted with the 
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c-d-e-f building block (the synthesis of this block is described above) in the presence of 
Triphosgen and Collidin. The final deprotection is achieved with Phenylsilane and 
[Pd(PPh3)4]. 




j 1. Boc-Asn-OH, DCC 2. 4 M HCI in Dioxan 3. Nitro-pABA-OSu, TEA 
Scheme 6: Shows a reaction pathway for providing a building block -b-c-d-. Details are given 
in the experimental section. 
A reaction pathway to the a-b-c-d-e-f backbone starting from the above depicted building 
blacks -b-c-d- is depicted in scheme 8. 
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Scheme 8: Shows a reaction pathway to the a-b-c-d-e-f backbone starting from the building 
blacks -b-c-d- (A, B, C) of scheme 7. The reaction conditions are similar to the previously 
discussed reduction, coupling and deprotection conditions (see e.g. Scheme 4). Details are 
given in the experimental section. 
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scheme 9 a d Y for building blocks . . PCT/EP2014/052922 An alternative pathwa . 
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Scheme 9: Shows a reaction pathway to the a-b-c-d-e-f backbone comprising a -S02- linker 
in place of 0 4• The reaction conditions are similar to the previously discussed reduction, 
coupling and deprotection conditions (see e.g. Scheme 4). Oetails are given in the 
experimental section. 
0 
1.Boc deprotection d 
2.coupling reaction ~ 1 ~ 0~ 
02Nn I BocHN~N ô ~ ' 1 Cl :: H ,, s~ ' // ,, CN 0 0 
1 OAllylO 




1.Deprotection I OAllylO 
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1 /S, . N AllylO~ ::::,.... ~N~ ô 
2.coupllng rear I H Il I H 
::::,... ~ OH 0/ 'ü = H 
' O CN I OAllylO 
1 OAllylO O~OAllyl 
AllylOY') I O O~NA) 
~~'(-7) 0 ~NA) H 
0 ~SJJ_N)l) H 
.--------- c/ 1) ~ H 
final deprotection 'cN 
Scheme 10: Shows a reaction pathway to the a-b-c-d-e-f backbone comprising a -S02- linker 
in place of 02. The reaction conditions are similar to the previously discussed reduction, 
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coupling and deprotection conditions (see e.g. Scheme 4). Details are given in the 
experimental section. 





2 ~ /J 
57 
:,T~A .. BocHN ~N (Ycoo"" 
DMF,RT ~ ~ 
16 h, 86 % H 66 





1 DMF, RT 





Scheme 11: Compound 65 may be purchased as the respective an amino acid glycine and 
subsequently protected according to standard procedures. The compound 68 may be used 
according to scheme 1 to provide an analogue derivative of compound 55, which can be 
used as an intermediate for the last coupling reaction under similar conditions as described 
previously, in particular in scheme 4. 
An analogue procedure applies to BC moieties selected from 
wherein the NH2 or the 
COOH moieties may be protected by a suitable protecting group and the COOH, in an 
analogue way as described above, moiety may be activated- if necessary - in an analogue 
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way as described above. These building blacks (comparable to compound 68) may be used 
according to scheme 1 to provide an analogue derivative of compound 55, which can be 
used as an intermediate for the last coupling reaction under similar conditions as described 
previously, in particular in scheme 4. 
Examples of synthetic pathways for a few representative compounds are given in the 
following. Other compounds with comparable BC moieties may be produced analogously. 
Derivatives containing building block BC variations are depicted below. If not mentioned 
otherwise, the reaction conditions are the same or similar to the previously described 
coupling reactions. Further details could be found in the experimental section. 
OH 
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HO O ~ N 
~~Yn H d~ A H 
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1 H O 1 ~ ~ .& N'Oy O dN .& 
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OH 
HO 
OH MeO ~ ~eoxi'o ~co2H 
Yn ~ 1~ NA) 
0 ~tJ)~) ~ A H 
0 j\ H 
(a-amin · o1sobutyric acid-de . . nvat1ve) 
HO 





o ~ H N I N ~ 1 ~ ~ H 
NH 2 
( 1 • ys1ne-derivative) 
(praline-conta· . 1ning d · . envat1ve) 
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oc-protected . gcyc1ne- and . am1no acids were use a-am1noisobutyric acid- . . d as starting material: denvat1ve, the following 
BocHN~COOH 
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The above mentioned five starting materials were coupled to tert-butyl 4-aminobenzoate 



















BocHNX)l ,, N 
H 
AllylO 
Deprotection of these compounds was carried out using 4 M HCI in dioxanes yielding the 
following compounds as hydrochlorides. 







Ù COOH 0 H2N1 .. )l~ 
AllylO~ 



























L-Proline methyl ester was reacted with 4-nitrobenzoyl chloride yielding a methyl ester which 
was hydrolysed to carboxylic acid. This acid was coupled with tert-butyl -4-aminobenzoate 
yielding the protected carboxylic acid moiety which was treated with 4 N HCI in dioxane 
yielding the tripetide comprising a carboxylic acid. 
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The tripeptides . were coupled t PCT/ y1elding compound . o the allyl protected C EP2014/052922 s. -term· 1 ina dipeptid e compound 53 
02N ~o NC02A11y1 
Y) H ~ ~I O N 1 : ~A('oA11y1 
~N'y""-N).,,J H Ol'J"1 OMe 
0 \" OMe 
NHAlloc 
These corn pounds were 
terminal NH . reacted with Tin( 2 mo1ety instead of Il) chloride dihydr . the NO m . ate y1elding th 2 o1ety, and were s b e respective 
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(Allyloxy)phenyl)-2-methylacrylic acid yielding a protected compound of the formula 1. After 
global deprotection Pd(PPh3)4 and purification via HPLC the beta-alanine-derivative, L-
propargylgcycine-derivative, threonine-derivative, a-aminoisobutyric acid-derivative, lysine-
derivative or proline-containing derivative, as depicted above, were provided. 
Possible ways to obtain derivatives of building blacks, in particular of building blacks BE and 
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OH K2C03 OAllyl OAllyl 
~co,H Allyl-Br oco2AII~ KOH i:(~H DMF, RT • THF/H 20/MeOH 
d) 0 2N 12 h, 90 % 0 2N RT, 12 h, 94 % 0 2N 
SnCI /2H 20 ! 
EtOH, 60 "C 





Meoùco2H All~I-Br • MeOÙC02AII~ SnCI 2*2H 20 MeOÙC02Allyl 
DMF, RT EtOH, 60 °C 
e) 0 2N ~ 12 h, 98 % 0 2N ~ 6 h, 65 % H2N ~ 
Scheme 12: The 2-hydroxy-3-methoxy-4-nitro-benzaldehyde can be synthesised according 
to Pérez, R., A., Fernandez-Alvarez, E., Nieto, O., Javier Piedrafita, F., J. Med. Chem., 1992, 
35, 4584-4588, wherein the other starting materials can be purchased. The compounds may 
be deprotected or activated for further reactions. Different building blacks, in particular 
building blacks (e.g. with a heteroaryl moiety or a bicyclic aryl or heteroaryl system, or with 
different substituents an the phenyl moiety, in particular may be the COOH moiety of building 
block BF be replaced with the substituent T (as defined above) may be employed in a similar 
manner. 
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An example for a BA building block comprising a different functional group is given in 
scheme 13: 
~COOH 
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a) To a solution of the cinematic acid in anhydrous DCM was added S0C'2 (1.2 eq) and the 
mixture was stirred for 3 hours at room temperature. Anhydrous methanol was added (10 eq) 
and the Mixture was stirred for 10 min. The solvent was removed under reduced pressure. 
Column chromatography (n-hexane:ethyl acetate 3:1) yielded the ester as a white solid (95 
%). 
b) To a solution of the ester in anhydrous THF was added Tetrazole (3 eq) and 
Diallyl N,N-diisopropylphosphoramidite (2 eq) at O °C. The mixture was stirred for 3 hours at 
room temperature, cooled to O °C and tert-Butyl hydroperoxide (3 eq) was slowly added. 
Stirring was continued for 1 hour at O °C. The Reaction mixture was poured into a solution of 
NaS03 (10 %) and extracted three times with ethyl acetate. After drying over Na2SÜ4 and 
filtration, the solvent was removed under reduced pressure. Column chromatography (n-
hexane:ethyl acetate 2:1) yielded the allyl protected ester as a clear oil (50 %), which was 
taken up in dioxane/1 N LiOH and the mixture was stirred at room temperature for 16 hours. 
The mixture was acidified to pH 1 with 1 N HCI and extracted three times with ethyl acetate. 
After drying over Na2SÜ4 and filtration, the solvent was removed under reduced pressure. 
Column chromatography (Chloroform:Methanol 100:1) yielded the allyl protected acid as a 
clear oil (46 %). 
c) BTC (0.766 eq, 0.0667 mmol, 19.8 mg) was dissolved in dry THF (10 ml) under an 
atmospher of argon. The allyl protected acid (2.37 eq, 0.207 mmol, 70 mg) was added. syn-
Collidine (8 eq, 0.697 mmol, 91 µI) was slowly added via syrringe and the white suspension 
was stirred at room temperature for 20 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA 
(10 eq, 0.872 mmol, 0.150 ml) were added via syrringe. The reaction mixture was stirred for 
12 h at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and 
brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the solvent was removed under 
reduced pressure. Column chromatography (CHCb:MeOH; 1.5 % MeOH) yielded the fully 
protected compound as an orange oil (78 mg, 79 %), which was (1 eq, 0.0534 mmol, 60 mg) 
with phenylsilane (20 eq, 1.07 mmol, 132 µI) dissolved in dry THF under an atmosphere of 
argon and exclusion of light. Pd[P(Ph)3]4 (1 eq, 0.0534 mmol, 62 mg) was added and the 
mixture was stirred 12 h at room temperature. After adding 3 drops of acetic acid the solvent 
was removed under reduced pressure. The final product was isolated after preparative HPCL 
purification as a white powder 
Further functional groups may be introduced in the "finished backbone a-b-c-d-e-f according 
to standard procedures, like fro example oxidation, reduction or halogenations. 
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ln an embodiment the synthesis of compounds with the following molecular structure of 
formula (2) 
1 OH OtrCOOH 
1 
1 OH O cr I RO~ oo:cfN ~ 
1 H I H ~ .& N~ 0 ~N ~ 
0 ~~~~À) H 
0 3'..,l,....2' R R 
wherein 
R1 is H or CO(NH2), 
R2' is CO(NH2) or CN, 
R3' is H or OCH3, and 
* indicates a stereo center of a L- or D- enantiomer, which is located on the tertiary 
carbon atom below the asterisk *, and wherein 
the compound of the general formula (1) is an essentially pure L-enantiomer, an 
essentially pure D-enantiomer or a mixture of the L- and D-enantiomer of the same 
molecular formula, wherein in particular the compound of the general formula (1) is an 
essentially pure L-enantiomer or an essentially pure D-enantiomer. 
may be carried out as described in the following. 










wherein R1 is H or CO(NH2), R2 is CN or CO(NH2) and R3 is H or OCH3. 
The method of choice of linking these building blacks is a selective coupling reaction between 
the (activated) carboxylic acid moiety of one block (acid partner), and a amino moiety of 
another block (amino partner), whereby other functional groups of the amino and acid partner 
are protected. The reactive hydroxyl groups of block a, e and f need to be transitionally 
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(reversibly) protected by any of the many suitable protection groups for hydroxyl groups (PGH) 
known in the art. Likewise, the carboxylic acid moiety of the amino partner will be protected by 
any of the many suitable protection groups (PGA) known in the art for carboxylic acid groups 
to prevent homopolymer formation. Furthermore, any amino moiety of the acid partner will 
likewise be protected by any of the many suitable protection groups for amino groups (PGN) 
known in the art. Additionally, the group R1 will be transitionally (reversibly) protected by a 
protecting group R1PG, whereby R1PG is, in case of R1 being H, the protection group for 
hydroxyl groups PGH (QPGH) and, in case of R1 being -CO(NH2), the protection group for amino 
groups (PGN) attached to the -CO(NH2) moiety of R1 (-CO(NPGN)). Likewise, the group R2 will 
be, in case of R2 being CO(NH2), transitionally (reversibly) protected by a protecting group 
PGN attached to the -CO(NH2) moiety of R2' 
(-CO(NPGN)), whereby in case of R2 being CN no protection group is applied. 
Activation of the carboxylic acid moiety of the acid partner may be applied before the reaction 
of the acid partner with the amino partner and can be achieved by any of the methods known 
in the art for increasing the reactivity of carboxylic acids to amide formation with primary 
amines, in particular reference is made to the activation of the carboxylic acid as discussed. 
Thus, derivatives of the six building blacks are employed as intermediates in the synthesis of 
the invention as building blacks of the general formula 
a: (a-COOH): 




~ 1 ,4 coacl 
OCOOH OC0"1 "-:: 




H,NXCOOH FN * COact 



















R1PG is, for embodiments for which R1 is H, a hydroxyl protecting group PGH, in 
other words the 0R1 PG moiety can be read as an oPGH moiety, or, 
in case of R1 being CO(NH2), a -CO(NPGN) moiety, and, 
in case of R1 being H, a hydroxyl protecting group PGH yielding a QPGH 
moiety, or, 
in case of R1 being CO(NH2), a - CO(NPGN) moiety, and 
R3 is H or OCH3, and 
R2 is CO(NPGN) or CN, except in case of FN-c-COOH, then R2 is CO(NH2) 
FN is NPGN or M, wherein 
M is a masked functional group, in particular M is -N02 or -N3, and 
wherein, 
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NPGN, cooPGA or oPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an activated 
carboxylic acid moiety, 
are employed as intermediates, and 
i. the carboxylic acid moiety a-COOH or the activated carboxylic acid moiety a-
coact of the acid partner a is linked to the amine moiety H2N-b of the amino 
partner b, 
ii. the carboxylic acid moiety b-COOH or the activated carboxylic acid moiety b-
coact of the acid partner b is linked to the amine moiety H2N-c of the amino 
partner c, 
iii. the carboxylic acid moiety c-COOH or the activated carboxylic acid moiety c-
coact of the acid partner c is linked to the amine moiety H2N-d of the amino 
partner d, 
iv. the carboxylic acid moiety d-COOH or the activated carboxylic acid moiety d-
coact of the acid partner d is linked to the amine moiety H2N-e of the amino 
partner e, and 
v. the carboxylic acid moiety e-COOH or the activated carboxylic acid moiety e-
coact of the acid partner e is linked to the amine moiety H2N-f of the amino 
partner f. 
ln some embodiments, only the activated carboxylic acid moiety of the acid partner is used in 
one of the steps i. to v., in particular in all the steps i. to v. is the carboxylic acid moiety of the 
acid partner activated. 
lt is apparent to the skilled persan that the above coupling reactions i. to v. will not necessarily 
involve the isolated building blacks in each case, but will take place between combinations of 
the above mentioned building blacks in order to arrive at the full sequence of six blacks (a-b-
c-d-e-f). Therefore, the above is to be understood as a teaching regarding the sequence of 
blacks, i.e. which block links to which other one through the amino and carboxylic acid moiety. 
ln other words, which block will function as an acid partner and which as an amino partner in 
the above coupling reactions in order to arrive at the full sequence of six blacks (a-b-c-d-e-f). 
For example, the reaction of the acid partner b with the amino partner c will yield a building 
compound b-c, wherein the amino moiety of the block band the carboxylic acid moiety of block 
c are protected. This compound b-c can react as an acid partner as well as an amino partner 
in subsequent reactions. By removing the protection group of the amino moiety of block b a 
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reaction with an acid partner a can be established, yielding compound a-b-c, wherein the 
carboxylic acid moiety of block c is protected. After removal of the carboxylic acid moiety of 
block c compound a-b-c can function as an acid partner for the amino partner d. The same 
applies to further subsequent reactions in order to arrive at the full sequence of six blacks. 
lt is further possible that by removing the protection group of the carboxylic acid moiety of block 
c of the compound b-c, the carboxylic acid moiety of block c will function as an acid partner 
and a reaction with an amino partner d can be established, yielding compound 
b-c-d. The amino moiety of the block b and the carboxylic acid moiety of block d of the 
compound b-c-d are protected. Thus, compound b-c-d can function after the removal of the 
protection group on the amino moiety of block b or on the carboxylic acid moiety of block d, 
comparable to compound b-c, as an acid partner for a reaction with the amino partner e or as 
an amino partner for the reaction with the acid partner a. The same applies to further 
subsequent reactions in order to arrive at the full sequence of six blacks. 
Many ways to achieve the full albicidin sequence a-b-c-d-e-f are possible. The following 
examples show - without being limited to these combinations - three further possible 
combinations such as 
e + f yielding (e-f), d + (e-f) yielding (d-e-f), c + (d-e-f) yielding (c-d-e-f), a+ b yielding 
(a-b), (a-b) + (c-d-e-f) yielding (a-b-c-d-e-f), 
b + c yielding (b-c), (b-c) + d yielding (b-c-d), e + f yielding (e-f), (b-c-d) + (e-f) 
yielding (b-c-d-e-f), a+ (b-c-d-e-f) yielding (a-b-c-d-e-f) or 
c + d yielding (c-d), b + (c-d) yielding (b-c-d), e + f yielding (e-f), (b-c-d) + (e-f) 
yielding a+ (b-c-d-e-f) yielding (a-b-c-d-e-f), 
whereby the coupling of the respective building blacks may be achieved in a similar manner 
as discussed in the previous sections. 
ln embodiments of the synthesis of the invention where one last peptide coupling step is 
made to arrive at the albicidin backbone (this "last step" may be followed by subsequent 
reactions to remove protecting groups or to introduce modifications of the reactive groups), 
this last step of backbone formation can be: 
a+ b-c-d-e-f, or 
a-b + c-d-e-f, or 
a-b-c + d-e-f, or 
a-b-c-d + e-f, or 
a-b-c-d-e + f. 
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ln embodiments of the synthesis of the invention where one peptide coupling step is made to 
arrive at the albicidin intermediate a-b-c-d-e this step can be: 
a + b-c-d-e, or 
a-b + c-d-e, or 
a-b-c + d-e, or 
a-b-c-d + e. 
ln embodiments of the synthesis of the invention where one peptide coupling step is made to 
arrive at the albicidin intermediate b-c-d-e-f, this step can be: 
b-c-d-e +f, or 
b-c-d + e-f, or 
b-c + d-e-f, or 
b +c-d-e-f. 
ln embodiments of the synthesis of the invention where one peptide coupling step is made to 
arrive at the albicidin intermediate b-c-d-e, this step can be: 
b-c-d + e, or 
b-c + d-e, or 
b +c-d-e. 
ln certain embodiments, a compound (a-b-c-d-e-coac1): 
is reacted with compound (H2N-f), yielding compound a-b-c-d-e-f 
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wherein 
R1PG is, for embodiments for which R1 is H, a hydroxyl protecting group PGH, in 
other words the 0R1 PG moiety can be read as an oPGH moiety, or, 
in case of R1 being CO(NH2), a -CO(NPGN) moiety, wherein in particular R1PG is a 
hydroxyl protecting group PGH with R1 being H, yielding a QPGH moiety, and 
R3 is H or OCH3, and 
R2 is CO(NPGN) or CN, and 
NPGN, cooPGA or oPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an activated 
carboxylic acid moiety, 
wherein from compound (a-b-c-d-e-f) albicidin is obtained by removal of the protecting groups 
PGN, PGH and PGA. Alternatively the not activated carboxyl acid moiety a-b-c-d-e-COOH may 
be used instead of the activated carboxyl moiety a-b-c-d-e-coac1• 
ln certain embodiments, a compound (a-b-c-d-coact): 
is reacted with a compound (H2N-e-f): 
wherein 
R1PG is, for embodiments for which R1 is H, a hydroxyl protecting group PGH, in 
other words the 0R1 PG moiety can be read as an oPGH moiety, or, 
in case of R1 being CO(NH2), a -CO(NPGN) moiety, wherein in particular R1PG is a 
hydroxyl protecting group PGH with R1 being H, yielding a QPGH moiety, and 
R3 is H or OCH3, and 
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R2 is CO(NPGN) or CN, and 
NPGN, cooPGA or oPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an activated 
carboxylic acid moiety, 
wherein from compound (a-b-c-d-e-f) albicidin is obtained by removal of the protecting groups 
PGN, PGH and PGA. Alternatively the not activated carboxyl acid moiety a-b-c-d-COOH may 
be used instead of the activated carboxyl moiety a-b-c-d-coac1. 
ln certain embodiments, a compound (a-b-c-coact) 
is reacted with a compound (H2N-d-e-f) 
wherein 
R1PG is, for embodiments for which R1 is H, a hydroxyl protecting group PGH, in 
other words the 0R1 PG moiety can be read as an oPGH moiety, or, 
in case of R1 being CO(NH2), a -CO(NPGN) moiety, wherein in particular R1PG is 
a hydroxyl protecting group PGH with R1 being H, yielding a OPGH moiety, and 
R3 is H or OCH3, and 
R2 is CO(NPGN) or CN, and 
NPGN, cooPGA or oPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an activated 
carboxylic acid moiety, 
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wherein from compound (a-b-c-d-e-f) albicidin is obtained by removal of the protecting groups 
PGN, PGH and PGA. Alternatively the not activated carboxyl acid moiety a-b-c-COOH may be 
used instead of the activated carboxyl moiety a-b-c-coact. 
ln certain embodiments, a compound (a-b-coact): 
is reacted with a compound (H2N-c-d-e-f) 
wherein 
R1PG is, for embodiments for which R1 is H, a hydroxyl protecting group PGH, in 
other words the 0R1 PG moiety can be read as an oPGH moiety, or, 
in case of R1 being CO(NH2), a -CO(NPGN) moiety, wherein in particular R1PG is a 
hydroxyl protecting group PGH with R1 being H, yielding a QPGH moiety, and 
R3 is H or OCH3, and 
R2 is CO(NPGN) or CN, and 
NPGN, cooPGA or oPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an activated 
carboxylic acid moiety, 
wherein from compound (a-b-c-d-e-f) albicidin is obtained by removal of the protecting groups 
PGN, PGH and PGA. Alternatively the not activated carboxyl acid moiety a-b-COOH may be 
used instead of the activated carboxyl moiety a-b- coact. 
ln certain embodiments, compound (a-coac1) is reacted with a compound (H2N-b-c-d-e-f): 
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wherein 
R1PG is, for embodiments for which R1 is H, a hydroxyl protecting group PGH, in 
other words the 0R1 PG moiety can be read as an oPGH moiety, or, 
in case of R1 being CO(NH2), a -CO(NPGN) moiety, wherein in particular R1PG is 
a hydroxyl protecting group PGH with R1 being H, yielding a QPGH moiety, and 
R3 is H or OCH3, and 
R2 is CO(NPGN) or CN, and 
NPGN, cooPGA or oPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an activated 
carboxylic acid moiety, 
wherein from compound (a-b-c-d-e-f) albicidin is obtained by removal of the protecting groups 
PGN, PGH and PGA as discussed above. Alternatively the not activated carboxyl acid moiety 
a-COOH may be used instead of the activated carboxyl moiety a-coac1• 
ln some embodiments of the synthesis of the invention the peptide coupling steps to arrive at 
the albicidin backbone can be achieved by using combined building blacks (a-b); (c-d) and (e-
f). 
ln some embodiments, compound (e-coac1) is reacted with compound (H2N-f), 
yielding a compound (e-f): 
l:&GH 
l lfoPGHo O 7" 1 cooPGA 
0 7" N ~ 
1 H 
FN ~ 
and/or compound (a-coac1) is reacted with compound (H2N-b), yielding a compound (a-b): 
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and/or compound (c-coact) is reacted with compound (H2N-d) 
yielding a compound (c-d): 
wherein 
R1PG is, for embodiments for which R1 is H, a hydroxyl protecting group PGH, in 
other words the 0R1 PG moiety can be read as an oPGH moiety, or, 
in case of R1 being CO(NH2), a -CO(NPGN) moiety, wherein in particular R1PG is 
a hydroxyl protecting group PGH with R1 being H, yielding a QPGH moiety, and 
R3 is H or OCH3, and 
R2 is CO(NPGN) or CN, and 
NPGN, cooPGA or oPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an activated 
carboxylic acid moiety. 
ln some embodiments, concerning any step of the synthesis it is possible to use the -COOH 
building blacks instead of the -coact building blacks, whereby the -COOH moiety may be 
activated with a catalytic amount of a proton or a lewis acid, as discussed above. 
ln some embodiments, the carboxyl protecting group PGA of compound (a-b) is selectively 
removed, yielding a compound (a-b-COOH): 
and optionally the carboxylic acid moiety of compound (a-b-COOH) is activated, yielding a 
compound (a-b-coact ): 
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and the carboxyl protecting group of compound (c-d) is selectively removed, yielding a 
compound (c-d-COOH): 
and optionally the carboxylic acid moiety of compound (c-d-COOH) is activated, yielding a 
compound (c-d-coact): 
and subsequently compound (c-d-COOH) or compound (c-d-coact) is reacted with (H2N-e-f), 
yielding a compound (c-d-e-f): 
from which the amino-protecting group PGN of FN is selectively removed or the masked 
functional group M of FN is selectively reduced to -NH2, yielding compound (H2N-c-d-e-f), and 
(a-b-COOH) or (a-b-coac1) is reacted with (H2N-c-d-e-f), yielding compound (a-b-c-d-e-f), from 
which albicidin is obtained by removal of the protecting groups PGN, PGH and PGA. 
ln some embodiments, the amino protecting group PGN of compound (c-d) is selectively 
removed, yielding a compound (H2N-c-d): 
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and subsequently, (H2N-c-d) is reacted with compound (a-b-COOH) or with compound (a-b-
coac1), yielding a compound (a-b-c-d): 





1 '.::: H 




and optionally the carboxylic acid moiety of compound (a-b-c-d-COOH) is activated, yielding 
compound (a-b-c-d-coact), and subsequently 
compound (a-b-c-d-COOH) or compound (a-b-c-d-coact) is reacted with compound (H2N-e-f), 
yielding compound (a-b-c-d-e-f), from which albicidin is obtained by removal of the protecting 
groups PGN, PGH and PGA. 
ln some embodiments, compound (a-b-coact) or compound (a-b-COOH) is reacted with 
compound (H2N-c), yielding a compound (a-b-c): 
thereafter, the carboxyl protecting group PGA of compound (a-b-c) is selectively removed, 
yielding a compound (a-b-c-COOH): 
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and optionally the carboxylic acid moiety of compound (a-b-c-COOH) is activated, yielding 
compound (a-b-c-coact), and 
compound (H2N-e-f) is reacted with compound (d-COOH) or (d-coac1), yielding a compound 
( d-e-f): 
FN 
IXYGH lgGHo O ~ 1 cooPGA 
d
oo ~ 1 ~ ~ 
N ~ 
H 
and thereafter, the amino-protecting group PGN of FN of compound (d-e-f) is selectively 
removed or the masked functional group M of FN of compound (d-e-f) is selectively reduced 
to -NH2, to render compound (H2N-d-e-f), which is thereafter 
reacted with compound (a-b-c-COOH) or (a-b-c-coact ), yielding compound (a-b-c-d-e-f), from 
which albicidin is obtained by removal of the protecting groups PGH and PGA. 
ln some embodiments, compound (H2N-e-f) is reacted with compound (d-coac1) or compound 
(d-COOH), yielding compound (d-e-f), subsequently, the amino-protecting group PGN of FN 
of compound (d-e-f) is selectively removed or the masked functional group M of FN of 
compound (d-e-f) is selectively reacted to -NH2, yielding compound (H2N-d-e-f); then 
compound (H2N-d-e-f) is reacted with compound (c-coact) or compound (c-COOH), yielding 
compound (c-d-e-f), from which the amino-protecting group PGN is selectively removed, 
yielding compound (H2N-c-d-e-f), and compound (H2N-c-d-e-f) is reacted with compound 
(a-b-coact) or compouind (a-b-COOH), yielding compound (a-b-c-d-e-f), from which albicidin 
is obtained by removal of the protecting groups PGN, PGH and PGA. 
ln some embodiments, compound (H2N-e-f) is further reacted 
with compound (d-COOH) or (d-Coact), yielding compound (d-e-f), 
subsequently, the amino-protecting group PGN of FN of compound (d-e-f) is 
selectively removed or the masked functional group M of FN of compound (d-e-f) is 
selectively reacted to -NH2, yielding compound (H2N-d-e-f); then 
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compound (H2N-d-e-f) is reacted with compound (c-COOH) or (c-coac1), yielding 
compound (c-d-e-f), from which the amino-protecting group PGN of FN of 
compound (c-d-e-f) is selectively removed or the masked functional group M of FN 
of compound (c-d-e-f) is selectively reacted to -NH2, yielding compound 
(H2N-c-d-e-f ), and 
compound (H2N-c-d-e-f ) is reacted with compound (a-b-COOH) or (a-b-coact), 
yielding compound (a-b-c-d-e-f), from which albicidin is obtained by removal of the 
protecting groups PGN, PGH and PGA. 
ln some embodiments, compound (b-COOH) or (b-coact) is further reacted 
with compound (H2N-c-d), yielding compound (b-c-d), subsequently, the carboxyl 
protecting group PGA of compound (b-c-d) is selectively removed, yielding 
compound (b-c-d-COOH), the carboxylic acid moiety is optionally activated, yielding 
compound (b-c-d-coact); then 
compound (b-c-d-COOH) or (b-c-d-coac1) is further reacted with compound (H2N-
e-f), yielding compound (b-c-d-e-f), from which the amino-protecting group PGN of 
FN of compound (b-c-d-e-f) is selectively removed or the masked functional group 
M of FN of compound (b-c-d-e-f) is selectively reacted to -NH2, yielding compound 
(H2N-b-c-d-e-f), and 
compound (H2N-b-c-d-e-f) is reacted with compound (a-COOH) or (a-coac1), 
yielding compound (a-b-c-d-e-f), from which albicidin is obtained by removal of the 
protecting groups PGN, PGH and PGA. 
Alternatively the compound (b-c-d) may be achieved by a reaction of the compound (b-c) with 
block d in a similar manner. 




R3 is H or OCH3, and 
FN is NPGN or M, wherein 
M is a masked functional group, in particular M is -N02 or -N3, further in 
particular N02, and wherein, and 
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NPGN signifies an NH2 moiety reversibly inactivated by a removable protecting 
group, 
is reacted with compound (H2N-d) yielding compound (c-d): 
compound (c-d) is reacted with compound (H2N-e) yielding compound (c-d-e): 
, and 
compound (c-d-e) is reacted with compound (H2N-f) yielding compound (c-d-e-f) 
wherein R2 of compound (c-d), (c-d-e) or (c-d-e-f) is, due to the reaction conditions, CN and 
the protecting group PGA is removed and the COOH-moiety may be activated before the 
reaction with amino partner, as discussed above. Concerning the combination of the 
compounds with further building blacks to achieve albicidin (a-b-c-d-e-f) reference is made to 
the above mentioned methods and combinations. 
lt is understood that in all the above mentioned embodiments only the activated carboxyl 
moiety coact may be used for the reactions of the acid partner with the amino partner. 
lt is further understood that in all the above mentioned embodiments R1 PG can be a hydroxyl 
protecting group PGH yielding a QPGH moiety, and, thus, after removal of the protecting group 
PGH R1 is H. 
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ln some embodiments, the reactions are carried out between -30° C to 80° C, in particular 
between 25° C to 60° C and further in particular between 25 to 30 °C. 
ln some embodiments, the reactions are carried out between -30° C to 30° C, in particular 
between -30° C and 0° C, in order to suppress racemisation reactions. 
ln some embodiments, the PGN protecting groups are tert-butyloxycarbonyl (t-Boc), 
allyloxycarbonyl (Alloc), 9-fluorenylmethoxycarbonyl (Fmoc), para-methoxybenzyl carbamate 
(Moz) and benzyloxycarbonyl (Z). 
ln some embodiments, the PGN protecting groups are, in case of a CO(NPGN) moiety, in 
particular for the amide sidechain of asparagine (building block c), 9-Xanthenyl (Xan), Trityl 
(Trt), 4-Methyltrityl (Mtt), Cyclopropyldimethylcarbinyl (Cpd), 4,4'-Dimethoxybenzhydryl (Mbh), 
2,4,6-Trimethoxybenzyl (Tmob). 
ln some embodiments, the PGH protecting groups are C4H9 (t-Butyl), para-methoxybenzyl 
(PMB), benzyl or CH2CHCH2 (allyl). 
ln some embodiments, the PGA protecting groups are C4H9 (t-Butyl), para-methoxybenzyl 
(PMB), benzyl 9-fluorenylmethyl (Fm) or CH2CHCH2 (allyl). 
ln some embodiments, the activated carboxyl moiety is 
( 0-(7-azabenzotriazol-1-yl)-N, N, N, N-tetramethyluronium hexafluorophosphate) 
(HATU) ester, achieved by a coupling with HATU, or 
BTC, achieved by a coupling with BTC, or 
acyl chloride, achieved by a coupling with S0Cb or 
N,N'-Diisopropylcarbodiimide (DIC) ester, achieved by a coupling with DIC, or 
N,N'-Dicyclohexylcarbodiimide (DCC) ester, achieved by a coupling with DCC. 
ln some embodiments the coupling reactions to the activated carboxyl moiety may be 
supported by addition of bases selected from (N,N-diisopropylethylamine) (DIEA), N-
methylmorpholine (NMM), 4-dimethylaminopyridine (DMAP), triethylamine (TEA), 2,4,6-
trimethylpyridin (sym-collidine), pyridine, N,N'-Diisopropylcarbodiimid (DIC), 2,6-di-tert-butyl-
4-dimethylaminopyridine (DBDMAP), in particular from N,N-diisopropylethylamine (DIEA) or 
2,4,6-Trimethylpyridin (sym-collidine). The addition of bases allows a deprotonation of the 
carboxylic acid and facilitate the reaction to the respective activated carboxylic acid. 
ln some embodiments, if an acyl halogenide, in particular an acyl chloride, is used as the 
activated carboxyl moiety, a base selected from N,N-diisopropylethylamine (DIEA), N-
methylmorpholine (NMM), triethylamine (TEA), 4-dimethylaminopyridine (DMAP), 2,4,6-
trimethylpyridin (sym-collidine), 2,6-di-tert-butyl-4-dimethylaminopyridine (DBDMAP), in 
297 
wo 2014/125075 PCT /EP2014/052922 
particular from N,N-diisopropylethylamine) (DIEA), or 2,4,6-trimethylpyridin (sym-collidine), is 
added in order to prevent a removal of the protecting group due to acidic by-products. 
ln some embodiments the solvent of the reactions is tetrahydrofuran, dioxane, acetonitrile, 
tert-butyl methyl ether, dichlormethane, chloroform, 1-methyl-2-pyrrolidinone, N,N-
dimethylacetamide (DMA), or dimethylformamide, in particular tetrahydrofuran or 
dimethylformamide. Other solvents may be applied if necessary. 
ln the above described synthesis of albicidin of the formula 2 intermediates are used which 
acan be described by the following formulas: 
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1,JG: 
6lfoPGHo O ,(J COOH 
~ 1 ~ 
FN ~ 
iii. (H2N-e-f ) : 




methoxy-benzoic acid (unprotected ( e-f)) 











iii. 4-[[ 4-[ ( 4-am inobenzoyl)am ino ]-2-hydroxy-3-methoxy-benzoyl]am ino ]-2-
hydroxy-3-methoxy-benzoic acid (unprotected (d-e-f)) 
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j. 
iii. unprot ected b-c-d-e-f 
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R1 is H or CO(NH2), 
R3 or R3' is H or OCH3 
R2' is CO(NH2) or CN, and wherein 
R1PG is, 
in case of R1 being H, a hydroxyl protecting group PGH yielding 
a oPGH moiety, or, 
in case of R1 being CO(NH2), a -CO(NPGN) moiety, and 
FN is NPGN or M, wherein in particular FN is NPGN, wherein 
Mis a masked functional group, and wherein, 
NPGN, cooPGA or oPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an 
activated carboxylic acid moiety, wherein 
each PGH independently of any other PGH is a hydroxyl protecting 
group selected from CH2CHCH2 (allyl), THP (tetrahydropyranyl), 
SiR'3 (trialkylsilicon), C4H9 (t-Butyl), CH2C5Hs (benzyl), H3CCO 
(acetyl), CH2C5H4QCH3 (4-methoxybenzyl) or C19H1s 
(T riphenylmethyl), 
with each R' being independently from any other R' a C1 to 
c4 alkyl 
each PGA independently of any other PGA is a carboxylic protecting 
group selected from CH2CHCH2 (allyl), THP (tetrahydropyranyl), 
SiR'3 (trialkylsilicon), or C4H9 (t-Butyl), CH2C5Hs (benzyl), 
CH2C5H4QCH3 (4-methoxybenzyl) or C19H1s (Triphenylmethyl), 
with each R' being independently from any other R' a C1 to 
c4 alkyl 
each PGN independently of any other PGN is an amino protecting 
group selected from t-Butyloxycarbonyl (Boc), (CO)OCH2C5Hs 
(benzyloxycarbonyl), (CO)OCH2C5H4QCH3 (4-
methoxybenzyloxycarbonyl) or Allyloxycarbonyl (Alloc), 
M is -N02 or -N3, wherein M is in particular N02 
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each coact independently from any other coact is acyl fluoride, acyl 
chloride, benzotriazole esters or carbodiimide esters, generated by 
use of the carboxylic acid and coupling agents such as 
Benzotriazolyloxytris-( dimethylamino )-phosphoniu m hexafluoro-
phosphate (BOB), Benzotriazol-1-yl-oxy-tripyrrolidino-phosphonium 
hexafluorophosphate (pyBOP), N,N,N',N'-Tetramethyl-0-(1 H-
benzo-triazol-1-yl)uronium hexafluorophosphate (HBTU), ( 0-(7-
azabenzotriazol-1-yl)-N, N, N, N-tetramethyluronium hexafluoro-
phosphate) (HATU), N,N-Di-cyclohexylcarbodiimide (DCC), N,N-
Di-isopropylcarbodiimid (DIC), 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC). 
ln some embodiments, concerning the above mentioned intermediates, 
R1 is H, 
R3 or R3' is H or OCH3 
R2' is CO(NH2) or CN, in particular R2îs CN, and wherein 
R1 PG is a hydroxyl protecting group PGH yielding a OPGH moiety, 
and 
R2 is -CO(NtGN or CN, in particular R2 is CN 
FN is NPGN or M, wherein in particular FN is NPGN, wherein 
Mis a masked functional group, and wherein, 
NPGN, COOPGA or OPGH signifies an NH2, COOH or OH moiety reversibly 
inactivated by a removable protecting group, and coact signifies an 
activated carboxylic acid moiety, wherein 
each PGH independently of any other PGH is a hydroxyl protecting 
group selected from CH2CHCH2 (allyl), THP (tetrahydropyranyl), 
SiR'3 (trialkylsilicon), C4H9 (t-Butyl), CH2C5Hs (benzyl), H3CCO 
(acetyl) or C19H1s (Triphenylmethyl), 
with each R' being independently from any other R' a C1 to 
c4 alkyl 
each PGA independently of any other PGA is a carboxylic protecting 
group selected from CH2CHCH2 (allyl), THP (tetrahydropyranyl), 
SiR'3 (trialkylsilicon), or C4H9 (t-Butyl), CH2C5Hs (benzyl) or C19H1s 
(T riphenylmethyl), 
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with each R' being independently from any other R' a C1 to 
c4 alkyl 
each PGN independently of any other PGN is a amino protecting 
group selected from t-Butyloxycarbonyl (Boc), (CO)OCH2C5Hs 
(benzyloxycarbonyl) or Allyloxycarbonyl (Alloc), 
M is -N02 or -N3, wherein M is in particular N02 
each coact independently from any other coact is acyl fluorid, acyl 
chloride, benzotriazole esters or carbodiimide esters, generated by 
use of the carboxylic acid and coupling agents such as 
Benzotriazolyloxytris-( dimethylamino )-phosphoniu m hexafluoro-
phosphat (BOB), Benzotriazol-1-yl-oxy-tripyrrolidino-phosphonium 
hexafluorophosphate (pyBOP), N,N,N',N'-Tetramethyl-0-(1 H-
benzo-triazol-1-yl)uronium hexafluorophosphate (HBTU), ( 0-(7-
azabenzotriazol-1-yl)-N, N, N, N-tetramethyluronium hexafluoro-
phosphate) (HATU), N,N-Di-cyclohexylcarbodiimide (DCC), N,N-
Di-isopropylcarbodiimide (DIC), 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC). 
Wherever alternatives for single separable features such as, for example, a moiety R1 or R2' 
or R3' a medical indication specifying a particular pathogen or a particular synthetic route are 
laid out herein as "embodiments", it is to be understood that such alternatives may be 
combined freely to form discrete embodiments of the invention disclosed herein. 
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Scheme 14 depicts a general reaction pathway to the compound beta albicidin from the 
compound (c-d) over (b-c-d) to compound (b-c-d-e-f) and the unprotected (a-b-c-d-e-f). 
M:00 PGH 
M~O PGH _ 
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Alternatively, instead of using a reaction between (FN-c-COOH) and (H2N-d) a reaction 
between (C-COOH) respectively (c-coact) and (H2N-d) may be applied, wherein the CO(NH2) 
moiety of R2 of building block c is protected (CO)NPGN_ 
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Scheme 17 depicts a reaction pathway to beta-Albicidin from the compound (d-e) over the 
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lt is understood that the compound Carbamoyl-Albicidin can be produced according to a similar 
reactions pathway as depicted in schemes 14 to 17, whereby the CO(NH2) moiety of building 
block ais protected ((CO)NPGN) until the global deprotection. 
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Furthermore, the compound Asn-Albicidin can be produced according to a similar reactions 
pathway as depicted in schemes 14 to 17, by using a reaction between (C-COOH) respectively 
(c-coact) and (H2N-d), wherein the CO(NH2) moiety of R2 of building block c is protected 
(CO)NPGN_ The same applies to the compound Carbamoyl-Asn-Albicidin, whereby additionally 
the CO(NH2) moiety of building block ais protected ((CO)NPGN) until the global deprotection. 
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lt is understood that the compounds Asn-Albicidin, Carbamoyl-Albicidin, Carbamoyl-Asn-
Albicidin, beta-OMe-Albicidin, Asn-OMe-Albicidin, Carbamoyl-OMe-Albicidin or Carbamoyl-
OMe-Asn-Albicidin are producible according to a similar pathway as depicted in the schemes 
14 to 17, whereby the l building block c comprises the respective substituents R1, R2 and R3. 
lt is further understood that the compounds Enantio-beta-Albicidin, Enantio-Asn-Albicidin, 
Enantio-Carbamoyl-Albicidin, Enantio-Carbamoyl-Asn-Albicidin, Enantio-beta-OMe-Albicidin, 
Enantio-Asn-OMe-Albicidin, Enantio-Carbamoyl-OMe-Albicidin or Enantio-OMe-Carbamoyl-
Asn-Albicidin are producible according to a similar pathway as depicted in the schemes 14 to 
17, whereby instead of a l building block c moiety a D building block c moiety is used or 
generated. 
These schemes are only exemplary. Different protecting groups, activations, deprotection and 
combinations of the respective building blacks may be used. Reference is made in particular 
to the detailed description und specifically mentioned reagents hereinbefore and hereinafter. 
lt is further possible to transform one of the above mentioned albicidin compounds (or the 
respective intermediates) in another. For example is it possible to remove selectively the PGH 
protecting group of the building block a of the compound (a-b-c-d-e-f) and convert the OH-
moiety in a carbamoyl-moiety, wherein subsequently the, e.g. Pd-labile, remaining protecting 
groups will be removed afterwards yielding another albicidin compound (conversion of e.g. 
beta-Albicidin to Carbamoyl-Albicidin; see scheme 5). Alternatively the beta-Albacidin may be 
converted to the Asn-albicidin, as described below. Further conversions are also possible and 
are part of the invention. 
Synthesis of Asn-Albicidin from Albicidin 
Albicidin (1.2 mg) is dissolved in 0.5 ml THF under argon atmosphere at room temperature 
21 °C. Then one equivalent of an aqueous solution of LiOH (1 mg/ml) is slowly added via a 
syringe pump. The resulting suspension is stirred at room temperature for 20 min. Stirring is 
continued for 3 h at room temperature. the process of hydrolysis is controlled by ESl-mass 
spectrometry. The organic solvent is removed under reduced pressure and EtOAc is added. 
The mixture is washed successively with saturated NaHC03, water and brine. The organic 
solvent is dried over Na2SÜ4, filtered and removed under reduced pressure. The product is 
purified by column chromatography. 
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The spectral analysis of the albicidin derivatives of formula 2 obtained by the just described 
method is depicted in the Figures 1-10 described in detail further below. 
General synthetic methods and procedures as applied in the present case are described in the 
following. 
General procedure for synthesis of cinnamic acids 
Method A 
The aldehyde (1.00 eq) and the malonic acid (2.00 eq) were dissolved in pyridine and 
piperidine (2.00 eq) was added. The mixture was stirred at 100 °C for 16 h. After cooling down 
to room temperature the reaction mixture was poured onto conc. HCI on ice. The precipitated 
cinnamic acid was filtered and dried in vacuo. 
Method B 
To a stirred solution of the aldehyde (1.50 eq) and propanoic acid (1.00 eq) in dry THF was 
slowly added TiCl4 (2.00 eq) at O °C. The mixture was stirred for 30 min and TEA (4.00 eq) 
was added. The reaction was allowed to warm up to room temperature and stirred for an 
additional 48 h. The reaction was quenched with water and the aqueous layer was extracted 
3 x with DCM. The combined organic layers were dried over Na2SÜ4 and the solvent was 
removed. The crude product was chromatographically purified. 
Method C 
A mixture of the aldehyde/ketone (1.00 eq), malonic acid (2.00 eq), SnC'2·H20 (0.50 eq) and 
pyridine (2.00 eq) were stirred at 80 °C for 72 h. The mixture was filtered through a pad of 
celite and the solvent was evaporated. The crude product was chromatographically purified. 
Several derivatives of cinnamic acid obtained by at least one of the above described methods 
are depicted below. 
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Introduction of an Allylprotecting group 
The cinnamic acid (1.0 eq) was dissolved in DMF and Allylbromide (3.0 eq) and K2CÜ3 
(3.0 eq) was added. The mixture was stirred at room temperature for 16 h. EtOAc was added 
and the organic layer was washed with H20 and brine. After drying over Na2SÜ4 the solvent 
was evaporated. The residue was purified via silica gel column chromatography. 
Allyl deprotection 
KOH (2.0 eq) was dissolved in MeOH and added to the protected cinnamic acid. After stirring 
at room temperature for 12 h the mixture was acidified with conc. HCI. The precipitate was 
collected and dried in vacuo. If no precipitate was formed the MeOH was removed under 
reduced pressure and the residue was dissolved again in H20. The product was extracted 
with EtOAc. After drying the organic layer over Na2SÜ4 the solvent was removed and the 
product dried in vacuo. 
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General procedure for coupling of an acid partner with an amino partner: 
Method A 
Bis-(trichloromethyl)carbonate (1.2 eq) and acid partner (3.5 eq) are dissolved in dry THF 
under argon atmosphere. 2,4,6-Collidine (8.0 eq) is added slowly via a syringe pump. The 
resulting suspension is stirred at raom temperature for 20 min and a solution of the amino 
partner (1; 1.0 eq) and DIPEA (10.0 eq) in dry THF is added. Stirring is continued for 3 h at 
room temperature and the reaction is quenched by addition of water. The organic solvent is 
removed under reduced pressure and EtOAc is added. The mixture is washed successively 
with saturated NaHC03, water and brine. The organic solvent is dried over Na2SÜ4, filtered 
and removed under reduced pressure. The praduct is purified by crystallisation and column 
chromatography if necessary (TLC contrai, HPLC contrai). 
Method B 
The acid partner (1 eq) is refluxed in S0C'2 for 2h. The solvent is removed under reduced 
pressure and traces of S0C'2 are removed by coevaporation with toluene. The amino partner 
(1, 1 eq) and a base (e. g. DIPEA, 5 eq) in an organic solvent (e. g. THF, c = 0.2 M) are 
added and the mixture is stirred for 12-16 h. After completion of the reaction (TLC contrai), 
the solvent is removed under reduced pressure and the residue is diluted with EtOAc. The 
organic layer is washed successively with saturated NaHC03, HCI (5 %), water and brine. 
After drying over Na2SÜ4 and filtration the praduct is isolated by column chramatography or 
crystallisation. 
Method C 
Commercially available acid chlorides (carboxylic acid chloride or sulfonic acid chloride; 3 eq) 
are added to a solution of DIPEA (5 eq) and the amino partner (1, 1 eq). The solution is 
stirred for 16 h at room temperature and quenched by the addition of water. The organic 
solvent is removed under reduced pressure and the residue diluted with EtOAc. The organic 
layer is washed successively with saturated NaHC03, HCI (5 %), water and brine. After 
drying over Na2SÜ4 and filtration the praduct is isolated by column chramatography or 
crystallisation. 
General procedure for coupling an isocyanate for the synthesis of compounds including an 
urea moiety: 
The amine (1 eq) was dissolved in dry THF under an atmosphere of argon. lsocyanate (5 eq) 
was added and after stirring for 16 h the solvent was removed under reduced pressure. The 
product was isolated by column chromatography or crystallisation. 
General procedure for reductive amination: 
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Free amine (1.0 eq) and aldehyde (1.0 eq) were dissolved in MeOH and acetic acid (3.5 eq) 
was added. To this solution NaBH3CN (1.2 eq) was added and the mixture was stirred for 16 
h at room temperature. The reaction mixture was quenched with saturated NaHC03 solution 
and extracted with EtOAc. The organic solvent was dried over Na2SÜ4, filtered and removed 
under reduced pressure. The residue was dissolved in 4 N HCI in dioxane. After 5 h of 
stirring at room temperature the organic solvent was removed under reduced pressure. The 
residue was dissolved in 10% NaHC03 and filtrated. Acidification with conc. HCI precipitated 
the pure carboxylic acid which was isolated by filtration. 
General procedure for synthesizing amine compounds 
Carboxylic acid (5 eq) and triethylamine (10 eq) were dissolved in dry DMF HATU (5 eq) was 
added and the mixture was stirred for 60 min. The amine, dissolved in dry DMF, was added 
dropwise and the mixture was stirred for 16 h at room temperature. The mixture was diluted 
with EtOAc and washed successively with brine (3 x), 1 N HCI (2 x) and saturated NaHC03 
(2 x) The organic solvent was dried over Na2SÜ4, filtered and removed under reduced 
pressure. The product was purified by column chromatography or crystallisation. 
General procedure for converting a nitro group into an amine: 
The nitro compound (1 eq) is dissolved in EtOH and SnC'2*2H20 (5 eq) and the reaction 
mixture is stirred at 60 °C until the starting material has disappeared (TLC- and LCMS-
monitoring, approximately 4-6 h). The solvent is removed under reduced pressure and the 
residue diluted with EtOAc. After addition of NaHC03 (saturated) and separation of the 
phases, the aqueous phase is further extracted with EtOAc (2 x). The combined organic 
layers are washed with brine (1 x), dried over Na2SÜ4 and filtered. After removing the solvent 
under reduced pressure, the product was isolated by column chromatography or 
crystallisation. 
General procedure for coupling of an aldehyde partner with an amino partner under reductive 
conditions: 
The amine (1.0 eq) and aldehyde (1.0 eq) were dissolved in dry THF under argon 
atmosphere and a catalytic amount of acetic acid was added. After stirring for 60 min at room 
tempearature NaBH3CN (1.3 eq) was added. The reaction mixture was stirred for 3 h at room 
temperature and another 1.3 eq of NaBH3CN was added and the mixture was stirred for 16 h 
at room temperature. The reaction was quenched by addition of 1 N HCI and extracted three 
times with EtOAc. The organic solvent was dried over Na2SÜ4, filtered and removed under 
reduced pressure. The product was purified by column chromatography or crystallisation. 
General procedure for removal of protection groups: 
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A fully protected derivative of the compound according to the formula 1 (1.0 eq) was 
dissolved in dry THF under argon atmosphere and exclusion of light. Phenylsilane (8.0 eq) 
and Pd[P(Ph)3]4 (0.5 eq) were added and the reaction mixture was stirred for 10 h at room 
temperature. AcOH was added, the solvent was removed under reduced pressure and the 
sample was freeze dried. Purification was achieved by crystallization or preparative HPLC. 
General procedure for providing deuterium atoms in the structure: 
The provision of deuterium instead of hydrogen in a structure is basic knowledge for the 
expert in the field. For example, deuterium-containing compounds may be synthesized 
according to known methods (e.g. David S. Wisharta, Brian D. Sykesa, Frederic M. Richards, 
Biochimica et Biophysica Acta - Protein Structure and Molecular Enzymology, Volume 1164, 
Issue 1, 1993, Pages 36-46). Furthermore, the respective intermediates may comprise one 
or more deuterium instead of hydrogen or only deuterium. Thus, by applying the synthesis 
pathways as discussed above compounds characterized by the general formula 1 are 
produced, which comprise at least one deuterium in their structure. Such intermediates may 
be purchased or may be produced to known literature procedures. 
Coupling reactions: 
Reaction conditions for coupling primary amines or aryl amines with carboxylic acids to yield 
amide linkages are known to those of ordinary skill in the art and may be found in any 
compendium of standard synthetic methods or literature related to the synthesis of peptides 
and proteins. See e.g., March, J., Advanced Organic Chemistry; Reactions, Mechanisms and 
Structure, 4th ed., 1992; Larock, Comprehensive Organic Transformations, VCH, New York, 
1999; Bodanzsky, Principles of Peptide Synthesis, Springer Verlag, 1984; Bodanzsky, Practice 
of Peptide Synthesis, Springer Verlag, 1984; Lloyd-Williams et al., Chemical Approaches to 
the Synthesis of Peptides and Proteins, CRC Press, 1997 (see especially pp. 105-114); and 
Atherton & Sheppard, Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, 1989). 
Alternative reactive groups can be utilized, such as compounds exemplified herein after or 
discussed above, in methods known in the art or described hereinafter. 
Protecting groups 




The amine (1 eq) and di-tert-butyl dicarbonate (1.5 eq) are dissolved in a solvent ( e. g. DCM; 
c = 0.2 M) and a base ( e. g. NEb, 3 eq) is added. The mixture is stirred at room temperature 
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for 16 h. After removing the solvent under reduced pressure the product is isolated after column 
chromatography or crystallisation. 




The amine (1 eq) and a base ( e. g. NEb, 1.1 eq) are dissolved in a solvent ( e. g. H20, c = 0.2 
M) and Moz-ONC(CN)Ph (1 eq) is added in a solvent ( e. g. dioxane, c = 0.1 M). The mixture 
is stirred at room temperature for 6-12 h and water is added. The mixture is washed with EtOAc 
and the aqueous layer is adjusted to pH 2 (5 % HCI) and extracted with EtOAc. After drying 
over Na2SÜ4 and filtration the organic solvent is removed under reduced pressure. The product 
is isolated after column chromatography or crystallisation. 




The amine (1 eq) and a base (e. g. pyridine, 3 eq) are dissolved in a solvent (e. g. DCM; c = 
0.2 M) and slowly allyloxycarbonyl chloride (2 eq) is added. Stirring is continued for 16 h and 
the reaction mixture is washed successively with HCI (5 %) and brine. After drying over 
Na2SÜ4, filtration and removal of the solvent the product is isolated by column chromatography 
or crystallisation. 
Protection of phenols with acid labile protecting groups: 
)-
BF3*0Et2 
R,O)( R-OH H3P04 
solvent 
The phenol (1 eq) is dissolved in a solvent (e. g. DCM; c = 0.2 M) and cooled to -75°C. H3PQ4 
and BF3*0Eb and isobutylene (excess) are added and the mixture is stirred 16 h at room 
temperature. After quenching the reaction by the addition of NH4QH (2 N) and extraction with 
organic solvent ( e. g. DCM) the product is isolated by column chromatography or 
crystallisation. 









The phenol (1 eq), para-methoxybenzyl chloride (PMB-CI; 1.1 eq) 1- (e. g. Bu4N-I, 1.1 eq) and 
a base ( e. g. K2CÜ3, 1.5 eq) are dissolved in a solvent ( e. g. acetone; c = 0.2 M) and heated 
to 55 °C for 6-12h. The solvent is removed un der reduced pressure and the residue diluted with 
EtOAc. The organic phase is washed successively with saturated NaHC03, HCI (5 %) and 
brine. After drying over Na2SÜ4 and filtration the organic solvent is removed under reduced 
pressure. The product is isolated by column chromatography or crystallisation. 





R ... O~ 
X= 1, Br 
The phenol (1 eq) is dissolved in a solvent ( e. g. DMF, c = 0.2 M) and a base ( e. g. K2CÜ3, 3 
eq) is added. Allylhalogenide (1.5 eq) is added via a syringe pump and stirring is continued at 
room temperature for 12 h. The solvent is removed under reduced pressure and the product 
is isolated by column chromatography or crystallisation. 




The carboxylic acid (1 eq) is dissolved in a solvent (e. g. DCM; c = 0.2 M) and cooled to -75°C. 
H3PQ4 and BF3*0Eb and isobutylene (excess) are added and the mixture is stirred 16 h at 
room temperature. After quenching the reaction by the addition of NH4QH (2 N) and extraction 
with organic solvent ( e. g. DCM) the product is isolated by column chromatography or 
crystallisation. 
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The carboxylic acid (1 eq) and a base (e. g. NEb, 1 eq) are dissolved in a solvent (e. g. DCM 
c = 0.2 M) and cooled to O °C. PMB-Br (1 eq) is added and the mixture is stirred 24 h at room 
temperature. The solution is washed successively with water, saturated NaHC03, water and 
brine. After drying over Na2SÜ4 and filtration the organic solvent is removed under reduced 
pressure. The product is isolated by column chromatography or crystallisation. 
Deprotection 








The protected amine, phenol or acid is dissolved in an acid (e. g. TFA - 5-95 % in DCM) and 
scavenger ( e. g. triethylsilane, 3 eq) is added. Stirring is continued for 12 h (TLC contrai) and 
the solvent is removed under reduced pressure. Purification is performed by column 
chromatography or crystallisation. 
Deprotection of Pd-labile protecting groups of the N-terminus of phenols and f the carboxylic 
acids 
Pd0 
R,O~ scavenger .. R 'OH 
solvent 
The protected amine (carbamate), phenol (ether) or carboxylic acid (ester) (1 eq) is dissolved 
in a solvent (e. g. THF), then scavenger (e. g. phenylsilane, 1.5 eq) and Pd0 (e. g. Pd[P(Ph)3]4, 
0.1 eq) are added under argon or nitrogen atmosphere and the exclusion of light. Stirring is 
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continued for 12 h at room temperature and the solvent is removed under reduced pressure. 
Column chromatography or crystallisation yields the pure product. 
While the method illustrated above using acid or Palladium labile protecting groups, a persan 
having ordinary skill in the art will recognize that other protecting groups may be employed. 
Groups suitable for protecting a wide variety of different functionalities, as well as conditions 
for their removal, are well known and will be apparent to those of ordinary skill in the art. 
Specific guidance for selectively protecting a wide variety of functionalities may be found, for 
example, in Greene & Wuts, Protective Groups in Organic Synthesis, 3rd edition, 1999 
("Greene & Wuts"). Preferred protecting groups are those that may be easily removed. 
Preferred groups for protecting primary amines and aryl amines are tert-butyloxycarbonyl ("t-
Boc"), allyloxycarbonyl (Alloc), 9-fluorenylmethoxycarbonyl ("Fmoc"), para-methoxybenzyl 
carbamate (Moz) and benzyloxycarbonyl ("Z"). 
Preferred groups for protecting carboxylic acids are tert-butyl ("t-Bu"), allyl (Ali), 9-
fluorenylmethyl ("Fm"), para-methoxybenzyl (PMB) and benzyl ("Bzl"). 
Preferred groups for protecting phenols are tert-butyl ("t-Bu"), allyl (Ali), para-methoxybenzyl 
(PMB) and benzyl ("Bzl"). 
Preferred groups for protecting amides are 9-xanthenyl ("Xan"), Trityl (Trt), 4-Methyltrityl (Mtt) 
and benzyl ("Bzl"). 
General methods for peptide coupling 
Coupling reaction with Bis-(trichloromethyl)carbonate (BTC) 
0 





Bis-(trichloromethyl)carbonate (1.2 eq) and carboxylic acid (3.5 eq) are dissolved in dry organic 
solvent ( e. g. THF) under argon atmosphere. 2,4,6-Collidine (8.0 eq) is added slowly via 
syringe. The resulting suspension is stirred at room temperature for 20 min and a solution of 
the amine (1.0 eq), DIPEA (10.0 eq) in dry THF is added. Stirring is continued for 3 h at room 
temperature and the reaction is quenched by addition of water. The organic solvent is removed 
under reduced pressure and EtOAc is added. The mixture is washed successively with 
saturated NaHC03, water and brine. The organic solvent is dried over Na2SÜ4, filtered and 
removed under reduced pressure. The product is purified by column chromatography or 
crystallisation. 










Carboxylic acid ( 1.1 eq) is dissolved in dry organic solvent ( e. g. DMF) and cooled to O °C. 
DIPEA (3 eq) and HATU (2 eq) is added. After five minutes the amine (1 eq) is added and 
stirring was continued for 12 h at room temperature. EtOAc is added and the mixture is washed 
successively with brine (3 x), saturated NaHC03, 5% HCI, water and brine. After drying over 
Na2SÜ4 and filtration the solvent is removed under reduced pressure. The product is purified 
by column chromatography or crystallisation. 
While the method illustrated above using a peptide coupling in the presence of BTC or HATU, 
a persan having ordinary skill in the art will recognize that other coupling methods may be 
employed. Peptide coupling methods are well known and will be apparent to those of ordinary 
skill in the art. 
ln some embodiments, masked functional group M is N02 or N3. The reduction of the masked 
functional group M is carried out under conditions which are state of the art and can be 
performed by a chemist experienced in the state of the art. The reduction of the nitro group 
and of the azide group is not limited to the use of hydrogen gas in combination with a catalyst. 
The azide or the nitro-group containing compound is dissolved in appropriate solvents as ethyl 
acetate, acetonitrile, alcohols. A catalyst (Pd, Pt02, 10%Pd/C) is added under 1 atm hydrogen 
gas (H2). The reaction stirred preferably at room temperature may be performed between 1 h 
and 20h. The application of higher or lower reaction temperatures as well as elevated pressure 
of hydrogen gas may be applied. 
lt is understood that other methods exist which are state of the art for reduction: Applying 
Fe/CaCb enables the reduction of nitroarenes by catalytic transfer hydrogenation (S. 
Chandrappa, T. Vinaya, T. Ramakrishnappa, K. S. Rangappa, Synlett, 2010, 3019-3022). 
GENERAL METHODS 
Materials: 
Commercially available reagents were used throughout the syntheses, without further 
purification unless otherwise stated; solvents were dried using standard procedures. Unless 
otherwise specified, reactions were performed under an inert atmosphere of dry nitrogen or 
argon using absolute solvents purchased from Acros or freshly taken over the PureSolv 
(lnnovative Technologies, USA) .. Amino acids and coupling reagents were obtained from 
either IRIS (Marktredwitz, Germany), Novabiochem (Darmstadt, Germany) or Bachem 
(Basel, Switzerland). Analytical thin layer chromatography was carried out using aluminium-
backed plate coated with Merck Kieselgel 60 GF2s4. Plates were visualized under UV light (at 
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D = 254 and /or 360 nm) and stained with KMnQ4 solution or ninhydrin solution. Flash 
chromatography was carried out using silica gel 60 (Merck, Darmstadt, Germany). Column 
chromatography was performed on silica gel (0.04 - 0.063 mm) purchased from MACHERY-
NAGEL GmbH & Co. KG. 
Instrumentation and methods: 
1 H and 13G NMR spectra were recorded using Bruker Avance 400, DPX 500, 700 MHz 
instruments (Bruker, Karlsruhe, Germany) (corresponding 13C frequencies are 100, 125, 175 
MHz); Jvalues are in Hz. The 13C signais assigned from APT, HSQC and HMBC. Data are 
reported as parts per million (ppm) downfield shift from tetramethylsilane (TMS) using 
residual solvent peaks of chloroform (CDCl3, 7.26 ppm and 77.2 ppm) or dimethyl sulfoxide 
(DMS0-d6, 2.50 ppm and 39.5 ppm) as internai references. Chemical shifts (o, ppm), 
multiplicity (br= broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling 
constant (J Hz), relative integrals and assignment are quoted where possible. 
LCMS/high-resolution mass spectra were recorded on a Orbitrap high resolution mass 
spectrometer using electrospray ionization (ESI) in positive mode unless otherwise specified. 
Analytical Thin Layer Chromatography (TLC) was performed using pre-prepared plates 
(Merck Kieselgel 60, 0.25 mm F254) using UV light (D = 254 nm) or ninhydrin stain for 
visualization. Flash column chromatography was performed using 230-400 mesh Kieselgel 
60 silica gel using a mobile phase of the indicated solvents expressed as volume/volume 
ratios (v/v). 
HPLC measurements were performed on a Agilent 1100-HPLC with diode array detection 
(Agilent, Waldbronn, Germany). Unless otherwise noted the following parameters have been 
used; Coulmn: Luna C18, 100 A, 100x4.6 mm, 5 um. Gradient: H20/ACN (A/B) + 0.1% 
HCOOH, starting with 5% B to 100% B in 10 min, holding 2 min 100% B, reconditioning zo 5% 
B in 3 min, with a constant flow rate of 1 mUmin 
HPLC-MS/high-resolution mass spectra were recorded on a Exactive Orbitrap high resolution 
mass spectrometer (Thermo Scientific, Bremen, Germany) using electrospray ionization (ESI) 
in positive mode unless otherwise specified. Column: Thermo Hypersil-Gold, 50 x 2.1 mm, 5 
um. Gradient: H20/MeOH (A/B) + 0.1 % HCOOH, starting with 5 %B to 100%B in 6 min, holding 
for 4 min at 100% B, with a constant flow rate of 0.25 mUmin. 
MS/MS experiments were performed on a ESI-Triple-Quadrupol-MS, 6460 series (Agilent 
Technologies, Waldbronn, Germany). 
333 
wo 2014/125075 PCT /EP2014/052922 
HPLC-ESI-MS was performed on a L TQ Orbitrap XL (Thermo Fisher Scientific, Waltham, 
USA) mass spectrometer and an using a Grom-Sil-120-0DS-4-HE column (Grace, Maryland, 
USA), length 50 mm, i.d. 2 mm, particle size 3 µm. 
Gradient: 
Eluent 1: H20 + 0.1% HC02H 
Eluent 2: MeCN + 0.1 % HC02H 
0 - 10 min: Eluent 2: 20% to 100% 
10 - 13 min: Eluent 2: 100 % 
13 - 17 min: Eluent 2: 20 % 
flow: 0.3 ml/ min 
Circular dichroism (CD) spectra were recorded on a JASCO J-815 CD spectrometer (JASCO, 
Tokyo, Japan). The parameters are the following: constant temperature at 20 °C, cell length 
10 mm, range of measurement 700-200 nm, data intervall 0.1 mm, scanning speed 100 
nm/min. Each CD-spectrum was accumulated four times. Unless otherwise noted all spectra 
presented were recorded in DMSO as a solvent. CD-spectra of the albicidins were obtained 
after subtraction of the blank spectrum (DMSO). 
Preparative/semipreparative HPLC for purification was performed with a system from Agi lent 
1260 lnfinity (Agilent, Santa Clara, USA) using a C18 - RP - Column (Agilent, Santa Clara, 
USA), length 250 mm, i. d. 21.2 mm, particle size 10 µm. 
Isolation protocol 
Isolation protocol was established, testing bioactive fractions by the agar diffusion assay with 
E. coti. To the fermentation broth of X. axonopodis pv. vesicatoria XAD-7 was added to absorb 
metabolites from the liquid media. Albicidins were purified from XAD-7 with a MeOH-step-
gradient (20%), separating undesirable crude material. The elution of albicidins was achieved 
with 100% MeOH. The eluted fraction was concentrated in a Genevac Speedvac (Great 
Britain, Ipswich) and dissolved in MeOH. After centrifugation, the supernatant was used for 
further purification by preparative HPLC-DAD (at A= 310 nm) on a C18 reversed phase column 
using a linear MeOH-gradient. Albicidins eluted at the R1 = 33 min. The freeze-dried material 
was dissolved in 44 % THF + 1% CH3COOH and further purified with HPLC-DAD (at 310 nm) 
using isocratic conditions and H20/THF as the solvent system on a polymeric reversed phase 
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(PRP) column. Six albicidins eluted under this conditions (Figure 10). After a last third step 
albicidins were obtained as white solids. The conditions are shown in Table 1. 
Solvent system Gradient Column 
(A/8) 
Step 1 H20/MeOH 35% MeOH + 0.1 % HCOOH Grace (Germany, 
to Rottenburg-Hailfingen) 
80% MeOH + 0.1 % HCOOH C18-HPlC 
in 40 min GromSil 120 ODS 5 ST, 
Flow rate: 15 mUmin 10 um; 250 x 20 mm 
Step 2 H20/THF 44% THF + 1% CH3QQH Hamilton (Switzerland, 
lsocratic for 80 min Bonaduz) 
Flow rate: 1 mUmin PRP-1, 
5 um; 305 x 7mm 
Step 3 H20/CAN + 10% MeOH + 0.1 % HCOOH Zorbax RX-C18 
0.05% TFA to 220 x 4.6 mm 
80% MeOH + 0.1 % HCOOH 
in 60 min 
Flow rate: 1 mUmin 
Table 1: Chromatographie conditions for purification of albicidins with HPlC-DAD. 
Liquid cultures of heterologous host Xanthomonas axonopodis pv. vesicatoria were prepared 
in plastic falcon tubes of 500 ml, to avoid adsorption sticking of albicidins to the glass surfaces. 
Cultures were grown under agitation at 28 °C, for 5 days, in 72 tubes each containing 200 ml 
of a modified XaBMM (used for wild-type)/XVM2B (previously used for heterologous host) 
medium, now called XVM3B medium (see table 2). 
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Glycerol 0.5 % (v/v) 
6 g/L 
K2HPQ4 0.32 mM 
(NH4)2SÜ4 10 mM 
MgSQ4*?H20 5mM 
Casamino acids 0.015 % 
FeS04 0.01 mM 
CaCb 1 mM 
KH2PÜ4 0.16 mM 
NaCI 20 mM 
pH 6.7 
Table 2: Medium composition per liter for the production of albicidins in X. axonopodis pv. 
vesicatoria 
Unless otherwise specified, reactions were performed under an inert atmosphere of dry 
nitrogen using absolute solvents, freshly taken over the PureSolv (lnnovative Technologies, 
USA) or purchased from Acros. Amino acids, coupling reagents were obtained from either IRIS 
(Marktredwitz, Germany), Novabiochem (Darmstadt, Germany) or Bachem (Basel, 
Switzerland). 
Preparation of the test substrate 
The dry compounds were dissolved in DMSO (1 mg/ml) and the so obtained stock solution 
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DMSO 100% 
Preparation of the inoculum 
20 µI of cryo stock of each strain were inoculated to 20 ml of Mueller-Hinton medium and 
grown overnight at 30 °C or 37 °C on a vertical shaker with 160 rpm . The inoculum for the 
test was adjusted by the 0.5 McFarland Standard (OD62s from 0.08 to 0.1) 
Strains: 
Staphylococcus aureus DSM 2569 
Pseudomonas aeruginosa DSM1117 
Bacillus subtilis DSM10 
Micrococcus luteus DSM1790 
Escherichia coli DHsa 
Escherichia coli albi-res (Montpellier) 
Bacillus megaterium 
Mycobacterium phlei DSM 750 
Escherichia coti K12 (W1130) 
[gram. Pos.] Medium: MHB / 37°C 
[gram. Neg.] Medium: MHB / 37°C 
[gram. Pos.] Medium: MHB / 30°C 
[gram. Pos.] Medium: MHB / 37°C 
[gram. Neg.] Medium: MHB / 37°C 
[gram. Neg.] Medium: MHB / 37°C 
[gram. Pos.] Medium: MHB / 30°C 
[gram. Pos.] Medium: MHB / 30°C 
[gram. Neg.] Medium: MHB / 37°C 
DSM 10, 1117 1790 2569 are the order numbers of the "Leibniz-Institut DSMZ- Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH", one of the largest biological 
resource centres worldwide (www.dsmz.de) 
Preparation of the test agar plates 
Every plate is prepared by pouring 10ml Mueller-Hinton agar into standard petri dishes (diam 
94mm). The so obtained Mueller-Hinton plates are overlayed with 4ml Mueller-Hinton soft 
agar containing 100µ1 suspension of the test strain. 
After the soft agar turned solid, sterile susceptibility test dises were circular placed on the 
agar and on every test dise 1 OµI compound was added. Each concentration is tested in 
triplicate. The agar dishes were incubated for 18 hours at a temperature of 30 °Cor 37°C. 
Results are obtained by measuring the diameter of inhibition area around each test dise. 
EN-ISO standard test: 
Furthermore, compounds were tested against the following bacteria 
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Escherichia coti (ATCC 25922, 100-2-49 and 100-2-56 ), 
Salmonella enteritidis (PEG-10-3-58), 
Pseudomonas aeruginosa (ATCC 27853 and PEG-10-2-61) 
Staphylococcus aureus (ATCC 29213 and PEG 10-38-22) 
according to EN-ISO standard (ISO 20776-1: 2006. Clinical laboratory testing and in vitro 
diagnostic test systems -- Susceptibility testing of infectious agents and evaluation of 
performance of antimicrobial susceptibility test devices -- Part 1 :Reference method for testing 
the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in 
infectious diseases; German version EN ISO 20776-1 :2006. Beuth-Verlag, Berlin). 
ATCC 25922, 27853, 29213 are the order numbers of the "American Type Culture 
Collection", a biological resource centre. 
RESULTS 
Characterisation of the natural occurring L-albicidin of the general formula (1 L): 
The natural occurring L-albicidin of the general formula (1 L) were characterised by mass 
spectrometry (MS and MS2), CD spectroscopy and NMR spectroscopy (1 H, 13C) and the 
molecular formulas of the respective albicidin was determined (see e.g. Figure 2). 
Purification of the albicidin compounds 
The albicidin compounds were purified by column chromatography or crystallization. 
Activity of the albicidin compounds 
Results are obtained by determining the diameter of inhibition area around each test dise, 
which could be seen in table 1. 
Table: Antibacterial activity against selected strains. A= Albicidin; EA = Enantio-Albicidin ("-" 




compound subtilis phlei a COii K12 
[mg/ml] megaterium luteus DSM10 DSM750 (W1130) 
Apramycin 1 2,0 3,5 2,2 1,8 1,7 
A 1 2,8 2,0 1,5 2,8 2,6 
A 0,1 1,4 1,2 - 2,0 1,9 
EA 1 2,8 2,4 1,4 2,9 2,6 
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Test agar plates (active substance 1 mg/ml) 
Contrai substance: 




Natural albicidin showed in the same tests a diameter of inhibition of more than 1 cm. 
Staphylococcus aureus DSM 2569: 
Compounds 1 to 5, 7 to 12, 15, 16, 30 and 34 to 36 show a diameter of inhibition of 
more than 1 cm and more than 2 cm. 
Micrococcus luteus DSM1790: 
Compounds 1 to 5, 9 to 13, 16, 30, 36 and 44 show a diameter of inhibition of more 
than 1 cm and more than 2 cm. 





Compounds 1 to 5, 7,, 10 to 13, 26, 29, 30, 34, 35, 36, 43 and 44 show a diameter of 
inhibition of more than 1 cm or more than 2 cm. 
Bacillus subtilis DSM10 
Compounds 1 to 5, 7 to 16, 26, 29, 30, 34, 35, 36, 38 to 41 , 43 and 44 show a diameter 
of inhibition of more than 1 cm or more than 3,9 cm 
Escherichia coli albi-res (Montpellier): 
Compounds 1 to 5, 7 to 16, 26, 29, 30, 34, 35, 36, 38 to 41 , 43, 44 and 49 show a 
diameter of inhibition of more than 1 cm or more than 2 cm. 
Escherichia coli DHsa: 
Compounds 1 to 5, 8 to 13, 16, 30, 34, 35, 36 and 44 show a diameter of inhibition of 
more than 1 cm or more than 2 cm. 
EN-ISO standard test: 
Escherichia coli (ATCC 25922, 100-2-49 and 100-2-56): 
Compounds 1, 5, 16, 30, 35, 36 and 43 show an activity with good to very good MIC values 
(minimal inhibitory concentration). 
Salmonella enteritidis (PEG-10-3-58): 
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Compounds 1, 5, 16, 30, 35, 36 and 43 show an activity with good to very good MIC values. 
Pseudomonas aeruginosa (ATCC 27853): 
Compounds 1, 5, 30, 35 and 36 show an activity with good to very good MIC values. 
Pseudomonas aeruginosa (PEG-10-2-61 ): 
Compounds 1, 5 and 36 show an activity with good to very good MIC values. 
Staphytococcus aureus (ATCC 29213) 
Compounds 1, 5, 30 and 36 show an activity with good to very good MIC values. 
Staphytococcus aureus (PEG 10-38-22) 
Compounds 1, 5 and 36 show an activity with good to very good MIC values. 
Several of the herein tested strains are of importance for development of antibacterial 
therapy, particularly due to their resistance breaking potential against ciprofloxacin. 
The lnfectious Diseases Society of America in the January 2009 highlighted the impact of the 
ESKAPE pathogens (Enterococcus faecium, Staphytococcus aureus, Ktebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) as a group 
of particularly troublesome bacteria having the ability to "escape" the effects of current 
antimicrobial agents [Boucher HW, Talbot GH, Bradley JS, et al Bad bugs, no drugs: no 
ESKAPE! An update from the lnfectious Diseases Society of America. Clin Infect Dis 
2009;48:1-12.]. The bacterium E. coti is the predominant etiologic pathogen for gram-
negative infections and it represents a great total burden of disease. Livermore et al 
[Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. BSAC Working Parties on Resistance 
Surveillance. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the 
UK and lreland, 2001-06. J Antimicrob Chemother 2008;62(Suppl 2):ii41-54.] point out that 
E. coti infections currently account for -20% of all cases of bacteraemia in the United 
Kingdom. This rivais the incidence of S. aureus infection and is nearly double that associated 
with any other pathogen. Ciprofloxacin is commonly used for urinary tract and intestinal 
infections (traveler's diarrhea), used to treat especially tenacious infections. Many bacteria 
have developed resistance to this drug in recent years, leaving it significantly less effective 
than it would have been otherwise. Numerous pathogens, including Staphytococcus aureus, 
enterococci, Streptococcus pyogenes and Ktebsiella pneumoniae (quinolone-resistant) now 
exhibit resistance worldwide. 
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Compound 1 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. (E)-3-(4-fluorophenyl)-2-methylacrylic acid (3.5 eq, 0.305 mmol, 55 mg) was added. 
syn-Collidine (8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white 
suspension was stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 
mg) and DIPEA (10 eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture 
was stirred for 12 h at room temperature and quenched by the addition of water. After 
removing the organic solvent under reduced pressure the aqueous phase was extracted with 
EtOAc (3 x 50 ml). The organic phase was washed with saturated NaHC03 solution (2 x 50 
ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After 
drying over Na2SÜ4 and filtration, the solvent was removed under reduced pressure. Column 
chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (76 mg, 
91 %). The oil (1 eq, 0.069 mmol, 67 mg) and phenylsilane (8 eq, 0.556 mmol, 0.069 ml) 
were dissolved in dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 
(0.5 eq, 0.035 mmol, 40 mg) was added and the mixture was stirred 12 h at room 
temperature. After adding 3 drops of acetic acid the solvent was removed under reduced 
pressure. The product was isolated after preparative HPLC purification as a white powder 
(18 mg, 31 %). 
1H-NMR (DMS0-d6, 500 MHz): o [ppm] 2.10 (s, 3H), 3.06 (dd, J1 = 16.84 Hz, J2 = 8.72 Hz, 
1 H), 3.15 (m, 1 H), 3.77 (s, 1 H), 3.90 (s, 1 H), 4.98 (m, 1 H), 7.28 (t, J = 8.82 Hz, 2H), 7.33 (s, 
1 H), 7.55 (m, 4H), 7.79 (m, 3H), 7.84 (d, J = 8.72 Hz, 2H), 7.93 (d, J = 8.72 Hz, 2H), 8.00 (m, 
3H), 9.02 (d, J = 7.53 Hz, 1 H), 9.68 (s, 1 H), 10.19 (s, 1 H), 10.56 (s, 1 H), 11.13 (s, 1 H), 11.52 
(bs, 1 H). 
HRMS (ESI): [M-HJ- calculated: 843.2421 
found: 843.2441 
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Compound 2 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. (E)-2-methyl-3-phenylacrylic acid (3.5 eq, 0.305 mmol, 49 mg) was added. syn-
Collidine (8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white 
suspension was stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 
mg) and DIPEA (10 eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture 
was stirred for 12 h at room temperature and quenched by the addition of water. After 
removing the organic solvent under reduced pressure the aqueous phase was extracted with 
EtOAc (3 x 50 ml). The organic phase was washed with saturated NaHC03 solution (2 x 50 
ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After 
drying over Na2SÜ4 and filtration, the solvent was removed under reduced pressure. Column 
chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (65 mg, 
79 %). The oil (1 eq, 0.055 mmol, 52 mg) and phenylsilane (8 eq, 0.430 mmol, 0.054 ml) 
were dissolved in dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 
(0.5 eq, 0.027 mmol, 32 mg) was added and the mixture was stirred 12 h at room 
temperature. After adding 3 drops of acetic acid the solvent was removed under reduced 
pressure. The product was isolated after preparative HPLC purification as a white powder 
(16 mg, 35 %). 
1H-NMR (DMS0-d6, 500 MHz): o [ppm] 2.12 (s, 3H), 3.07 (dd, J1 = 16.84 Hz, J2 = 8.72 Hz, 
1 H), 3.15 (m, 1 H), 3.77 (s, 3H), 3.91 (s, 3H), 4.98 (m, 1 H), 7.36 (m, 2H), 7.46 (m, 4H), 7.57 
(m, 2H), 7.79 (m, 3H), 7.86 (d, J = 8.72 Hz, 2H), 7.93 (m, 2H), 7.98 (d, J = 8.52 Hz, 2H), 
8.04 (d, J = 8.92 Hz, 1 H), 9.02 (d, J = 7.73 Hz, 1 H), 10.19 (s, 1 H), 10.57 (s, 1 H), 11.16 (s, 
1 H), 11.52 (s, 1 H). 
HRMS (ESI): [M-H]- calculated: 825.2515 
found: 825.2533 
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Compound 3 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Cinnamic acid (3.5 eq, 0.305 mmol, 45 mg) was added. syn-Collidine (8 eq, 0.700 
mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at room 
temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 0.872 
mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at room 
temperature and quenched by the addition of water. After removing the organic solvent under 
reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The organic 
phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 
2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the 
solvent was removed under reduced pressure. Column chromatography (CHCb:MeOH; 1.5 
% MeOH) yielded the product as an orange oil (80 mg, 99 %). The oil (1 eq, 0.049 mmol, 46 
mg) and phenylsilane (8 eq, 0.395 mmol, 0.049 ml) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.025 mmol, 29 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (7 mg, 18 %). 
1H-NMR (DMS0-d6, 500 MHz): o [ppm] 3.06 (dd, J1 = 16.84 Hz, J2 = 8.72 Hz, 1 H), 3.15 (m, 
1 H), 4.98 (m, 1 H), 6.85 (d, J = 15.66 Hz, 1 H), 7.43 (m, 3H), 7.60 (m, 5H), 7.80 (m, 5H), 7.93 
(d, J = 8.72 Hz, 2H), 7.98 (d, J = 8.72 Hz, 2H), 8.05 (d, J = 8.92 Hz, 1 H), 9.02 (d, J = 7.73 
Hz, 1 H), 9.68 (s, 1 H), 10.48 (s, 1 H), 10.55 (s, 1 H), 11.16 (s, 1 H), 11.51 (s, 1 H), 11.58 (bs, 
1 H). 
HRMS (ESI): [M-HJ- calculated: 811.2358 
found: 811.2373 
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Compound 4 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. (E)-2-methyl-3-(4-(trifluoromethyl)phenyl)acrylic acid (3.5 eq, 0.305 mmol, 70 mg) was 
added. syn-Collidine (8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the 
white suspension was stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 
70 mg) and DIPEA (10 eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction 
mixture was stirred for 12 h at room temperature and quenched by the addition of water. 
After removing the organic solvent under reduced pressure the aqueous phase was 
extracted with EtOAc (3 x 50 ml). The organic phase was washed with saturated NaHC03 
solution (2 x 50 ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 
50 ml). After drying over Na2SÜ4 and filtration, the solvent was removed under reduced 
pressure. Column chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an 
orange oil (86 mg, 97 %). The oil (1 eq, 0.077 mmol, 78 mg) and phenylsilane (8 eq, 0.614 
mmol, 0.076 ml) were dissolved in dry THF under an atmosphere of argon and exclusion of 
light. Pd[P(Ph)3]4 (0.5 eq, 0.038 mmol, 44 mg) was added and the mixture was stirred 12 h at 
room temperature. After adding 3 drops of acetic acid the solvent was removed under 
reduced pressure. The product was isolated after preparative HPLC purification as a white 
powder (20 mg, 29 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 2.12 (s, 3H), 3.06 (dd, J1 = 16.79 Hz, J2 = 8.73 Hz, 
1 H), 3.15 (m, 1 H), 3.76 (s, 3H), 3.90 (s, 3H), 4.97 (m, 1 H), 7.39 (s, 1 H), 7.55 (m, 2H), 7.68 
(d, J = 8.06 Hz, 2H), 7.79 (m, 5H), 7.85 (d, J = 8.60 Hz, 2H), 7.93 (m, 2H), 7.98 (d, J = 8.60 
Hz, 2H), 8.03 (d, J = 8.87 Hz, 1 H), 9.04 (d, J = 7.52 Hz, 1 H), 9.70 (s, 1 H), 10.28 (s, 1 H), 
10.58 (s, 1 H), 11.16 (s, 1 H), 11.54 (s, 1 H). 
HRMS (ESI): [M-HJ- calculated: 893.2389 
found: 893.2410 
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Compound 5 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. (E)-3-(1,3-dihydroisobenzofuran-5-yl)acrylic acid (3.5 eq, 0.305 mmol, 59 mg) was 
added. syn-Collidine (8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the 
white suspension was stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 
70 mg) and DIPEA (10 eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction 
mixture was stirred for 12 h at room temperature and quenched by the addition of water. 
After removing the organic solvent under reduced pressure the aqueous phase was 
extracted with EtOAc (3 x 50 ml). The organic phase was washed with saturated NaHC03 
solution (2 x 50 ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 
50 ml). After drying over Na2SÜ4 and filtration, the solvent was removed under reduced 
pressure. Column chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an 
orange oil (56 mg, 66 %). The oil (1 eq, 0.057 mmol, 56 mg) and phenylsilane (8 eq, 0.460 
mmol, 0.057 ml) were dissolved in dry THF under an atmosphere of argon and exclusion of 
light. Pd[P(Ph)3]4 (0.5 eq, 0.029 mmol, 33 mg) was added and the mixture was stirred 12 h at 
room temperature. After adding 3 drops of acetic acid the solvent was removed under 
reduced pressure. The product was isolated after preparative HPLC purification as a white 
powder (10 mg, 20 %). 
1H-NMR (DMS0-d6, 700 MHz): o [ppm] 3.05 (dd, J1 = 16.75 Hz, J2 = 8.82 Hz, 1 H), 3.14 (m, 
1 H), 3.76 (s, 3H), 3.90 (s, 3H), 4.97 (m, 1 H), 6.08 (s, 2H), 6.67 (d, J = 15.66 Hz, 1 H), 6.98 (d, 
J = 7.93 Hz, 1 H), 7.15 (D, J = 7.93 Hz, 1 H), 7.19 (s, 1 H), 7.55 (m, 3H), 7.79 (m, 5H), 7.92 (d, 
J = 8.52 Hz, 2H), 7.97 (d, J = 8.72 Hz, 2H), 8.03 (d, J = 8.92 Hz, 1 H), 9.00 (d, J = 7.53 Hz, 
1 H), 9.67 (s, 1 H), 10.37 (s, 1 H), 10.54 (s, 1 H), 11.15 (s, 1 H), 11.50 (s, 1 H), 11.57 (bs, 1 H). 
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Chemical Formula: C43H36N60 12 
Exact Mass: 828,2391 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. (E)-3-(4-(Allyloxy)phenyl)acrylic acid (3.5 eq, 0.305 mmol, 62 mg) was added. syn-
Collidine (8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white 
suspension was stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 
mg) and DIPEA (10 eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture 
was stirred for 12 h at room temperature and quenched by the addition of water. After 
removing the organic solvent under reduced pressure the aqueous phase was extracted with 
EtOAc (3 x 50 ml). The organic phase was washed with saturated NaHC03 solution (2 x 50 
ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After 
drying over Na2SÜ4 and filtration, the solvent was removed under reduced pressure. Column 
chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (55 mg, 
64 %). The oil (1 eq, 0.058 mmol, 57 mg) and phenylsilane (8 eq, 0.462 mmol, 0.057 ml) 
were dissolved in dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 
(0.5 eq, 0.029 mmol, 33 mg) was added and the mixture was stirred 12 h at room 
temperature. After adding 3 drops of acetic acid the solvent was removed under reduced 
pressure. The product was isolated after preparative HPLC purification as a white powder 
(10 mg, 20 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.07 (dd, J1 = 16.79 Hz, J2 = 8.73 Hz, 1 H), 3.16 (s, 
1 H), 3.78 (s, 3H), 3.92 (s, 3H), 4.99 (m, 1 H), 6.64 (d, J = 15.58 Hz, 1 H), 6.84 (d, J = 8.33 Hz, 
2H), 7.54 (m, 5H), 7.80 (m, 5H), 7.93 (d, J = 8.87 Hz, 2H), 7.99 (d, J = 8.87 Hz, 2H), 8.06 (d, 
J = 8.87 Hz, 1 H), 9.03 (d, J = 7.52 Hz, 1 H), 9.71 (s, 1 H), 9.98 (bs, 1 H), 10.37 (s, 1 H), 10.57 
(s, 1 H), 11.18 (s, 1 H), 11.54 (s, 1 H), 11.60 (bs, 1 H). 
HRMS (ESI): [M-HJ- calculated: 827.2307 found: 827.2331 
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~~Y') 0 ~N--l) H 
0 ~~0~AJ H 
O 'CN 
Chemical Formula: C41H34N5012 
Exact Mass: 802,2235 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 4-(Allyloxy)benzoic acid (3.5 eq, 0.305 mmol, 67 mg) was added. syn-Collidine (8 eq, 
0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (58 mg, 69 %). The oil (1 
eq, 0.058 mmol, 56 mg) and phenylsilane (8 eq, 0.466 mmol, 0.057 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.029 mmol, 
34 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (19 mg, 41 %). 
1H-NMR (DMS0-d6, 500 MHz): o [ppm] 3.07 (dd, J1 = 16.65 Hz, J2 = 8.72 Hz, 1 H), 3.16 (m, 
1 H), 3.77 (s, 3H), 3.90 (s, 3H), 4.98 (m, 1 H), 6.87 (d, J = 8.52 Hz, 2H), 7.57 (dd, J1 = 8.92 
Hz, J2 = 4.56 Hz, 2H), 7.80 (m, 3H), 7.94 (m, 1 OH), 9.02 (d, J = 7.53 Hz, 1 H), 9.68 (s, 1 H), 
10.16 (s, 1 H), 10.23 (s, 1 H), 10.59 (s, 1 H), 11.14 (s, 1 H), 11.52 (s, 1 H). 









wo 2014/125075 PCT /EP2014/052922 
Compound 8 
BTC (1.15 eq, 0.100 mmol, 29 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 4-Morpholinobenzoic acid (3.5 eq, 0.305 mmol, 63 mg) was added. syn-Collidine (8 
eq, 0.697 mmol, 91 µI) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (72 mg, 84 %). The oil (1 
eq, 0.069 mmol, 68 mg) and phenylsilane (8 eq, 0.552 mmol, 68 µI) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.035 mmol, 
40 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (6 mg, 10 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.07 (dd, J1 = 16.12, J2 = 8.87 Hz, 1 H), 3.16 (dd, J1 = 
16.12, J2= 5.10 Hz, 1 H), 3.27 (m, 4H), 3.76 (m, 4H), 3.79 (s, 3H), 3.85 (s, 3H), 4.99 (dd, J1 = 
13.43, J2= 7.79 Hz, 1 H), 7.05 (d, J = 9.40 Hz, 2H), 7.42 (m, 2H), 7.56 (m, 2H), 7.63 (m, 2H), 
7.78 (d, J = 8.87 Hz, 2H), 7.93 (m, 6H), 8.93 (s, 1 H), 9.04 (d, J = 7.79 Hz, 1 H), 10.22 (s, 1 H), 
10.58 (s, 1 H), 10.64 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 872.2886 
found: 872.2882 
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~Yn O ~Nv H 
o ~~y1l~V H 
O 'cN 
Chemical Formula: C47H38N6011 
Exact Mass: 862,2599 
BTC (1.15 eq, 0.100 mmol, 29 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Biphenyl-4-carboxylic acid (3.5 eq, 0.305 mmol, 60 mg) was added. syn-Collidine (8 
eq, 0.697 mmol, 91 µI) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (60 mg, 70 %). The oil (1 
eq, 0.055 mmol, 54 mg) and phenylsilane (8 eq, 0.440 mmol, 54 µI) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.028 mmol, 
32 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (7 mg, 15 %). 
HRMS (ESI): [M+H]+ calculated: 863.2671 
found: 863.2666 
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~~Y'n O ~NJl) H 
0 ~~y1l~JlJ H 
O 'cN 
Chemical Formula: C42H35N5012 
Exact Mass: 816,2391 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 4-Methoxybenzoic acid (3.5 eq, 0.305 mmol, 46 mg) was added. syn-Collidine (8 eq, 
0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (43 mg, 53 %). The oil (1 
eq, 0.046 mmol, 43 mg) and phenylsilane (8 eq, 0.367 mmol, 0.045 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.023 mmol, 
26 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (5 mg, 13 %). 
1H-NMR (DMS0-d6, 700 MHz): o [ppm]3.08 (m, 1 H), 3.17 (m, 1 H), 3.78 (s, 3H), 3.83 (s, 1 H), 
3.86 (s, 3H), 5.00 (s, 1 H), 6.55 (bs, 1 H), 7.10 (d, J = 8.37 Hz, 2H), 7.56 (m, 2H), 7.81 (m, 
3H), 7.97 (m, 9H), 9.05 (d, J = 7.18 Hz, 1 H), 9.68 (s, 1 H), 10.35 (s, 1 H), 10.58 (s, 1 H), 11.06 
(s, 1 H), 11.54 (s, 1 H). 
HRMS (ESI): [M-H]- calculated: 815.2307 
found: 815.2310 
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Chemical Formula: C42 H33N7011 
Exact Mass: 811,2238 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 4-Cyanobenzoic acid (3.5 eq, 0.305 mmol, 45 mg) was added. syn-Collidine (8 eq, 
0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (59 mg, 73 %). The oil (1 
eq, 0.064 mmol, 59 mg) and phenylsilane (8 eq, 0.509 mmol, 0.063 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.032 mmol, 
37 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (11 mg, 21 %). 
1 H-NMR (DMS0-d6, 500 MHz): o [ppm] 3.09 (dd, J1 = 16.84 Hz, J2 = 8.92 Hz, 1 H), 3.18 (dd, 
J1 = 17.14 Hz, J2 = 5.85 Hz, 1 H), 3.79 (s, 3H), 3.91 (s, 3H), 5.01 (m, 1 H), 7.02 (s, 1 H), 7.12 
(s, 1 H), 7.22 (s, 2H), 7.57 (d, J = 8.72 Hz, 2H), 7.81 (m, 4H), 7.93 (d, J = 8.52 Hz, 3H), 7.99 
(m, 5 H), 8.96 (d, J = 8.13 Hz, 2H), 8.14 (d, J = 8.32 Hz, 2H), 9.08 (d, J =7.93 Hz, 1 H), 9.68 
(s, 1 H), 10.59 (s, 1 H), 10.74 (s, 1 H), 11.07 (bs, 1 H), 11.55 (bs, 1 H). 
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Compound 12 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 3-(Trifluoromethyl)benzoic acid (3.5 eq, 0.305 mmol, 61 mg) was added. syn-Collidine 
(8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (86 mg, 99 %). The oil (1 
eq, 0.077 mmol, 75 mg) and phenylsilane (8 eq, 0.617 mmol, 0.076 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.039 mmol, 
45 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (43 mg, 65 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.08 (dd, J1 = 16.79 Hz, J2 = 9.00 Hz, 1 H), m (3.17, 
1 H), 3.78 (s, 3H), 3.91 (s, 3H), 5.00 (m, 1 H), 7.58 (m, 2H), 7.81 (m, 4H), 7.99 (m, 8H), 8.31 
(m, 2H), 9.09 (d, J = 8.09 Hz, 1 H), 9.72 (s, 1 H), 10.60 (s, 1 H), 10.73 (s, 1 H), 11.18 (s, 1 H), 
11.55 (s, 1 H). 








~Y') 0 ~N)l) H 
0 ~~yl~JlJ H 
O 'cN 
Chemical Formula: C47H3aN5011 
Exact Mass: 862,2599 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Biphenyl-2-carboxylic acid (3.5 eq, 0.305 mmol, 61 mg) was added. syn-Collidine (8 
eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (86 mg, 99 %). The oil (1 
eq, 0.079 mmol, 78 mg) and phenylsilane (8 eq, 0.635 mmol, 0.078 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.040 mmol, 
46 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (35 mg, 51 %). 
1 H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.06 (dd, J1 = 16.66 Hz, J2 = 8.60 Hz, 1 H), 3.15 (m, 
1 H), 3.78 (s, 3H), 3.92 (s, 1 H), 4.98 (m, 1 H), 7.29 (m, 1 H), 7.37 (t, J = 7.52 Hz, 2H), 7.44 (m, 
2H), 7.50 (m, 2H), 7.61 (m, 6H), 7.80 (m, 3H), 7.87 (d, J = 8.60 Hz, 2H), 7.99 (d, J = 8.60 Hz, 
2H), 8.06 (d, J = 8.87 Hz, 1 H), 9.01 (d, J = 7.79 Hz, 1 H), 9.71 (s, 1 H), 10.50 (s, 1 H), 10.57 (s, 
1 H), 11.19 (s, 1 H), 11.58 (m, 2H). 
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Chemical Formula: C39H33N7011 
Exact Mass: 775,2238 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon.1 H-pyrrole-2-carboxylic acid (3.5 eq, 0.305 mmol, 29 mg) was added. syn-Collidine (8 
eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.8 % MeOH) yielded the product as an orange solid (54 mg, 69 %). The solid 
(1 eq, 0.058 mmol, 56 mg) and phenylsilane (8 eq, 0.466 mmol, 0.057 ml) were dissolved in 
dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.029 
mmol, 34 mg) was added and the mixture was stirred 12 h at room temperature. After adding 
3 drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (17 mg, 38 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.07 (m, 1H), 3.16 (m, 1H), 3.77 (s, 3H), 3.91 (s, 3H), 
4.99 (m, 1 H), 6.18 (m, 1 H), 7.00 (m, 1 H), 7.12 (m, 1 H), 7.58 (t, J = 9.1 Hz, 2H), 7.80 (m, 3H), 
7.88 (m, 4H), 7.99 (d, J = 8.9 Hz, 2H), 8.06 (d, J = 8.9 Hz, 1 H), 9.02 (d, J = 7.5 Hz, 1 H), 9.71 
(s, 1 H), 9.99 (s, 1 H), 10.58 (s, 1 H), 11.18 (s, 1 H), 11.54 (s, 1 H). 
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Chemical Formula: C39H32N5012 
Exact Mass: 776,2078 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Furan-2-carboxylic acid (3.5 eq, 0.305 mmol, 29 mg) was added. syn-Collidine (8 eq, 
0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (72 mg, 89 %). The oil (1 
eq, 0.078 mmol, 70 mg) and phenylsilane (8 eq, 0.625 mmol, 0.077 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.039 mmol, 
45 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (16 mg, 27 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.07 (m, 1H), 3.16 (m, 1H), 3.77 (s, 3H), 3.91 (s, 3H), 
4.99 (m, 1 H), 6.73 (s, 1 H), 7.39 (d, J = 3.0 Hz, 1 H), 7.57 (t, J = 8.3 Hz, 2H), 7.80 (m, 3H), 
7.94 (m, 6H), 8.04 (d, J = 8.6 Hz, 1 H), 9.05 (d, J = 7.3 Hz, 1 H), 9.71 (s, 1 H), 10.44 (s, 1 H), 
10.58 (s, 1 H), 11.57 (s, 1 H), 11.55 (s, 1 H). 








S,v?l -~ d )l) H 
"" Îf H O 1 '-::: ~ 
0 N0N -& 
: H 
O 'cN 
Chemical Formula: C38H31 N7011S 
Exact Mass: 793, 1802 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Thiazole-4-carboxylic acid (3.5 eq, 0.305 mmol, 34 mg) was added. syn-Collidine (8 
eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an yellow solid (69 mg, 86 %). The solid 
(1 eq, 0.073 mmol, 67 mg) and phenylsilane (8 eq, 0.587 mmol, 0.072 ml) were dissolved in 
dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.037 
mmol, 34 mg) was added and the mixture was stirred 12 h at room temperature. After adding 
3 drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (21 mg, 38 %). 
1H-NMR (DMS0-d6, 500 MHz): o [ppm] 3.07 (dd, J1 = 16.79 Hz, J2 = 8.73 Hz, 1 H), 3.17 (m, 
1 H), 3.78 (s, 3H), 3.92 (s, 3H), 4.99 (m, 1 H), 7.47 (m, 3H), 7.58 (m, 2H), 7.81 (m, 3H), 7.87 
(d, J = 8.87 Hz, 2H), 7.94 (m, 2H), 8.00 (d, J = 8.60 Hz, 2H), 8.05 (d, J = 8.87 Hz, 1 H), 9.04 
(d, J= 7.79 Hz, 1H), 9.71 (s, 1H), 10.22 (s, 1H), 10.59 (s, 1H), 11.17 (s, 1H), 11.54 (s, 1H). 
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Chemical Formula: C39H32Na011 
Exact Mass: 788,2191 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Pyrazine-2-carboxylic acid (3.5 eq, 0.305 mmol, 33 mg) was added. syn-Collidine (8 
eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange solid (70 mg, 88 %). The solid 
(1 eq, 0.073 mmol, 67 mg) and phenylsilane (8 eq, 0.590 mmol, 0.073 ml) were dissolved in 
dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.037 
mmol, 34 mg) was added and the mixture was stirred 12 h at room temperature. After adding 
3 drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (19 mg, 33 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.07 (m, 1H), 3.17 (m, 1H), 3.77 (s, 3H), 3.91 (s, 1H), 
4.99 (m, 1 H), 7.58 (t, J = 8.9 Hz, 2H), 7.80 (m, 3H), 7.98 (m, 4H), 8.06 (m, 3H), 8.84 (m, 1 H), 
8.94 (m, 1 H), 9.09 (d, J = 7.8 Hz, 1 H), 9.32 (s, 1 H), 9.71 (s, 1 H), 10.58 (s, 1 H), 11.00 (s, 1 H), 
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Compound 18 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argonPyridazine-3-carboxylic acid (3.5 eq, 0.305 mmol, 33 mg) was added. syn-Collidine (8 
eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (58 mg, 73 %). The oil (1 
eq, 0.058 mmol, 56 mg) and phenylsilane (8 eq, 0.466 mmol, 0.057 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.029 mmol, 
34 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (7 mg, 15 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.08 (m, 1H), 3.17 (m, 1H), 3.77 (s, 3H), 3.91 (s, 3H), 
5.00 (m, 1 H), 7.57 (t, J = 9.0 Hz, 1 H), 7.80 (m, 4H), 7.99 (m, 5H), 8.04 (m, 1 H), 8.11 (d, J = 
8.9 Hz), 8.35 (dd, J = 1.6 Hz), 9.10 (d, J = 7.0 Hz), 9.49 (dd, J1 = 5.0 Hz, J2 = 1.5 Hz), 9.71 
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Chemical Formula: C40H32CIN7011 
Exact Mass: 821, 1848 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 6-chloronicotinic acid (3.5 eq, 0.305 mmol, 42 mg) was added. syn-Collidine (8 eq, 
0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange solid (73 mg, 89 %). The solid 
(1 eq, 0.075 mmol, 71 mg) and phenylsilane (8 eq, 0.600 mmol, 0.074 ml) were dissolved in 
dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.038 
mmol, 44 mg) was added and the mixture was stirred 12 h at room temperature. After adding 
3 drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (4 mg, 7 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.07 (m, 1H), 3.16 (m, 1H), 3.77 (s, 3H), 3.91 (s, 3H), 
4.99 (m, 1 H), 6.18 (m, 1 H), 7.00 (m, 1 H), 7.12 (m, 1 H), 7.58 (t, J = 9.1 Hz, 2H), 7.80 (m, 3H), 
7.88 (m, 4H), 7.99 (d, J = 8.9 Hz, 2H), 8.06 (d, J = 8.9 Hz, 1 H), 9.02 (d, J = 7.5 Hz, 1 H), 9.71 
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Chemical Formula: C39H32N5012 
Exact Mass: 776,2078 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Furan-3-carboxylic acid (3.5 eq, 0.305 mmol, 29 mg) was added. syn-Collidine (8 eq, 
0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (72 mg, 92 %). The oil (1 
eq, 0.078 mmol, 70 mg) and phenylsilane (8 eq, 0.625 mmol, 0.077 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.039 mmol, 
45 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (6 mg, 10 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.08 (dd, J = 8,6 Hz, 1 H), 3.16 (dd, J = 5.4 Hz), 3.77 
(s, 3H), 3.91 (s, 3H), 4.99 (m, 1 H), 7.02 (d, J = 1.3 Hz, 1 H), 7.57 (m, 1 H), 7.82 (m, 6H), 7.97 
(m, 5H), 8.05 (d, J = 8.9 Hz, 1 H), 8.43 (s, 1 H), 9.05 (d, J = 7.3 Hz, 1 H), 9.71 (s, 1 H), 10.17 (s, 
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Chemical Formula: C39H32N5011S 
Exact Mass: 792, 1850 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Thiophene-3-carboxylic acid (3.5 eq, 0.305 mmol, 34 mg) was added. syn-Collidine (8 
eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange solid (79 mg, 98 %). The oil 
(1 eq, 0.087 mmol, 79 mg) and phenylsilane (8 eq, 0.693 mmol, 0.085 ml) were dissolved in 
dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (1.0 eq, 0.087 
mmol, 100 mg) was added and the mixture was stirred 12 h at room temperature. After 
adding 3 drops of acetic acid the solvent was removed under reduced pressure. The product 
was isolated after preparative HPLC purification as a white powder (20 mg, 29 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.07 (m, 1 H), 3.17 (m, 1 H), 3.77 (s, 3H), 3.91 (s, 1 H), 
4.99 (m, 1 H), 7.25 (t, J = 1.1, 1 H), 7.57 (d, 1 H), 7.80 (m, 3H), 7.89 (m, 4H), 7.98 (m, 4H), 
8.04 (m, 1 H), 8.07 (d, J = 2.7 Hz, 1 H) 9.06 (d, J = 7.8 Hz, 1 H), 9.70 (s, 1 H), 10.47 (s, 1 H), 






wo 2014/125075 PCT /EP2014/052922 
Compound 22 
The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (7 eq, 0.611 mmol, 0.100ml) were 
dissolved in dry THF (5 ml) under an atmosphere of argon. 3,5-Dichlorobenzoyl chloride (5 
eq, 0.436 mmol, 91 mg) was added an the reaction mixture was stirred for 12 hours and the 
reaction was quenched by the addition of water.After removing the organic solvent under 
reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The organic 
phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 
2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the 
solvent was removed under reduced pressure. Column chromatography (CHCb:MeOH; 1.5 
% MeOH) yielded the product as an orange oil (82 mg, 99 %). The oil (1 eq, 0.075 mmol, 73 
mg) and phenylsilane (8 eq, 0.375 mmol, 0.046 ml) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.037 mmol, 43 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (18 mg, 28 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.08 (dd, J1 = 16.79 Hz, J2 = 8.73 Hz, 1 H), 3.17 (m, 
1 H), 3.78 (s, 3H), 3.92 (s, 3H), 5.00 (m, 1 H), 7.58 (m, 2H), 7.81 (m, 3H), 7.91 (m, 3H), 8.01 
(m, 7H), 9.09 (d, J = 7.79 Hz, 1 H), 9.70 (s, 1 H), 10.59 (s, 1 H), 10.67 (s, 1 H), 11.17 (s, 1 H), 
11.54 (s, 1 H). 
HRMS (ESI): [M-H]- calculated: 853.1422 
found: 853.1459 
362 
wo 2014/125075 PCT /EP2014/052922 
Compound 23 
The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (7 eq, 0.611 mmol, 0.100ml) were 
dissolved in dry THF (5 ml) under an atmosphere of argon. 4-Fluorobenzoyl chloride (5 eq, 
0.436 mmol, 69 mg) was added an the reaction mixture was stirred for 12 hours and the 
reaction was quenched by the addition of water.After removing the organic solvent under 
reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The organic 
phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 
2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the 
solvent was removed under reduced pressure. Column chromatography (CHCb:MeOH; 1.5 
% MeOH) yielded the product as an orange oil (78 mg, 97 %). The oil (1 eq, 0.081 mmol, 75 
mg) and phenylsilane (8 eq, 0.651 mmol, 0.080 ml) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.041 mmol, 47 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (6 mg, 9 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.01 (dd, J1 = 16.79 Hz, J2 = 8.73 Hz, 1 H), 3.10 (m, 
1 H), 4.93 (m, 1 H), 7.33 (m, 2H), 7.50 (d, J = 8.87 Hz, 2H), 7.73 (m, 3H), 7.93 (m, 9H), 9.00 
(d, J = 7.79 Hz, 1 H), 9.63 (s, 1 H), 10.45 (s, 1 H), 10.52 (s, 1 H), 11.06 (s, 1 H), 11.47 (s, 1 H). 
HRMS (ESI): [M-H]- calculated: 803.2108 
found: 803.2130 
363 
wo 2014/125075 PCT /EP2014/052922 
Compound 24 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Nicotinic acid (3.5 eq, 0.305 mmol, 66 mg) was added. syn-Collidine (8 eq, 0.700 
mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at room 
temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 0.872 
mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at room 
temperature and quenched by the addition of water. After removing the organic solvent under 
reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The organic 
phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 
2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the 
solvent was removed under reduced pressure. Column chromatography (CHCb:MeOH; 1.5 
% MeOH) yielded the product as an yellow solid (64 mg, 80 %). The solid (1 eq, 0.068 mmol, 
62 mg) and phenylsilane (8 eq, 0.546 mmol, 0.066 ml) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.034 mmol, 39 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (6 mg, 12 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.08 (m, 1 H), 3.17 (m, 1 H), 3.78 (s, 3H), 3.92 (s, 3H), 
5.00 (m, 1 H), 7.58 (m, 4H), 7.80 (dd, J1 = 8.60 Hz, J2 = 6.18 Hz, 3H), 7.92 (m, 2H), 7.99 (m, 
5H), 8.06 (d, J = 8.9 Hz, 1 H), 8.33 (d, J = 7.8 Hz, 1 H) 9.08 (d, J = 7.3 Hz, 1 H), 9.71 (s, 1 H), 
10.59(s, 1H), 10.70(s, 1H), 11.18(s, 1H), 11.54(s, 1H). 
HR-MS: [M-H]- calculated: 786.21543 
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Chemical Formula: C39H32Na011 
Exact Mass: 788,2191 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Pyrimidine-5-carboxylic acid (3.5 eq, 0.305 mmol, 67 mg) was added. syn-Collidine (8 
eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an yellow solid (55 mg, 65 %). The solid 
(1 eq, 0.058 mmol, 53 mg) and phenylsilane (8 eq, 0.467 mmol, 0.057 ml) were dissolved in 
dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.029 
mmol, 34 mg) was added and the mixture was stirred 12 h at room temperature. After adding 
3 drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (9 mg, 20 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.08 (m, 1H), 3.17 (dd, J1 = 17.1 Hz, J2= 5.2 Hz, 
1 H), 3.77 (s, 3H), 3.92 (s, 3H), 4.99 (m, 1 H), 7.56 (d, J = 8.9 Hz, 1 H), 7.81 (m, 3H), 7.91 (d, J 
= 8.9 Hz, 2H), 7.99 (d, J = 8.4 Hz, 5H) 8.32 (d, J = 9.4 Hz, 1 H), 9.11 (d, J = 7.5 Hz, 1 H), 9.32 
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Chemical Formula: C42H35CIN6011 
Exact Mass: 834,2052 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 2-(4-Chlorophenyl)acetic acid (3.5 eq, 0.305 mmol, 52 mg) was added. syn-Collidine 
(8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (35 mg, 42 %). The oil (1 
eq, 0.037 mmol, 35 mg) and phenylsilane (8 eq, 0.293 mmol, 0.036 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.018 mmol, 
21 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (7 mg, 23 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.05 (m, 1 H), 3.15 (m, 1 H), 3.70 (s, 2H), 3.77 (s, 3H), 
3.91 (s, 3H), 4.97 (m, 1 H), 7.38 (m, 4H), 7.57 (d, J = 8.33 Hz, 2H), 7.76 (m, 5H), 7.96 (m, 
5H), 9.02 (d, J = 5.91 Hz, 1 H), 9.69 (s, 1 H), 10.46 (s, 1 H), 10.57 (s, 1 H), 11.15 (s, 1 H), 11.54 
(bs, 1 H). 
HRMS (ESI): [M-H]- calculated: 833.1969 
found: 833.1962 
366 
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Chemical Formula: C42H35N5012 
Exact Mass: 816,2391 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 2-(4-(Allyloxy)phenyl)acetic acid (3.5 eq, 0.305 mmol, 59 mg) was added. syn-
Collidine (8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white 
suspension was stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 
mg) and DIPEA (10 eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture 
was stirred for 12 h at room temperature and quenched by the addition of water. After 
removing the organic solvent under reduced pressure the aqueous phase was extracted with 
EtOAc (3 x 50 ml). The organic phase was washed with saturated NaHC03 solution (2 x 50 
ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After 
drying over Na2SÜ4 and filtration, the solvent was removed under reduced pressure. Column 
chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (68 mg, 
80 %). The oil (1 eq, 0.072 mmol, 70 mg) and phenylsilane (8 eq, 0.576 mmol, 0.071 ml) 
were dissolved in dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 
(0.5 eq, 0.036 mmol, 42 mg) was added and the mixture was stirred 12 h at room 
temperature. After adding 3 drops of acetic acid the solvent was removed under reduced 
pressure. The product was isolated after preparative HPLC purification as a white powder 
(30 mg, 51 %). 
1H-NMR (DMS0-d6, 700 MHz): o [ppm] 3.05 (dd, J1 = 16.79 Hz, J2 = 8.73 Hz, 1 H), 3.15 (m, 
1 H), 3.54 (s, 2H), 3.78 (s, 3H), 3.92 (s, 3H), 4.97 (m, 1 H), 6.71 (d, J = 8.60 Hz, 2H), 7.13 (d, 
J = 8.60 Hz, 2H), 7.58 (m, 2H), 7.71 (d, J = 8.87 Hz, 2H), 7.80 (m, 3H), 7.90 (d, J = 8.87 Hz, 
2H), 7.99 (d, J = 8.87 Hz, 2H), 8.05 (d, J = 8.87 Hz, 1 H), 9.01 (d, J = 7.79 Hz, 1 H), 9.28 (s, 
1H), 9.70 (s, 1H), 10.35 (s, 1H), 10.57 (s, 1H), 11.18 (s, 1H), 11.53 (s, 1H). 
HRMS (ESI): [M-HJ- calculated: 815.2307 
found: 815.2321 
367 
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Chemical Formula: C42H35FN5011 
Exact Mass: 818,2348 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 2-(4-Fluorophenyl)acetic acid (3.5 eq, 0.305 mmol, 47 mg) was added. syn-Collidine 
(8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (60 mg, 74 %). The oil (1 
eq, 0.057 mmol, 54 mg) and phenylsilane (8 eq, 0.456 mmol, 0.056 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.029 mmol, 
33 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (23 mg, 49 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.06 (dd, J1 = 16.79 Hz, J2= 8.73 Hz, 1 H), 3.15 (m, 
1 H), 3.69 (s, 2H), 3.78 (s, 3H), 3.92 (s, 3H), 4.97 (m, 1 H), 7.16 (m, 2H), 7.37 (m, 2H), 7.58 
(m, 2H), 7.72 (d, J = 8.06 Hz, 2H), 7.80 (m, 3H), 7.91 (d, J = 8.60 Hz, 2H), 7.99 (d, J = 8.60 
Hz, 2H), 8.06 (d, J = 8.87 Hz, 1 H), 9.02 (d, J = 7.79 Hz, 1 H), 9.70 (s, 1 H), 10.45 (s, 1 H), 
10.57 (s, 1 H), 11.18 (s, 1 H), 11.53 (s, 1 H), 11.60 (bs, 1 H). 
HRMS (ESI): [M-HJ- calculated: 817.2264 
found: 817.2283 
368 
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Chemical Formula: C42 H37N7011 
Exact Mass: 815,2551 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 3-(Pyridin-2-yl)propanoic acid (3.5 eq, 0.305 mmol, 46 mg) was added. syn-Collidine 
(8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (47 mg, 58 %). The oil (1 
eq, 0.047 mmol, 44 mg) and phenylsilane (8 eq, 0.377 mmol, 0.046 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.024 mmol, 
27 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (8 mg, 21 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 2.74 (s, 2H), 3.10 (m, 4H), 3.77 (s, 3H), 3.91 (s, 3H), 
4.97 (m, 1 H), 7.63 (m, 6H), 7.84 (m, 6H), 8.02 (m, 4H), 9.01 (d, J = 7.25 Hz, 1 H), 9.70 (s, 
1 H), 10.24 (s, 1 H), 10.57 (s, 1 H), 11.18 (s, 1 H), 11.55 (s, 1 H). 
HRMS (ESI): [M-HJ- calculated: 814.2467 
found: 814.2487 
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Compound 30 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 2-Phenoxyacetic acid (3.5 eq, 0.305 mmol, 46 mg) was added. syn-Collidine (8 eq, 
0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (73 mg, 90 %). The oil (1 
eq, 0.070 mmol, 66 mg) and phenylsilane (8 eq, 0.561 mmol, 0.069 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.024 mmol, 
27 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (11 mg, 19 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.06 (m, 1H), 3.16 (m, 1H), 3.77 (s, 3H), 3.91 (s, 3H), 
4.74 (s, 2H), 4.98 (m, 1 H), 6.99 (m, 3H), 7.32 (m, 3H), 7.79 (m, 4H), 7.93 (d, J = 8.06 Hz, 
2H), 7.99 (d, J = 8.60 Hz, 2H), 8.05 (d, J = 8.60 Hz, 1 H), 9.05 (d, J = 6.98 Hz, 1 H), 9.70 (s, 
1 H), 10.37 (s, 1 H), 10.58 (s, 1 H), 11.17 (s, 1 H), 11.54 (s, 1 H). 
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Chemical Formula: C43H3sN5012 
Exact Mass: 830,2548 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 3-(4-(Allyloxy)phenyl)propanoic acid (3.5 eq, 0.305 mmol, 63 mg) was added. syn-
Collidine (8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white 
suspension was stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 
mg) and DIPEA (10 eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture 
was stirred for 12 h at room temperature and quenched by the addition of water. After 
removing the organic solvent under reduced pressure the aqueous phase was extracted with 
EtOAc (3 x 50 ml). The organic phase was washed with saturated NaHC03 solution (2 x 50 
ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After 
drying over Na2SÜ4 and filtration, the solvent was removed under reduced pressure. Column 
chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (84 mg, 
97 %). The oil (1 eq, 0.080 mmol, 79 mg) and phenylsilane (8 eq, 0.640 mmol, 0.079 ml) 
were dissolved in dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 
(0.5 eq, 0.040 mmol, 46 mg) was added and the mixture was stirred 12 h at room 
temperature. After adding 3 drops of acetic acid the solvent was removed under reduced 
pressure. The product was isolated after preparative HPLC purification as a white powder 
(13 mg, 20 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 2.59 (t, J = 7.79 Hz, 2H), 2.80 (t, J = 7.52 Hz, 2H), 
3.06 (dd, J1 = 16.92 Hz, J2 = 8.60 Hz, 1 H), 3.15 (m, 1 H), 3.77 (s, 3H), 3.92 (s, 3H), 4.97 (m, 
1 H), 6.66 (d, J = 8.33 Hz, 2H), 7.03 (d, J = 8.33 Hz, 2H), 7.58 (m, 2H), 7.70 (d, J = 8.60 Hz, 
2H), 7.80 (m, 3H), 7.90 (d, J = 8.87 Hz, 2H), 7.99 (d, J = 8.87 Hz, 2H), 8.06 (d, J = 8.87 Hz, 
1H), 9.01 (d, J= 8.06 Hz, 1H), 9.17 (bs, 1H), 9.71 (s, 1H), 10.17 (s, 1H), 10.57 (s, 1H), 11.19 
(s, 1 H), 11.54 (s, 1 H), 11.61 (bs, 1 H). 
HRMS (ESI): [M-H]- calculated: 829.2464 
found: 829.2483 
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Chemical Formula: C43H37FN6011 
Exact Mass: 832,2504 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. 3-(4-Fluorophenyl)propanoic acid (3.5 eq, 0.305 mmol, 51 mg) was added. syn-
Collidine (8 eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white 
suspension was stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 
mg) and DIPEA (10 eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture 
was stirred for 12 h at room temperature and quenched by the addition of water. After 
removing the organic solvent under reduced pressure the aqueous phase was extracted with 
EtOAc (3 x 50 ml). The organic phase was washed with saturated NaHC03 solution (2 x 50 
ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After 
drying over Na2SÜ4 and filtration, the solvent was removed under reduced pressure. Column 
chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (72 mg, 
87 %). The oil (1 eq, 0.071 mmol, 67 mg) and phenylsilane (8 eq, 0.566 mmol, 0.070 ml) 
were dissolved in dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 
(0.5 eq, 0.035 mmol, 41 mg) was added and the mixture was stirred 12 h at room 
temperature. After adding 3 drops of acetic acid the solvent was removed under reduced 
pressure. The product was isolated after preparative HPLC purification as a white powder 
(29 mg, 49 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 2.66 (d, J = 7.66 Hz, 2H), 2.91 (d, J = 7.52 Hz, 2H), 
3.06 (dd, J1 = 16.79 Hz, J2 = 8.73 Hz, 1 H), 3.15 (m, 1 H), 3.78 (s, 3H), 3.92 (s, 3H), 4.97 (m, 
1 H), 7.11 (m, 2H), 7.29 (m, 2H), 7.58 (m, 2H), 7.70 (d, J = 8.87 Hz, 2H), 7.80 (m, 3H), 7.90 
(d, J = 8.60 Hz, 2H), 7.99 (d, J = 8.60 Hz, 2H), 8.06 (d, J = 8.87 Hz, 1 H), 9.01 (d, J = 7.79 
Hz, 1H), 9.71 (s, 1H), 10.20 (s, 1H), 10.57 (s, 1H), 11.18 (s, 1H), 11.54 (s, 1H), 11.65 (bs, 
1 H). 
HRMS (ESI): [M-HJ- calculated: 831.2421 
found: 831.2437 
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Compound 34 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Hexanoic acid (3.5 eq, 0.305 mmol, 35 mg) was added. syn-Collidine (8 eq, 0.700 
mmol, 0.092 ml) was slowly added via syringe and the white suspension was stirred at room 
temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 0.872 
mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h at room 
temperature and quenched by the addition of water. After removing the organic solvent under 
reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The organic 
phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 
2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the 
solvent was removed under reduced pressure. Column chromatography (CHCb:MeOH; 1.5 
% MeOH) yielded the product as an orange oil (39 mg, 50 %). The oil (1 eq, 0.039 mmol, 35 
mg) and phenylsilane (8 eq, 0.311 mmol, 0.038 ml) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.019 mmol, 22 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (4 mg, 13 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 0.85 (m, 4H), 1.20 (m, 7H), 3.05 (m, 1 H), 3.12 (m, 
1 H), 3.75 (s, 3H), 3.84 (s, 3H), 4.95 (m, 1 H), 7.51 (d, J = 8.60 Hz, 2H), 7.68 (d, J = 8.87 Hz, 
3H), 7.76 (m, 3H), 7.87 (d, J = 8.87 Hz, 2H), 7.96 (d, J = 8.60 Hz, 2H), 8.97 (d, J = 7.79 Hz, 
1 H), 9.63 (s, 1 H), 10.12 (s, 1 H), 10.55 (s, 1 H), 10.82 (bs, 1 H). 
HRMS (ESI): [M+H]+ calculated: 781.2828 
found: 781.2837 
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Chemical Formula: C41 H40N60 11 
Exact Mass: 792,2755 
PCT /EP2014/052922 
BTC (1.15 eq, 0.100 mmol, 30 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Cyclohexanecarboxylic acid (3.5 eq, 0.305 mmol, 40 mg) was added. syn-Collidine (8 
eq, 0.700 mmol, 0.092 ml) was slowly added via syringe and the white suspension was 
stirred at room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 
eq, 0.872 mmol, 0.150 ml) were added via syringe. The reaction mixture was stirred for 12 h 
at room temperature and quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (61 mg, 77 %). The oil (1 
eq, 0.062 mmol, 57 mg) and phenylsilane (8 eq, 0.500 mmol, 0.062 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.031 mmol, 
36 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (9 mg, 18 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 1.10 (m, 2H), 1.20 (m, 2H), 1.34 (m, 2H), 1.59 (m, 
1 H), 1.72 (m, 4H), 2.99 (dd, J1 = 16.66 Hz, J2 = 8.87 Hz, 1 H), 3.08 (m, 1 H), 3.71 (s, 3H), 3.84 
(s, 1 H), 4.90 (m, 1 H), 7.50 (d, J = 8.87 Hz, 2H), 7.66 (d, J = 8.60 Hz, 2H), 7.73 (m, 3H), 7.82 
(d, J = 8.87 Hz, 2H), 7.92 (m, 3H), 8.93 (d, J = 7.79 Hz, 1 H), 9.63 (s, 1 H), 10.03 (s, 1 H), 
10.51 (s, 1 H), 11.06 (s, 1 H), 11.47 (bs, 1 H). 







wo 2014/125075 PCT /EP2014/052922 
Compound 36 
The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (7 eq, 0.611 mmol, 0.100ml) were 
dissolved in dry THF (5 ml) under an atmosphere of argon. AdCOCI (5 eq, 0.436 mmol, 87 
mg) was added an the reaction mixture was stirred for 12 hours and the reaction was 
quenched by the addition of water.After removing the organic solvent under reduced 
pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The organic phase was 
washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 2 x 50 ml), 
water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the solvent 
was removed under reduced pressure. Column chromatography (CHCb:MeOH; 1.5 % 
MeOH) yielded the product as an orange oil (73 mg, 87 %). The oil (1 eq, 0.071 mmol, 69 
mg) and phenylsilane (8 eq, 0.568 mmol, 0.070 ml) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.036 mmol, 41 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (33 mg, 55 %). 
1H-NMR (DMS0-d6, 700 MHz): o [ppm] 1.72 (s, 6H), 1.94 (s, 6H), 2.04 (s, 3H), 3.07 (m, 1 H), 
3.16 (m, 1 H), 3.79 (s, 3H), 3.92 (s, 3H), 4.99 (m, 1 H), 7.59 (m, 2H), 7.81 (m, 5H), 7.91 (d, J = 
8.37 Hz, 2H), 8.00 (d, J = 8.37 Hz, 2H), 8.05 (d, J = 8.67 Hz, 1 H), 9.00 (d, J = 7.78 Hz, 1 H), 
9.39 (s, 1 H), 9.70 (s, 1 H), 10.58 (s, 1 H), 11.70 (s, 1 H), 11.54 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 845.3141 
found: 845.3134 





Chemical Formula: C36H32N6011 
Exact Mass: 724,2129 
PCT /EP2014/052922 
The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (7 eq, 0.611 mmol, 0.100ml) were 
dissolved in dry THF (5 ml) under an atmosphere of argon. Acetyl chloride (5 eq, 0.436 
mmol, 34 mg) was added an the reaction mixture was stirred for 12 hours and the reaction 
was quenched by the addition of water.After removing the organic solvent under reduced 
pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The organic phase was 
washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 2 x 50 ml), 
water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the solvent 
was removed under reduced pressure. Column chromatography (CHCb:MeOH; 1.5 % 
MeOH) yielded the product as an orange oil (40 mg, 54 %). The oil (1 eq, 0.057 mmol, 48 
mg) and phenylsilane (8 eq, 0.455 mmol, 0.056 ml) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.028 mmol, 33 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (2 mg, 5 %). 
1 H-NMR (DMS0-d6, 800 MHz): o [ppm] 2.09 (s, 3H), 3.07 (dd, J1 = 16.17 Hz, J2 = 8.40 Hz, 
1 H), 3.16 (m, 1 H), 3.78 (s, 3H), 3.93 (s, 3H), 4.98 (m, 1 H), 7.58 (d, J = 8.68 Hz, 1 H), 7.60 (d, 
J = 8.68 Hz, 1 H), 7.70 (d, J = 8.68 Hz, 2H), 7.81 (m, 3H), 7.91 (d, J = 9.59 Hz, 2H), 8.00 (d, J 
= 8.98 Hz, 2H), 8.06 (d, J = 8.96 Hz, 1 H), 9.00 (d, J = 8.40 Hz, 1 H), 9.70 (s, 1 H), 10.22 (s, 
1 H), 10.57 (s, 1 H), 11.17 (s, 1 H), 11.54 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 725.2202 
found: 725.2209 
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Chemical Formula: C38H34 N5011 
Exact Mass: 750,2286 
PCT /EP2014/052922 
Cyclopropanecarbonyl chloride (5 eq, 0.436 mmol, 39.5 µI) was added via syringe to a 
solution of amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (5 eq, 0.436 mmol,76 µI) under an 
atmosphere of argon. The reaction mixture was stirred for 12 h at room temperature and 
quenched by the addition of water. After removing the organic solvent under reduced 
pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The organic phase was 
washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 2 x 50 ml), 
water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the solvent 
was removed under reduced pressure. Column chromatography (CHCb:MeOH; 1.5 % 
MeOH) yielded the product as an orange oil (64 mg, 84 %). The oil (1 eq, 0.069 mmol, 60 
mg) and phenylsilane (8 eq, 0.552 mmol, 68 µI) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.035 mmol, 40 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (15 mg, 29 %). 
1H-NMR (DMS0-d6, 500 MHz): o [ppm] 0.83 (m, 4H), 1.83 (m, 1 H), 3.07 (dd, J1 = 17.24, J2 = 
9.12 Hz, 1H), 3.16 (dd, J1 = 16.84, J2= 6.14 Hz, 1H), 3.78 (s, 3H), 3.91 (s, 3H), 4.97 (dd, J1 = 
14.27, J2= 8.32 Hz, 1H), 7.58 (t, J= 8.82 Hz, 2H), 7.72 (d, J= 8,72 Hz, 2H), 7.80 (t, J= 8.50 
Hz, 3H), 7.90 (d, J = 8.72 Hz, 2H), 7.98 (d, J = 8.52 Hz, 2H), 8.04 (d, J = 8.92 Hz, 1 H), 9.00 
(d, J= 7.73 Hz, 1H), 9.68 (s, 1H), 10.51 (s, 1H), 10.61 (s, 1H), 11.16 (s, 1H), 11.52 (s, 1H). 
HRMS (ESI): [M+H]+ calculated: 751.2358 
found: 751.2358 
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Chemical Formula: C40H40N5011 
Exact Mass: 780,2755 
PCT /EP2014/052922 
2-Ethylbutanoyl chloride (5 eq, 0.436 mmol, 59.7 µI) was added via syringe to a solution of 
amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (5 eq, 0.436 mmol,76 µI) under an atmosphere 
of argon. The reaction mixture was stirred for 12 h at room temperature and quenched by the 
addition of water. After removing the organic solvent under reduced pressure the aqueous 
phase was extracted with EtOAc (3 x 50 ml). The organic phase was washed with saturated 
NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and 
brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the solvent was removed under 
reduced pressure. Column chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product 
as an orange oil (75 mg, 96 %). The oil (1 eq, 0.078 mmol, 70 mg) and phenylsilane (8 eq, 
0.624 mmol, 77 µI) were dissolved in dry THF under an atmosphere of argon and exclusion 
of light. Pd[P(Ph)3]4 (0.5 eq, 0.039 mmol, 45 mg) was added and the mixture was stirred 12 h 
at room temperature. After adding 3 drops of acetic acid the solvent was removed under 
reduced pressure. The product was isolated after preparative HPLC purification as a white 
powder (32 mg, 53 %). 
1H-NMR (DMS0-d6, 500 MHz): o [ppm] 0.86 (t, J = 7.43 Hz, 6H), 1.46 (m, 2H), 1.57 (m, 2H), 
2.26 (m, 1 H), 3.06 (dd, J1 = 17.04, J2 = 8.72 Hz, 1 H), 3.15 (dd, J1 = 16.64, J2 = 5.35 Hz, 1 H), 
3.78 (s, 3H), 3.91 (s, 3H), 4.98 (dd, J1 = 13.67, J2 = 8.13 Hz, 1 H), 7.57 (d, J = 8.72 Hz, 1 H), 
7.75 (d, J = 8.72 Hz, 2H), 7.79 (d, J = 8.72 Hz, 1 H), 7.81 (d, J = 9.12 Hz, 1 H), 7.90 (d, J = 
8.72 Hz, 2H), 7.98 (d, J = 8.52 Hz, 2H), 8.04 (d, J = 8.52 Hz, 1 H), 8.98 (d, J = 7.53 Hz, 1 H), 
9.68 (s, 1 H), 10.13 (s, 1 H), 10.55 (s, 1 H), 11.15 (s, 1 H), 11.52 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 781.2826 
found: 781.2828 








~~'Oy O ~N)l) H 




Chemical Formula: C39H38 N5011 
Exact Mass: 766,2599 
PCT /EP2014/052922 
Trimethylacetyl chloride (5 eq, 0.436 mmol, 53.7 µI) was added via syringe to a solution of 
amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (5 eq, 0.436 mmol,76 µI) under an atmosphere 
of argon. The reaction mixture was stirred for 12 h at room temperature and quenched by the 
addition of water. After removing the organic solvent under reduced pressure the aqueous 
phase was extracted with EtOAc (3 x 50 ml). The organic phase was washed with saturated 
NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 2 x 50 ml), water (1 x 50 ml) and 
brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the solvent was removed under 
reduced pressure. Column chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product 
as an orange oil (52 mg, 67 %). The oil (1 eq, 0.054 mmol, 48 mg) and phenylsilane (8 eq, 
0.432 mmol, 53 µI) were dissolved in dry THF under an atmosphere of argon and exclusion 
of light. Pd[P(Ph)3]4 (0.5 eq, 0.027 mmol, 31 mg) was added and the mixture was stirred 12 h 
at room temperature. After adding 3 drops of acetic acid the solvent was removed under 
reduced pressure. The product was isolated after preparative HPLC purification as a white 
powder (15 mg, 36 %). 
1 H-NMR (DMS0-d6, 400 MHz): o [ppm] 1.24 (s, 9H), 3.06 (dd, J1 = 16.39, J2 = 8.33 Hz, 1 H), 
3.13 (dd, J1 = 16.79, J2 = 5.24 Hz, 1 H), 3.77 (s, 3H), 3.91 (s, 3H), 4.97 (dd, J1 = 13.70, J2= 
7.52 Hz, 1 H), 7.56 (d, J = 8.87 Hz, 2H), 7.79 (m, 5H), 7.90 (d, J = 8.60 Hz, 2H), 7.99 (d, J = 
8.33 Hz, 2H), 8.04 (d, J = 8.60 Hz, 1 H), 9.01 (d, J = 7.52 Hz, 1 H), 9.46 (s, 1 H), 9.71 (s, 1 H), 
10.59(s, 1H), 11.17(s, 1H), 11.55(s, 1H). 
HRMS (ESI): [M+H]+ calculated: 767.2671 
found: 767.2670 
[M+Na]+ calculated: 789.2491 
found: 789.2490 
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Chemical Formula: C40H3aN5011 
Exact Mass: 778,2599 
Cyclopentanecarbonyl chloride (5 eq, 0.436 mmol, 53 µI) was added via syringe to a solution 
of amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (5 eq, 0.436 mmol,76 µI) under an 
atmosphere of argon. The reaction mixture was stirred for 12 h at room temperature and 
quenched by the addition of water. After removing the organic solvent under reduced 
pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The organic phase was 
washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI solution (5 %, 2 x 50 ml), 
water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 and filtration, the solvent 
was removed under reduced pressure. Column chromatography (CHCb:MeOH; 1.5 % 
MeOH) yielded the product as an orange oil (67 mg, 86 %). The oil (1 eq, 0.069 mmol, 62 
mg) and phenylsilane (8 eq, 0.552 mmol, 68 µI) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.035 mmol, 40 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (2 mg, 4 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 1.56 (m, 2H), 1.70 (m, 4H), 1.86 (m, 2H), 2.80 (m, 
1 H), 3.06 (dd, J1 = 16.92, J2 = 8.87 Hz, 1 H), 3.15 (dd, J1 = 16.79, J2 = 4.70 Hz, 1 H), 3.77 (s, 
3H), 3.89 (s, 3H), 4.97 (dd, J1 = 14.24, J2= 7.79 Hz, 1 H), 7.55 (d, J = 8.60 Hz, 2H), 7.63 (m, 
1 H), 7.73 (d, J = 8.60 Hz, 2H), 7.79 (t, J = 7.80 Hz, 3H), 7.89 (d, J = 8.60 Hz, 2H), 7.98 (d, J 
= 8.87 Hz, 2H), 9.01 (d, J = 7.25 Hz, 1 H), 9.69 (s, 1 H), 10.16 (s, 1 H), 10.58 (s, 1 H), 11.03 (s, 
1 H), 11.56 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 779.2671 
found: 779.2672 
[M+Na]+ calculated: 801.2491 
found: 801.2487 
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Chemical Formula: C42H42N5011 
Exact Mass: 806,2912 
BTC (2.9 eq, 0.253 mmol, 75 mg) was dissolved in dry THF (5 ml) under an atmosphere of 
argon. Cycloheptanecarboxylic acid (9 eq, 0.785 mmol, 112 mg) was added. syn-Collidine (8 
eq, 0.697 mmol, 91 µI) was slowly added via syringe and the white suspension was stirred at 
room temperature for 10 min. The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (10 eq, 
0.872 mmol, 0.150 ml) were added via syrringe. The reaction mixture was stirred for 12 h at 
room temperature and quenched by the addition of water. After removing the organic solvent 
under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). The 
organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (48 mg, 60 %). The oil (1 
eq, 0.049 mmol, 45 mg) and phenylsilane (8 eq, 0.392 mmol, 48 µI) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.025 mmol, 
28 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (10 mg, 25 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 1.54 (m, 4H), 1.72 (m, 4H), 1.84 (m, 4H), 2.54 (m, 
1H), 3.06 (dd, J1 = 17.19, J2= 9.13 Hz, 1H), 3.13 (dd, J1= 16.92, J2= 5.37 Hz, 1H), 3.77 (s, 
3H), 3.90 (s, 3H), 4.97 (dd, J1 = 13.97, J2 = 8.06 Hz, 1 H), 7.56 (d, J = 8.87 Hz, 2H), 7.71 (d, J 
= 8.87 Hz, 2H), 7.79 (m, 4H), 7.89 (d, J = 8.60 Hz, 2H), 7.98 (d, J = 8.60 Hz, 2H), 9.00 (d, J = 
7.79 Hz, 1H), 9.70 (s, 1H), 10.08 (s, 1H), 10.58 (s, 1H), 11.11 (s, 1H), 11.55 (s, 1H). 
HRMS (ESI): [M-HJ- calculated: 805.2839 
found: 805.2826 
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Compound 43 
The amine (1 eq, 0.087 mmol, 70 mg) and phenyl isocyanate (5 eq, 0.435 mmol, 0.047ml) 
were dissolved in dry THF (5 ml) under an atmosphere of argon. The reaction mixture was 
stirred at room temperature for 12 h and another portion of phenyl isocyanate (5 eq, 0.435 
mmol, 0.047ml) was added. The solvent was removed under reduced pressure. Column 
chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (78 mg, 
97 %). The oil (1 eq, 0.073 mmol, 67 mg) and phenylsilane (8 eq, 0.584 mmol, 0.072 ml) 
were dissolved in dry THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 
(0.5 eq, 0.036 mmol, 42 mg) was added and the mixture was stirred 12 h at room 
temperature. After adding 3 drops of acetic acid the solvent was removed under reduced 
pressure. The product was isolated after preparative HPLC purification as a white powder (8 
mg, 14 %). 
1H-NMR (DMS0-d6, 500 MHz): o [ppm] 3.08 (dd, J1 = 16.84, J2= 8.72 Hz, 1H), 3.16 (m, 1 H), 
3.79 (s, 3H), 3.93 (s, 3H), 4.99 (m, 1 H), 7.00 (t, J = 7.43 Hz, 1 H), 7.30 (t, J = 7.83 Hz, 2H), 
7.48 (d, J = 7.93 Hz, 2H), 7.59 (m, 4H), 7.81 (m, 3H), 7.91 (d, J = 8.52 Hz, 2H), 8.00 (d, J = 
8.72 Hz, 2H), 8.06 (d, J = 8.92 Hz, 1 H), 8.79 (s, 1 H), 8.97 (d, J = 7.73 Hz, 1 H), 9.02 (s, 1 H), 
9.69 (s, 1 H), 10.56 (s, 1 H), 11.17 (s, 1 H), 11.53 (s, 1 H), 11.60 (bs, 1 H). 
HRMS (ESI): [M+H]+ calculated: 802.2461 
found: 802.2467 
[M+Na]+ calculated: 824.2287 
found: 824.2279 
382 
wo 2014/125075 PCT /EP2014/052922 
Compound 44 
Amino derivative (1.0 eq, 0.062 mmol, 50 mg) and biphenyl-4-carbaldehyde (1 eq, 0.062 
mmol, 11 mg) were dissolved in dry THF under argon atmosphere and a catalytic amount of 
acetic acid was added. After stirring this solution for 60 min NaBH3CN (1.3 eq, 0.081 mmol, 5 
mg) was added. After 3 h of stirring at room temperature another 1.3 eq of NaBH3CN was 
added and the Mixture was stirred for 16 h. The reaction was quenched by addition of 1 N 
HCI and extracted three times with EtOAc. The organic solvent was dried over Na2SÜ4, 
filtered and removed under reduced pressure. Column chromatography (CHCl3:MeOH; 1.5 % 
MeOH) yielded the product as an orange oil (55 mg, 62 %). The oil (1 eq, 0.059 mmol, 50 
mg) and phenylsilane (8 eq, 0.472 mmol, 58 µI) were dissolved in dry THF under an 
atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.030 mmol, 35 mg) was 
added and the mixture was stirred 12 h at room temperature. After adding 3 drops of acetic 
acid the solvent was removed under reduced pressure. The product was isolated after 
preparative HPLC purification as a white powder (8 mg, 16 %). 
1H-NMR (DMS0-d6, 400 MHz): o [ppm] 3.02 (dd, J1 = 17.19, J2 = 9.13 Hz, 1 H), 3.11 (dd, J1 = 
16.79, J2 = 5.51 Hz, 1 H), 3.77 (s, 3H), 3.90 (s, 3H), 4.40 (d, J = 5.37 Hz, 2H), 4.92 (dd, J1 = 
13.97, J2= 8.06 Hz, 1 H), 6.65 (d, J = 8.87 Hz, 2H), 7.44 (d, J = 8.06 Hz, 4H), 7.63 (d, J = 
6.72 Hz, 2H), 7.65 (d, J = 5.91 Hz, 2H), 7.70 (d, J = 8.87 Hz, 2H), 7.78 (m, 4H), 7.92 (d, J = 
8.33 Hz, 2H), 7.97 (d, J = 8.87 Hz, 2H), 8.01 (d, J = 8.33 Hz, 1 H), 8.64 (d, J = 7.52 Hz, 1 H), 
9.69 (s, 1 H), 10.51 (s, 1 H), 11.07 (s, 1 H), 11.57 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 849.2879 
found: 849.2878 
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Compound 48 
The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (7 eq, 0.611 mmol, 0.100ml) were 
dissolved in dry THF (5 ml) under an atmosphere of argon. 4-Fluorobenzene-1-sulfonyl 
chloride (5 eq, 0.435 mmol, 84 mg) was added and the reaction mixture was stirred for 12 
hours and the reaction was quenched by the addition of water. After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (62 mg, 89 %). The oil (1 
eq, 0.072 mmol, 58 mg) and phenylsilane (8 eq, 0.576 mmol, 71 µI) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.036 mmol, 
42 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (23 mg, 38 %). 
1H-NMR (DMS0-d6, 700 MHz): o [ppm] 3.02 (dd, J1 = 16.75, J2= 8.68 Hz, 1 H), 3.12 (dd, J1 = 
16.75, J2= 5.39 Hz, 1 H), 3.78 (s, 3H), 3.92 (s,3H), 4.94 (dd, J1 = 13.76, J2= 8.08 Hz, 1 H), 
7.21 (d, J = 8.68 Hz, 2H), 7.41 (t, J = 8.68 Hz, 2H), 7.58 (t, J = 8.40 Hz, 2H), 7.76 (d, J = 8.38 
Hz, 2H), 7.81 (m, 3H), 7.88 (dd, J1 = 8.68, J2 = 5.09 Hz, 2H), 7.97 (d, J = 8.68 Hz, 2H), 8.03 
(d, J= 8.68 Hz, 1H), 8.95 (d, J= 7.78 Hz, 1H), 9.63 (s, 1H), 10.47 (s, 1H), 10.68 (s, 1H), 
11.12 (s, 1H), 11.47 (s, 1H). 
HRMS (ESI): [M+H]+ calculated: 841.1934 
found: 841.1929 
[M+Na]+ calculated: 863.1753 
found: 863.1746 
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Compound 49 
The amine (1 eq, 0.087 mmol, 70 mg) and DIPEA (7 eq, 0.611 mmol, 0.100ml) were 
dissolved in dry THF (5 ml) under an atmosphere of argon. 4-Methoxy-sulfonic carbonyl 
chloride (3 eq, 0.262 mmol, 54 mg) was added an the reaction mixture was stirred for 12 
hours and the reaction was quenched by the addition of water.After removing the organic 
solvent under reduced pressure the aqueous phase was extracted with EtOAc (3 x 50 ml). 
The organic phase was washed with saturated NaHC03 solution (2 x 50 ml), aqueous HCI 
solution (5 %, 2 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). After drying over Na2SÜ4 
and filtration, the solvent was removed under reduced pressure. Column chromatography 
(CHCl3:MeOH; 1.5 % MeOH) yielded the product as an orange oil (23 mg, 26 %). The oil (1 
eq, 0.022 mmol, 22 mg) and phenylsilane (8 eq, 0.181 mmol, 0.022 ml) were dissolved in dry 
THF under an atmosphere of argon and exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.011 mmol, 
13 mg) was added and the mixture was stirred 12 h at room temperature. After adding 3 
drops of acetic acid the solvent was removed under reduced pressure. The product was 
isolated after preparative HPLC purification as a white powder (9 mg, 46 %). 
1H-NMR (DMS0-d6, 700 MHz): o [ppm] 3.02 (dd, J1 = 16.75, J2= 8.68 Hz, 1 H), 3.12 (dd, J1 = 
16.75, J2 = 5.39 Hz, 1 H), 3.78 (s, 3H), 3.92 (s,3H), 4.94 (dd, J1 = 13.76, J2= 8.08 Hz, 1 H), 
7.21 (d, J = 8.68 Hz, 2H), 7.41 (t, J = 8.68 Hz, 2H), 7.58 (t, J = 8.40 Hz, 2H), 7.76 (d, J = 8.38 
Hz, 2H), 7.81 (m, 3H), 7.88 (dd, J1 = 8.68, J2 = 5.09 Hz, 2H), 7.97 (d, J = 8.68 Hz, 2H), 8.03 
(d, J = 8.68 Hz, 1 H), 8.95 (d, J = 7.78 Hz, 1 H), 9.63 (s, 1 H), 10.47 (s, 1 H), 10.68 (s, 1 H), 
11.12 (s, 1H), 11.47 (s, 1H). 
HRMS (ESI): [M+H]+ calculated: 841.1934 
found: 841.1929 
[M+Na]+ calculated: 863.1753 
found: 863.1746 
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Compound 50 
General deprotection of compound 53 
1H-NMR (DMS0-d6, 500 MHz): o [ppm]3.08 (dd, J1 = 16.84 Hz, J2= 8.72 Hz, 1H), 3.18 (m, 
1 H), 3.77 (s, 3H), 3.90 (s, 3H), 5.02 (m, 1 H), 7.55 (d, J= 8.92 Hz, 2H), 7.79 (m, 3H), 7.97 (m, 
3H), 8.17 (d, J = 8.72 Hz, 2H), 8.37 (d, J = 8.72 Hz, 2H), 9.53 (d, J = 7.53 Hz, 1 H), 9.68 (s, 
1 H), 10.62 (s, 1 H), 11.09 (s, 1 H), 11.54 (bs, 1 H). 
HRMS (ESI): [M+H]+ calculated: 713.1838 
found: 713.1862 
Compound 51 
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General deprotection of compound 54 
1H-NMR (DMS0-d6, 500 MHz): o [ppm] 3.03 (d, J1 = 16.84 Hz, J2 = 8.72 Hz, 1 H), 3.11 (m, 
1 H), 3.77 (s, 3H), 3.91 (s, 3H), 4.92 (m, 1 H), 6.63 (d, J = 8.52 Hz, 2H), 7.33 (m, 1 H), 7.58 (m, 
3H), 7.68 (d, J = 8.52 Hz, 2H), 7.79 (m, 3H), 7.97 (d, J = 8.52 Hz, 2H), 8.05 (d, J = 8.92 Hz, 
1 H), 8.64 (d, J = 7.73 Hz, 1 H), 9.68 (s, 1 H), 10.51 (s, 1 H), 11.17 (s, 1 H), 11.53 (bs, 1 H). 
HRMS (ESI): [M+H]+ calculated: 683.2096 
found: 683.2123 
[M+Na]+ calculated: 705.1916 
found: 705.1940 
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Compound 52 
( S)-4-(3-Cyano-2-( 4-nitrobenzamido )propanamido )benzoic acid 
( S)-tert-Butyl 4-(2-(tert-butoxycarbonylamino )-3-cyanopropanamido)benzoate (56) (1.0 eq, 
0.81 mmol, 314 mg) was dissolved in HCl/dioxane (4 M, 5 ml) and the reaction mixture was 
stirred at room temperature until cleavage of the Boc group and tert-butyl ester was 
completed (lC/MS monitoring, approximately 6 hours). The solvent was removed under 
reduced pressure and the residue resolved in dry DMF (10 ml) under argon atmosphere. 
Triethylamine (3.0 eq, 2.42 mmol, 0.73 ml) and 2,5-dioxopyrrolidin-1-yl 4-nitrobenzoate (1.1 
eq, 0.89 mmol, 234 mg) were added and the mixture was stirred at room temperature for 16 
h. EtOAc (50 ml) was added and the mixture was washed successively with brine (3 x 25 
ml), saturated NaHC03 solution (2 x 25 ml), HCI (5 %, 2 x 25 ml) and brine (1 x 25 ml). 
The organic phase was dried over Na2SÜ4, filtered and the solvent was removed under 
reduced pressure. Column chromatography (CHCl3:CH3QH - 9:0.5) yielded the product as a 
white solid (119 mg, 39 %) 
Compound 53 
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Allyl 2-(allyloxy)-4-(2-(allyloxy)-3-methoxy-4-nitrobenzamido)-3-methoxybenzoate (63) (1.0 
eq, 2.41 mmol, 1.2 g) and SnC'2*2H20 (7.0 eq, 16.86 mmol, 3.8 g) were dissolved in EtOH 
(40 ml) and stirred at 60 °C for 1 h. The solution was concentrated under reduced pressure 
and diluted with water (100 ml). The pH was adjusted to 8-9 by adding saturated NaHC03 
solution and the aqueous suspension was extracted with EtOAc (3 x 250 ml). The phases 
were separated and the organic phase was washed with brine (1 x 250 ml), dried over 
Na2SÜ4 and filtered. After removing the solvent under reduced pressure, column 
chromatography (H:EA - 3:1) yielded the product as an orange oil (892 mg, 79 %). 
Compound 54 
( S)-Allyl 2-( allyloxy)-4-(2-( allyloxy)-4-( 4-(3-cyano-2-( 4-nitrobenzam ido )propanamido) 
benzam ido )-3-methoxybenzamido )-3-methoxybenzoate 
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Bis-(trichloromethyl)carbonate (0.5 eq, 0.13 mmol, 37 mg) and ( S)-4-(3-Cyano-2-(4-
nitrobenzamido)propanamido)benzoic acid (52) (1.5 eq, 0.38 mmol, 146 mg) were dissolved 
in dry THF (3 ml) under argon atmosphere. 2,4,6-Collidine (8.0 eq, 2.04 mmol, 270 DL) was 
added slowly via syringe. The resulting suspension was stirred at room temperature for 1 h 
and a solution of (53) (1.0 eq, 0.26 mmol, 119 mg), DIPEA (10.0 eq, 2.55 mmol, 430 DL) in 
dry THF (2 ml) was added. Stirring was continued for 20 h at room temperature and the 
reaction was quenched by addition of MeOH (2 ml). The organic solvent was removed under 
reduced pressure and EtOAc (20 ml) was added. The mixture was washed successively 
with saturated NaHC03 (2 x 10 ml), HCI (5 %, 2 x 10 ml), water (1 x 10 ml) and brine (1 x 
10 ml). The organic solvent was dried over Na2SÜ4, filtered and removed under reduced 
pressure. Purification by column chromatography (H:EA - 1 :1) yielded the product as a white 
solid (115 mg, 54 %). 
Compound 55 
(S)-Allyl 2-( allyloxy)-4-(2-( allyloxy)-4-( 4-(2-( 4-aminobenzam ido )-3-cyanopropanamido) 
benzam ido )-3-methoxybenzamido )-3-methoxybenzoate 
OAllyl 
1 
OAllyl OXYCOOAllyl Ill ~I OO ~ N ~ 
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(S)-Allyl 2- (allyloxy) -4- (2- (allyloxy) -4- (4- (3-cyano -2- (4-nitrobenzamido) propanamido) 
benzamido)-3-methoxybenzamido)-3-methoxybenzoate (54) (1.0 eq, 0.13 mmol, 106 mg) 
and SnC'2*2H20 (5.0 eq, 0.63 mmol, 143 mg) were dissolved in EtOH (10 ml) and stirred at 
60 °C for 6 h. The solution was concentrated under reduced pressure and diluted with water 
(10 ml). The pH was adjusted to 8-9 by adding saturated NaHC03 solution and the aqueous 
suspension was extracted with EtOAc (3 x 50 ml). The phases were separated and the 
organic phase was washed with brine (1 x 25 ml), dried over Na2SÜ4 and filtered. After 
removing the solvent under reduced pressure, column chromatography (CHCl3:CH3QH -
9:0.3) yielded the product as a slightly yellow solid (69 mg, 67 %). 
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Compound 56 
( S)-tert-Butyl 4-(2-( tert-butoxycarbonylamino )-3-cyanopropanamido )benzoate 
0 /:"", BocHN * COOH 
Method A: 
Boc-l-Asn-OH (1.0 eq, 4.31 mmol, 1.0 g), DIPEA (5.0 eq, 21.53 mmol, 3.7 ml) and HATU 
(2.0 eq, 8.61 mmol, 3.3 g) were dissolved in dry DMF (40 ml) under argon atmosphere. After 
stirring for 10 min at room temperature tert-butyl 4-aminobenzoate (1.0 eq, 4.31 mmol, 0.8 g) 
was added and stirring was continued for 19 h. EtOAc (200 ml) was added and the mixture 
was washed successively with brine (3 x 80 ml), saturated NaHC03 solution (2 x 80 ml), 
HCI (5 %, 2 x 80 ml) and brine (1 x 80 ml). The organic phase was dried over MgS04, 
filtered and the solvent was removed under reduced pressure. Column chromatography 
(H:EA - 4:1) yielded the product as a white solid (1.4 g, 84 %). 
Method B: 
Boc-l-Asn-OH (1.0 eq, 4.31 mmol, 1.0 g), DIPEA (5.0 eq, 21.53 mmol, 3.7 ml) and HATU 
(2.0 eq, 8.61 mmol, 3.3 g) were dissolved in dry DMF (40 ml) under argon atmosphere. After 
stirring for 10 min at room temperature tert-butyl 4-aminobenzoate (1.0 eq, 4.31 mmol, 0.8 g) 
was added and stirring was continued for 19 h. EtOAc (200 ml) was added and the mixture 
was washed successively with brine (3 x 80 ml), saturated NaHC03 solution (2 x 80 ml), 
HCI (5 %, 2 x 80 ml) and brine (1 x 80 ml). The organic phase was dried over MgS04, 
filtered and the solvent was removed under reduced pressure. Column chromatography 
(H:EA - 4:1) yielded the product as a white solid (1.4 g, 84 %). 
Boc-l-Asn-OH (2.0 eq, 2.07 mmol, 481 mg) and DCC (4.0 eq, 4.14 mmol, 854 mg) are 
dissolved in dry DMF (10 ml) under an atmosphere of argon. tert-butyl 4-aminobenzoate 
(1.0 eq, 1.04 mmol, 200 mg) is added and the reaction mixture is stirred at room temperature 
for 12 h. EtOAc (50 ml) is added and the mixture is washed with brine (3 x 20 ml). The 
mixture was washed successively with brine (3 x 80 ml), saturated NaHC03 solution (2 x 20 
ml), HCI (5 %, 2 x 20 ml) and brine (1 x 20 ml). The organic phase was dried over MgS04, 
filtered and the solvent was removed under reduced pressure. Column chromatography 
(H:EA - 4:1) yielded the product as a white solid (331 mg, 65 %). 
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Compound 63 
Allyl 2-( allyloxy)-4-(2-( allyloxy)-3-methoxy-4-n itrobenzamido )-3-methoxybenzoate 
Bis-(trichloromethyl)carbonate (0.5 eq, 1.31 mmol, 388 mg) and 2-(allyloxy)-3-methoxy-4-
nitrobenzoic acid (1.5 eq, 4.01 mmol, 1014 mg) were dissolved in dry THF (25 ml) under 
argon atmosphere. 2,4,6-Collidine (8.0 eq, 21.38 mmol, 2.8 ml) was added slowly via 
syringe. The resulting suspension was stirred at room temperature for 15 min and a solution 
of allyl 2-(allyloxy)-4-amino-3-methoxybenzoate (1.0 eq, 2.67 mmol, 703 mg), DIPEA (10.0 
eq, 26.72 mmol, 4.5 ml) in dry THF (25 ml) was added. Stirring was continued for 11 h at 
room temperature and the reaction was quenched by addition of water (10 ml). The organic 
solvent was removed under reduced pressure and EtOAc (70 ml) was added. The mixture 
was washed successively with saturated NaHC03 (2 x 25 ml), HCI (5 %, 2 x 25 ml), water 
(1 x 25 ml) and brine (1 x 25 ml). The organic solvent was dried over Na2SÜ4, filtered and 
removed under reduced pressure. Purification by column chromatography (heaxane (H): 
ethyl acetate (EA); H:EA- 8:1) yielded the product as a slightly yellow oil (1.2 g, 91 %). 
Compound 64 
PGH O ~ COQ 
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Free amine (1.0 eq) and aldehyde (1.0 eq) were dissolved in MeOH and acetic acid (3.5 eq) 
was added. To this solution NaBH3CN (1.2 eq) was added and the mixture was stirred for 16 
h at room temperature. The reaction mixture was quenched with saturated NaHC03 solution 
and extracted with EtOAc. The organic solvent was dried over Na2SÜ4, filtered and removed 
under reduced pressure. The residue was dissolved in 4 N HCI in dioxane. After 5 h of 
stirring at room temperature the organic solvent was removed under reduced pressure. The 
residue was dissolved in 10% NaHC03 and filtrated. Acidification with conc. HCI precipitated 
the pure carboxylic acid which was isolated by filtration 
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Compound 66 
Boc-Gly-OH (2.0 eq, 20.8 mmol, 3.64 g), DIPEA (5.0 eq, 52.0 mmol, 8.8 ml) and HATU (1.9 
eq, 19.8 mmol, 7.51 g) were dissolved in dry DMF (200 ml) under argon atmosphere. After 
stirring for 10 min at room temperature tert-butyl 4-aminobenzoate (1.0 eq, 10.4 mmol, 2.00 
g) was added and stirring was continued for 18 h. EtOAc (400 ml) was added and the 
mixture was washed successively with brine (3 x 160 ml), saturated NaHC03 solution (2 x 
160 ml), HCI (5 %, 2 x 160 ml) and brine (1 x 160 ml). The organic phase was dried over 
Na2S04, filtered and the solvent was removed under reduced pressure. Column 
chromatography (H:EA - 5:2) yielded the product as a white solid (3.15 g, 86 %). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 1.38 (s, 3H), 1.52 (s, 3H), 3.73 (d, J = 6.18 Hz, 2H), 
7.07 (t, J = 6.04 Hz, 1 H), 7.68 (d, J = 8.60 Hz, 2H), 7.84 (d, J = 8.87 Hz, 2H), 10.23 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 351.1914 
found: 351.1911 
[M+Na]+ calculated: 373.1734 
found: 373.1729 
Compound 68 
Compound (66) (1.0 eq, 8.57 mmol, 3.0 g) was dissolved in HCl/dioxane (4 M, 20 ml) and 
the reaction mixture was stirred at room temperature until cleavage of the boc group and tert-
butyl ester was completed (lC/MS monitoring, approximately 6 hours). The solvent was 
removed under reduced pressure and the residue resolved in dry DMF (25 ml) under argon 
atmosphere. Triethylamine (2.0 eq, 17.14 mmol, 2.4 ml) and 2,5-dioxopyrrolidin-1-yl 4-
nitrobenzoate (1.1 eq, 9.43 mmol, 2.5 g) were added and the mixture was stirred at room 
temperature for 16 h. EtOAc (300 ml) was added and the mixture was washed successively 
with HCI (5 %, 1 x 100 ml) and brine (3 x 100 ml). The product was filtered and lyophilized 
and obtained as a white solid (1.6 g, 54 %, two steps). 
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1H-NMR (dmso-d6, 400 MHz): o [ppm] 4.14 (d, J= 5.64 Hz, 2H), 7.73 (d, J= 8.87 Hz, 2H), 
7.90 (d, J = 8.60 Hz, 2H), 8.14 (d, J = 9.13 Hz, 2H), 8.35 (d, J = 8.87 Hz, 2H), 9.27 (t, J = 






MeOXYC02Allyl OAllylO "' I 
MeO~ ~ 0 I N 




Bis-(trichloromethyl)carbonate (1.15 eq, 0.61 mmol, 182 mg) and (68) (3.5 eq, 1.87 mmol, 
641 mg) were dissolved in dry THF (15 ml) under argon atmosphere. 2,4,6-Collidine (8.0 eq, 
4.27 mmol, 0.6 ml) was added slowly via syringe. The resulting suspension was stirred at 
room temperature for 1 h and a solution of (53) (1.0 eq, 0.53 mmol, 250 mg), DIPEA (10.0 
eq, 5.34 mmol, 0.9 ml) in dry THF (10 ml) was added. Stirring was continued for 20 h at 
room temperature and the reaction was quenched by addition of water (10 ml). The organic 
solvent was removed under reduced pressure and EtOAc (50 ml) was added. The mixture 
was washed successively with saturated NaHC03 (2 x 20 ml), HCI (5 %, 2 x 20 ml), water 
(1 x 20 ml) and brine (1 x 20 ml). The organic solvent was dried over Na2SÜ4, filtered and 
removed under reduced pressure. Purification by column chromatography (C:M - 18:1) 
yielded the product as a white solid (228 mg, 54 %). 
1 H-NMR (dmso-d6, 400 MHz): o [ppm] 3.92 (s, 3H), 3.93 (s, 3H), 4.16 (d, J = 5.91 Hz, 2H), 
4.45 (d, J = 5.64 Hz, 2H), 4.78 (d, J = 5.64 Hz, 2H), 4.80 (d, J = 6.18, 2H), 5.27 (m, 3H), 5.40 
(m, 3H), 6.08 (m, 3H), 7.57 (d, J = 8.87 Hz, 1 H), 7.80 (m, 3H), 7.93 (d, J = 8.87 Hz, 1 H), 7.98 
(d, J = 8.87 Hz, 2H), 8.15 (d, J = 8.87 Hz, 2H), 8.33 (d, J = 8.87 Hz, 1 H), 8.37 (d, J = 8.87 
Hz, 2H), 9.27 (t, J = 5.78 Hz, 1 H), 10.46 (s, 1 H), 10.66 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 794.2668 
found: 794.2678 
[M+Na]+ calculated: 816.2487 
found: 816.2497 
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Compound 70 
OAllyl 
MeOÙC02Allyl OAllylO -, I MeOB ~ 0 I N 
H2NY') 0 ~N ~ H 
~~0N~ H 
0 H 70 
Compound (69) (1.0 eq, 0.26 mmol, 200 mg) and SnC'2*2H20 (7.0 eq, 1.80 mmol, 400 mg) 
were dissolved in EtOH (10 ml) and stirred at 60 °C for 3 h when another portion of 
SnC'2*2H20 (3.5 eq, 0.90 mmol, 200 mg) and the stirring continued for another 3 h. The 
solution was concentrated under reduced pressure and diluted with EtOAc (200 ml). 
Saturated NaHC03 solution (400 ml) was added and extracted with EtOAc (2 x 300 ml). 
The phases were separated and the organic phase was washed with brine (1 x 400 ml), 
dried over Na2SÜ4 and filtered. After removing the solvent under reduced pressure, column 
chromatography (CHCl3:CH3QH - 1.5 % MeOH) yielded the product as a slightly yellow solid 
(140 mg, 71 %). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 3.92 (s, 3H), 3.93 (s, 3H), 4.04 (d, J = 5.91 Hz, 2H), 
4.54 (d, J = 5.91 Hz, 2H), 4.79 (m, 4H), 5.33 (m, 6H), 5.67 (s, 2H), 6.08 (m, 3H), 6.57 (d, J = 
8.60 Hz, 2H), 7.57 (d, J = 8.87 Hz, 1 H), 7.63 (d, J = 8.60 Hz, 2H), 7.79 (m, 3H), 7.95 (m, 
3H), 8.34 (d, J = 8.87 Hz, 1 H), 8.40 (t, J = 5.78 Hz, 1 H), 9.66 (s, 1 H), 10.35 (s, 1 H), 10.66 (s, 
1 H). 





0 0 ~ 
HOY') I H ~eo~~ ,.. 
~NY) 0 ~N~ 
O ~~~N~ H 
0 H 
70 
BTC (2.0 eq, 0.19 mmol, 56 mg) was dissolved in dry THF (5 ml) under an atmospher of 
argon. (E)-3-(4-(allyloxy)phenyl)-2-methylacrylic acid (6.0 eq, 0.56 mmol, 123 mg) was 
added. syn-Collidine (8.0 eq, 0.94 mmol, 0.1 ml) was slowly added via syrringe and the white 
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suspension was stirred at room temperature for 20 min. 18 (1 eq, 0.09 mmol, 72 mg) and 
DIPEA (10 eq, 1.13 mmol, 0.19 ml) dissolved in dry THF (5 ml) were added via syrringe. 
The reaction mixture was stirred for 4 h at room temperature and quenched by the addition of 
water. After removing the organic solvent under reduced pressure the aqueous phase was 
extracted with EtOAc (3 x 40 ml). The organic phase was washed with saturated NaHC03 
solution (2 x 25 ml), aqueous HCI solution (5 %, 2 x 25 ml), water (1 x 25 ml) and brine (1 x 
25 ml). After drying over Na2SÜ4 and filtration, the solvent was removed under reduced 
pressure. Column chromatography (CHCl3:MeOH; 1.5 % MeOH) yielded the product as an 
orange oil (61 mg, 67 %). The oil (1 eq, 0.06 mmol, 56 mg) and phenylsilane (8 eq, 0.47 
mmol, 0.057 ml) were dissolved in dry THF (5 ml) under an atmosphere of argon and 
exclusion of light. Pd[P(Ph)3]4 (0.5 eq, 0.03 mmol, 34 mg) was added and the mixture was 
stirred 12 h at room temperature. After adding 3 drops of acetic acid the solvent was 
removed under reduced pressure. The product was isolated by preparative HPlC purification 
as a white powder (8 mg, 17 %). 
1 H-NMR (DMS0-d6, 700 MHz): o [ppm] 2.12 (s, 3H), 3. 78 (s, 3H), 3.92 (s, 3H), 4.11 (d, J = 
5.31 Hz, 2H), 6.85 (d, J = 8.47, 2H), 7.27 (s, 1 H), 7.36 (d, J = 8.47 Hz, 2H), 7.59 (t, J = 9.28 
Hz, 2H), 7.81 (m, 5H), 7.89 (d, J = 9.59 Hz, 2H), 7.98 (d, J = 7.77 Hz, 2H), 8.07 (d, J = 9.03 
Hz, 1 H), 8.81 (t, J = 5.39 Hz, 1 H), 9.71 (s, 1 H), 9.80 (s, 1 H), 8.81 (s, 1 H), 10.42 (s, 1 H), 
11.20 (s, 1 H), 11.56 (s, 1 H), 11.63 (bs, 1 H). 
HRMS (ESI): [M-HJ- calculated: 802.2355 
found: 802.2362 
Compound 71 
Al lyl 2-al lyloxy-4-[[2-al lyloxy-4-[[ 4-[[ ( 2S )-2-[[ 5-[[ ( E)-3-( 4-al lyloxyph enyl)-2-methyl-prop-2-
en oyl]am ino ]pyridine-2-carbonyl]amino ]-3-cyano-propanoyl]amino ]benzoyl]am ino ]-3-
methoxy-benzoyl]am ino ]-3-methoxy-benzoate (65 mg, 0.065 mmol, 1.00 eq), was dissolved in 
THF (5 ml). Phenylsilane (56 mg, 64 µI, 0.518 mmol, 8.00 eq) and [Pd(PPh3)4] (38 mg, 0.032 
mmol, 0.50 eq) were added and the mixture was stirred for 16 h. After adding 3 drops of acetic 
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acid the solvent was removed and the crude product was purified via HPLC chromatography 
to give the product as a white solid (42 %). 
1H-NMR (400 MHz, DMS0-d6): 3.21 - 3.27 (m, 2H), 3.77 (s, 3H), 3.91 (s, 3H), 5.02- 5.07 (m, 
1 H), 6.85 (d, J = 8.6 Hz, 2H), 7.34 (s, 1 H), 7.38 (d, J = 8.6 Hz, 2H), 7.55 - 7.60 (m, 3H), 7.76 
- 7.82 (m, 2H), 7.99 (d, J = 8.6 Hz, 2H), 8.04 - 8.09 (m, 2H), 8.36 - 8.39 (m, 1 H), 9.02 (s, 









1 OH O I ~ OH 
1 h h ~'Oy O r-:"NJN I h H 
0 ~ 1 ~0N)l) H 
= H 
O 'CN 
Chemical Formula: C43H37N7012 
Exact Mass: 843,2500 
Al lyl 2-al lyloxy-4-[[2-al lyloxy-4-[[ 5-[[ ( 2S )-2-[[ 4-[[ ( E)-3-( 4-al lyloxyph enyl)-2-methyl-prop-2-
en oyl]am ino ]benzoyl]amino ]-3-cyano-propanoyl]am ino ]pyridine-2-carbonyl]amino ]-3-
methoxy-benzoyl]am ino ]-3-methoxy-benzoate (1.00 eq) was dissolved in THF. Phenylsilane 
(8.00 eq) and [Pd(PPh3)4] (0.50 eq) were added and the mixture was stirred for 16 h. After 
adding 3 drops of acetic acid the solvent was removed and the crude product was purified via 
HPLC chromatography to give the product as a solid. 
Compound 73 
1 OH 0 
1 OH o
0ijoH 
HO~ I H 0 o~~ ,,; 
~NVy O r-:"NJN)l) 
O ~ 1 ~~ )l) H 
N . N 
= H 
O 'cN 
Chemical Formula: C42H36N80 12 
Exact Mass: 844,2453 
Al lyl 2-al lyloxy-4-[[2-al lyloxy-4-[[ 5-[[ ( 2S )-2-[[ 5-[[ ( E)-3-( 4-al lyloxyph enyl)-2-methyl-prop-2-
en oyl]am ino ]pyridine-2-carbonyl]amino ]-3-cyano-propanoyl]amino ]pyridine-2-
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carbonyl]amino]-3-methoxy-benzoyl]amino]-3-methoxy-benzoate (1.00 eq) was dissolved in 
THF. Phenylsilane (8.00 eq) and [Pd(PPh3)4] (0.50 eq) were added and the mixture was stirred 
for 16 h. After adding 3 drops of acetic acid the solvent was removed and the crude product 
was purified via HPLC chromatography to give the product as a solid. 
Compound 74 





1 H O,, /? 1 H 
~ .o N~ 0 r(YS'N .o 
0 ~ 1 ~J ~ H 
. N 
0 = H 
'CN 
Chemical Formula: C43H3sN5013S 
Exact Mass: 878,2218 
Al lyl 2-al lyloxy-4-[[2-al lyloxy-4-[[ 4-[[ ( 2S )-2-[[ 4-[[ ( E)-3-( 4-al lyloxyph enyl)-2-methyl-prop-2-
enoyl]am i no ]benzoyl]am in o ]-3-cyan o-propan oyl (1.00 eq) was dissolved in THF. Phenylsilane 
(8.00 eq) and [Pd(PPh3)4] (0.50 eq) were added and the mixture was stirred for 16 h. After 
adding 3 drops of acetic acid the solvent was removed and the crude product was purified via 
HPLC chromatography to give the product as a solid. 
Compound 75 
1 OH O ~ I OH 
~ 1 0 ~y') O ~N ~ 1 H 
0 ~s--~JN)l) H 
cf 'ü ~ H 
'cN 
Chemical Formula: C43H3sN5013S 
Exact Mass: 878,2218 
Al lyl 2-al lyloxy-4-[[2-al lyloxy-4-[[ 4-[[ ( 2S )-2-[[ 4-[[ ( E)-3-( 4-al lyloxyph enyl)-2-methyl-prop-2-
enoyl]am ino ]phenyl]su lfonylamino ]-3-cyano-propanoyl]am ino ]benzoyl]amino ]-3-methoxy-
benzoyl]amino ]-3-methoxy-benzoate (1.00 eq) was dissolved in THF. Phenylsilane (8.00 eq) 
and [Pd(PPh3)4] (0.50 eq) were added and the mixture was stirred for 16 h. After adding 3 
drops of acetic acid the solvent was removed and the crude product was purified via HPLC 
chromatography to give the product as a solid. 
Compound 76 
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OH O 
O=~-OH O ~OH 
0
~H o~NYoH ::::,...l~N dl~HOMe Y) 0 ~ N OH 
0 ~~yÂN 1 ~ H OMe 
0 : H 
'cN 
Allyl 2-allyloxy-4-[[2-allyloxy-4-[[4-[[(2S)-3-cyano-2-[[4-[[(E)-3-(4-diallyloxyphosphoryloxy 
phenyl)-2-methyl-prop-2-enoyl]amino ]benzoyl]am ino ]propanoyl]am ino ]benzoyl]am ino ]-3-
methoxy-benzoyl]am ino ]-3-methoxy-benzoate (1 eq, 0.0534 mmol, 60 mg) with phenylsilane 
(20 eq, 1.07 mmol, 132 µI) dissolved in dry THF under an atmosphere of argon and exclusion 
of light. Pd[P(Ph)3]4 (1 eq, 0.0534 mmol, 62 mg) was added and the mixture was stirred 12 h 
at room temperature. After adding 3 drops of acetic acid the solvent was removed under 




2-Hydroxy-4-nitrobenzoic acid (1.0 eq, 27.32 mmol, 5.0 g) was dissolved in DMF (150 ml) 
and K2CÜ3 (4.0 eq, 109.28 mmol, 15.1 g) were added. Allyl-Br (3.0 eq, 81.96 mmol, 7.1 ml) 
were slowly added via syringe and the reaction mixture was stirred 12 h at room 
temperature. lt was diluted with EtOAc (200 ml) and washed with brine (3 x 100 ml). The 
organic solvent was dried over Na2SÜ4, filtered and purified by column chromatography 
(H:EE - 10:1 ). The product was isolated as an orange oil (6.5 g, 90 %). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 4.80 (m, 4H), 5.27 (m, 2H), 5.42 (m, 2H), 6.01 (m, 2H), 
7.87 (m, 3H). 
HRMS (ESI): [M+H]+ calculated: 264.0866 
found: 264.0869 
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2-(Allyloxy)-4-nitrobenzoic acid 
Allyl 2-(allyloxy)-4-nitrobenzoate (1.0 eq, 3.72 mmol, 1.0 g) was dissolved in THF (50 ml) 
and MeOH (75 ml). KOH (5.0 eq, 18.58 mmol, 1.0 g) dissolved in H20 (50 ml) was added 
and the reaction mixture was stirred at room temperature for 23 h. The organic solvents were 
removed and the aqueous phase acidified with HCI (5%) and the product was filtered and 
freeze dried. The product was isolated as a white solid (775 mg, 94%). 
1H-NMR (dmso-d6, 500 MHz): o [ppm] 4.81 (d, J = 4.76 Hz, 2H), 5.30 (m, 1 H), 5.49 (m, 1 H), 
6.05 (m, 1 H), 7.84 (m, 3H). 
HRMS (ESI): [M-HJ- calculated: 222.0397 
found: 222.0400 
Allyl 2-(allyloxy)-4-aminobenzoate 
Allyl 2-(allyloxy)-4-nitrobenzoate (1.0 eq, 3.80 mmol, 1.0 g) was dissolved in EtOH (20 ml), 
SnC'2*2H20 (5.0 eq, 19.0 mmol, 4.3 g) was added and the reaction mixture was stirred at 60 
°C for 4 h. The solvent was removed under reduced pressure and the residue diluted with 
EtOAc (100 ml). Saturated NaHCQ3-solution (300 ml) was added and after phase 
separation the aqueous phase was extracted with EtOAc (2 x 200 ml). The organic solvent 
was washed with brine (1 x 400 ml), dried over Na2SÜ4, filtered and removed under reduced 
pressure. The product was obtained after column chromatography (H:EE - 3:1) as a yellow 
oil (779 mg, 88%). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 4.49 (m, 2H), 4.63 (m, 2H), 5.22 (m, 2H), 5.35 (m, 
1 H), 5.53 (m, 1 H), 6.01 (m, 4H), 6.18 (m, 2H), 7.55 (d, J = 8.33 Hz, 1 H). 
HRMS (ESI): [M+H]+ calculated: 234.1125 
found: 234.1115 
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Allyl 3-methoxy-4-nitrobenzoate 
3-Methoxy-4-nitrobenzoic acid (1.0 eq, 5.07 mmol, 1.0 g) and K2CÜ3 (2.0 eq, 10.15 mmol, 
1.4 g) were dissolved in DMF (20 ml) and Allyl-Br (1.2 eq, 6.09 mmol, 0.5 ml) was added. 
The reaction mixture was stirred at room temperature for 20 h and diluted with EtOAc (100 
ml). Water (100 ml) was added and the phases were separated. The organic phase was 
washed with brine (3 x 100 ml), dried over Na2SÜ4, filtered and removed under reduced 
pressure. The product was obtained after column chromatography (H:EE - 10:1) as a 
colorless oil (1.2 g, 98%). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 4.00 (s, 3H), 4.86 (m, 2H), 5.31 (m, 1 H), 5.43 (m, 1 H), 
6.06 (m, 1 H), 7.69 (dd, J1 = 8.33 Hz, J2 = 1.61 Hz, 1 H), 7.78 (d, J = 1.34 Hz, 1 H), 8.00 (d, J = 
8.33 Hz, 1 H). 
HRMS (ESI): [M+Na]+ calculated: 260.0529 
found: 260.0236 
Allyl 4-amino-3-methoxybenzoate 
Allyl 3-methoxy-4-nitrobenzoate (1.0 eq, 4.64 mmol, 1.1 g) and SnC'2*2H20 (5.0 eq, 23.20 
mmol, 5.2 g) were dissolved in EtOH (50 ml). The reaction mixture was stirred for 6 h at 60 
°C and the solvent was removed under reduced pressure. The residue was diluted with 
EtOAc (100 ml) and saturated NaHC03 (50 ml) was added. After separating the phases, 
the aqueous phase was extracted with EtOAc (100 ml). The combined organic layers were 
washed with brine (1 x 200 ml), dried over Na2SÜ4 and filtered. After removing the solvent 
under reduced pressure the product was obtained after column chromatography (H:EE - 3:1) 
as a brown oil (720 mg, 75%). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 3.81 (s, 3H), 4.71 (m, 2H), 5.23 (m, 1 H), 5.36 (m, 1 H), 
5.67 (s, 2H), 6.02 (s, 1 H), 6.66 (d, J = 8.33 Hz, 1 H), 7.31 (d, J = 1.61 Hz, 1 H), 7.42 (dd, J1 = 
8.19 Hz, J2= 1.75 Hz, 1H). 










2-Hydroxy-3-methoxy-4-nitrobenzaldehyde (1.0 eq, 72 mmol, 14.25 g) was dissolved in DMF 
(400 ml) and K2C03 (2.0 eq, 145 mmol, 20.00 g) was added. Allyl bromide (1.5 eq, 108 
mmol, 9.4 ml) was added via syringe and the mixture was stirred at room temperature for 12 
h. EtOAc (500 ml) was added and the mixture was washed with brine (3 x 200 ml). After 
drying over Na2S04 and filtration the solvent was removed under reduced pressure. 
Purification by column chromatography (H:EA - 10:1) yielded the product as an orange oil 
(14.0 g, 82 %). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 3.95 (s, 3H), 4.71 (s, 2H), 5.29 (dd, J1 = 10.48 Hz, J2 = 
1.61 Hz, 1 H), 5.41 (dd, J1 = 17.19 Hz, J2 = 1.34 Hz, 1 H), 6.12 (m, 1 H), 7.61 (d, J = 8.60 Hz, 
1H), 7.74 (d, J= 8.33 Hz, 1H), 10.28 (s, 1H). 
HRMS (ESI): [M+H]+ calculated: 238.0710 
found: 238.0750 
2-(Allyloxy)-3-methoxy-4-nitrobenzoic acid 
2-(Allyloxy)-3-methoxy-4-nitrobenzaldehyde (1.0 eq, 5.87 mmol, 1.39 g) was dissolved in 
tBuOH (44 ml) and 2-methylbut-2-ene (1.2 mUmmol) and NaCI02 (1.2 eq, 7.04 mmol, 0.8 g 
- 80 %) in NaH2PÜ4 (0.5 M in water, 7 ml) was added. The mixture was stirred at room 
temperature for 3 h and the solvent was removed under reduced pressure. After diluting with 
water the pH was adjusted to 2 (5 % HCI). After cooling the precipitate was filtered and dried. 
The product was obtained as a white solid (1.4 g, 92 %). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 3.90 (s, 3H), 4.57 (s, 2H), 5.24 (dd, 1 H, J1 = 10.34 Hz, 
J2 = 1.48 Hz, 1 H), 5.37 (dd, J1 = 17.19 Hz, J2 = 1.61 Hz, 1 H), 6.03 (m, 1 H), 7.52 (d, J = 8.60 
Hz, 1 H), 7.67 (d, J = 8.60 Hz, 1 H). 
HRMS (ESI): [M+H]+ calculated: 254.0659 
found: 254.0662 
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Allyl 2-(allyloxy)-3-methoxy-4-nitrobenzoate 
2-(Allyloxy)-3-methoxy-4-nitrobenzoic acid (1.0 eq, 1.76 mmol, 445 mg) was dissolved in 
DMF (10 ml) and K2CÜ3 (2.0 eq, 3.52 mmol, 486 mg) was added. Allyl iodide (1.5 eq, 2.66 
mmol, 0.24 ml) was added via syringe and the mixture was stirred at room temperature for 
12 h. EtOAc (100 ml) was added and the mixture was washed with brine (3 x 30 ml). After 
drying over Na2SÜ4 and filtration the solvent was removed under reduced pressure. 
Purification by column chromatography (H:EA - 12:1) yielded the product as an orange oil 
(471 mg, 87 %). 
1 H-NMR (dmso-d6, 400 MHz): o [ppm] 3.92 (s, 3H), 4.56 (d, J = 5.91 Hz, 1 H), 4.80 (d, J = 
5.37 Hz, 1 H), 5.32 (m, 4H), 6.02 (m, 2H), 7.58 (d, J = 8.60 Hz, 1 H), 7.71 (d, J = 8.60 Hz, 1 H). 
HRMS (ESI): [M+H]+ calculated: 294.0972 
found: 294.0990 
Allyl 2-(allyloxy)-4-amino-3-methoxybenzoate 
Allyl 2-(allyloxy)-3-methoxy-4-nitrobenzoate (1.0 eq, 1.61 mmol, 471 mg) and SnC'2*2H20 
(5.0 eq, 8.04 mmol, 1.81 g) were dissolved in EtOH (20 ml) and stirred at 60 °C for 1 h. The 
solution was concentrated under reduced pressure and diluted with water (50 ml). The pH 
was adjusted to 8-9 by adding saturated NaHC03 solution and the aqueous suspension was 
extracted with EtOAc (3 x 100 ml). The phases were separated and the organic phase was 
washed with brine (1 x 100 ml), dried over Na2SÜ4 and filtered. After removing the solvent 
under reduced pressure, column chromatography (H:EA - 8:1) yielded the product as an 
orange oil (355 mg, 84 %). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 3.67 (s, 3H), 4.43 (m, 2H), 4.64 (m, 2H), 5.19 (m, 2H), 
5.34 (m, 2H), 5.77 (s, 2H), 6.01 (m, 2H), 6.44 (d, J = 8.60 Hz, 1 H), 7.33 (d, J = 8.60 Hz, 1 H). 
HRMS (ESI): [M+H]+ calculated: 264.1230 
found: 264.1233 
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(E)-Allyl 3-(4-(allyloxy)phenyl)-2-methylacrylate 
(E)-3-(4-hydroxyphenyl)-2-methyl-prop-2-enoic acid (1.0 eq, 5.60 mmol, 1.0 g), which can be 
synthesised according to Yamamoto, A., Nakamura, K., Furukawa, K., Konishi, Y., Ogino, T., 
Higashiura, K., Yago, H., Okamoto, K., Otsuka, M., Chem. Pharm. Bull., 2002, 50, 47-52, 
was dissolved in DMF (50 ml) and K2CÜ3 (3.0 eq, 16.8 mmol, 2.32 g) was added. Allyl 
iodide (3.0 eq, 16.8 mmol, 1.53 ml was added via syringe and the mixture was stirred at 
room temperature for 12 h. EtOAc (150 ml) was added and the mixture was washed with 
brine (3 x 50 ml). After drying over Na2SÜ4 and filtration the solvent was removed under 
reduced pressure. Purification by column chromatography (H:EA - 12:1 --> 4:1)) yielded the 
product as an orange oil (1.3 g, 90 %). 
1 H-NMR (dmso-d6, 400 MHz): o [ppm] 2.08 (s, 3H), 4.62 (d, J = 4.61 Hz, 2H), 4.68 (d, J = 
5.37 Hz, 2H), 5.32 (m, 4H), 6.03 (m, 2H), 7.02 (d, J = 8.87 Hz, 1 H), 7.47 (d, J = 8.87 Hz, 1 H), 
7.60 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 259.1329 
found: 259.1335 
(E)-3-(4-(Allyloxy)phenyl)-2-methylacrylic acid 
(E)-Allyl 3-(4-(allyloxy)phenyl)-2-methylacrylate (1.0 eq, 1.93 mmol, 500 mg) and KOH (2.0 
eq, 3.86 mmol, 217 mg) were dissolved in MeOH (10 ml) and stirred for 16 h at room 
temperature. The solvent was removed under reduced pressure and the residue suspended 
in HCI (1 M, 10 ml). The aqueous phase was extracted with EtOAc (3 x 25 ml). The 
combined organic layers were washed with brine (1 x 25 ml), dried over Na2SÜ4 and filtered. 
The product was obtained as a slightly brown - white solid (384 mg, 87 %). 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 2.03 (s, 3H), 4.61 (m, 2H), 5.27 (m, 1H), 5.41 (m, 1H), 
6.06 (m, 1 H), 7.01 (d, J = 8.87 Hz, 1 H), 7.44 (d, J = 8.60 Hz, 1 H), 7.55 (s, 1 H), 12.38 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 219.1016 
found: 219.1034 
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(E)-Allyl 3-(4-(allyloxy)phenyl)-2-methylacrylate 
E)-3-(4-(Allyloxy)phenyl)-2-methylacrylic acid (1.0 eq, 5.60 mmol, 1.0 g) was dissolved in 
DMF (50 ml) and K2CÜ3 (3.0 eq, 16.8 mmol, 2.32 g) was added. Allyl iodide (3.0 eq, 16.8 
mmol, 1.53 ml was added via syringe and the mixture was stirred at room temperature for 
12 h. EtOAc (150 ml) was added and the mixture was washed with brine (3 x 50 ml). After 
drying over Na2SÜ4 and filtration the solvent was removed under reduced pressure. 
Purification by column chromatography (H:EA - 12:1 --> 4:1)) yielded the product as an 
orange oil (1.3 g, 90 %). 
1 H-NMR (dmso-d6, 400 MHz): o [ppm] 2.08 (s, 3H), 4.62 (d, J = 4.61 Hz, 2H), 4.68 (d, J = 
5.37 Hz, 2H), 5.32 (m, 4H), 6.03 (m, 2H), 7.02 (d, J = 8.87 Hz, 1 H), 7.47 (d, J = 8.87 Hz, 1 H), 
7.60 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 259.1329 
found: 259.1335 
2,5-dioxopyrrolidin-1-yl 4-nitrobenzoate 
2,5-dioxopyrrolidin-1-yl 4-nitrobenzoate can be synthesised according to Adamczyk, M., 
Fino, J., R., Org. Prep. Proced. !nt., 2009, 28, 470-474. 
Allyl 2-(allyloxy)-4-(2-(allyloxy)-3-methoxy-4-nitrobenzamido)-3-methoxybenzoate 
Bis-(trichloromethyl)carbonate (0.5 eq, 1.31 mmol, 388 mg) and 2-(allyloxy)-3-methoxy-4-
nitrobenzoic acid (1.5 eq, 4.01 mmol, 1014 mg) were dissolved in dry THF (25 ml) under 
argon atmosphere. 2,4,6-Collidine (8.0 eq, 21.38 mmol, 2.8 ml) was added slowly via 
syringe. The resulting suspension was stirred at room temperature for 15 min and a solution 
of allyl 2-(allyloxy)-4-amino-3-methoxybenzoate (1.0 eq, 2.67 mmol, 703 mg), DIPEA (10.0 
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eq, 26.72 mmol, 4.5 ml) in dry THF (25 ml) was added. Stirring was continued for 11 h at 
room temperature and the reaction was quenched by addition of water (10 ml). The organic 
solvent was removed under reduced pressure and EtOAc (70 ml) was added. The mixture 
was washed successively with saturated NaHC03 (2 x 25 ml), HCI (5 %, 2 x 25 ml), water 
(1 x 25 ml) and brine (1 x 25 ml). The organic solvent was dried over Na2SÜ4, filtered and 
removed under reduced pressure. Purification by column chromatography (H:EA - 8:1) 
yielded the product as a slightly yellow oil (1.2 g, 91 %). 
1H-NMR (dmso-d6, 500 MHz): i5 [ppm] 3.90 (s, 3H), 3.99 (s, 3H), 4.53 (d, J = 4.53 Hz, 2H), 
4.76 (d, J = 4.76 Hz, 2H), 4.78 (d, J = 5.35 Hz, 2H), 5.27 (m, 3H), 5.41 (m, 3H), 6.07 (m, 3H), 
7.57 (d, J = 8.72 Hz, 1 H), 7.74 (d, J = 8.72 Hz, 1 H), 7.79 (d, J = 8.52 Hz, 1 H), 8.21 (d, J = 
8.72, 1 H), 10.43 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 499.1711 
found: 499.1701 
[M+Na]+ calculated: 521.1530 
found: 521.1520 
Allyl 2-(allyloxy)-4-(2-(allyloxy)-4-amino-3-methoxybenzamido)-3-methoxybenzoate 
Allyl 2-(allyloxy)-4-(2-(allyloxy)-3-methoxy-4-nitrobenzamido)-3-methoxybenzoate (1.0 eq, 
2.41 mmol, 1.2 g) and SnC'2*2H20 (7.0 eq, 16.86 mmol, 3.8 g) were dissolved in EtOH 
(40 ml) and stirred at 60 °C for 1 h. The solution was concentrated under reduced pressure 
and diluted with water (100 ml). The pH was adjusted to 8-9 by adding saturated NaHC03 
solution and the aqueous suspension was extracted with EtOAc (3 x 250 ml). The phases 
were separated and the organic phase was washed with brine (1 x 250 ml), dried over 
Na2SÜ4 and filtered. After removing the solvent under reduced pressure, column 
chromatography (H:EA - 3:1) yielded the product as an orange oil (892 mg, 79 %). 
1H-NMR (dmso-d6, 400 MHz): i5 [ppm] 3.76 (s, 3H), 3.91 (s, 3H), 4.54 (d, J = 5.75 Hz, 2H), 
4.78 (m, 4H), 5.26 (dd, J1 = 17.54 Hz, J2 = 10.40, 3H), 5.41 (m, 3H), 5.87 (s, 2H), 6.08 (m, 
3H), 6.58 (d, J = 8.72 Hz, 1 H), 7.54 (d, J = 8.92 Hz, 1 H), 7.59 (d, J = 8.92 Hz, 1 H), 8.36 (d, J 
= 8.92 Hz, 1 H), 10.64 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 469.1969 
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found: 469.1958 





- N ~ H 
'cN 
Boc-l-Asn-OH (2.0 eq, 34.44 mmol, 8.0 g) and DCC (4.0 eq, 68.87 mmol, 14.2 g) were 
dissolved in dry DMF (150 ml) under argon atmosphere. After stirring for 10 min at room 
temperature tert-butyl 4-aminobenzoate (1.0 eq, 17.22 mmol, 3.9 g) was added and stirring 
was continued for 19 h. EtOAc (400 ml) was added and the mixture was washed 
successively with brine (3 x 150 ml), saturated NaHC03 solution (2 x 150 ml), HCI (5 %, 2 x 
150 ml) and brine (1 x 150 ml). The organic phase was dried over Na2SÜ4, filtered and the 
solvent was removed under reduced pressure. Column chromatography (H:EA - 4:1) yielded 
the product as a white solid (4.2 g, 57 %). 
1 H-NMR (dmso-d6, 400 MHz): o [ppm] 1.40 (s, 9H), 1.53 (s, 9H), 2.83 (dd, J1 = 16.92 Hz, 1 H), 
2.99 (dd, J1 = 16.92 Hz, J2 = 5.10 Hz, 1 H), 4.46 (dd, J1 = 13.70 Hz, J2 = 8.86 Hz, 1 H), 7.58 
(d, J = 7.79 Hz, 1 H), 7.71 (d, J = 8.60 Hz, 2H), 7.87 (d, J = 8.60 Hz, 2H), 10.48 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 390.2034 
found: 390.2017 
[M+Na]+ calculated: 412.1843 
found: 412.1834 
(S)-4-(3-Cyano-2-(4-nitrobenzamido)propanamido)benzoic acid 
(S)-tert-Butyl 4-(2-(tert-butoxycarbonylamino)-3-cyanopropanamido)benzoate (1.0 eq, 0.81 
mmol, 314 mg) was dissolved in HCl/dioxane (4 M, 5 ml) and the reaction mixture was 
stirred at room temperature until cleavage of the boc group and tert-butyl ester was 
completed (lC/MS monitoring, approximately 6 hours). The solvent was removed under 
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reduced pressure and the residue resolved in dry DMF (10 ml) under argon atmosphere. 
Triethylamine (3.0 eq, 2.42 mmol, 0.73 ml) and 2,5-dioxopyrrolidin-1-yl 4-nitrobenzoate (1.1 
eq, 0.89 mmol, 234 mg) were added and the mixture was stirred at room temperature for 16 
h. EtOAc (50 ml) was added and the mixture was washed successively with brine (3 x 25 
ml), saturated NaHC03 solution (2 x 25 ml), HCI (5 %, 2 x 25 ml) and brine (1 x 25 ml). 
The organic phase was dried over Na2SÜ4, filtered and the solvent was removed under 
reduced pressure. Column chromatography (CHCl3:CH3QH - 9:0.5) yielded the product as a 
white solid (119 mg, 39 %). 
1 H-NMR (dmso-d6, 400 MHz): o [ppm] 3.06 (dd, J1 = 16.92 Hz, J2 = 8.60 Hz, 1 H), 3.17 (dd, J1 
=16.92 Hz, J2 = 5.37 Hz, 1 H), 5.01 (m, 1 H), 7.74 (d, J = 8.87 Hz, 1 H), 7.92 (d, J = 8.87 Hz, 
1 H), 8.16 (d, J = 9.13 Hz, 1 H), 8.38 (d, J = 8.87 Hz, 1 H), 9.53 (d, J = 7.79 Hz, 1 H), 10.61 (s, 
1 H). 





Chemical Formula: C7H8N20 2 
Exact Mass: 152,0586 
6-Amineonicotinic acid ( 1.00 g, 7.246 mmol, 1.00 eq) was dissolved in abs. MeOH (40 ml) 
and cooled to O °C. S0C'2 (2.587 g, 1.70 ml, 21.739 mmol, 3.00 eq) was added and the reaction 
mixture was allowed to warm up to room temperature. After stirring for 16 h the solvent was 
evaporated to give the product as a pale yellow solid (60 %). 
1H-NMR (400 MHz, DMS0-d6): 3.75 (s, 3H), 6.43 - 6.46 (dd, J1 = 8.7 Hz, J2 = 0.7 Hz, 1 H), 
6.84 (s, 2H), 7.81 - 7.83 (dd, J1 = 8.9 Hz, J2 = 2.4 Hz, 1 H), 8.50 (d, J = 2.1 Hz, 1 H), 
13C-NMR (100.6 MHz, DMS0-d6): 51.36, 107.13, 113.19, 137.60, 151.04, 162.52, 165.72 









Allyl04 I H 
Chemical Formula: C20H20N20 4 
Exact Mass: 352, 1423 
The Allyl protected cinnamic acid (200 mg, 0.917 mmol, 1.00 eq) was dissolved in DCM (10 
ml) and a catalytic amount of DMF (100 µI) was added. S0C'2 (545 mg, 0.36 ml, 4.579 mmol, 
5.00 eq) was added dropwise and the mixture was stirred for 16 h. The solvents were removed 
and the residue redissolved in DMF. Methyl-6-amineonicotinate (139 mg, 0.917 mmol, 1.00 
eq) was dissolved in DMF and added. After stirring for another 16 h the mixture was diluted 
with EE and the organic layer was washed 3 x with 1 N HCI, sat. NaHC03 and brine. The 
organic layer was dried over Na2SÜ4 and the solvent was evaporated. The crude product was 




Allyl04 I H 
Chemical Formula: C19H18N20 4 
Exact Mass: 338, 1267 
Methyl 6-[[ (E)-3-( 4-allyloxyphenyl)-2-methyl-prop-2-enoyl]amino ]pyridine-3-carboxylate ( 1 .00 
eq) was dissolved in Dioxane/H20 (1 :1) and LiOH (3.00 eq) was added. The mixture was 
stirred for 4 h. The Dioxane was removed and the aqueous layer acidified with conc. HCI. The 
aqueous layer was extracted 3 x with EE and the combined organic layers were dried over 
Na2SÜ4. The solvent was evaporated to give the product. 
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Al lyl 2-allyloxy-4-[ [2-a llyloxy-4-[ [ 4-[ [ (2S)-2-[ [6-[ [( E)-3-( 4-a llyloxyphenyl)-2-methyl-prop-2-
enoyl]am ino] pyridi ne-3-carbonyl]ami no ]-3-cya no-propa noyl]am ino] benzoyl] 
1 OAllylO 
1 OAllylO opOAllyl 
Allylün I O O~Nv 
~~'OyN H O ~Nv H 
0 ~ 1 N0NV H 
= H 
O 'CN 
Chemical Formula: C55H53N7012 
Exact Mass: 1003,3752 
6-[[ ( E)-3-( 4-allyloxyphenyl)-2-methyl-prop-2-enoyl]amino ]pyridine-3-carboxylic acid ( 1 .50 eq) 
was dissolved in THF. Triphosgen (0.50 eq) and Collidin (8.00 eq) were added and stirred for 
20 min. The aminee (1.00 eq) and DIPEA (10.00 eq) were dissolved in THF and added to 
mixture. After stirring for 16 h the mixture was diluted with EE and the organic layer was 
washed 3 x with 1 N HCI, sat. NaHC03 and brine. After drying the organic layer over Na2SÜ4 
the solvent was removed and the crude product was chromatographically purified to give the 
product. 
4-[[(2S)-3-cyano-2-[(S-nitropyridine-2-carbonyl)amino]propanoyl]amino]benzoic acid 
0 02NVy O ~OH 
1 h ~J )J 
N . N 
: H 
O 'cN 
Chemical Formula: C17H13N505 
Exact Mass: 383,0866 
(S)-1-((4-carboxyphenyl)amineo)-3-cyano-1-oxopropan-2-amineium chloride (424 mg, 1.58 
mmol, 1.00 eq) was dissolved in abs. DMF (10 ml) and TEA (479 mg, 665 µI, 4.74 mmol, 3.00 
eq) was slowly added. 2,5-dioxopyrrolidin-1-yl 5-nitropicolinate (440 mg, 1.66 mmol, 1.05 eq) 
was dissolved in DMF (10 ml) and added to the reaction mixture. After stirring for 16 h at room 
temperature the mixture was diluted with EE (50 ml) and the organic layer was washed 4 x 
with 1 N HCI and brine. The solvent was evaporated and the crude product was 
chromatographically purified (Hex:EE 1 :1) to give the product as a pale yellow solid (78 %). 
1H-NMR (400 MHz, DMS0-d6): 3.19-3.28 (m, 2H), 5.04- 5.10 (m, 1 H), 7.72 (d, J= 8.9 Hz, 
2H), 7.92 (d, J = 8.6 Hz, 2H), 8.32 (d, J = 8.6 Hz, 1 H), 8.79 - 8.82 (dd, J1 = 8.6 Hz, J2 = 2.4 
Hz, 1 H), 9.46 (d, J = 2.4 Hz, 1 H), 9.55 (d, J = 8.3 Hz, 1 H), 10.53 (s, 1 H), 12.73 (br, 1 H) 
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13C-NMR (100.6 MHz, DMS0-d6): 20.30, 50.08, 117.96, 118.99, 123.12, 125.78, 130.35, 





Al lyl 2-allyloxy-4-[ [2-a llyloxy-4-[ [ 4-[ [ (2S)-3-cyano-2-[ (5-n itropyridi ne-2-carbonyl) 
amino]propanoyl]amino]benzoyl]amino]-3-methoxy-benzoyl]amino]-3-methoxy-benzoate 
1 OAllylO 
1 OAllylO O~OAllyl 
o 0~NAJ 
02NVy O ~NA) H 
1 ~ ~J A) H 
N . N 
= H 
O 'CN 
Chemical Formula: C42H39N7012 
Exact Mass: 833,2657 
(S)-4-(3-cyano-2-(5-nitropicolinamido)propanamido)benzoic acid (404 mg, 1.05 mmol, 2.00 
eq) was dissolved in THF (20 ml), BTC (104 mg, 0.35 mmol, 0.66 eq) and Collidin (510 mg, 
558 µI, 4.22 mmol, 8.00 eq) was added and stirred 20 min at room temperature. Allyl 2-
(allyloxy)-4-(2-(allyloxy)-4-amineo-3-methoxybenzamido)-3-methoxybenzoate (246 mg, 0.52 
mmol, 1.00 eq) and DIPEA (679 mg, 940 µI, 5.27 mmol, 10.00 eq) were dissolved in THF (10 
ml) and added to the reaction mixture. After stirring for 16 h the mixture was diluted with EE 
(50 ml) and washed 3 x with 1 N HCI, sat. NaHC03 and brine. After drying over Na2SÜ4 the 
solvent was evaporated. The crude product was chromatographically purified (Hex:EE 1 :1) to 
give the product as a yellow solid (69 %). 
1 H-NMR (400 MHz, DMS0-d6): 3.24 - 3.29 (m, 2H), 3.91 (s, 3H), 3.93 (s, 3H), 4.53 - 4.55 (m, 
2H), 4.76 - 4.81 (m, 4H), 5.06 - 5.12 (m, 1 H), 5.23 - 5.31 (m, 3H), 5.36 - 5.44 (m, 3H), 5.99 
- 6.16 (m, 3H), 7.57 (d, J = 8.6 Hz, 1 H), 7.77 (d, J = 8.6 Hz, 2H), 7.80 (d, J = 8.9 Hz, 1 H), 7.90 
- 7.92 (m, 1 H), 7.99 (d, J = 8.9 Hz, 2H), 8.32 - 8.35 (m, 2H), 8.80 - 8.83 (m, 1 H), 9.48 (dd, J1 
= 2.6 Hz, J2 = 0.7 Hz, 1 H), 9.57 (d, J = 8.6 Hz, 1 H), 9.70 (s, 1 H), 10.55 (s, 1 H), 10.65 (s, 1 H) 









1 OAllylO O~OAllyl 
o 0~NAJ 
H2NVy O ~NA} H 
1 /, ~J A) H 
N . N 
0 = H 
'CN 
Chemical Formula: C42 H41N7010 
Exact Mass: 803,2915 
(S)-allyl2-(allyloxy)-4-(2-(allyloxy)-4-(4-(3-cyano-2-(5-nitropicolinamido)propanamido)benz-
amido)-3-methoxybenzamido)-3-methoxybenzoate (335 mg, .402 mmol, 1.00 eq) was 
dissolved in EtOH (30 ml) and SnC'2·H20 was added. The mixture was stirred at 60 °C for 6 h. 
The solvent was evaporated and the residue was redissolved in EE. The organic layer was 
washed with sat. NaHC03 and the aqueous layer extracted twice with EE. The organic layer 
was washed with brine, dried over Na2SÜ4 and evaporated. The crude product was 
chromatographically purified (CHCb:MeOH 9:0.1) to give the product as a yellow solid (60 %). 
1 H-NMR (400 MHz, DMS0-d6): 3.18 - 3.23 (m, 1 H), 3.27 - 3.32 (m, 1 H), 3.91 (s, 3H), 3.93 (s, 
3H), 4.53 - 4.55 (m, 2H), 4.77 - 4.81 (m, 4H), 4.99 - 5.04 (m, 1 H), 5.23 - 5.31 (m, 3H), 5.36 
- 5.44 (m, 3H), 5.99 - 6.16 (m, 3H), 7.29 (dd, J1 = 7.72 Hz, J2 = 2.6 Hz, 1 H), 7.57 (d, J = 8.6 
Hz, 1 H), 7.76 - 7.81 (m, 3H), 7.91 (dd, J1 = 8.7 Hz, J2 = 2.8 Hz, 2H), 7.99 (d, J = 8.6 Hz, 2H), 
8.18 (d, J = 2.4 Hz, 1 H), 8.33 (d, J = 8.9 Hz, 1 H), 8.85 (d, J = 1.6 Hz, 1 H), 8.93 (d, J = 8.3 Hz, 
1H), 9.14 (s, 1H), 9.69 (s, 1H), 10.56 (s, 1H), 10.65 (s, 1H) 
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Al lyl 2-allyloxy-4-[ [2-a llyloxy-4-[ [ 4-[ [ (2S)-2-[ [S-[ [( E)-3-( 4-a llyloxyphenyl)-2-methyl-prop-2-
enoyl]am ino] pyridi ne-2-carbonyl]ami no ]-3-cya no-propa noyl]am ino] benzoyl]a mi no ]-3-methoxy-
benzoyl]ami no ]-3-methoxy-benzoate 
1 OAllylO 




~~Vy O ~NJJ H 
O 1 ~ ~J JJ H 
N . N 
0 = H 
'CN 
Chemical Formula: C55H53N7012 
Exact Mass: 1003,3752 
(E)-3-(4-(allyloxy)phenyl)-2-methylacrylic acid (42 mg, 0.194 mmol, 3.00 eq) was dissolved in 
THF. BTC (19 mg, 0.065 mmol, 1.00 eq) and Collidin (63 mg, 69 µI, 0.518 mmol, 8.00 eq) were 
added and the mixture was stirred at room temperature. After 20 min (S)-allyl 2-(allyloxy)-4-(2-
( allyloxy)-4-( 4-(2-(5-am ineopicolinam ido )-3-cyanopropanam ido )benzamido )-3-
methoxybenzam ido )-3-methoxybenzoate (52 mg, 0.065 mmol, 1.00 eq) and DIPEA ( 83 mg, 
116 µI, 0.647 mmol, 10.00 eq) were dissolved in THF, added to the reaction mixture and stirred 
for an additional 16 h. The reaction mixture was diluted with EE and washed 3 x with 1 N HCI, 
sat. NaHC03 and brine. After drying over Na2SÜ4 the solvent was removed. The crude product 
was chromatographically purified (CHCl3:MeOH 9:0.2) to give the product as a yellow solid (95 
%). 
1 H-NMR (400 MHz, DMS0-d6): 2.15 (s, 3H), 3.91 (s, 3H), 3.93 (s, 3H), 4.53 - 4.55 (m, 2H), 
4.60 -4.63 (m, 2H), 4.76- 4.81 (m, 4H), 5.01 - 5.08 (m, 1 H), 5.26- 5.29 (m, 4H), 5.38 - 5.44 
(m, 4H), 6.00 - 6.10 (m, 4H), 7.04 - 7.06 (m, 2H), 7.46 - 7.49 (m, 2H), 7.56 - 7.58 (m, 1 H), 
7.77 - 7.82 (m, 3H), 7.91 - 7.93 (m, 1 H), 7.98 - 8.01 (m, 2H), 8.07 - 8.09 (m, 1 H), 8.33 (d, J 
= 8.9 Hz, 1 H), 8.36 - 8.39 (dd, J1 = 8.6 Hz, J2 = 2.1 Hz, 1 H), 9.03 (d, J = 2.6 Hz, 1 H), 9.18 (d, 










Chemical Formula: C10H12N204 
Exact Mass: 224,0797 
PCT /EP2014/052922 
DIC (3.00 eq), tBuOH (4.00 eq) and CuCI (0.02 eq) were stirred under an Argon-athmosphere 
at room temperature for 5 d. The mixture was filtered through a pad of celite and diluted with 
DCM (4:1 ). 5-Nitropicolinic acid (1.00 g, 5.952 mmol, 1.00 eq) was dissolved in DMF (20 ml) 
and the activated tBuOH was added via a dropping tunnel. After stirring for 4 h at room 
temperature the mixture was cooled to O °C. Hexane (40 ml) was added and it was stirring for 
an additional 30 min. The mixture was filtered through celite and the filtrate was washed 3 x 
with H20. The solvent was removed and the crude product was chromatographically purified 
(Hex/EE 5:1) to give the product as a white solid (70 %). 
1H-NMR (400 MHz, DMS0-d6): 1.58 (s, 9H), 8.21 - 8.23 (dd, J1 = 8.6 Hz, J2 = 0.8 Hz, 1 H), 
8.72 - 8.75 (dd, J1 = 8.6 Hz, J2 = 2.7 Hz, 1 H), 9.44 - 9.45 (d, J = 2.6 Hz, 1 H) 









Chemical Formula: C10H1 4N202 
Exact Mass: 194, 1055 
Tert-Butyl-5-nitro-picolinate (822 mg, 3.67 mmol) was dissolved in EE/MeOH (9:1) (20 ml) and 
Pd/C 10 % (82 mg) was added. The mixture was stirred at room temperature under a 
Hydrogen-atmosphere for 5 h. The mixture was filtrated through a pad of celite and the solvents 
were evaporated to give the product as an white solid (90 %). 
1H-NMR (400 MHz, DMS0-d6): 1.50 (s, 9H), 6.08 (s, 2H), 6.89 (dd, J1 = 8.6 Hz, J2 = 2.7 Hz, 
1 H), 7.68 (d, J = 8.6 Hz, 1 H), 7.95 (d, J = 2.7 Hz, 1 H) 

















Chemical Formula: C19H26N40 5 
Exact Mass: 390, 1903 
Tert-butyl-5-amineo-picolinate (727 mg, 3.747 mmol, 1.00 eq) and Boc-Asn-OH (1.739 g, 
7.495 mmol, 2.00 eq) were dissolved in DMF (30 ml) and DCC (3.092 g, 14.989 mmol, 4.00 
eq) was added. After stirring for 16 h at room temperature the mixture was filtrated and the 
filtrate diluted with EE (60 ml). The organic layer was washed 3 x with 1 N HCI, sat. NaHC03 
and brine. The organic layer was dried over Na2SÜ4 and the solvent was removed. The crude 
product was chromatographically purified (Hex/EE 1 :2) to give the product as a white solid (60 
%). 
1 H-NMR (400 MHz, DMS0-d6): 1.41 (s, 9H), 1.54 (s, 9H), 6.08 (s, 2H), 6.89 (dd, J1 = 8.6 Hz, 
J2 = 2.7 Hz, 1 H), 7.68 (d, J = 8.6 Hz, 1 H), 7.95 (d, J = 2.7 Hz, 1 H) 
13C-NMR (100.6 MHz, DMS0-d6): 27.95, 79.57, 118.07, 126.09, 135.60, 147.72, 164.06 
[(lS)-2-[(6-carboxy-3-pyridyl)amino]-1-(cyanomethyl)-2-oxo-ethyl]ammonium chloride 
Tert-butyl 
Chemical Formula: C10H11N403+ 
Exact Mass: 235,0826 
5-[[ ( 2S )-2-(tert-butoxycarbonylam i no )-3-cyan o-propan oyl]am i no ]pyrid i ne-2-
carboxylate (900 mg, 2.310 mmol) was dissolved in 4 M HCI in Dioxane (20 ml). The solution 
was stirred at room temperature for 5 h. The solvent was evaporated and the product dried in 
vacuo (quant.). 
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5-[[(2S)-3-cyano-2-[(4-nitrobenzoyl)amino]propanoyl]amino]pyridine-2-carboxylic acid 
0 




Chemical Formula: C17H13N50 6 
Exact Mass: 383,0866 
[(1 S)-2-[(6-carboxy-3-pyridyl)amino]-1-(cyanomethyl)-2-oxo-ethyl]ammonium chloride (1.00 
eq) was dissolved in DMF and TEA (3.00 eq) was added dropwise. 2,5-Dioxopyrrolidin-1-yl-4-
nitrobenzoate (1.05 eq) was dissolved in DMF and added to the mixture. After stirring at room 
temperature for 16 h the mixture was diluted with EE and washed 4 x with 1 N HCI and brine. 
The organic layer was dried over Na2SÜ4 and the solvent was removed. The crude product 




1 OAllylO opOAllyl 
o 0~N)l) 
02NUy O (."'NJN)l) H ~ 1 ~J )l) H 
. N 
0 =- H 
"CN 
Chemical Formula: C42H39N7012 
Exact Mass: 833,2657 
5-[[(2S)-3-cyano-2-[(4-nitrobenzoyl)amino]propanoyl]amino]pyridine-2-carboxylic acid (2.00 
eq) was dissolved in THF and Triphosgen (0.66 eq) and Collidin (8.00 eq) were added. The 
mixture was stirred at room temperature for 40 min. The amine (1.00 eq) and DIPEA (10.00 
eq) were dissolved in THF, added to the mixture and it was stirred for an additional 16 h at 
room temperature. The reaction was diluted with EE and washed 3 x with 1 N HCI, sat. NaHC03 
and brine. After drying over Na2SÜ4 the solvent was removed. The crude product was 
chromatographically purified to give the product as a yellow solid. 
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1 OAllylO opOAllyl 
o 0~N)l) 
H2N'Oy O ~N0NJlJ H ~ 1 ~__)l Jl) H 
. N 
0 = H 
'CN 
Chemical Formula: C42H41N7010 
Exact Mass: 803,2915 
Allyl 2-allyloxy-4-[[2-allyloxy-4-[[5-[[(2S)-3-cyano-2-[(4-nitrobenzoyl)amino]propanoyl] 
am ino ]pyridine-2-carbonyl]am ino ]-3-methoxy-benzoyl]am ino ]-3-methoxy-benzoate ( 1 .00 eq) 
was dissolved in EtOH and SnC'2·H20 (5.00 eq) was added. The mixture was stirred at 60 °C 
for 6 h. The solvent was removed and the residue uptaken in EE. Sat. NaHC03 was added 
and the aqueous layer was extracted 3 x with EE. The combined organic layers were dried 
over Na2SÜ4 and the solvent was removed. The crude product was chromatographically 
purified to give the product as a yellow solid. 
Allyl 2-allyloxy-4-[[2-allyloxy-4-[[S-[[(2S)-2-[[4-[[(E)-3-(4-allyloxyphenyl)-2-methyl-prop-2-
enoyl]amino]benzoyl]amino]-3-cyano-propanoyl]amino]pyridine-2-carbonyl]amino]-3-methoxy-
benzoyl]ami no ]-3-methoxy-benzoate 
1 OAllylO 
1 OAllylO opOAllyl 
AllylOÜJy O OxYN)l) 
~I ô ~ d lô H Y') 0 " N 
O 0y~yl~ 1 6 H 
O 'CN 
Chemical Formula: C55H53N70 12 
Exact Mass: 1003,3752 
The cinnamic acid (3.00 eq) was dissolved in THF. Triphosgen (1.00 eq) and Collidin (8.00 eq) 
were added and it was stirred for 15 min. Allyl 2-allyloxy-4-[[2-allyloxy-4-[[5-[[(2S)-2-[(4-
aminobenzoyl)amino]-3-cyano-propanoyl]amino]pyridine-2-carbonyl]amino]-3-methoxy-
benzoyl]amino]-3-methoxy-benzoate (1.00 eq) and DIPEA (10.00 eq) were dissolved in THF 
and added to the mixture. After stirring for 16 h the mixture was diluted with EE and the organic 
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layer was washed 3 x with 1 N HCI, sat. NaHC03 and brine. After drying over Na2SÜ4 the 
solvent was removed. The crude product was chromatographically purified to give the product 
as a yellow solid. 
5-[[(2S)-3-cyano-2-[(S-nitropyridine-2-carbonyl)amino]propanoyl]amino]pyridine-2-carboxylic acid 
0 
02NVy O (."'N00H ~ 1 ~J )l) 
N . N 
: H 
O 'CN 
Chemical Formula: C16H12N60 6 
Exact Mass: 384,0818 
The amine (1.00 eq) was dissolved in DMF and TEA (3.00 eq) was added dropwise. 2,5-
Dioxopyrrolidin-1-yl-5nitropicolinate (1.05 eq) was dissolved in DMF and added to the mixture . 
. After stirring at room temperature for 16 h the mixture was diluted with EE and washed 4 x 
with 1 N HCI and brine. The organic layer was dried over Na2SÜ4 and the solvent was removed. 





1 OAllylO opOAllyl 
o 0~N)l) 
02NVy O (."'N0N)l) H 
~ 1 ~J )l) H 
N . N 
: H 
O 'CN 
Chemical Formula: C41 H3sNs012 
Exact Mass: 834,2609 
5-[[(2S)-3-cyano-2-[(5-nitropyridine-2-carbonyl)amino]propanoyl]amino]pyridine-2-carboxylic 
acid (2.00 eq) was dissolved in THF and Triphosgen (0.66 eq) and Collidin (8.00 eq) were 
added. The mixture was stirred at room temperature for 40 min. The amine (1.00 eq) and 
DIPEA (10.00 eq) were dissolved in THF, added to the mixture and it was stirred for an 
additional 16 h at room temperature. The reaction was diluted with EE and washed 3 x with 1 
N HCI, sat. NaHC03 and brine. After drying over Na2SÜ4 the solvent was removed. The crude 
product was chromatographically purified to give the product as a yellow solid. 
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1 OAllylO opOAllyl 
o 0~N)l) 
H2NVy O ,<N0NJlJ H ~ 1 ~J )l) H 
N . N 
= H 
O 'CN 
Chemical Formula: C41 H40Ns010 
Exact Mass: 804,2867 
5-[[(2S)-3-cyano-2-[(5-nitropyridine-2-carbonyl)amino]propanoyl]amino]pyridine-2-carboxylic 
acid (1.00 eq) was dissolved in EtOH and SnC'2·H20 (5.00 eq) was added. The mixture was 
stirred at 60 °C for 6 h. The solvent was removed and the residue uptaken in EE. Sat. NaHC03 
was added and the aqueous layer was extracted 3 x with EE. The combined organic layers 
were dried over Na2SÜ4 and the solvent was removed. The crude product was 





1 OAllylO opOAllyl 
AllylOÜJy O OxYN)l) 
~I ô ~ d lô H Y') 0 " N 
0 s,.)Î(~0~ 1 6 H 
O 'CN 
Chemical Formula: C54H52N80 12 
Exact Mass: 1004,3705 
The cinnamic acid (3.00 eq) was dissolved in THF. Triphosgen (1.00 eq) and Collidin (8.00 eq) 
were added and it was stirred for 15 min. Allyl 2-allyloxy-4-[[2-allyloxy-4-[[5-[[(2S)-2-[(5-
am i nopyrid i ne-2-carbonyl) ami no ]-3-cyano-propanoyl]am i no ]pyrid i ne-2-carbo nyl]am i no ]-3-
methoxy-benzoyl]am i no ]-3-methoxy-benzoate (1.00 eq) and DIPEA (10.00 eq) were dissolved 
in THF and added to the mixture. After stirring for 16 h the mixture was diluted with EE and the 
organic layer was washed 3 x with 1 N HCI, sat. NaHC03 and brine. After drying over Na2SÜ4 
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the solvent was removed. The crude product was chromatographically purified to give the 





I OAllylO 0p0Allyl 
OxYN~ O,, ,9 1 H 
O S,N .ô H 
Chemical Formula: C31 H31 N3011 S 
Exact Mass: 653, 1679 
The amine (500 mg, 1.068 mmol, 1.00 eq) was dissolved in DCM and DMAP (100 mg, w/w 10 
%) and Pyridin (2.5 ml) were added. 4-Nitrobenzene-1-sulfonyl chloride (710 mg, 3.205 mmol, 
3.00 eq) was added and it was stirred at room temperature for 72 h. The mixture was washed 
3 x with 1 N HCI and brine. After drying over Na2SÜ4 the solvent was removed. The crude 
product was chromathographically (Hex/EE 3:1) purified to give the product as a yellow solid. 
1H-NMR (400 MHz, DMS0-d6): 3.59 (s, 3H), 3.87 (s, 3H), 4.50 -4.52 (m, 2H), 4.63-4.65 (m, 
2H), 4.75 - 4.76 (m, 2H), 5.24 - 5.28 (m, 2H), 5.34 - 5.42 (m, 2H), 5.92 - 6.12 (m, 3H), 7.29 
(d, J = 8.9 Hz, 1 H), 7.54 (d, J = 8.9 Hz, 1 H), 7.69 (d, J = 8.9 Hz, 1 H), 8.09 (d, J = 8.9 Hz, 2H), 
8.26 (d, J = 8.9 Hz, 1 H), 8.42 (d, J = 8.9 Hz, 2H), 10.51 (s, 1 H), 10.59 (s, 1 H) 
13C-NMR (100.6 MHz, DMS0-d6): 59.76, 60.95, 65.11, 114.87, 117.86, 118.14, 120.21, 
120.38, 124.70, 126.24, 128.30, 132.45, 132.61, 133.93, 136.37, 142.52, 144.59, 149.74, 











1 OAllylO opOAllyl OxYN)l) O~/? 1 H 
O S,N .ô H 
Chemical Formula: C31 H33N30 9S 
Exact Mass: 623, 1938 
Allyl 2-allyloxy-4-[[2-allyloxy-3-methoxy-4-[ ( 4-n itrophenyl)sulfonylamino ]benzoyl]amino ]-3-
methoxy-benzoate (320 mg, 0.490 mmol, 1.00 eq), was dissolved in EtOH (30 ml) and and 
SnC'2·H20 (554 mg, 2.45 mmol, 5.00 eq) was added. The mixture was stirred at 60 °C for 6 h. 
The solvent was removed and the residue uptaken in EE. Sat. NaHC03 was added and the 
aqueous layer was extracted 3 x with EE. The combined organic layers were dried over 
Na2SÜ4 and the solvent was removed. The crude product was chromatographically (Hex/EE 
1 :1) purified to give the product as a yellow solid (90 %). 
1H-NMR (400 MHz, DMS0-d6): 3.64 (s, 3H), 3.88 (s, 3H), 4.50 -4.52 (m, 2H), 4.67-4.69 (m, 
2H), 4.75 - 4.76 (m, 2H), 5.24 - 5.30 (m, 2H), 5.34 - 5.42 (m, 2H), 5.96 - 6.12 (m, 3H), 6.04 
(s, 2H), 6.55 (d, J = 8.6 Hz, 2H), 7.32 (d, J = 9.1 Hz, 1 H), 7.48 (d, J = 8.6 Hz, 2H), 7.54 (d, J = 
8.9 Hz, 1 H), 7.67 (d, J = 8.9 Hz, 1 H), 8.28 (d, J = 8.9 Hz, 1 H), 9.69 (s, 1 H), 10.54 (s, 1 H) 
13C-NMR (100.6 MHz, DMS0-d6): 60.85, 60.98, 65.09, 74.54, 74.84, 112.51, 114.75, 115.13, 
117.85, 118.13, 120.18, 120.24, 121.65, 124.20, 125.73, 126.27, 128.88, 132.51, 132.63, 












I OAllylO 0p0Allyl OxYN)l) o,, ,() 1 H 




Chemical Formula: C40 H45N5012S 
Exact Mass: 819,2785 
The amine (1.00 eq) and Boc-Asn-OH (2.00 eq) were dissolved in DMF. DCC (4.00 eq) was 
added and the mixture was stirred at room temperature for 72 h. The mixture was diluted with 
EE and washed with 3 x with 1 N HCI, sat. NaHC03 and brine. After drying over Na2SÜ4 the 
solvent was evaporated. The crude product was chromatographically purified to give the 




Chemical Formula: C35H38N50 10s+ 
Exact Mass: 720,2334 
2-al lyloxy-4-[[2-al lyloxy-4-[[ 4-[[ ( 2S )-2-(tert-butoxycarbo nylam i no )-3-cyano-
propanoyl]am ino ]phenyl]su lfonylam ino ]-3-methoxy-benzoyl]amino ]-3-methoxy-benzoate was 
dissolved in 4 M HCI in Dioxane and stirred for 1 h. The solvent was removed and the product 
dried in vacuo. 
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Al lyl 2-allyloxy-4-[ [2-a llyloxy-4-[ [ 4-[ [ (2S)-3-cyano-2-[ ( 4-n itrobenzoyl)ami no] 
propanoyl]amino]phenyl]sulfonylamino]-3-methoxy-benzoyl]amino]-3-methoxy-benzoate 
The amine (1.00 eq) was dissolved in DMF and TEA (3.00 eq) was added dropwise. 2,5-
Dioxopyrrolidin-1-yl-4-nitrobenzoate (1.05 eq) was dissolved in DMF and added to the mixture. 
After stirring at room temperature for 16 h the mixture was diluted with EE and washed 4 x with 
1 N HCI and brine. The organic layer was dried over Na2SÜ4 and the solvent was removed. 





1 OAllylO opOAllyl Oxi'N)l) O,, 19 1 H 
H2N~ 0 ('yS'N h' 




Chemical Formula: C42H42N5011S 
Exact Mass: 838,2632 
2-al lyloxy-4-[[2-al lyloxy-4-[[ 4-[[ ( 2S )-3-cyan o-2-[ ( 4-n itrobenzoyl) ami no] 
propanoyl]am ino ]phenyl]su lfonylam ino ]-3-methoxy-benzoyl]amino ]-3-methoxy-benzoate 
(1.00 eq), was dissolved in EtOH and and SnC'2·H20 5.00 eq) was added. The mixture was 
stirred at 60 °C for 6 h. The solvent was removed and the residue uptaken in EE. Sat. NaHC03 
was added and the aqueous layer was extracted 3 x with EE. The combined organic layers 
were dried over Na2SÜ4 and the solvent was removed. The crude product was 
chromatographically purified to give the product as a yellow solid. 
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Al lyl 2-allyloxy-4-[ [2-a llyloxy-4-[ [ 4-[ [ (2S)-2-[ [ 4-[ [( E)-3-( 4-a llyloxyphenyl)-2-methyl-prop-2-
enoyl]am ino] benzoyl]a mino ]-3-cyano-propa noyl 
1 OAllylO 
I OAllylO 0p0Allyl 
AllylO~ 0:6{ ~ 
1 H 0,, /) 1 ~ 
~ .o N'Oy O r(YS'N .o 
0 ~ 1 ~J ~ H 
. N 
0 .: H 
'CN 
Chemical Formula: C55H54N5013S 
Exact Mass: 1038,3470 
The cinnamic acid (3.00 eq) was dissolved in THF. Triphosgen (1.00 eq) and Collidin (8.00 eq) 
were added and it was stirred for 15 min. Allyl 2-allyloxy-4-[[2-allyloxy-4-[[4-[[(2S)-2-[(4-
aminobenzoyl)am ino ]-3-cyano-propanoyl]am ino ]phenyl]sulf onylamino ]-3-methoxy-
benzoyl]amino ]-3-methoxy-benzoate (1.00 eq) and DIPEA (10.00 eq) were dissolved in THF 
and added to the mixture. After stirring for 16 h the mixture was diluted with EE and the organic 
layer was washed 3 x with 1 N HCI, sat. NaHC03 and brine. After drying over Na2SÜ4 the 
solvent was removed. The crude product was chromatographically purified to give the product 
as a yellow solid. 
[(lS)-2-(4-benzyloxycarbonylanilino)-1-(cyanomethyl)-2-oxo-ethyl]ammonium 
0 




Chemical Formula: C18H18N303 + 
Exact Mass: 324, 1343 
The Boc-protected amine (1.49 g, 3.45 mmol) was dissolved in 4 M HCI in Dioxane (20 ml). 
After stirring for 1 h at room temperature the solvent was evaporated and the product dried in 
vacuo (quant.). 
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benzyl 4-[[(2S)-3-cyano-2-[(4-nitrophenyl)sulfonylamino]propanoyl]amino]benzoate 
0 
02NY) H O ~0Bn 
~S~NJN~ 
ü"'ü ~ H 
'CN 
Chemical Formula: C24H20N40 7S 
Exact Mass: 508, 1053 
The amine (400 mg, 1.11 mmol, 1.00 eq) was dissolved in DCM (20 ml). DMAP (50 mg, 3.88 
mmol, 3.50 eq) and Pyridine (2 ml), followed by 4-nitrobenzene-1-sulfonyl chloride (741 mg, 
mmol, 3.00 eq). The reaction was stirred at room temperature for 72 h and subsequently 
washed 3 x with 1 N HCI and brine. After drying over Na2SÜ4 the solvent was evaporated and 
the crude product chromatographically purified (Hex/EE 2:1) to give the desired product as a 
yellow solid (60 %). 
4-[[(2S)-2-[(4-aminophenyl)sulfonylamino]-3-cyano-propanoyl]amino]benzoic acid 
0 
H2NY'îi O ~OH 
~S~~JN)l) 
ü"'ü ~ H 
'cN 
Chemical Formula: C17H16N40 5S 
Exact Mass: 388,0841 
The peptide was dissolved in EE/MeOH 9:1 and Pd/C 10 % (w/w 10 %) was added. Linder a 
Hydrogen-atmosphere it was stirred at room temperature for 2 h. The reaction mixture was 





BocHNYil H O ~OH 
~S~NJN)l) 
ü"'ü ~ H 
'cN 
Chemical Formula: C22H24N40 7S 
Exact Mass: 488, 1366 
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The amineoacid (1.00 eq) was dissolved in dioxane/H20 and K2CÜ3 (2.20 eq) and B0c20 (1.10 
eq) were added. After stirring at room temperature for 16 h the Dioxane was removed. The 
aqueous layer was extracted with MTBE. Subsequently the aqueous layer was acidified with 
2 M HCI and extracted 3 x with EE. After drying the combined organic layers over Na2SÜ4 the 
solvents was evaporated to give the product. 
Allyl 2-allyloxy-4-[[2-allyloxy-4-[[4-[[(2S)-2-[[4-(tert-butoxycarbonylamino)phenyl]sulfonylamino]-
3-cya no-propa noyl]a mi no] benzoyl]ami no ]-3-methoxy-benzoyl]a mi no ]-3-methoxy-benzoate 
1 OAllylO 
1 OAllylO O~OAllyl 
o 0~NA) 
BocHNÙ d JJ H 
1 
H O I N ~ S .... NJN ~ H 
,.,. ,, : H 
0 0 = 
'CN 
Chemical Formula: C47H50N5013S 
Exact Mass: 938,3157 
4-[[ (2S )-2-[[ 4-(tert-butoxycarbonylam ino )phenyl]sulfonylami no ]-3-cyano-
propanoyl]am ino ]benzoic acid (2.00 eq) was dissolved in THF and Triphosgen (0.66 eq) and 
Collidin (8.00 eq) were added. The mixture was stirred at room temperature for 40 min. The 
amine (1.00 eq) and DIPEA (10.00 eq) were dissolved in THF, added to the mixture and it was 
stirred for an additional 16 h at room temperature. The reaction was diluted with EE and 
washed 3 x with 1 N HCI, sat. NaHC03 and brine. After drying over Na2SÜ4 the solvent was 





1 OAllylO O~OAllyl 
0°:(rNA) 
+ 1 H 
H3Ny') O ~N ~ 
~s .... ~JND H 
o"'o ~ H 
'CN 
Chemical Formula: C42H43N60 11 s+ 
Exact Mass: 839,2705 
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The Boc-protected amine was dissolved in 4 M HCI in Dioxane. After stirring for 1 h at room 
temperature the solvent was evaporated and the product dried in vacuo. 
Allyl 2-allyloxy-4-[[2-allyloxy-4-[[4-[[(2S)-2-[[4-[[(E)-3-(4-allyloxyphenyl)-2-methyl-prop-2-
enoyl]amino]phenyl]sulfonylamino]-3-cyano-propanoyl]amino]benzoyl]amino]-3-methoxy-
benzoyl]ami no ]-3-methoxy-benzoate 
1 OAllyK) 
1 OAllylO O~OAllyl 
AllylOn 1 0 o~NN 
~~y') 0 ~NA) H 
0 ~s--~JN)l) H 
//,, : H 0 0 = 
'CN 
Chemical Formula: C55H54N5013S 
Exact Mass: 1038,3470 
The cinnamic acid (3.00 eq) was dissolved in THF. Triphosgen (1.00 eq) and Collidin (8.00 eq) 
were added and it was stirred for 15 min. The amine (1.00 eq) and DIPEA (10.00 eq) were 
dissolved in THF and added to the mixture. After stirring for 16 h the mixture was diluted with 
EE and the organic layer was washed 3 x with 1 N HCI, sat. NaHC03 and brine. After drying 
over Na2SÜ4 the solvent was removed. The crude product was chromatographically purified 






1 H d I H 
::::,.... .-,,::;. N~ O ç," N ô 
O :::::,....1 ~__Jl :::::,....1 H 
- N 
: H 
0 'cN 14 
Bis-(trichloromethyl)carbonate (1.2 eq, 0.10 mmol, 29 mg) and (E)-3-(4-(allyloxy)phenyl)-2-
methylacrylic acid (3.5 eq, 0.30 mmol, 66 mg) were dissolved in dry THF (2 ml) under argon 
atmosphere. 2,4,6-Collidine (8.0 eq, 0.69 mmol, 91 µL) was added slowly via syringe. The 
resulting suspension was stirred at room temperature for 20 min and a solution of ( S)-Allyl 2-
(allyloxy)- 4-(2-( allyloxy) -4-( 4-(2-( 4-aminobenzamido) -3-cyanopropanamido) benzamido )-3-
methoxybenzamido )-3-methoxybenzoate (12) (12) (1.0 eq, 0.09 mmol, 69 mg), DIPEA (10.0 
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eq, 0.86 mmol, 146 µl) in dry THF (3 ml) was added. Stirring was continued for 3 h at room 
temperature and the reaction was quenched by addition of water (2 ml). The organic solvent 
was removed under reduced pressure and EtOAc (20 ml) was added. The mixture was 
washed successively with saturated NaHC03 (3 x 10 ml), water (1 x 10 ml) and brine (1 x 10 
ml). The organic solvent was dried over Na2SÜ4, filtered and removed under reduced 
pressure. Purification by column chromatography (CHCl3 - 2 % MeOH) yielded the product as 
a slightly yellow oil (64 mg, 75 %). 
R1 (CHCl3:CH3QH - 9:0.5) = 0.15 
1H-NMR (dmso-d6, 500 MHz): o [ppm] 2.14 (s, 3H), 3.08 (dd, J1 = 16.75 Hz, J2 = 8.82 Hz, 1 H), 
3.17 (dd, J1 = 16.84 Hz, J2 = 5.35 Hz, 1 H), 3.93 (s, 3H), 3.94 (s, 3H), 4.55 (d, J = 5.55 Hz, 
2H), 4.63 (d, J = 5.15 Hz, 2H), 4.78 (d, J = 5.35 Hz, 2H), 4.81 (d, J = 6.14 Hz, 2H), 5.00 (dd, 
J1 = 13.87 Hz, J2= 8.13 Hz, 1H), 5.28 (m, 4H), 5.41 (m, 4H), 6.09 (m, 4H), 7.05 (d, J= 8.72 
Hz, 2H), 7.32 (s, 1 H), 7.46 (d, J = 8.72 Hz, 2H), 7.58 (d, J = 8.72 Hz, 1 H), 7.81 (m, 3H), 7.86 
(d, J = 8.72 Hz, 2H), 7.94 (m, 3H), 8.00 (d, J = 8.72 Hz, 2H), 8.34 (d, J = 8.72 Hz, 1 H), 9.03 
(d, J = 7.53 Hz, 1 H), 9.69 (s, 1 H), 10.15 (s, 1 H), 10.59 (s, 1 H), 10.66 (s, 1 H). 
HRMS (ESI): [M+H]+ calculated: 1003.3873 
found: 1003.3880 








1 H d I H ~ ô N'Oy O -:?' N .ô 
0 ~ 1 ~J ~ 1 H 
- N 
= H 
0 "CN 15 
( S, E)-Allyl 2-( allyloxy)-4-(2-( allyloxy)-4-( 4-(2-( 4-(3-( 4-( allyloxy)phenyl)-2-methylacrylam ido) 
benzam ido )-3-cyanopropanamido )benzam ido )-3-methoxybenzam ido )-3-methoxybenzoate 
(14) (1.0 eq, 30 µmol, 30 mg) was dissolved in dry THF (5 ml) under argon atmosphere and 
exclusion of light. Phenylsilane (8.0 eq, 239 µmol, 30 µI) and Pd[P(Ph)3]4 (0.5 eq, 15 µmol, 17 
mg) were added and the reaction mixture was stirred for 10 hours at room temperature. AcOH 
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(1 ml) was added, the solvent was removed under reduced pressure and the sample was 
freeze dried. Purification was achieved by preparative HPLC and yielded the product as a 
white solid (12 mg, 48 %). 
1H-NMR (THF-ds, 500 MHz): o 2.05 (s, 3H), 3.01 (dd, J1 = 16.84 Hz, J2 = 8.72 Hz, 1 H), 3.09 
(m, 1 H), 3.71 (s, 3H), 3.84 (s, 3H), 4.92 (m, 1 H), 6.78 (d, J = 8.32 Hz, 2H), 7.21 (s, 1 H), 7.29 
(d, J = 8.32 Hz, 2H), 7.50 (d, J = 8.92 Hz, 2H), 7.74 (m, 3H), 7.78 (d, J = 8.52 Hz, 2H), 7.86 
(m, 2H), 7.94 (m, 3H), 8.96 (d, J = 7.53 Hz, 1 H), 9.63 (s, 1 H), 9.72 (s, 1 H), 10.04 (s, 1 H), 10.52 
(s, 1 H), 11.08 (s, 1 H), 11.48 (s, 1 H). 







02N~ H 20 
Allyl 2-(allyloxy)-4-(2-(allyloxy)-4-amino-3-methoxybenzamido)-3-methoxybenzoate (4) (1.0 
eq, 0.49 mmol, 210 mg) was dissolved in dry THF and DIPEA (7.0 eq, 3.14 mmol, 533 µI) 
and p-nitro benzoic acid chloride (3.0 eq, 1.34 mmol, 250 mg) was added under argon 
atmosphere. The solution was stirred for 18 h at room temperature. The solvent was removed 
under reduced pressure and the crude product was purified by column chromatography (H:EA 
- 4:1) to yield the product as a yellow solid (84 mg, 30 %). 
R1 (H:EA- 3:1) = 0.19 
1H-NMR (CDCl3, 400 MHz): o [ppm] 3.99 (s, 3H), 4.06 (s, 3H), 4.57-4.60 (m, 2H), 4.77 (d, J= 
6.42 Hz 2H), 4.81 (dt, J1 = 5.73 Hz, J2 = 1.34 Hz, 2H), 5.23-5.45 (m, 6 H), 6.00-6.21 (m, 3 H), 
7.69 (d, J = 8.9 Hz, 1 H), 8.06-8.09 (m, 3 H), 8.38-8.41 (m, 2H), 8.45 (dd, J1 = 9.14 Hz, J2 = 
3.15 Hz, 2H), 8.69 (s, 1 H) . 














d l H N ~ H H2N 17 
Allyl 2-(allyloxy) -4-((2-(allyloxy) -3-methoxy -4-(4-nitrobenzamido) benzoyl) oxy)-3-methoxy 
benzoate (20) (1.0 eq, 0.13 mmol, 82 mg) was dissolved in ethanol/dioxane (1 :1, 1.8 ml) and 
SnC'2·H20 (5.0 eq, 0.66 mmol, 150 mg) was added. The solution was stirred for 17 h at room 
temperature. 1 M KOH was added, the aqueous phase was extracted with EtOAc, the 
combined organic layers were washed with brine and dried over Na2SÜ4. The solvent was 
removed under reduced pressure and the crude product was purified by column 
chromatography (H:EA - 1 :1) to yield the product as a yellow solid (65 mg, 83 %). 
R1 (H:EA - 1 :1) = 0.23 











O ~ND H 




Allyl 2-(allyloxy) -4-(2-(allyloxy) -4-(4-aminobenzamido) -3-methoxybenzamido) -3-methoxy 
benzoate (17) (1.0 eq, 0.095 mmol, 56 mg) was dissolved in dry DMF under argon atmosphere. 
Boc-Asn-OH (3.0 eq, 0.29 mmol, 67 mg), HATU (6.1 eq, 0.58 mmol, 220 mg) and DIPEA (7 
eq, 0.67 mmol, 113 µI) were added. The mixture was stirred at room temperature for 14 h. 
EtOAc was added and the organic layer was washed with saturated NH4CI solution, saturated 
NaHC03 solution, brine and dried over Na2SÜ4. The solvent was removed under reduced 
pressure and the crude product was purified by column chromatography (CHCl3:CH3QH -
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9:0.2) to yield the product as a yellow, viscous oil. Since the product still contained impurities 
after chromatography the yield was determined after the last coupling step. 
R1 (C:M - 9:0.2) = 0.08 
HRMS (ESI): [M+Na]+ calculated: 806.3008 
found: 806.3007 
(S)-allyl 2-(allyloxy)-4-(2-(allyloxy)-4-(4-(2-amino-3-cyanopropanamido)benzamido)-3-
methoxybenzam ido )-3-methoxybenzoate 
( S)-allyl 2-( allyloxy)-4-(2-( allyloxy)-4-( 4-(2-( (tert-butoxycarbonyl)amino )-3-cyanopropanamido) 
benzamido)-3-methoxybenzamido)-3-methoxybenzoate (21) was dissolved in dioxane and 4 
M HCI in dioxane was added. The mixture was stirred at room temperature for 1.5 h. The 
solvent was removed under reduced pressure and the crude product was used for the next 
step without further purification. The yield was determined after the last coupling step. 
R1 (C:M - 9:1) = 0.34 









a,,._ ,,; 0 N~O, 
22 o 
(E)-3-(4-allyloxyphenyl)-2-methyl-prop-2-enoic acid (13) (1.0 eq, 0.72 mmol, 157 mg) was 
dissolved in dry DCM under argon atmosphere and thionyl chloride (10.0 eq, 7.20 mmol, 522 
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µl) was added The solution was stirred at room temperature for 20 h. The solvent and thionyl 
chloride were removed under reduced pressure. The residue was dissolved in dry THF and 
methyl 4-aminobenzoate (0.7 eq, 0.48 mmol, 73 mg) and DIPEA (8.0 eq, 5.76 mmol, 976 µl) 
were added. The mixture was stirred at room temperature for 20 h, DCM was added and the 
organic layer was washed with saturated NH4CI solution and brine and dried over MgSQ4. The 
solvent vas evaporated and the crude product was purified using reversed phase flash 
chromatography (water/MeOH) to yield the product as a white sol id (121 mg, 71 %). 
R1 (CHCl3:CH3QH - 100:1) = 0.71 
1 H-NMR (dmso-d6, 400 MHz): o [ppm] 2.12 (d, J1 = 0.9 Hz, 3H), 3.83 (s, 3H), 4.60-4.63 (m, 
2H), 5.25-5.30 (m, 1 H), 5.38-5.45 (m, 1 H), 6.00-6.10 (m, 1 H), 7.01-7.05 (m, 2H), 7.29 (s, 1 H), 
7.44-7.46 (m, 2H), 7.86-7.95 (m, 4H), 10.23 (s, 1H). 
HRMS (ESI): [M+H]+ calculated: 352.1543 
found: 352.1550 




~~ 0 'OyoH 
19 o 
(E)-Methyl 4-(3-(4-(allyloxy)phenyl)-2-methylacrylamido)benzoate (22) ( 1 eq, 0.34 mmol, 121 
mg) was dissolved in THF (2 ml). 0.5 M LiOH in water (2.5 eq, 0.86 mmol, 1.7 ml) was added. 
The mixture was stirred at room temperature for 20 h, then acidified to pH 2 and extracted with 
EtOAc. The combined organic layers were washed with water and brine, dried over MgS04 
and the solvent was evaporated to yield the product as a white solid (99 mg, 85 %). 
R1 (CHCl3:CH3QH - 9:1) = 0.35 
1H-NMR (dmso-d6, 400 MHz): o [ppm] 2.12 (d, J1 = 0.98 Hz, 3H), 4.61 (d, J = 5.2 Hz, 2H), 5.28 
(dd, J1 = 10.2 Hz, J2 = 1.5 Hz, 1 H), 5.42 (dd, J1 = 17.3 Hz, J2 = 1.5 Hz, 1 H), 6.02-6.10 (m, 1 
H), 7.03 (d, J = 8.7, 2H), 7.29 (s, 1H), 7.45 (d, J= 8.7 Hz, 2H), 7.83-7.92 (m, 4H), 10.18 (s, 
1 H). 
HRMS (ESI): [M-HJ- calculated: 336.1241 
found: 336.1237 
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Short description of the figures 
Fig. 1 shows a comparison of 1 H-NMR spectra of natural beta-Albicidin and 
synthesized beta-Albicidin measured with a Bruker A vance/1 700 MHz 
spectrometer. A) natural beta-Albicidin in dB-THF (50 µ/) B) synthesized 
beta-Albicidin dB-THF (500 µ/); 
Fig. 2 shows a HPLC-LR-ESl-(+)-MS2 experiment with A) beta-Albicidin (natural) 
B) Asn-Albicidin (natural) and C) Carbamoyl-Albicidin (natural) determining the 
structure of the compounds. HPLC-DAD-LR-ESl-(+)-MS/MS data were 
recorded on a triple quad mass spectrometer (ESI-Triple-Quadrupol-MS, 6460 
series, Agilent Technologies, Waldbronn, Germany; Collision energy 10 eV); 
Fig. 3 A 
Fig. 3 B 
Fig. 3 C 
Fig. 3 D 
Fig. 3 E 




shows a CD spectra of beta-Albicidin (natural); 
shows a UV spectra of beta-Albicidin (natural); 
shows a CD spectra of beta-Albicidin (synthesized); 
shows a UV spectra of beta-Albicidin (synthesized); 
shows a CD spectra of Enantio-beta-Albicidin (synthesized); 
shows a UV spectra of Enantio-beta-Albicidin (synthesized); 
shows a HPLC-DAD-Chromatogram (Agi lent 1100) of beta-(L)-Albicidin 
(À-= 280 nm); 
shows a UV spectrum of the beta-(L)-albicidin measured on the Exactive 
Orbitrap HPLC-MS instrument (HPLC-DAD photodiode array detection,, Agilent 
1100 HPLC). 
shows HPLC-LR-ESl-(+)-MS/MS data: A) beta-Albicidin m/z = 843.3 [M+H]+; B) 
Asn-OMe-Albicidin m/z = 861.28 [M+H]+; C) beta-OMe-Albicidin m/z = 873.31 
[M+H]+; D) Asn-OMe-Albicidin m/z = 891.32 [M+H]+. HPLC-DAD-LR-ESl-(+)-
MS/MS data were recorded on a triple quad mass spectrometer (ESI-Triple-
Quadrupol-MS, 6460 series, Agilent Technologies, Waldbronn, Germany; 
Collision energy 10 eV). 
Fig. 7 shows HPLC-LR-ESl-(+)-MS/MS data: A) beta-Albicidin m/z = 843.3 [M+H]+;. 
E) Carbamoyl-Albicidin m/z = 886.31 [M+H]+; F) Carbamoyl-OMe-Albicidin m/z 
= 916.31 [M+H]+; G) Carbamoyl-OMe-Asn-Albicidin m/z = 934.33 [M+H]+. 
HPLC-DAD-LR-ESl-(+)-MS/MS data were recorded on a triple quad mass 
spectrometer (ESI-Triple-Quadrupol-MS, 6460 series, Agilent Technologies, 
Waldbronn, Germany; Collision energy 10 eV). 
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Fig. 8 shows HR-ESl-(+)-Orbitrap-MS data: beta-OMe-Albicidin m/z = 873.31 [M+H]+; 
Carbamoyl-Albicidin m/z = 886.31 [M+H]+; Asn-OMe-Albicidin m/z = 891.32 
[M+H]+; Carbamoyl-OMe-Albicidin m/z = 916.31 [M+H]+; Carbamoyl-OMe-Asn-
Albicidin m/z = 934.33 [M+H]+. 
Fig. 9 shows the High-resolution-ESl-(+)-Orbitrap-MS analysis performed on a 
Orbitrap XL LC-MS (Thermo Fisher Scientific GmbH, Bremen). beta-Albicidin 
m/z = 843.30 [M+H]+ ; Asn-OMe-Albicidin m/z = 861.28 [M+H]+; beta-OMe-
Albicidin m/z = 873.31 [M+H]+; Carbamoyl-Albicidin m/z = 886.31 [M+H]+; Asn-
OMe-Albicidin m/z = 891.32 [M+H]+; Carbamoyl-OMe-Albicidin m/z = 916.31 
[M+H]+; Carbamoyl-OMe-Asn-Albicidin m/z = 934.33 [M+H]+. 
Fig. 10 
Fig. 11 
shows a HPLC-DAD-Chromatogram at 310 nm after the step 2 purification 
protocol, summarized in Table 1. R115 min = Carbamoyl-OMe-Asn-Albicidin 
(labeled o-albicidin); R118 min= Asn-OMe-Albicidin (labeled a-3-albicidin); R124 
min = Carbamoyl-Albicidin (labelled y-albicidin); R129 min = Carbamoyl-OMe-
Albicidin (labelled E-albicidin); R132 min = beta-Albicidin (labelled 13-Albicidin); 
R138 min= beta-OMe-Albicidin (labelled s-albicidin). 
shows a Table of biological test results of synthetic albicidin in comparison to 
natural albicidin syntesized by heterologous expression. The microbiological 
assay described by Zhang et al., (J Appt Microbiol., 1998, 85, 1023-8) was used 
to study cross-resistance between synthetic albicidin (10) and the natural 
product albicidin purified from albicidin heterologous host developed by Vivien 
et al. (Antimicrob Agents Chemother., 2007, 51, 1549-52). Several Escherichia 
coti strains expressing a wide range of albicidin resistance determinants were 
used for this microbiological bioassay: strain DH5aAlbr (a spontaneous 
albicidin-resistant DH5a derivative;Rott et al., (J. Bacteriol., 1996, 178, 4590-
4596.) and strains harboring albD (an albicidin-detoxifying gene, Zhang and 
Birch (Proc. Nat!. Acad. Sei. USA, 1997, 94, 9984-9989.),alb14 (an albicidin 
efflux pump gene conferring albicidin resistance in E. coti, Bostock et al., (J. 
Appt. Microbiol., 2006, 101, 151-160.), alb19 (a McbG gene conferring albicidin 
resistance in E. coti, Hashimi et al. (Antimicrob. Agents Chemother., 2007, 51, 
181-187.), or sbmC (a microcin B17 resistance gene, Baquero et al. (Mol. 
Microbiol., 1995, 18, 301-311.). The resistance pattern was exactly the same 
for both toxins (synthetic albicidin (10) and the natural product albicidin purified 
from albicidin heterologous host), confirming that both toxins exhibit the same 
mode of action. 
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PREPARATIONS OF ALBICIDIN DERIVATIVES 
According to another aspect, the invention relates to preparations of an antibiotically active 
compound having a molecular structure as defined by formula 1, characterized in that the 
purity of the preparation is greater than 95%, 97%, 99%, 99,5% or 99,9%. 
ln some embodiments, the purity of the preparation is about 99%. 
ln some embodiments, the purity of the preparation is greater than 99%. 
ln some embodiments, the purity of the preparation is greater than 99,5%. 
ln some embodiments, the purity of the preparation is greater than 99,9%. 
Similarly, a dosage form for the prevention or treatment of bacterial infection is provided, 
comprising a compound or preparation according to any of the above described aspects or 
embodiments of the invention. Dosage forms may be for enterai administration, such as 
nasal, buccal, rectal, transdermal or oral administration, or as an inhalation form or 
suppository. Alternatively, parenteral administration may be used, such as subcutaneous, 
intravenous, intrahepatic or intramuscular injection forms. Optionally, a pharmaceutically 
acceptable carrier and/or excipient may be present. 
According to another aspect, the invention relates to a pharmaceutical preparation of an 
antibiotically active compound having a molecular structure as defined by formula 1 as active 
ingredient, characterized in that said pharmaceutical preparation is essentially free of (has a 
content of less than 5%, 3%, 1 %, 0,5%, 0, 1 % (w/w) ) contaminants. 
ln some embodiments, the pharmaceutical preparation has a content of less than 1 % (w/w) 
contaminants. 
ln some embodiments, the pharmaceutical preparation has a content of less than 0,5 % 
(w/w) contaminants. 
ln some embodiments, the pharmaceutical preparation has a content of less than 0, 1 % 
(w/w) contaminants. 
ln some embodiments, the pharmaceutical preparation is essentially free of contaminants. 
According to a further aspect, the invention relates to an isolated antibiotically active 
compound having a molecular structure as defined by formula 1, or to a pharmaceutical 
preparation of at least one antibiotically active compound having a molecular structure as 
defined by formula 1 as active ingredient for use in a method of treatment of disease, 
particularly in a method for the treatment of bacterial infections. 
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ln some embodiments, the pharmaceutical preparation of at least one antibiotically active 
compound comprises one essentially pure enantiomer according to the general formula 1 Lor 
1 O. 
ln some embodiments, the pharmaceutical preparation of an antibiotically active compound 
comprises a mixture of L- or 0-enantiomers selected independently from each other from the 
compounds of the general formula 1. 
ln some embodiments, the pharmaceutical preparation of an antibiotically active compound 
comprises mixture of the L-enantiomer and the respective 0-enantiomer according to the 
general formula 1 Land 10, wherein Z and Y of the general formula 1 Lare the same as Z 
and Y of the general formula 10, thus, pharmaceutical preparation comprises a mixture of 
the L- and 0-enantiomer with the same molecular formula. 
ln some embodiments, the pharmaceutical preparation of at least one antibiotically active 
albicidin compound comprises one essentially pure enantiomer selected from the group of 
beta-Albicidin or Asn-Albicidin. 
ln some embodiments, the pharmaceutical preparation of at least one antibiotically active 
albicidin compound comprises one essentially pure enantiomer selected from the group of 
Enantio-beta-Albicidin or Enantio-Asn-Albicidin. 
ln some embodiments, the pharmaceutical preparation comprises beta-Albicidin as N 
essentially pure enantiomer. 
ln some embodiments, the pharmaceutical preparation comprises Enantio-beta-Albicidin as N 
essentially pure enantiomer. 
ln some embodiments, the pharmaceutical preparation of an antibiotically active albicidin 
compound comprises a mixture of L- or 0-enantiomers selected from the group of beta-
Albicidin, Asn-Albicidin, Carbamoyl-Albicidin, Carbamoyl-Asn-Albicidin, beta-OMe-Albicidin, 
Asn-OMe-Albicidin, Carbamoyl-OMe-Albicidin, Carbamoyl-OMe-Asn-Albicidin, Enantio-beta-
Albicidin, Enantio-Asn-Albicidin, Enantio-Carbamoyl-Albicidin, Enantio-Carbamoyl-Asn-
Albicidin, Enantio-beta-OMe-Albicidin, Enantio-Asn-OMe-Albicidin, Enantio-Carbamoyl-OMe-
Albicidin or Enantio-OMe-Carbamoyl-Asn-Albicidin. This includes also the previously 
discussed diastereoisomers (1 L 1, 1 L2, 1 01, 1 02), which are not specifically mentioned due to 
simplicity reasons. 
ln some embodiments, the pharmaceutical preparation of an antibiotically active albicidin 
compound comprises a mixture of L- Enantiomers selected from the group of beta-Albicidin, 
Asn-Albicidin Carbamoyl-Albicidin, Carbamoyl-Asn-Albicidin, beta-OMe-Albicidin, Asn-OMe-
Albicidin, Carbamoyl-OMe-Albicidin, Carbamoyl-OMe-Asn-Albicidin. 
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ln some embodiments, the pharmaceutical preparation of an antibiotically active albicidin 
compound comprises a mixture of D- Enantiomers selected from the group of Enantio-beta-
Albicidin, Enantio-Asn-Albicidin, Enantio-Carbamoyl-Albicidin, Enantio-Carbamoyl-Asn-
Albicidin Enantio-beta-OMe-Albicidin, Enantio-Asn-OMe-Albicidin, Enantio-Carbamoyl-OMe-
Albicidin or Enantio-OMe-Carbamoyl-Asn-Albicidin. 
ln some embodiments, the pharmaceutical preparation of an antibiotically active albicidin 
compound comprises mixture of the L-enantiomer and the respective D-enantiomer according 
to the general formula (1 L) and (1 D), wherein R1', R2' and R3' of the general formula (1 L) are 
the same as R1', R2' and R3 ' of the general formula (1 D), thus, pharmaceutical preparation 
comprises a mixture of the L- and D-enantiomer with the same molecular formula. 
ln some embodiments, the pharmaceutical preparation of an antibiotically active albicidin 
compound comprises mixture of 
beta-Albicidin and Enantio-beta-Albicidin, or 
Asn-Albicidin and Enantio-Asn-Albicidin. 
ln some embodiments, the pharmaceutical preparation of an antibiotically active albicidin 
compound comprises mixture of 
beta-Albicidin and Enantio-beta-Albicidin. 
ln some embodiments, the bacterial infection is an infection by a gram-negative bacterium. 
ln some embodiments, the bacterial infection is an infection by a gram-negative bacterium. 
ln some embodiments, the bacterial infection is an infection by a gram-negative bacterium of 
the genus Acinetobacter, Bordatella, Borellia, Brucella, Camphylobacter, Chlamydia, 
Chlamydophila, Enterobacter, Escherichia, Francisella, Haemophilus, Helicobacter, 
Klebisella, Legionella, Leptospira, Morganella, Moraxella, Neisseria, Proteus, Pseudomonas, 
Rickettsia, Shigella, Salmonella, Stenotrophomonas, Treponema or Yersinia. 
ln some embodiments, the bacterial infection is an infection by a gram-negative bacterium of 
the genus Bacteroides, Escherichia, Enterobacter, Salmonella, Klebisella, Pseudomonas, 
Haemophilus, Serratia, Shigella, Proteus or Morganella. 
ln some embodiments, the bacterial infection is an infection by a gram-negative bacterium 
selected from the group of Acinetobacter baumannii, Bacteriodis fragilis, Bordatella pertussis, 
Borrelia burgdorferi, Bruce/la abortus, Bruce/la abortus, Bruce/la canis, Bruce/la melitensis, 
Bruce/la suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, 
Chlamydophila psittaci, Enterobacter aerogenes, Enterobacter cloacae, Enterobacter 
sakazakii, Cronobacter sakazakii, Escherichia coti, Francise/la tularensis, Haemophilus 
influenzae, Helicobacter pylori, Klebisella pneumonia, Legionella pneumophila, Leptospira 
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interrogans, Moraxella catarrhalis, Morgane/la morganii, Moraxella lacunata, Moraxella bovis, 
Neisseria gonorrhoeae, Neisseria meningitidis, Proteus vulgaris, Proteus mirabilis, 
Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella typhi, Salmonella enteritidis, 
Serratia marcescens, Shigella sonnei, Stenotrophomonas maltophilia, Treponema pallidum, 
Vibrio cholerae or Yersinia pestis. 
ln some embodiments, the bacterial infection is an infection by a gram-negative bacterium 
selected from the group of Escherichia coti, Enterobacter aerogenes, Enterobacter cloacae, 
Enterobacter sakazakii, Cronobacter sakazakii, Salmonella typhi, Klebisella pneumonia, 
Pseudomonas aeruginosa, Haemophilus influenza, Shigella sonnei, Proteus vulgaris, 
Proteus mirabilis or Morgane/la morganii. 
ln some embodiments, the bacterial infection is an infection by a gram-positive bacterium. 
ln some embodiments, the bacterial infection is an infection by a gram-positive bacterium of 
the genus Bacillus, Clostridium, Corynebacterium, Enterococcus, Listeria, Micrococcus, 
Staphylococcus or Streptococcus. 
ln some embodiments, the bacterial infection is an infection by a gram-positive bacterium of 
the genus of Staphylococcus, Streptococcus, Bacillus or Micrococcus. 
ln some embodiments, the bacterial infection is an infection by a gram-positive bacterium 
selected from the group of Bacillus anthracis, Clostridium botulinum, Clostridium difficile, 
Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus 
faecalis, Enterococcus faecium, Usteria monocytogenes, Staphylococcus aureus, 
Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, 
Streptococcus pneumoniae or Streptococcus pyogenes. 
ln some embodiments, the bacterial infection is an infection by a gram-positive bacterium 
selected from the group of Staphylococcus aureus, Staphylococcus epidermidis, 
Streptococcus pyogenes, Bacillus subtilis, Bacillus megaterium or Micrococcus luteus. 
ln some embodiments, the bacterial infection is an infection by a bacterium of the family of 
Mycobacteriaceae, in particular a Mycobacterium, further in particular an infection by one of 
Mycobacterium tuberculosis, Mycobacterium leprae, Mycobacterium ulcerans or 
Mycobacterium avium. 
ln some embodiments, the bacterial infection is an infection by a bacterium of the family of 
Mycoplasmataceae, in particular of the genus Mycoplasma, further in particular an infection 
by Mycoplasma pneumonia. 
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ln some embodiments, the bacterial infection is an infection by a bacterium resistant to a 
fluoroquinolone antibiotic. ln some embodiments, the bacterium is resistant to the 
fluroquinolone antibiotic ciprofloxacin, levofloxacin or trovafloxacin. 
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Patent claims 
1. A compound characterized by a general formula (1 ), 
1 2 3 4 2 X-BB-D-BC-0-BD-D-BE-X 
( 1 ) ' 
a. with X1 being 
i. selected from a substituent group S 1 or S2, or 
ii. R4-01-, with R4 being selected from a substituent group S3, S4 or S5, or 
iii. BA-01- with BA-01-being selected from 
E--17'0_1 ~ 
, and 
with E being selected from a substituent group S3, S4 or S5, and 
b. with BB being selected from a substituent group S3 or S4, and 
c. with BC 





~?z, ', _)..__(CH2):--~ (CH2), 
, L or with p being 1, 2, 3, 4 or 5, 
in particular p being 2 or 3, and with r being 2, 3, 4 or 5, in particular r being 2, 
or 
ii. with -02-BC- being 
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0 
_Jl_ 0 ~ ,\A /"'7, 
(CH2)p 18 
R with p being 1, 2, 3, 4 or 5, in particular p 
being 2 or 3, and 
d. with BD being selected from a substituent group S3 or S4, and 
e. with BE being selected from a substituent group S3, and 
f. with X2 being 
i. selected from a substituent group S 1 or S2, and wherein a linker 0 5 may 
be optionally situated between BE and the substituent group S 1 or S2, or 
ii. being -05-BF, wherein BF is selected from a substituent group S2 
with S1 being 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -N02, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2CH3 or -CF3, 
with S2 being 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-
NRcC(=Ü)QRa, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other from -Ra or -ORa, 
- with Rba being selected independently from each other from -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
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with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
PCT /EP2014/052922 
- with each Ra, Rb or Re being selected, where applicable, independently 
from each other from 
- hydrogen, -CN, a substituent group S3, a substituent group S4 or a 
substituent group S5, 
with S3 being 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C5-C10 aryl, 
with S4 being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo 
heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, 
with S5 being 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-
C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or 
unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or 
a C1-C16 haloalkyl, 
with R2 and R3 of BA being selected, where applicable, independently from each 
other from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or 
unsubstituted C1-C3 alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 
haloalkyl , in particular from -H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, 
-CH2CH3, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -
CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3,more particularly with R2 and R3 being 
selected independently from each other from -H, -F or -CH3, 
with L 1, L2, L3, L 4 or L5 being selected independently from each other from -H, -CH3, -
CH2CH2CH2NHC(NRC)N(Rb)(Ra), -CH2CON(Rb)(Ra), -CH2C(=O)ORa, -CH2SRa, -
CH2CH2C(=O)N(Rb)(Ra), -CH2CH2C(=O)ORa, -CH2(C3H3N2), -CH2CH2CH2CH2, -
CH2CH2SCH3, -CH2(C6Hs), -CH2CH2CH2-, -CH20Ra, -CH(ORa)CH3, -CH2(CsH6N)ORa, 
-CH2(C6H4)0Ra, -CH(CH3)2, -CCH, -CN, -OCH3 -CF3, -Ra, -CH(Rb)(Ra), -CH2C(=O)Ra, 
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-C(=O)ORa, -OC(=O)NRbRa, -C(=O)NRbRa, -CH2C(=O)NRb (ORa), -CH2S(02)Ra, -
S(02)0Ra, -CH2S(02)0Ra, -CH2NRbC(=O)Ra, -CH2NRbS(02)Ra, -
CH2P(=O)(QRb)(QRa), -CH2P(=O)(QRb)(Ra), -CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
with Ra and Rb being selected, where applicable, independently from each 
other from hydrogen, -CN, a substituent group S3, a substituent group S4 or a 
substituent group S5, 
with R8 of -02-BC- being selected from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -
CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with R8 being 
selected from H or CH3, more particularly R8 is H. 
with Y being selected from -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -
C(=O)NHCH3, -C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -
C(=O)N(CH3)(CH2CH3), -CF3 or -C(=O)NH2, and 
with Z being selected from -H, -OH, -CH3, -CH2CH3, -OCH3 ,-NH2, -NHCH3, -N(CH3)2 -
N(CH3)3+, in particular Z is H and Y is CN or -C(=O)NH2, 
with 0 1 ,02 , 0 3 , 0 4 or 0 5 being each, independently from each other, a linker which 
comprises carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which is 
covalently connecting the moiety, BA and BB (0 1), BB and BC (02), BC and BD (03), 
BD and BE (04) and BE and BF (05). 
2. The compound according to claim 1, wherein the compound is characterized by a 
general formula (5), 
1 4 5 
X~ vD-BE-D-BF 
1 /. 3 "'" 1 
r/ D2 D ....._, 
'se ..... 
(formula 5), 
with X1, 02, BC, 03, 04, BE, 0 5 and BF having the same meaning as defined 
previously. 
3. The compound according to claim 1, wherein the compound is characterized by a 
general formula (7), 
(formula 7), 
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with X1, 0 2 , BC, 0 3 , 04, R11n, os and BF having the same meaning as defined 
previously. 
4. The compound according to claim 1, wherein the compound is characterized by a 
general formula (9), 
(formula 9), 
with X1, 0 2 , BC, 0 3 , 04, R11 , os and BF having the same meaning as defined 
previously. 
5. The compound according to claim 1, wherein the compound is characterized by a 
general formula (12), 
(formula 12), 
with X1, 0 2 , BC, 0 3 , 04, R11 , R10n, T and os having the same meaning as defined 
previously. 
6. The compound according to claim 1, wherein the compound is characterized by a 
general formula (13), 
(formula 13), 
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with E, R2, R3, 01, 0 2, BC, 0 3, 04, R11 , R10n, T and os having the same meaning as 
defined previously. 
7. The compound according to claim 1, wherein the compound is characterized by a 
general formula (14), 
(formula 14), 
with R2, R3, 01, 0 2, BC, 0 3, 04, R1n, R11 , R10n, T and os having the same meaning as 
defined previously. 
8. The compound according to claim 1, wherein the compound is characterized by a 
general formula (15), 
(formula 15), 
with Y, Z, R2,R3, 01, 0 2, 0 3, 04, R11 , R10n, R1n, T and os having the same meaning as 
defined previously. 
9. The compound according to any one of the claims 1 to 5, wherein 
x1 is 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, 
-CH2CH3 or -CF3, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
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C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-
NRcC(=Ü)ÜRa,-(CH2)m-NRcC(=S)Ra, -(CH2)m-NRCC(=S)NRaRb, -(CH2)m-
NRCC(=S)ORa, -(CH2)m-NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=O)-(M)-C(=O)ORa, -(CH2)m-O-C(=O)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü) (Rba)( Raa), -( CH2)m-C( =Ü )O-(CH2)q-P( =Ü )(Rba)( Raa_( CH2)m-C( =Ü)O-
( CH2)q-S( 02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other from -Ra or -ORa, 
- with Rba being selected independently from each other from -Rb or -QRb, 
- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
- with each Ra, Rb or Re being selected, where applicable, independently 
from each other from 
- hydrogen, -CN, 
- a substituted or unsubstituted C3-C1 o cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
- a substituted or unsubstituted C5-C10 aryl, 
- a substituted or unsubstituted C3-C1 o heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-
C10 halo heterocycle, or 
- a substituted or unsubstituted Cs-C10 heteroaryl, 
- a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted 
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C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a 
substituted or unsubstituted C1-Cs haloalkyl. 
1 O. The compound according to any one of the claims 1 to 5 or 9, wherein 
x1 is 
with Ra being a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted or 
unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or unsubstituted C2-
Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or a substituted or 
unsubstituted C1-Cs haloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or unsubstituted 
C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, in particular a substituted or 
unsubstituted 1,2,3-triazole, a substituted or unsubstituted 1,2,4-triazole, a 
substituted or unsubstituted indole, a substituted or unsubstituted isoindole, a 
substituted or unsubstituted quinoline or a substituted or unsubstituted 
isoquinoline, or 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8. 
11. The compound according to any one of the claims 1 to 5 or 9 to 10, wherein 
x1 is 
with Ra being a substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C2-Cs alkenyl, a substituted or unsubstituted C2-Cs alkynyl, or 
a substituted or unsubstituted C1-Cs haloalkyl. 
12. The compound according to any one of the claims 1 to 5, wherein X1 is R4-01-, with 
0 1 having the same meaning as defined previously, and wherein 
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a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-C16 
alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or 
unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or a 
C1-C16 haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, a 
substituted or unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted or 
unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-C10 cycloalkyl, or 
a substituted or unsubstituted C3-C10 halo cycloalkyl. 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or unsubstituted 
C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
13. The compound according to any one of the claims 1 to 5 or 12, wherein X1 is R4-01-, 
with 0 1 having the same meaning as defined previously, and wherein 
R4 is 
a substituted or unsubstituted Cs-CB halo heterocycle, in particular a Cs-CB halo 
heterocycle comprising one or two halogen atoms selected from Cl of F, 
particularly comprising one Cl or one F, 
a substituted or unsubstituted Cs-CB heteroaryl, 
a substituted C6 aryl, in particular a bicyclic C6 aryl such as tetraline or indane, 
a substituted or unsubstituted Cs-CB halo heteroaryl comprising one or two 
halogen atoms selected from Cl of F, particularly comprising one Cl or one F; or 
R4 is selected from the group of substituted or unsubstituted pyrrole, furan, 
thiophene, benzothiophene, chromene, thiazole, pyrazine, pyridazine, pyridine, 
1,2,3-triazole, 1,2,4-triazole, imidazole, oxazol, thiazol, indole, isoindole, 
quinoline, isoquinoline, naphatalene, coumarin, aminocoumarin, umbelliferon, 
benzotriazole, psoralen, benzofurane, benzothiophene, benzimidazol, 
benzthiazole, benzoxazole or benzpyridazin or hydroxylated, methylated or 
halogenated derivatives thereof. 
14. The compound according to any one of the claims 1 to 5 or 12 to 13, wherein X1 is 
R4-01-, with 0 1 having the same meaning as defined previously, and wherein 
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a substituted or unsubstituted C1-Cs alkyl or a substituted or unsubstituted C5-C10 
cycloalkyl, a substituted or unsubstituted Cs-C10 heteroaryl or a substituted or 








15. The compound according to any one of the claims 1 to 5 or 12 to 14, wherein X1 is 
R4-01-, with 0 1 having the same meaning as defined previously, and wherein 
an unsubstituted C1-Cs alkyl or an unsubstituted C5-C10 cycloalkyl. 
16. The compound according to any one of the claims 1 to 6, wherein X1 is BA-01-
with BA being selected from 
R2 
E~7;, 







in particular with BA being selected from BA 1, BA2 or BA4, more particularly BA is 
BA1, 
with 0 1 having the same meaning as defined previously, and 
with R2 and R3 being selected, where applicable, independently from each other from 
-H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, a substituted or unsubstituted C1-
C3 alkyl, a substituted or unsubstituted C1-C3 alkoxy or a C1-C3 haloalkyl, in particular 
with R2 and R3 being selected, where applicable, independently from each other from 
-H, -F, -CN, -OH, -NH2, -N02, -NHCH3, -NH(CH3)2, -CH3, -CH2CH3, -OCH3, -
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OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, 
-CH2F or -CF3, more particularly with R2 and R3 being selected independently from 
each other from -H, -For -CH3 
with E being 
- a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-C16 
alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or 
unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or a C1-
C16 haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, a substituted 
or unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs alkenyl, a 
substituted or unsubstituted C2-Cs alkynyl, a substituted or unsubstituted C1-Cs 
haloalkyl, a substituted or unsubstituted C3-C10 cycloalkyl, or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
- a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted 
C3-C10 halo cycloalkyl, 
- a substituted or unsubstituted C3-C10 heterocycle or a substituted or unsubstituted 
C3-C10 halo heterocycle; in particular a substituted or unsubstituted C4-C10 
heterocycle or a substituted or unsubstituted C4-C10 halo heterocycle, 
- a substituted or unsubstituted Cs-C10 heteroaryl, 
- a substituted or unsubstituted C5-C10 aryl. 
17. The compound according to any one of the claims 1 to 8, wherein X1 is BA-01- , with 
BA being selected from BA 1 to BA6, in particular from BA 1, BA 2 or BA4, more 
particularly BA is BA 1,with 0 1 and with R2 and R3 of BA 1 to BA6 having the same 
meaning as defined previously, and 
with E being 
- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n being 1, and 
- with each R1 independently from any other R1 being selected from 
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-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-
NRcC(=Ü)ÜRa, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted 
or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-
C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo 
cycloalkyl, 
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a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl. 
18. The compound according to any one of the claims 1 to 8 or 17, wherein X1 is BA-01-, 
with BA being selected from BA 1 to BA6, in particular from BA 1, BA 2 or BA4, more 
particularly BA is BA 1,with 0 1 and with R2 and R3 of BA 1 to BA6 having the same 
meaning as defined previously, and 
with E being 
- with n of R1n being 0, 1, 2, 3, 4 or 5, in particular n of R1n being 0, 1, 2 or 3, more 
particularly n of R1n 1, and 
- with each R1 independently from any other R1 being selected from 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NH CH3, 
-N(CH3)2, -CH3, -CH2-CH3, -CF3, -OCONH2 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)ORa, -
(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -
(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-
OC(=S)Ra, -(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-
C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -
(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-
NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)QRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -
(CH2)m-NRcC(=S)QRa, -(CH2)m-NRcS(02)Ra, -(CH2)m-
P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, 
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-(CH2)m-O-C( =0)-(M)-C( =O)OH, -(CH2)m-O-C( =0)-(M)-C( =0)0Ra, -
(CH2)m-O-C(=O)-(M)-Ra, -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), -
( CH2)m-C( =0)0-( CH2)q-P( =0 }( Rba) (Raa), -( CH2)m-C( =0 )O-(CH2)q-
S( 02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, , 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -ORb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from hydrogen, -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -
CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C5Hs -CH2C6Hs. 
19. The compound according to claim 1, wherein BB is 
or 
with n of R13n being 0, 1, 2, 3 or 4, in particular n of R13n being 0, 1 or 2, 
with each R13 independently from any other R13 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2CH3, -CF3 or -N02, in particular -OH, -F, -Cl, -Br, -1, -
CCH, -CN, -N3, -OCH3, -OCF3, -, -CH3, -CH2CH3 or -CF3, or 
with each R13 independently from any other R13 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2CH3, -CH3, -CF3 or -N02, in particular -OH, -F, -Cl, -Br, 
-1, -CCH, -CN, -N3, -OCH3, -OCF3, -, -CH3, -CH2CH3 or -CF3, wherein, each 
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carbon atom of the cyclic system which comprises no substituent R13 
comprises F instead of H. 
20. The compound according to any one of the claims 1 or 19, wherein 
BB is 
with n of R13n being 0, or 
with n of R13n being 1, 2, 3 or 4 with each R13 being F, in particular n is 4 and each R13 
is F. 
21. The compound according to any one of the claims 1 to 7, wherein 
BC is selected from 
with p being 1, 2, 3, 4 or 5, in particular p being 2 or 3, and 
with r being 2, 3, 4 or 5, in particular r being 2, 
with L 1, L2, L 4 or L5 being selected independently from each other from -H, -CH3, -
CH2CH2CH2NHC(NRC)N(Rb)(Ra), -CH2CON(Rb)(Ra), -CH2C(=O)ORa, -CH2SRa, -
CH2CH2C(=O)N(Rb)(Ra), -CH2CH2C(=O)ORa, -CH2(C3H3N2), -CH2CH2CH2CH2, -
CH2CH2SCH3, -CH2(C6Hs), -CH2CH2CH2-, -CH20Ra, -CH(ORa)CH3, -CH2(CsH6N)ORa, 
-CH2(C6H4)0Ra, -CH(CH3)2, -CCH, -CN, -OCH3, -CF3, -Ra, -CH(Rb)(Ra), -
CH2C(=O)Ra, -C(=O)ORa, -OC(=O)NRbRa, -C(=O)NRbRa, -CH2C(=O)NRb (ORa), -
CH2S(02)Ra, -S(02)0Ra, -CH2S(02)0Ra, -CH2NRbC(=O)Ra, -CH2NRbS(02)Ra, -
CH2P(=O)(QRb)(QRa), -CH2P(=O)(QRb)(Ra), -CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, 
and 
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with Ra and Rb being selected, where applicable, independently 
from each other from 
a substituted or unsubstituted C1-C4 alkyl, a substituted or 
unsubstituted C1-C4 alkoxy, a substituted or unsubstituted 
C1-C4 carboxy, a substituted or unsubstituted C2-C4 alkenyl, 
a substituted or unsubstituted C2-C4 alkynyl, or a C1-C4 
haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
with Y being -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) or -
C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, 
with -02-BC- being 
with 
p being 1, 2, 3, 4 or 5, in particular p being 2 or 3, and 
with, where applicable, each R8 being selected independently from each other from -
H, -CH3, -CH2CH3, -OCH3, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -
CF3, in particular with each R8 being selected independently from each other from H 
or CH3, more particularly each R8 being H. 
22. The compound according to any one of the claims 1 to 7 or 21, wherein 
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BC is selected from 
ty, 7z, ~x;' ~X 7z, 7z_ l' 7z, 7z_L7z, 
' ' ' ' 
with p being 1, 2, 3, 4 or 5, in particular p being 2 or 3, and 
with r being 2, 3, 4 or 5, in particular r being 2, 
with L1, L2, L 4 or L5 being selected independently from each other from H, -CH3, -
CH2CH2CH2NHC(NRC)N(Rb)(Ra), -CH2CON(Rb)(Ra), -CH2C(=O)ORa, -CH2SRa, -
CH2CH2C(=O)N(Rb)(Ra), -CH2CH2C(=O)ORa, -CH2(C3H3N2), -CH2CH2CH2CH2, -
CH2CH2SCH3, -CH2(C6Hs), -CH2CH2CH2-, -CH20Ra, -CH(ORa)CH3, -
CH2(CsH6N)ORa, -CH2(C6H4)0Ra, -CH(CH3)2, -CCH, -CN, -OCH3, -CF3, -Ra, -
CH(Rb)(Ra), -CH2C(=O)Ra, -C(=O)ORa, -OC(=O)NRbRa, -C(=O)NRbRa, -
CH2C(=O)NRb (ORa), -CH2S(02)Ra, -S(02)0Ra, -CH2S(02)0Ra, -
CH2NRbC(=O)Ra, -CH2NRbS(02)Ra, -CH2P(=Ü)(QRb)(QRa), -CH2P(=O)(QRb)(Ra), 
-CH2P(=O)(Rb)(Ra) or -CH2S(02)NRbRa, and with 
with Y being -CN, -C(=O)OH, -C(=O)OCH3, -C(=O)OCH2CH3, -C(=O)NHCH3, -
C(=O)NHCH2CH3, -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, -C(=O)N(CH3)(CH2CH3) 
or -C(=O)NH2, in particular Z is H and Y is CN and -C(=O)NH2, and wherein 
or 
with Ra and Rb being selected, where applicable, independently 
from each other from CH3, -CH2CH3, -CH2CH2CH3, -
CH2CH2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C5Hs ,-
CH2C6Hs, mono methoxybenzyl, in particular para methoxybenzyl, 
or dimethoxybenzyl or trimethoxybenzy, 
with -02-BC- being 
454 
wo 2014/125075 PCT /EP2014/052922 
with 
p being 1, 2, 3, 4 or 5, in particular p being 2 or 3, and 
with, where applicable, each R8 being selected independently from each other 
from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -CH2CF3, -CHFCF3, -CF2CF3, -CHF2, 
-CH2F or -CF3, in particular with each R8 being selected independently from 
each other from H or CH3, more particularly each R8 being H. 
23. The compound according to any one of the claims 1 to 7 or 21 to 22, wherein 
BC is selected from 
ty,7z, ~X7z, 7z_t,7z, o, 7z_L7z, 
'' '' 
with p, r, L1, L2 , L3 , L 4, L5 , Y, Z, Ra or Rb having the same meaning as defined 
previously, or 
with -02-BC- being 
with 
p being 1, 2, 3, 4 or 5, in particular p being 2 or 3, and 
with R8 being H or CH3. 
24. The compound according to any one of the claims 1 to 7 or 21 to 23, wherein BC 
is 
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with p, r L1, L2 , L3 , L4, L5 , Y, Z, Ra or Rb having the same meaning as defined 
previously. 
25. The compound according to any one of the claims 1 to 7 or 21 to 24, wherein BC is 
t-y~ ~x~ 1-Y~ ~x~ 
L L or , in particular or 
t'y~ 
with p, r L1, L2 , L3 , L4, L5 , Y, Z, Ra Rb having the same meaning as defined previously. 
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with n of R12n being 0, 1, 2, 3 or 4, in particular n of R12n being 0, 1 or 2, 
with each R12 independently from any other R12 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3, -CF3 or -N02, in particular -OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -
OCH3, -OCF3, -CH3, -CH2CH3 or -CF3, or 
with each R12 independently from any other R12 being 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2CH3, -CH3, -CF3 or -N02, in particular -OH, -F, -Cl, -Br, 
-1, -CCH, -CN, -N3, -OCH3, -OCF3, -, -CH3, -CH2CH3 or -CF3, wherein each 
carbon atom of the cyclic system which comprises no substituent R12 
comprises F instead of H. 
27. The compound according to any one of the claims 1 to 8, or 26 wherein 
BD is 
with n of R12n being 0, or 
with n of R12n being 1, 2, 3 or 4 with each R12 being F, in particular n is 4 and each R12 
is F. 
28. The compound according to any one of the claims 1 to 8, wherein BE is 
with n of R11n being 0, 1, 2, 3 or 4, in particular n of R11n being 0, 1, 2 or 3, 
with each R11 being selected independently from any other R11 from -OH, -F, -Cl, -
Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -
CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -
N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
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with each R11 being selected independently from any other R11 from -OH, -F, -Cl, -
Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -CH2CH3, -
CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, -CH3, -CF3 or -
N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, wherein, each carbon atom 
of the cyclic system which comprises no substituent R11 comprises F instead of H. 
29. The compound according to any one of the claims 1 to 8 or 28, wherein BE is 
with n of R11n being 2, and with each R11 independently from any other R11 being -OH, 
-OCH3 or -OCF3, in particular -OCH3 or -OCF3, more particularly with one R11 being -
OH and the other R11 being -OCH3 or -OCF3, in particular -OCH3, wherein more 
particularly OH is in ortho and OCH3 or -OCF3 in meta position with respect to the 
attachment position of the phenyl moiety of BE to os, or 
with n of R11n being 1, and with R11 being -OH, wherein in particular OH is in ortho 
position with respect to the attachment position of the phenyl of BE to os or 
with n of R11n being 1, and with R11 being -OCH3 or -OCF3, in particular or -OCH3, 
wherein more particularly -OCH3 or -OCF3 is in meta position with respect to the 
attachment position of the phenyl of BE to os, or 
with n of R11n being 0, or 
with n of R11n being 4 and each R11 is F. 
30. The compound according to any one of the claims 1 to 8 or 28 to 29, wherein BE is 
with n of R11n being 1, 2 or 3, in particular n of R11n being 1, 2 or 3, 
with one R11 being a substituent Q, with Q being selected from 
-(CH2)m-C(=O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra,-
(CH2)m-O-S(02)0H, -(CH2)m-O-S(02)0Ra, in particular -(CH2)m-O-S(02)0H, -
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(CH2)m-O-S(02)0Ra, with m being selected from 0, 1 or 2, in particular from 0 
or 1, with Ra being -CH3, -CH2CH3, -C5Hs , -CH2CH2CH3, -CH(CH3)2, -CH2C6Hs 
or para-methoxybenzyl 
-C(=0)-0-Ra, -0-C(=O)-Ra, in particular -0-C(=O)-Ra, with Ra being a 
substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted C1-C14 
alkyl, 
-(CH2)m-[(CH2)m1-0-C(=O)-(CH2)m2]p1-C(=O)ORd, in particular -(CH2)-[-0-
C(=O)-(CH2)2]p1-C(=O)ORd with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-[(CH2)m1-0-(CH2)m2]p1-0Rd, in particular -[-O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
-(CH2)m-C(=O)O-(CH2)q-P(=O)(Rba)(Raa), -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), in 
particular from -(CH2)m-O-(CH2)q-P(=O)(Rba)(Raa), 
with Raa and Rba being selected, where applicable, independently from 
each other from -Ra or -ORa and 
and 
with Ra being hydrogen, -OCH3, -OCH2CH3, -CH3, -CH2CH3, -C5Hs , 
-CH2CH2CH3, -CH(CH3)2, -CH2C6Hs or para-methoxybenzyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
iii. with the other R11 being selected independently from any other R11 from -OH, -
F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, 
-CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, or 
iv. with the other R11 being selected independently from any other R11 from -OH, -
F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -CH3, -
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CH2CH3, -CH20CH3, -CHCH2, -CH20H, -S02NH2, -S02N(CH3)2, -S02NHCH3, 
-CH3, -CF3 or -N02, in particular from -OH, -F, -OCH3, -OCF3 or -CF3, wherein, 
each carbon atom of the cyclic system which comprises no substituent R11 
comprises F instead of H. 
31. The compound according to any one of the claims 1 to 8 or 28 to 30, wherein BE is 
with n of R11n being O or 2, and with one R11 being Q and the other R11 being -OCH3 
or -OCF3, more particularly Q is in ortho and OCH3 or -OCF3 is in meta position with 
respect to the attachment position of the phenyl moiety of BB to 0 5, with Q having the 
same meaning as defined above. 
32. The compound according to claim 1, wherein 
-OH, -F, -Cl, -Br, -1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2CH3, -CH3, -CF3 or -N02, 
-B(ORa)(ORb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(ORa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=O)Ra, -(CH2)m-NRcC(=O)ORa, -(CH2)m-
NRcC(=O)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)ORa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(ORb)(ORa), -(CH2)m-
P(=O)(ORb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=O)-(M)-C(=O)ORa, -(CH2)m-O-C(=O)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =O)(Rba)(Raa), -(CH2)m-C( =0)0-(CH2)q-P( =O)(Rba)(Raa), -(CH2)m-C( =0)0-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
- with Raa being selected independently from each other from -Ra or -ORa, 
- with Rba being selected independently from each other from -Rb or -ORb, 
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- with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
- with each Ra, Rb or Re being selected independently from each other from 
- hydrogen, -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -
CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C6Hs -CH2C6Hs. 
33. The compound according compound according to any one of the claims 1 to 4, 
wherein X2 is -os-BF, and wherein os has the same meaning as defined previously, 
and 
BF is 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or unsubstituted 
C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or unsubstituted 
C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C6-C10 aryl. 
34. The compound according to any one of the claims 1 to 8, wherein X2 is -os-BF and 
BF is 
wherein os has the same meaning as defined previously, and 
with T being selected from 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-
C(=O)ORa, -(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-
OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
C(=O)NRb(QRa), -(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, 
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-(CH2)m-OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -
(CH2)m-SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -
(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-
NRCC(=O)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-
NRcS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-P(=O)(QRb)(Ra) or -
(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=Ü)-(M)-C(=O)OH, -(CH2)m-O-C(=Ü)-
(M)-C(=O)ORa, -(CH2)m-O-C(=O)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently 
from each other from 
hydrogen, 
-CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a 
substituted or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted 
or unsubstituted C3-C10 halo heterocycle, in particular a substituted 
or unsubstituted C4-C10 heterocycle or a substituted or 
unsubstituted C4-C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl, 
with n of R10n being 0, 1, 2, 3 or 4, in particular n of R10n being 0, 1, 2 or 3, 4, and 
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with each R10 independently from any other R10 being selected from 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2, -
CH3, -CH2-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-C(=O)ORa, 
-(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -(CH2)m-
C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C1-C16 
carboxy, a substituted or unsubstituted C2-C16 alkenyl, a substituted 
or unsubstituted C2-C16 alkynyl, or a C1-C16 haloalkyl, in particular a 
substituted or unsubstituted C1-Cs alkyl, a substituted or 
unsubstituted C1-Cs alkoxy, a substituted or unsubstituted C2-Cs 
alkenyl, a substituted or unsubstituted C2-Cs alkynyl, a substituted 
or unsubstituted C1-Cs haloalkyl, a substituted or unsubstituted C3-
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C10 cycloalkyl, or a substituted or unsubstituted C3-C10 halo 
cycloalkyl, 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted 
C4-C10 halo heterocycle, 
a substituted or unsubstituted Cs-C10 heteroaryl, 
a substituted or unsubstituted C5-C10 aryl. 
35. The compound according to any one of the claims 1 to 8 or 34, wherein X2 is -05-BF 
and BF is 
ITYT 
~R:o 
wherein 0 5 and T have the same meaning as defined previously, 
with n of R10n being 0, 1, 2, 3 or 5, in particular n of R10n being 0, 1, 2 or 3, and 
with each R10 independently from any other R10 being selected from 
-OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NH CH3, 
-N(CH3)2, -CH3, -CH2-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -
(CH2)m-C(=O)ORa, -(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -
(CH2)m-OC(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-
NRCC(=O)ORa, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -
(CH2)m-C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-
OC(=S)ORa, -(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-
SRa, -(CH2)m-S(=O)Ra, -(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -
(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -(CH2)m-NRaRb, -(CH2)m-
NRCC(=O)Ra, -(CH2)m-NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -
(CH2)m-NRcC(=S)NRaRb, -(CH2)m-NRcC(=S)QRa, -(CH2)m-
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P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-
C( =O)O-(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl, in particular C1 to C2 alkyl, 
with m being selected from 0, 1 or 2, in particular O or 1, 
with q being selected from 0, 1 or 2, in particular O or 1, 
with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2CH2CH3, -
CH(CH3)2, -CH2CH(CH3)2, -C(CH3)3, -C5Hs -CH2C6Hs. 
36. The compound according to any one of the claims 5 to 8, wherein 
T is 
- -OH, -F, -Cl, -Br, 1, -CCH, -CN, -N3, -OCH3, -OCF3, -NH2, -NHCH3, -
N(CH3)2, -CH3, -CH2-CH3, -CF3 or -N02, 
-B(ORa)(QRb), -(CH2)m-Ra, -(CH2)m-ORa, -(CH2)m-C(=O)Ra, -(CH2)m-
C(=O)ORa, -(CH2)m-OC(=O)Ra, -(CH2)m-OC(=O)ORa, -(CH2)m-OC(=O)NRaRb, -
(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRaRb, -(CH2)m-C(=O)NRb(QRa), -(CH2)m-
C(=S)Ra, -(CH2)m-C(=S)ORa, -(CH2)m-OC(=S)Ra, -(CH2)m-OC(=S)ORa, -
(CH2)m-OC(=S)NRaRb, -(CH2)m-C(=S)NRaRb, -(CH2)m-SRa, -(CH2)m-S(=O)Ra, -
(CH2)m-S(02)Ra, -(CH2)m-S(02)0Ra, -(CH2)m-OS(02)Ra, -(CH2)m-OS(02)0Ra, -
(CH2)m-NRaRb, -(CH2)m-NRcC(=Ü)Ra, -(CH2)m-NRcC(=Ü)ÜRa, -(CH2)m-
NRcC(=Ü)NRaRb, -(CH2)m-NRcC(=S)Ra, -(CH2)m-NRcC(=S)NRaRb, -(CH2)m-
NRcC(=S)QRa, -(CH2)m-NRCS(02)Ra, -(CH2)m-P(=O)(QRb)(QRa), -(CH2)m-
P(=O)(QRb)(Ra) or -(CH2)m-S(02)NRbRa, -(CH2)m-O-C(=O)-(M)-C(=O)OH, -
(CH2)m-O-C(=Ü)-(M)-C(=O)ORa, -(CH2)m-O-C(=Ü)-(M)-Ra, -(CH2)m-O-(CH2)q-
P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-(CH2)q-P( =Ü)(Rba)(Raa), -(CH2)m-C( =Ü)O-
(CH2)q-S(02)0H or -(CH2)m-C(=O)O-(CH2)q-S(02)0Ra, 
with Raa being selected independently from each other being -Ra or -ORa, 
with Rba being selected independently from each other being -Rb or -QRb, 
with M being a substituted or unsubstituted C1-Cs alkyl, in particular an 
unsubstituted C1-Cs alkyl 
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with each Ra, Rb or Re being selected, where applicable, independently from 
each other from 
hydrogen, 
-CN 
a substituted or unsubstituted C1-C16 alkyl, a substituted or unsubstituted C1-
C16 alkoxy, a substituted or unsubstituted C1-C16 carboxy, a substituted or 
unsubstituted C2-C16 alkenyl, a substituted or unsubstituted C2-C16 alkynyl, or 
a C1-C16 haloalkyl, or 
a substituted or unsubstituted C3-C10 cycloalkyl or a substituted or 
unsubstituted C3-C10 halo cycloalkyl, or 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-C10 halo 
heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
37. The compound according to any one of the claims 5 to 8 or 36, wherein 
T is 
d. -B(OH)2, -CN, -NH2, -OH, -OCH3, -C(=O)NH2, -C(=O)NH(CN), -C(=O)NH(OH), 
-CH20H, -CH2C(=O)OH, -CH2C(=O)NH(OH), -CH2C(=O)NH2, -
CH2NHS(02)0H, -CH2NHC(=O)OH, -P(=O)(OH)(OH), -CH2P(=O)(OH)(OH), -
CH2S(02)0H, -S(02)0H or -S(02)NH2 or 
e. -Ra, -CH2Ra, -SRa, -CH2SRa, -S(=O)Ra, -C(=O)NHRa, -CH2C(=O)NHRa, -
CH2NHS(02)Ra, -C(=O)ORa, -ORa or -NHRa,-C(=O)ORa, -CH2C(=O)NH(ORa), 
-C(=O)NHORa, -C(=O)NHRa, -CH2NHS(02)Ra, -CH20Ra, -CH2NHC(=O)Ra, -
P(=O)(OH)(ORa), -CH2P(=O)(OH)(ORa), -P(=O)(OH)(Ra), -
CH2P(=O)(OH)(Ra), -CH2S(02)0Ra, -S(02)0Ra, -S(02)Ra or -CH2S(02)Ra, or -
S(02)NHRa, 
with Ra being selected from 
a substituted or unsubstituted C1-C16 alkyl, a substituted or 
unsubstituted C1-C16 alkoxy, a substituted or unsubstituted C2-C14 
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alkenyl, a substituted or unsubstituted C2-C14 alkynyl, or a C1-C14 
haloalkyl, in particular a substituted or unsubstituted C1-Cs alkyl, 
more particularly Rais -CH3, -CF3, -CH2CH3, -CH2CF3, -CN, ,-CH2CH2CH3, -
CH(CH3)2, -CH2C6Hs or para-methoxybenzy 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, -[(CH2)m1-C( =0)0-(CH2)m2]p1-0Rd in particular -
[-O-(CH2)2]p1-0Rd, -[-C(=O)O-(CH2)2]p1-0Rd, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
f. -Ra, -CH2Ra, -SRa, -CH2SRa, -S(=O)Ra, -C(=O)NHRa, -CH2C(=O)NHRa, -
CH2NHS(02)Ra, -C(=O)ORa, -ORa or -NHRa, 
with Ra being 
a substituted or unsubstituted C3-C10 heterocycle or a substituted or 
unsubstituted C3-C10 halo heterocycle, in particular a substituted or 
unsubstituted C4-C10 heterocycle or a substituted or unsubstituted C4-
C10 halo heterocycle, or 
a substituted or unsubstituted Cs-C10 heteroaryl, or 
a substituted or unsubstituted C5-C10 aryl. 
38. The compound according to any one of the claims 5 to 8 or 36 to 37, wherein 
T is -C(=O)ORa 
with Ra being 
a substituted or unsubstituted C1-C16 alkyl, in particular an unsubstituted 
C1-C16 alkyl, 
-[(CH2)m1-0-(CH2)m2]p1-0Rd, -[(CH2)m1-C( =0)0-(CH2)m2]p1-0Rd, in particular 
-[-O-(CH2)2]p1-0Rd, -[-C(=O)O-(CH2)2]p1,, with 
Rd being -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C5Hs 
m1 and m2 being selected independently from each other 
form 1, 2 or 3, in particular m1 and m2 are 2, and 
p1 being selected from 1 to 20, in particular from 1 to 8, 
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39. The compound according to any one of the previous claims, wherein each 0 1 to 0 5 is 
selected independently from each other from 
V 
~ ,,)l_N-~ ~~N-~ 
18 18 
R (01 ), R 
V 
S--o~~ ~ (010), (012), 
S/'"'-8_:? r,y-~ ~~-, ~ 
<: S (013), o (013'), o o (013"), 
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with each R8 being -H, or, where applicable, with each R8 being selected 
independently from each other from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -
CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with each R8 
being selected independently from each other from H or CH3, more particularly 
R8 being H, and 
with V being, where applicable, S, NH or 0, in particular V being O. 
40. The compound according to any one of the previous claims, wherein each 0 1 to 0 5 is 
selected independently from each other from 
V 
~ ,,)l_N-~ ~~N-~ 
18 18 




R (07), ~ ~-N)lO-~ ~0- 1 ! (D8), R8 (D9), 
V 
~-O~~ (D10), (012), 
with each R8 being -H, or, where applicable, with each R8 being selected 
independently from each other from -H, -CH3, -CH2CH3, -OCH3, -OCF3, -
CH2CF3, -CHFCF3, -CF2CF3, -CHF2, -CH2F or -CF3, in particular with each R8 
being selected independently from each other from H or CH3, more particularly 
R8 being H, and 
with V being, where applicable, S, NH or 0, in particular V being O. 
41. The compound according to any one of the previous claims, the compound 
characterized by the general formula 1 comprises at least one deuterium instead of a 
hydrogen. 
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42. The compound according to any one of the previous claims, wherein the compound is 
one of the compounds 1 to 50, 70 to 76 and 78 to 117 as depicted in the experimental 
section or the description. 
43. A compound according to any one of claims 1 to 42 for use in a method of treatment 
of diseases, in particular for use in a method of treatment of bacterial infections. 
44. The compound for use in a method according to claim 43, wherein the bacterial 
infection is an infection by a gram-negative bacterium, particularly an infection by one 
of the genus Acinetobacter, Bordatella, Borellia, Brucella, Camphylobacter, 
Chlamydia, Chlamydophila, Enterobacter, Escherichia, Francisella, Haemophilus, 
Helicobacter, Klebisella, Legionella, Leptospira, Morganella Moraxella, Neisseria, 
Proteus ,Pseudomonas, Rickettsia, Shigella, Salmonella, Stenotrophomonas, 
Treponema or Yersinia, further in particular by one of the genus Escherichia, 
Enterobacter, Salmonella, Klebisella, Pseudomonas, Haemophilus, Shigella, Proteus 
or Morganella. 
45. The compound for use in a method according to claim 44, wherein the bacterial 
infection is an infection 
by a gram-positive bacterium, particularly an infection by one of the genus 
Bacillus, Chlostridium, Corynebacterium, Enterococcus, Listeria, Micrococcus, 
Staphylococcus or Streptococcus, further in particular by one of the genus of 
Staphylococcus, Streptococcus, Bacillus or Micrococcus or 
by a bacterium of the family of Mycobacteriaceae, in particular of the genus 
Mycobacterium, further in particular an infection by one of Mycobacterium 
tuberculosis, Mycobacterium leprae, Mycobacterium ulcerans or 
Mycobacterium avium, or 
by a bacterium of the family of Mycoplasmataceae, in particular of the genus 
Mycoplasma, further in particular an infection by Mycoplasma pneumonia. 
46. The compound for use in a method according to claim 44 or 45, wherein the bacterial 
infection is an infection by one of Staphylococcus aureus, Staphylococcus 
epidermidis, Staphylococcus aureus Streptococcus pyogenes, Bacillus subtilis, 
Bacillus megaterium, Micrococcus luteus, Escherichia coti, Enterobacter aerogenes, 
Enterobacter cloacae, Enterobacter sakazakii, Cronobacter sakazakii, Salmonella 
typhi, Salmonella enteritidis, Klebisella pneumonia, Pseudomonas aeruginosa, 
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Figure 11 
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